[
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "Subtypes test 10"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-25T14:08:57Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-09-15T11:50:12Z"
    },
    "adminNotes": {},
    "link": {},
    "rrid": {},
    "accession": {},
    "labCatalogNumber": {}
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "Subtypes test 9"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-25T14:08:42Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-09-15T11:50:42Z"
    },
    "adminNotes": {},
    "link": {},
    "rrid": {},
    "accession": {},
    "labCatalogNumber": {}
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "Subtypes test 1"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-24T16:22:55Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Animal Model"
    },
    "addedDate": {
      "iv": "2021-09-15T13:34:15Z"
    },
    "adminNotes": {},
    "link": {},
    "rrid": {},
    "accession": {},
    "labCatalogNumber": {}
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "Subtypes test 3"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-24T16:22:54Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Assay"
    },
    "addedDate": {
      "iv": "2021-09-15T13:28:16Z"
    },
    "adminNotes": {},
    "link": {},
    "rrid": {},
    "accession": {},
    "labCatalogNumber": {}
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "Subtypes test 4"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-24T16:22:54Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Compound"
    },
    "addedDate": {
      "iv": "2021-09-15T11:59:52Z"
    },
    "adminNotes": {},
    "link": {},
    "rrid": {},
    "accession": {},
    "labCatalogNumber": {}
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "Subtypes test 5"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-24T16:22:54Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Microscopy & Imaging"
    },
    "addedDate": {
      "iv": "2021-09-15T13:29:54Z"
    },
    "adminNotes": {},
    "link": {},
    "rrid": {},
    "accession": {},
    "labCatalogNumber": {}
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "Subtypes test 7"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-24T16:22:54Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Software"
    },
    "addedDate": {
      "iv": "2021-09-15T13:30:09Z"
    },
    "adminNotes": {},
    "link": {},
    "rrid": {},
    "accession": {},
    "labCatalogNumber": {}
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "Subtypes test 8"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-24T16:22:53Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Spectroscopy"
    },
    "addedDate": {
      "iv": "2021-09-15T11:52:32Z"
    },
    "adminNotes": {},
    "link": {},
    "rrid": {},
    "accession": {},
    "labCatalogNumber": {}
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "Subtypes test 2"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-24T16:22:53Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Antibody"
    },
    "addedDate": {
      "iv": "2021-09-15T11:59:26Z"
    },
    "adminNotes": {},
    "link": {},
    "rrid": {},
    "accession": {},
    "labCatalogNumber": {}
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "Subtypes test 6"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-24T16:22:53Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Sample Prep"
    },
    "addedDate": {
      "iv": "2021-09-15T11:57:26Z"
    },
    "adminNotes": {},
    "link": {},
    "rrid": {},
    "accession": {},
    "labCatalogNumber": {}
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "700cf91e-88ee-55d4-ae62-e4a136511e86"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "addedDate": {
      "iv": "2021-05-21T13:18:31Z"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-19T11:48:16Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    }
  },
  {
    "title": {
      "iv": "a3482898-bad1-533b-8274-e04c1ad73f67"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:36:28Z"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-14T13:07:19Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "<p>Research Output Description test</p>"
    },
    "tags": {
      "iv": []
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "Mapping the LRRK2 signaling pathway as interplay with other Parkinson's disease components"
    },
    "type": {
      "iv": "Presentation"
    },
    "subtype": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-11-16T18:27:47Z"
    },
    "lastUpdatedPartial": {
      "iv": "2022-01-07T19:42:02Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "<p><iframe src=\"https://docs.google.com/presentation/d/e/2PACX-1vQb8gBj-RKXh0b2oaGL0MU-6MhaMuDPNAmvoaM80LBrszo0kKciGzjedeZ9L0wqgw/embed?start=false&amp;loop=true&amp;delayms=3000\" width=\"960\" height=\"749\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe></p>"
    },
    "tags": {
      "iv": []
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": null
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": "PXD027078"
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": "10.1234/abcde.12345"
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "Test ana"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-12-07T13:43:21Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:17Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "![image](https://cloud.squidex.io/api/assets/asap-hub-dev/e01541a1-4a40-4bef-8dc4-88f2e8049dc5/image.png 'image')<p>test content</p>\n\n| Column 1 | Column 2 | Column 3 |\n| -------- | -------- | -------- |\n| John     | Doe      | Male     |\n| Mary     | Smith    | Female   |\n\n<h1>Another title</h1>\n<p>Nulla ultricies eros nibh. Quisque fermentum mauris sed orci volutpat lacinia. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Maecenas eu arcu rhoncus, scelerisque ipsum vel, eleifend lorem.</p>\n#### <h1>Title</h1>\n<p>Quisque rutrum, lectus in imperdiet condimentum, purus justo dignissim orci, eget varius erat sapien ut orci. In luctus ultricies dui non sagittis. Integer id feugiat dui. Curabitur vitae sem iaculis, gravida nisl et, laoreet augue. Nullam hendrerit maximus ex, et vulputate leo sodales sed. Donec faucibus eu risus ut ornare. Cras leo elit, porttitor eleifend mauris sit amet, ultricies tristique eros. Nullam dignissim, elit quis accumsan volutpat, sapien sem tincidunt velit, eu dapibus odio eros id mauris. Donec pulvinar vitae ex ac vestibulum. Pellentesque ac libero scelerisque, interdum est non, placerat turpis. Maecenas sagittis viverra lectus, quis varius metus malesuada sed. Nulla dictum luctus enim vitae aliquet.</p>"
    },
    "tags": {
      "iv": [
        "sssss",
        "wwwwjfnc",
        "laallaa"
      ]
    },
    "accessInstructions": {
      "iv": "<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis gravida a nunc nec laoreet. Ut consectetur massa eu neque congue interdum finibus et lacus. Nam ac elit magna. Ut mattis elit eu quam porta, sit amet auctor sem mollis. Morbi vitae nibh leo. Mauris nec libero vitae massa sollicitudin mattis. Sed id pulvinar velit. Phasellus lobortis ipsum at augue auctor, non vestibulum libero gravida. Praesent eget hendrerit odio, ac porta libero.</p>\n<p>Nulla ultricies eros nibh. Quisque fermentum mauris sed orci volutpat lacinia. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Maecenas eu arcu rhoncus, scelerisque ipsum vel, eleifend lorem. Quisque rutrum, lectus in imperdiet condimentum, purus justo dignissim orci, eget varius erat sapien ut orci. In luctus ultricies dui non sagittis. Integer id feugiat dui. Curabitur vitae sem iaculis, gravida nisl et, laoreet augue. Nullam hendrerit maximus ex, et vulputate leo sodales sed. Donec faucibus eu risus ut ornare. Cras leo elit, porttitor eleifend mauris sit amet, ultricies tristique eros. Nullam dignissim, elit quis accumsan volutpat, sapien sem tincidunt velit, eu dapibus odio eros id mauris. Donec pulvinar vitae ex ac vestibulum. Pellentesque ac libero scelerisque, interdum est non, placerat turpis. Maecenas sagittis viverra lectus, quis varius metus malesuada sed. Nulla dictum luctus enim vitae aliquet.</p>"
    },
    "labs": {
      "iv": [
        "a61a6e09-29f3-46f4-99db-b03e50dce6b3"
      ]
    },
    "authors": {
      "iv": null
    },
    "asapFunded": {
      "iv": "No"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "The great sync test for ROMS and Algolia"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-11-17T13:22:00Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:17Z"
    },
    "link": {
      "iv": "https://test.com"
    },
    "description": {
      "iv": "<p>Test if the following will update after a sync:</p>\n<p>- user name change (for author)</p>\n<p>- lab name change</p>\n<p>- moving an external author to draft</p>\n<p>- changing name in external author</p>\n<p><iframe src=\"https://drive.google.com/file/d/1_ehdCZ_vRAKz-nkC4x7paYjg1lGSyJsd/preview\" width=\"640\" height=\"480\"></iframe></p>"
    },
    "tags": {
      "iv": null
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": [
        "a8a57909-d901-4d2d-ba91-20f48738bbad"
      ]
    },
    "authors": {
      "iv": [
        "f21fb988-cb68-4889-a444-6161006dff67",
        "58d375d7-df18-4083-a421-3d1f9c55a537",
        "b8f0d946-bfef-4673-b1f6-be2e9a97b1b2"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "test proposal Piotr"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-20T15:03:51Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:16Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": ""
    },
    "tags": {
      "iv": null
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": [
        "859bd247-1e49-4c88-a2c0-585b6e13ad05"
      ]
    },
    "authors": {
      "iv": null
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "693d57fa-afcb-5ddb-a207-56af2955bf89"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T14:10:10Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:16Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "Research Output Description"
    },
    "tags": {
      "iv": []
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": [
        "9912c4d4-58cb-4e10-9f93-44f4eb5f1e7b"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "test ana "
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-23T10:29:44Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:16Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": ""
    },
    "tags": {
      "iv": null
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": null
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "bdb62bcb-40d3-57f5-ad23-099df9532be4"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:15Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T13:36:27Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "010b3b18-2a7c-59fe-9b74-1e230ea7b11b"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:15Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T13:30:20Z"
    }
  },
  {
    "title": {
      "iv": "6fec7e03-a878-593f-a8b5-fa94bdb1fedb"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T13:36:52Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:15Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "Research Output Description"
    },
    "tags": {
      "iv": []
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": [
        "073583b2-932d-49b7-b98a-3bb25f04788b"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "96c0ac05-0ab5-57e9-b04e-626085c3c606"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:15Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T13:30:48Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "244006e8-1beb-53a1-8949-62c1be611660"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:15Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T13:33:48Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "c29f2fe2-1a60-52ed-8476-a9b399779b55"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:13Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:49:49Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "47f4f6de-1227-5429-9cb1-3b64b7efa2ba"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:13Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:56:45Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "67d58147-0b9d-5c82-9af4-df5dd0265949"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:13Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:49:33Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "7f68c35b-d81c-5f13-92ba-5c69f60d4356"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:12Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:35:37Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "da2e8fd0-861e-5064-baeb-94c2168400a7"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:12Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:48:54Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "9d17e89a-b69f-5589-acd8-a5dedc33ceec"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:12Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:33:52Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "b0628b33-354a-549f-8307-75dab9766448"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:12Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:33:05Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "58ce9727-4121-5153-bae6-f4c63415507f"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:12Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:33:26Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "53f0de01-1032-59ea-91dc-f48fdf8d6542"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:11Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:29:57Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "afaec1e0-f4c7-5f98-ade4-014655966c64"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:11Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:31:56Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8d84fcc1-8113-5fba-9fc9-a9f4ab95cf7f"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:11Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:28:50Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4e6c0e58-79e7-5837-9e69-7380913f8820"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:11Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:31:34Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "20c840e4-a3c7-5b8b-9aa2-87f197f46c48"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:11Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:31:02Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "ce5245a8-0ab6-545f-9a1b-bffafaea2ecc"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:11Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:30:24Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "08c2181f-1d81-5f78-a112-b1c930505dce"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:10Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:26:43Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "e3b17003-8068-5fde-99e0-1daede25bd33"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:10Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:27:39Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "6622b09f-9c85-5c4f-8071-0cf8e32cb3bb"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:10Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:27:07Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4231e523-d4f7-5b89-8b66-fd3619cf4a39"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:10Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:28:14Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "3eb3cc54-842f-5037-bc3f-dcf045be46fa"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:10Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:25:15Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "b568ef34-0e4a-5e99-9d74-4d6c6eff9ebf"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:09Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:14:55Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "87829b3f-cd88-5616-bb53-b82e1ed6c3f1"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:09Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:16:51Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "a308cd4a-6c92-581f-9eee-6623a5cc3da4"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:09Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:17:51Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "9fbb8ca2-b868-58f5-a7c4-b91cc8fc65a7"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:09Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:22:12Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "f9c413ba-7525-5c54-8f76-6c21ecdc68ec"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:09Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:16:05Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "dac957a2-6b3b-5f7f-afae-d60f7d2a2646"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:09Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:19:27Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "a89b182d-b482-5973-ab4a-f548e65e0f9f"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:09Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:19:45Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "15a8e342-49ec-56b6-bd10-408f11859a4a"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:08Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:12:08Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "ef1dfa52-e66b-52df-81fe-545682299b24"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:08Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:14:15Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "21aa3bc4-a1db-5739-9c9b-abc832ae8ba4"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:08Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:11:08Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "394fb262-6c6c-52ad-b236-1dcfd072b1aa"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:08Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:13:52Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4143c7d6-119d-594c-b5c0-6e1f20eac32c"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:08Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:11:34Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "2898adca-7e98-5fda-8576-0832a98f24f7"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:08Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:10:42Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4456a4cb-19ed-5106-9f0b-04a905f7a0ea"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:07Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:08:21Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "e1852504-dfbb-576d-9b24-209204d3a3ed"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:07Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:07:43Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "235c96ba-339a-5df9-9436-ae09e0264999"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:07Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:07:20Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "343b6bab-0a3a-57d2-bb69-0e88bb870047"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:07Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:09:44Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "d30bf5dd-1900-5618-acc1-fd2a95bc2fcd"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:07Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:10:14Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "dffb5629-0559-54cc-b03d-5b70a7826ff7"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:07Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:08:44Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8ae7254f-5657-5343-8ae2-323ebab9796e"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:06Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:06:01Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "d2451473-85f7-5be1-ace7-cca349a46f5e"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:06Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:02:59Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "3745bc32-219c-5586-a0ec-5d82ab5242d1"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:06Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:04:45Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8f701859-0c79-519a-93d0-6d58e013e541"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:06Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:04:14Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8b27134b-f2ed-5d32-a24f-7fa5e2a916c5"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:06Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:03:55Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "ce039761-9193-5ae3-9ccd-dd26f2344dfe"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:06Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:02:18Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "b9025cac-c274-5a8c-96d9-27e58bf5160b"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:06Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:05:25Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "a6811605-d2e2-5f3c-bdc4-ecabc49daa87"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:05Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T11:01:24Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "a351b853-3772-559b-9a1a-b7da68a107be"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:05Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:59:43Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "a9b97497-ff20-5887-90db-f5aea3b22589"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:05Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:57:33Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "7128dd0d-a61a-50cd-99e0-3ad84a9c7774"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:05Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:58:44Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "aa21b5ce-c330-5018-9aa0-47333f4c2ab3"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:05Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:58:16Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "60666f18-9965-5ab5-b360-4cd70d071069"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:05Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:57:00Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "c0ca35cc-da3e-5728-b190-9dc445a87353"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:04Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:40:50Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "e4b676a3-4b39-5c38-aa9d-be2a7feb2d4f"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:04Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:41:41Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "5ec6c73e-78fe-51ef-9ba4-650b7d540365"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:04Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:54:31Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "62e43e74-af05-5dbf-9f7e-60d79721149f"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:04Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:41:26Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "0468cf6b-162f-5998-997c-d865389818db"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:04Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:39:23Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "bcbeefbf-8be2-5860-87cb-75aef3ace684"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:04Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:55:11Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "ab6932e0-9387-54af-98eb-bd0b42e68621"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:04Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:42:08Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "cfccfbc1-2cd3-5f49-a74d-f3aafea6b360"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:03Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:28:42Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "ee669699-1834-5da7-9ea0-857c1ed03c0a"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:03Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:29:15Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "1e756b5b-4d37-5f64-9f1e-dbccaf1fc20b"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:03Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:34:27Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "ccefe5b8-c0ab-56f9-a48c-c0b9658f708a"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:03Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:30:36Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "195175a1-1300-5bbd-b1e5-a9a4eff6c8d2"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:03Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:38:16Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "dc64daea-07c9-59f7-aa26-39671e86745d"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:03Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:35:00Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4084c737-212d-5fa7-b255-634f0e055bbf"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:03Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:33:02Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "0b3313ea-8b78-5939-b020-9768671fa1e5"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:02Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:26:56Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4a6fd2b3-c857-5527-95fe-3bf11a3ce4cf"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:02Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:22:13Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "b79c95b4-8823-5da8-8081-76caf899098a"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:02Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:25:27Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "cfa1935e-718e-5ab5-94a6-d4077ef79cea"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:02Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:26:21Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8fd138f4-ba00-52d5-a1dc-d474497a6cbb"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:02Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:23:15Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "f8ad812b-e6a2-5d7f-b14a-0b47c8e6a742"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:02Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:23:03Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8873b82f-8917-5c4b-a8bb-f6a573e73c71"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:01Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:21:18Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "5a551d59-a7e7-590e-a6ac-6e6d65e61ff2"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:01Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:21:52Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "c7a62fc9-b734-5e8e-b784-039bfdcfdb4a"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:01Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:16:34Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "7bcacf6d-2747-583c-94e7-fc0175dcd4d0"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:01Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:17:53Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "3b542652-bce2-592b-bba7-8ff4de426095"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:01Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:21:39Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "228de242-43fc-50d9-ba6c-8e0f4b454388"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:00Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:11:57Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "0f00867a-5606-529a-9391-018cda47b68c"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:00Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:14:04Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "12193ca4-db51-5866-bcd3-da35de4ae9b1"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:00Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:12:20Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "75a05509-6d49-5b82-8c1b-f671fbedc2b8"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:00Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:15:41Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "87b94b36-90be-528d-9572-2a03d177b320"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:00Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:13:04Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8afcc5f1-da09-5737-8510-03ba9d3d7efe"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:00Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:14:54Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "101fd54e-764f-5652-a475-d0872d495240"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:43:00Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:16:12Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "03cd988e-949f-5635-94a5-8549b3ab5f41"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:59Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:10:13Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "ea4eb917-7fef-59f7-8b07-28dceab23a47"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:59Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:08:52Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8bc74cae-add9-59ce-b30c-d0d77a135bda"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:59Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:11:11Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "f5deac94-b3eb-52cf-98fe-96cb8829fb30"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:59Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:08:27Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "c550e6c0-3017-5989-93d1-804804881271"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:59Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:10:32Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "e6c8884c-b176-5411-8eee-779f039d9ad3"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:59Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:09:19Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "1fd54119-15b0-5bcb-bd5a-5c3bab8db35e"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:58Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:06:40Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "891c1afe-2009-5d49-89b1-88e9224455f6"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:58Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:07:35Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "e2cab80a-755e-5141-b99a-371797bab7ff"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:58Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:07:56Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "5892b33f-993b-571a-8a79-7960b074ccc5"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:58Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:06:27Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "1b6ff293-aee1-5f9e-bca8-699a176defea"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:58Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:05:11Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "654a51bc-de57-5d1b-8bd2-004ead8de661"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:58Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:05:59Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "34b1abf2-11f2-5204-be57-c4dd99e8b98c"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:57Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:04:21Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "86234f42-5db6-592e-a3e9-2d01de9d43fe"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:57Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:03:35Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8fbcc2b8-1693-518a-8113-744bf393ae31"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:57Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:02:27Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4378d2e0-7124-559e-a19c-8383926a9145"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:57Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:01:45Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "2239c474-c3d7-55b8-8bdd-7167c53b70f4"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:57Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:04:48Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "30f66a53-097d-5312-9a39-3dbe99476d6f"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:56Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:51:59Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "d179f5c8-417b-594f-a7a0-c9ff47638294"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:56Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:57:58Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "2644f76f-78ea-5443-bfbc-e868f2c8a083"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:56Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:00:35Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "ba28bb5d-1cc5-5a03-b2e3-f20b35c7bc26"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:56Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:01:22Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "b732ca2b-8c19-570e-8db5-d6ed38800309"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:56Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T10:00:17Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "6f8b22ee-8aec-5832-ac39-06134b11633f"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:56Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:59:32Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8ba19634-4af5-5463-9c27-f576eb8dd0d4"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:55Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:44:56Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "5eb56fd9-c91a-5b35-bb9c-84f941551d71"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:55Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:40:56Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "f49b03cb-1a9a-55f9-b816-31f685a36a94"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:55Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:46:30Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "aadfb3a7-868b-56dc-b372-8f419492d12f"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:55Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:41:40Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "afe2763a-005f-511c-a7df-53ada5ad1dca"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:55Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:49:01Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "a6894513-912c-51a1-900f-44da1a097d73"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:54Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:37:26Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "19733032-94c1-5f36-8431-18b785390bf4"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:54Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:40:11Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "28d21968-189c-579e-93c6-6d84a31f5276"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:54Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:39:37Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "10cddafd-2981-5348-a065-0a4f34226e57"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:54Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:40:39Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "782d442b-d267-51e2-929e-0f171046ff92"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:54Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:38:55Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "a4279fcb-d984-59c9-9326-4b5aada346bc"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:54Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:38:10Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "32ff6f26-544b-5b4d-999c-66dc20373949"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:53Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:36:04Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "e2b3b7c9-f9d1-5efe-a354-d5bb552a5065"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:53Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:36:59Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "ec4a01b8-bef8-5c5c-8106-5f0d0570a1d8"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:53Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:35:06Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "2ed7d5f3-521a-516f-b1c2-2e61676eb9bf"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:53Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:34:48Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "1d1c3b34-bf4d-5270-8abf-bdcd5214c08c"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:53Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:35:30Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "b6252779-379f-5911-b5f3-6a10c1f2c6c7"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:53Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:33:12Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "7591f52a-3553-55d0-8f29-0c7b2111703d"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:52Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:30:50Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "f84d6b6f-aa75-5e31-9033-0241f99c4ec3"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:52Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:32:42Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "7503c122-61ed-523f-ad61-7d07a8542dd3"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:52Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:26:59Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "a0871711-9e19-5be3-9b34-8301742df6a7"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:52Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:32:20Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8b68e497-c20c-531d-af51-709fe576e82b"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:52Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:31:41Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "45df1d5d-1bfc-5fc1-99b8-b33915564c8e"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:51Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:24:06Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "17f0aa7f-b6b3-5b11-a75b-3dadf6bca42e"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:51Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:24:52Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "43817816-e298-54ad-baca-c1360e8ab3ee"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:51Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:26:38Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "06d7c443-25be-5d50-a8ed-f9eb3525a4f5"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:51Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:25:13Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "136dadbc-bab3-5d05-a026-00d01d0132cd"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:51Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:23:45Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "97f34194-fcfa-59bf-8e31-51354b87f285"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:50Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:21:39Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "6f591a67-6f35-5299-96de-b8be1dd214ac"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:50Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:18:39Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "a78fe6a9-cb28-50fc-948e-91a83640a4a0"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:50Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:19:31Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "e1cba785-eb79-59f6-be29-02e0ea3a690f"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:50Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:22:41Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "496eea22-01e6-5346-b721-8c0d85afe0f2"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:50Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:23:12Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "36cf85eb-349f-5340-a52f-a7ce5f14bdfc"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:49Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:17:48Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "948e5605-5eb1-5bcb-9701-7d8860be9ea8"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:49Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:17:13Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8da3a0e8-d429-511b-9b95-a7af82b0e157"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:49Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:14:23Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "84611b7e-9db3-5596-ba18-2c223c308f71"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:49Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:16:08Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "cb9ec683-b459-5cbd-ae46-778d0789c029"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:49Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:15:35Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "a170949e-2c08-5be1-b1b8-dbc6b15c2f77"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:49Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:17:29Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "2a26f8d4-97b3-550a-9657-cd0fb42eecc3"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:48Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:13:27Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "96784626-393d-5daa-9154-78c2524538e8"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:48Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:11:53Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "8ade1a3e-5eec-5b66-9779-680e3cb271e1"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:48Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:10:47Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "291ed68e-a93b-5574-8f8e-545192f2d1cf"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:48Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:12:25Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "e8311e47-2f4d-5254-a1bd-03eb3fa03542"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:48Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:14:01Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "97aeb604-b701-55bf-9998-2921e99d6988"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:47Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:01:46Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4ecacd76-f494-5ee6-abd4-1e69b4f54506"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:47Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:09:40Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4b122744-98a1-550a-a2f8-4ff607a277d1"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:47Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:09:23Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "d5e0e1a7-9d55-5257-bfe0-f0ab46795b03"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:47Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:02:21Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "7f87d7f4-0c0c-548d-8236-4a5cf4957750"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:47Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T09:08:55Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "524790d3-2e80-5562-ab6f-eaaf6e1864e7"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:46Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:59:34Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "e5eefda5-2638-5237-84fb-7bc0d7a9222c"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:46Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:56:00Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "0289b94f-7d47-57d4-91bb-b95744c66eaa"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:46Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:58:23Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4b66c42c-7f86-55da-b7ca-33421fd2fb1d"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:46Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:57:04Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "b291e51d-d557-5031-bf55-8cdf35084a89"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:45Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:49:29Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "dd30274c-993a-503e-b46c-a0e57d8d8c5e"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:45Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:53:56Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "3445e64a-fbe6-52f1-bdf2-527f19a2c296"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:45Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:54:25Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "ec653c59-fd2e-590f-a817-a8de7633d60e"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:45Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:55:30Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "74e299da-a6bd-5b6e-9a66-b3dfed9eea47"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:45Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:54:50Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4589606e-73ca-5479-aee9-15081984bd79"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:45Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:48:35Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "eaa61533-a233-5628-8ea0-2afeaeb2b7bd"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:44Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:47:10Z"
    }
  },
  {
    "title": {
      "iv": "Unforgettable Dataset"
    },
    "type": {
      "iv": "Dataset"
    },
    "subtype": {
      "iv": "Analysis"
    },
    "addedDate": {
      "iv": "2021-08-25T14:50:54Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:44Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "Research Output Description"
    },
    "tags": {
      "iv": []
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": [
        "b8f0d946-bfef-4673-b1f6-be2e9a97b1b2",
        "3bdfb2ab-4e8a-450a-abf9-4b9bd519a76e",
        "14ace7a2-7631-460b-a82b-0c5ec802f042",
        "311a1779-aaf3-4ee3-b440-e96582115221"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "b7d8c83b-b2b1-5128-b0b1-ed82ffe6dd84"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-08-25T14:22:50Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:44Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "Research Output Description"
    },
    "tags": {
      "iv": []
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "9421204f-b703-5c71-b5cf-3eaa38583848"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:44Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:46:36Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "0732c585-556b-5735-b59d-1f9d68c7cd3d"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:44Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-15T08:48:21Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "c088bfdd-5864-55a1-b060-45e2e932464a"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:43Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-08-24T17:00:34Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "060e7d71-fb04-56c5-8cc6-8ea83ea3047e"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:43Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-08-25T08:11:54Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "f5d79014-647d-5329-a589-5477d4d5b872"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:43Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-08-24T16:59:44Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "4693fb7a-5c04-5287-a8e2-174606c3528b"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:43Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-08-25T08:14:31Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "92acfcb9-ab57-56db-8f60-d93e1204acf4"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:43Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-08-25T08:23:08Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "6f9651f1-13ed-5586-a749-27f41657bbd2"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:43Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-08-25T09:57:16Z"
    }
  },
  {
    "type": {
      "iv": "Grant Document"
    },
    "title": {
      "iv": "f5d7d321-090c-5429-8cd0-c2496d7ee6d7"
    },
    "description": {
      "iv": "Research Output Description"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "doi": {
      "iv": "10.5555/YFRU1371"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:42Z"
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": []
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-08-24T16:26:10Z"
    }
  },
  {
    "title": {
      "iv": "Another output with identifiers"
    },
    "type": {
      "iv": "Presentation"
    },
    "subtype": {
      "iv": "ASAP annual meeting"
    },
    "addedDate": {
      "iv": "2021-08-03T12:05:12Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:41Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "<p>We investigate the pricing of traits in the U.S. corn seed market under imperfect competition. In a multiproduct context, we examine how substitution/complementarity relationships among products can affect pricing. This is used to motivate generalizations of the Herfindahl-Hirschman index capturing cross-market effects of imperfect competition on pricing. The model is applied to pricing of U.S. conventional and biotech seeds from 2000 to 2007. We reject the standard component pricing in biotech traits in favor of subadditive bundle pricing. The econom</p>"
    },
    "tags": {
      "iv": null
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": [
        "4790eb83-85fb-464a-94fa-57f829b5bc94"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": "LabNumber123"
    },
    "doi": {
      "iv": "10.1093/ajae/aaq063"
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "Testing dates - Presentation - added date: NONE | published date: NONE | created date: 30 of April"
    },
    "type": {
      "iv": "Presentation"
    },
    "description": {
      "iv": "<p>Testing dates - Proposal - no dates!</p>"
    },
    "link": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-04-30T16:23:32Z"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:41Z"
    }
  },
  {
    "title": {
      "iv": "Output with Identifiers"
    },
    "type": {
      "iv": "Dataset"
    },
    "subtype": {
      "iv": "Cell Culture & Differentiation"
    },
    "addedDate": {
      "iv": "2021-06-23T08:03:11Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:41Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "<p>The authors would like to thank Michelle Bravo for expert advice on medical nutrition therapy. They would also like to thank Walter Thurman, two anonymous referees, and seminar participants at Lafayette College, AHRQ, ERS-USDA, GAO, the APPAM Fall Research Conference, and the AAEA Annual Meeting for helpful comments. The views expressed in this article are those of the authors and do not necessarily reflect those of the USDA.</p>"
    },
    "tags": {
      "iv": null
    },
    "accessInstructions": {
      "iv": "<p>Here's how to access:</p>\n<p>- open the internet</p>\n<p>- find the website</p>"
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": [
        "58d375d7-df18-4083-a421-3d1f9c55a537",
        "b8f0d946-bfef-4673-b1f6-be2e9a97b1b2",
        "0f3f3478-9af0-497f-a6e7-896bc801ff7b",
        "83c2befb-2c78-4994-aa4d-70fad211d7e7",
        "fcdfc4f5-5f6d-40d8-902e-5edb97f517ec"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": "RRID:SCR_007358"
    },
    "accession": {
      "iv": "CAB06652"
    },
    "labCatalogNumber": {
      "iv": "https://regexper.com/"
    },
    "doi": {
      "iv": "10.1371/journal.pgen.1001111"
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "Testing dates - Proposal - added date: NONE | published date: NONE | created date: 30 of April"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<p>Testing dates - Proposal - no dates!</p>"
    },
    "link": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-04-30T16:08:56Z"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:40Z"
    },
    "subtype": {
      "iv": "Proposal"
    }
  },
  {
    "title": {
      "iv": "Implications of Polyamine and Glucosylceramide Transport for Parkinsons Disease (IMPACT-PD)"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>Project Summary</h1>\n<p>Autophagiclysosomal dysfunction represents a critical defect in Parkinson&rsquo;s disease (PD)<sup>1</sup>. This project concerns two lysosomal Ptype transport ATPases that are genetically implicated in early onset PD, ATP13A2 (PARK9) and ATP10B (theme &lsquo;Biology of PDassociated Genes&rsquo;). We proved that PDassociated mutations in <em>ATP13A2 </em>and <em>ATP10B </em>disturb the lysosomal export of polyamines and glucosylceramide (GluCer), respectively, which may cause toxic lysosomal substrate accumulation and/or cytosolic substrate depletion<sup>2,3</sup>. While these novel findings indicate that disturbed cellular polyamine and GluCer distribution are implicated in PD, there is a major knowledge gap regarding the biology of polyamine and GluCer transporters, their crosstalk and their role in PD. Here, we will study at the molecular level the structure and autoregulation of related polyamine and GluCer transporters to identify strategies for transport modulation. In CRISPR/Cas9modified clonal cells and isogenic iPSCderived neurons and astrocytes, we will study the effect of these transporters on the polyamine and GluCer homeostasis, and on lysosomal and mitochondrial crosstalk. We will further validate polyamine and GluCer transporters as candidate therapeutic targets by studying their impact on PD pathways, such as mitophagy, and on <em>GBA1 </em>and &alpha; synuclein (&alpha;syn) pathology using patientderived iPSCs and murine PD models. In <em>GBA1 </em>carriers, we will search for genetic mutations in the transporter genes as modifiers of neurological symptoms, and analyze biosamples for altered polyamine and GluCer levels. Our project will provide new pathways and strategies to restore aberrant polyamine and GluCer distribution, as novel therapeutic approaches for PD.</p>\n<h1>Rationale and Hypothesis</h1>\n<p>The loss of dopaminergic neurons (DNs) in PD and &alpha;syn aggregation in Lewy bodies are the result of a complex interplay between genetic and environmental risk factors that lead to mitochondrial oxidative stress, lysosomal impairment and neuroinflammation. Strong genetic evidence points to a central role of the autophagiclysosomal system in PD<sup>1,4,5</sup>. We recently discovered the transport function of two lysosomal Ptype transport ATPases, ATP13A2<sup>3</sup> and ATP10B<sup>2</sup>, which are genetically implicated in PD<sup>2,6,7</sup>, providing fascinating new insights into the pathogenesis of PD that form the basis of this proposal.</p>\n<h2>ATP13A2</h2>\n<p>We reported that P5B ATPase ATP13A2 works as a lysosomal spermine/spermidine exporter, which is disturbed when ATP13A2 is mutated<sup>3</sup>. Spermine and spermidine are cellprotective polyamines serving as potent antioxidants, chemical chaperones and autophagy regulators<sup>8,9,10</sup>. Loss of ATP13A2 leads to lysosomal spermine accumulation, lysosomal rupture and cell death<sup>3</sup>. We found that ATP13A2 mediated spermine transport quenches superoxide (Fig. 1A)<sup>11</sup>, protects against mitochondrial complex I inhibitor rotenone<sup>12</sup>, a pesticide and environmental PD risk factor, and affects &alpha;syn aggregation (Fig. 1B).</p>\n<h2>ATP10B&nbsp;</h2>\n<p><strong> </strong>We described that the P4 ATPase ATP10B, in complex with the regulatory subunit CDC50A, functions as a lysosomal exporter of GluCer and phosphatidylcholine (PC), whereas PDassociated mutations impair these activities (supported by MJFF)<sup>2</sup>. ATP10B knockdown causes lysosomal dysfunction, and leads to lysosomal rupture in the presence of rotenone<sup>2</sup>. Lysosomal GluCer levels are also controlled by the lysosomal enzyme glucocerebrosidase 1 (GCase), encoded by <em>GBA1</em>, the most common genetic risk factor for PD<sup>13,14</sup>. Interestingly, ATP10B knockdown leads to lysosomal accumulation of fluorescent GluCer and results in increased expression of GCase in cells (Fig. 1CD), triggers neuronal cell death<sup>2</sup>, and in rat brain induces a motor phenotype (Fig. 1E). These insights regarding <em>ATP10B </em>and <em>GBA1 </em>show that lysosomal GluCer accumulation and/or impaired intracellular GluCer distribution play a central role in PD. While GluCer substrate reduction therapy via inhibition of GluCer synthase is explored for <em>GBA1</em> associated PD (trial NCT02906020), targeting GluCer transporters may represent an alternative approach. With CD3 (Centre for Drug Design and Discovery of KU Leuven), MJFF and a large pharmaceutical company, we initiated a drug discovery program to screen for ATP13A2 and ATP10B activators.</p>\n<h1>Hypothesis</h1>\n<p>While disturbed polyamine and GluCer distribution emerge as PD drivers<sup>2,3</sup>, our knowledge of polyamine and GluCer uptake and transport, as well as their neuroprotective role, cross talk and impact on PD pathways, remain incomplete and warrants further research. We hypothesize that loss of ATP13A2 or ATP10B exert synergistic effects causing lysosomal substrate accumulation and disruption of lysosomal membrane integrity, whereas reduced levels of cytosolic substrates may impair mitochondria and affect PD pathways. We also hypothesize that ATP10A and ATP10D, two plasma membrane isoforms contributing to cellular GluCer uptake<sup>15</sup>, play a role in PD or represent PD targets.</p>\n<p><u>Four</u> <strong><u>basic biology questions</u></strong><strong><u> </u></strong><u>will be addressed representing the</u> <strong><u>aims</u></strong><strong> </strong><u>of the project (Fig. 2  Workflow):</u></p>\n<p><strong><em>Q1. </em></strong><em>How is the ATP13A2 and ATP10B activity regulated at the molecular level and as a response to mitochondrial stress or PD gene mutations, and can we develop strategies for activity modulation?</em></p>\n<p><strong><em>Q2. </em></strong><em>How are polyamines and GluCer distributed within the cell, and will both substrates exert synergistic effects on lysosomal and mitochondrial functionality?</em></p>\n<p><strong><em>Q3. </em></strong><em>What is the role of ATP13A2 and ATP10B in PD related cell types (dopaminergic neurons, DNs; astrocytes with high transporter expression), and in PD pathways (mitophagy, GBA1 and &alpha;syn)?</em></p>\n<p><strong><em>Q4. </em></strong><em>Are other polyamine or GluCer transporters genetically or functionally implicated in PD, and are levels of both polyamines and GluCer disturbed in </em>GBA1 <em>patients and mouse models?</em></p>\n<h1>Research Tools, Models, and Resources</h1>\n<p>The aims will be addressed within a multidisciplinary team of experts in molecular cell biology and drug discovery of Ptype ATPases (P. Vangheluwe, PV), neurobiology and &alpha;syn pathophysiology (V. Baekelandt, VB), medical genetics and <em>GBA1 </em>pathophysiology (E. Sidransky, ES), stem cell biology and mitophagy (T. Ahfeldt, TA) and structural biology of Ptype ATPases (J. Lyons, JA). We will combine and exchange complementary model systems including purified protein, virally transduced stable gain and lossof function clonal cell lines <sup>2,3,12</sup>, CRISPR/Cas9 isogenic iPSCderived DNs and astrocytes<sup>16</sup>, knockout (KO) mouse models<sup>17</sup> and mouse PD models of <em>GBA1<sup>18,19</sup> </em>and &alpha;syn<sup>2022</sup> pathology, patientderived fibroblasts/iPSC DNs and biosamples from <em>GBA1 </em>mutation carriers<sup>23</sup> (Table 1). All cell systems express the transporter isoforms, except for SHSY5Y that doesn&rsquo;t express ATP10B. We will rely on engineered reporter iPSC lines to identify, track and isolate cell types (Tyrosine hydroxylase (TH), DNs; ALDH1L, astrocytes), and transduce cells with reporter constructs to quantify cell/organelle function&nbsp; (mitochondrial homeostasis, TOMM20Emerald/mitoTimer; mitophagy, mitoKeima; lysosomes, LAMP2AEmerald), and oxidative stress based on cytosolic or mitochondrial targeted sensors (Grx1 roGFP2 or HyPer3)<sup>16</sup>. An inducible <em>Atp13a2 </em>KO model is available<sup>17</sup>, and a similar <em>Atp10b </em>KO model will be generated. Models and tools will be made available for the research community</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/fe4c7f3e-4e3e-49fa-8986-61e929613066/table1.jpg\" alt=\"Table1\" /></p>\n<h1>Study Plan</h1>\n<h2>Basic Biology  Structure, regulation and cellular role of polyamine and GluCer transporters Outcome and impact</h2>\n<p>We will obtain detailed insights into the subcellular polyamine and GluCer transport routes and their role in organelle homeostasis and crosstalk, which remain unstudied. Understanding the regulation mechanism may offer strategies to modulate the transport activity in cells and for PD therapy.</p>\n<h3>WP1. Structure and biochemical analysis of polyamine and GluCer transporters (JL/PV)</h3>\n<p>To answer <strong>Q1</strong>, we will elucidate mechanisms of substrate binding, transporter function and regulation using biochemical analysis and structural approaches in the following tasks (<strong>T</strong>) and milestones (<strong>M</strong>).</p>\n<h4><strong>T1. Purify and biochemically analyze transporters &ndash; M1 (JL)</strong></h4>\n<p><strong> </strong>Transporters will be overexpressed in yeast (ATP13A2) or HEK293 cells (ATP10A,B,D/CDC50A)<sup>3,24</sup>. Proteins will be purified via biotin acceptor domain (ATP13A2)<sup>3</sup> or tandem TwinStrep and His (ATP10A,B,D) affinity tags. Expression and purification will be guided with GFP fusion constructs (Fig. 1F)<sup>25</sup>. <strong>M2 (JL/PV). </strong>Biochemical analysis of solubilized protein (ADP Glo luciferasebased ATPase assay) or reconstituted in proteoliposomes (translocation assay with radio/fluorescentlylabelled polyamines/lipids) will reveal substrate specificity and binding affinities<sup>2,3,26</sup>.</p>\n<p><strong>T2. Reveal the transporter structure via cryoelectron microscopy (cryoEM)  M3 (JL) </strong>With cryoEM, we will solve structures of purified transporters trapped in various conformations with state selective inhibitors<sup>24,27</sup> (collaborator for ATP13A2: Dr. P. Nissen<sup>28</sup>). To study the role of regulatory lipids we will perform structural studies using membrane mimetics (SMALPs, salipro, nanodiscs)<sup>26</sup>. Structural insights will be functionally validated by mutagenesis (<strong>T4</strong>)<sup>24</sup>. <strong>M4 (JL). </strong>Structures of complexes with regulatory partners (WP2) will be solved. Purification and solving structures is of high risk/high award, but experience on related targets is available<sup>3,</sup> <sup>24,28</sup>. <u>Mitigation strategy:</u> Explore transporter orthologues.</p>\n<h3>WP2. Regulation of polyamine and GluCer transporters (PV/VB/ES/TA/JL)</h3>\n<p>N or Cterminal stretches exert Ptype transport ATPase autoinhibition, which is relieved by protein, substrate or lipid interactions and/or posttranslational modifications (PTMs)<sup>12,24,29,30</sup>. To further address <strong>Q1</strong>, we aim to reveal mechanisms of ATP13A2 and ATP10B regulation, and later of ATP10A and ATP10D.</p>\n<p><strong>T3. Determine modalities of transporter activation &ndash; M5 (PV). </strong>Interacting regulatory lipids will be identified via protein/lipid overlays as before<sup>12</sup>. <strong>M6 (PV/TA). </strong>The ATP13A2 and ATP10B transport activity provides cell protection against rotenone<sup>11,12</sup>, which represents a &lsquo;<em>transport activating condition</em>&rsquo;. We will compare the network of rotenone responsive genes in SHSY5Y or H4 cells by quantitative transcriptomics and proteomics<sup>31</sup>. <strong>M7 (PV). </strong>We will compare the transporter interactome and PTMs (phosphorylation, ubiquitination, Fig. 1G) responding to rotenone after GFPpulldown in KO cells expressing a GFPlabeled transporter. Following bioinformatics analysis, genes/proteins/pathways identified by&nbsp; multiomics&nbsp; will be further validated by knockdown in T4 and WP3. Successful strategies will be repeated in selected iPSC derived models (WP4, <strong>TA</strong>). <strong>M8 (PV). </strong><u>Mitigation strategy:</u> Identify proteins proximal to the transporters by ascorbate peroxidase (APEX2) proximity labeling (Fig. 1H) and pulldown, followed by proteomics<sup>32</sup>.</p>\n<p><strong>T4. Elucidate the molecular mechanism of transporter activation &ndash; M9 (PV/JL). </strong>Guided by structural insights (WP1T2)<sup>24</sup> and identified PTM regions (WP2T3) we will validate proposed mechanisms of regulatory control and design constitutive active/inactive transporter variants via mutagenesis and limited proteolysis/truncation<sup>24</sup>. Mutants will be biochemically analyzed (Fig. 1GH)<sup>2,3</sup>. <u>Mitigation strategy:</u> <strong>M10 (PV). </strong>Test functional effects of short peptides corresponding to regulatory regions that compete with or mimic N/Cterminal autoinhibition (Fig. 1I). <strong>M11 (PV/VB/ES/TA). </strong>(In)active transport variants and functional peptides (T4) will be expressed, regulators (T3) knocked down and regulatory lipids (T3) pharmacologically suppressed<sup>12</sup> to modulate transport phenotypes in our cell models in WP35.</p>\n<h3>WP3. Cellular role of Polyamine and GluCer transporters (PV/ES/TA)</h3>\n<p>Defective crosstalk between lysosomes and mitochondria plays a central role in PD<sup>33</sup>, and ATP13A2 and ATP10B transport activity affects both organelles<sup>2,3,12,34,35</sup>. To answer <strong>Q2</strong>, we will follow polyamine/GluCer homeostasis and lysosomal/mitochondrial functionality in SHSY5Y and H4 cells with modulated transporter expression. Key phenotypes will be confirmed in iPS cell models (WP45, <strong>ES/TA</strong>).</p>\n<p><strong>T5. Analyze cellular polyamine/GluCer distribution and homeostasis &ndash; M12 (PV/TA). </strong>We will examine cellular uptake (flow cytometry), lysosomal accumulation and cellular distribution (confocal imaging) of fluorescently labeled polyamines<sup>3</sup> and GluCer (Fig. 1D). <strong>M13 (PV/TA). </strong>Via metabolomics<sup>3</sup> and lipidomics<sup>23,31</sup> of cell lysates, we will follow endogenous polyamine/GluCer levels and distribution, but also interconversion, since polyamine metabolites reflect oxidative stress<sup>8,36</sup> and GluCer is a building block for glycosphingolipids (Fig. 1J). <strong>M14 (PV/TA). </strong>We will study interplay between transporters and metabolism (polyamine/GluCer metabolism gene expression and sensitivity to inhibitors<sup>9,37</sup>). <u>Mitigation strategy:</u> Follow polyamines/GluCer in lysosome/mitochondria fractions if no changes in cell lysates are detected. <strong>T6. Examine lysosomal and mitochondrial functionality and crosstalk  M15 (PV/TA). </strong>We will determine the impact of modified polyamine and GluCer transporter activity on lysosomal functionality, membrane integrity and lysosomal dependent cell death<sup>2,3</sup>. <strong>M16 (PV/TA). </strong>We will follow mitochondrial health (ATP levels, mitochondrial membrane potential, mitochondrial network)<sup>11</sup>. ATP13A2 transport exerts a potent antioxidant response (Fig. 1A)<sup>11</sup>, but also promotes mitochondrial/lysosomal colocalization (Fig. 1K) and regulates autophagy/mitophagy<sup>34,38</sup>. Here, we will examine superoxide levels<sup>11</sup> and mitophagy using reporter constructs (Resources) and investigate the impact on mitochondrial/lysosomal contact sites (STED super resolution microscopy)<sup>39</sup>. <u>Mitigation strategy:</u> Study mitochondrial/lysosomal contacts via electron microscopy based proximity ligation in APEX2 models of M8<sup>40,41</sup>.</p>\n<h2>PD Impact  Role of polyamine and GluCer transporters in PD</h2>\n<h3>Outcome and impact</h3>\n<p>To address <strong>Q3 </strong>and <strong>Q4</strong>, we will study whether a disturbed polyamine and GluCer distribution affects major PD pathways using PDrelevant cell types, PD animal models and patients. This will offer novel insights in the PD mechanism and allow validation of new therapeutic targets/strategies.</p>\n<h3>WP4. Developing PDrelevant models with modified polyamine/GluCer transport activity (TA/VB/PV/ES)</h3>\n<p>We will develop PDrelevant cell models (human iPSC derived and primary cell models) and mouse KO models with modified polyamine and GluCer transporter expression.</p>\n<p><strong>T7. Develop and characterize models for the study of polyamine/GluCer transport deficiency  M17 (TA). </strong>We generated human iPSCs for DJ1, Parkin and ATP13A2<sup>16</sup>, and here we develop isogenic knockouts for other transporter genes (ATP10A,B,D) via CRISPR/Cas9 editing in three established reporter cell lines WAO1ESCs (male) BJSIPS (male), BMIPS (female)<sup>16</sup>. For three independent clones (targeted and&nbsp; control), we will derive DNs and astrocytes, to be studied independently and in mixed genetic coculture models to investigate DN vulnerability. To quantify phenotypes, we will employ automated highcontent confocal imaging (ThermoFisher CX7)<sup>16</sup> (Fig. 1LN). <strong>M18 (TA/PV). </strong>We will study viability, lysosomal/mitochondrial functionality (WP3), polyamine/GluCer levels, uptake and homeostasis (WP3), perform transcriptomics/proteomics on selected models (WP2)<sup>42</sup> and follow neurite outgrowth to identify DN deficits. <strong>M19 (PV/VB/ES). </strong>We will develop a conditional <em>Atp10b </em>KO mouse model (same strategy as&nbsp; for <em>Atp13a2<sup>17</sup></em>), and analyze motor deficits, dopaminergic cell loss and polyamine/sphingolipid&nbsp; levels<sup>43,44</sup>&nbsp; in blood and cerebrospinal fluid in fullbody <em>Atp13a2 </em>and <em>Atp10b </em>KO mice. To evoke phenotypes, we will challenge mice with/without spermidine (3 mM, drinking water<sup>45,46</sup>) or the GCase inhibitor conduritol B epoxide (CBE, 100 mg/kg, ip, 3x/week<sup>46</sup>), respectively, to induce lysosomal stress. <u>Mitigation strategy</u>:&nbsp; <strong>M20 (VB). </strong>In case iPSC models fail or to assess gainoffunction, we will turn to primary mouse cortical neurons and astrocytes for lentiviral knockdown or overexpression of the transporter genes, as before<sup>2,3</sup>.</p>\n<h3>WP5. Defining polyamine/GluCer transporter impact on PD pathways and mouse models (TA/VB/ES/PV)</h3>\n<p>Here, we will explore whether transporter or substrate modulation affects mitophagy, <em>GBA1 </em>and &alpha;syn. <strong>T8. Examine the role of polyamine and GluCer transporters on mitophagy pathways  </strong>Loss of <em>ATP13A2 </em>or <em>ATP10A,B,D </em>genes may decrease lysosomal functionality, affect auto/mitophagy and alter the cellular capacity to respond to oxidative stress<sup>2,3,11,34,38</sup>. <strong>M21 (TA/PV/VB). </strong>In iPS derived cell types/cocultures, we will lentivirally transduce reporter constructs (Resources) to follow autophagic flux, mitophagy, mitochondrial function, and oxidative stress. Parkin and DJ1 cell models<sup>16</sup> will be examined for changes&nbsp;&nbsp; in polyamine/GluCer levels and distribution, and expression of transporter/metabolism genes (WP3).</p>\n<p><strong>T9. Investigate the role of polyamine and GluCer transporters in &alpha;syn pathology  </strong>Polyamine/GluCer transporters may impact on &alpha;syn pathology (Fig. 1B). <strong>M22 (VB). </strong>We will analyze &alpha;syn levels, toxicity and aggregation following seeding with &alpha;syn preformed fibrils (PFFs) in clonal cell models of polyamine/GluCer transporters<sup>22</sup>. <strong>M23 (VB/TA). </strong>We will examine the effect of lentiviral knockdown/overexpression of transporters in primary neurons and astrocytes with &alpha;syn overexpression or PFFs. We will assess polyamine/GluCer levels, &alpha;syn aggregation and autophagiclysosomal markers. <strong>M24 (VB/PV). </strong>We will use AAV vectors to overexpress &alpha;syn in the brain of <em>Atp13a2 </em>and <em>Atp10b </em>KO mice (Fig. 1R), and to knockdown Atp13a2 and Atp10b in a combined AAV&alpha;syn PFF model of &alpha;syn pathology<sup>20,21</sup>. Readouts will include motor deficits (cylinder test), DA loss and &alpha;syn oligomerisation/aggregation (TH and pS129 &alpha;syn immunostaining; <em>in situ </em>proximity ligation assay)<sup>21,47,48</sup>.</p>\n<p><strong>T10. Study the impact of polyamine and GluCer transporters on <em>GBA1 </em>pathology  </strong>We hypothesize that both polyamine and GluCer transporters may impact <em>GBA1 </em>pathology. <strong>M25 (ES/PV/TA). </strong>We will study <em>GBA1 </em>expression, GCase activity and sensitivity to CBE in clonal cells and iPS derived DAs/astrocytes with modulated polyamine/GluCer transporter expression. <strong>M26 (ES/TA). </strong>We will introduce via CRISPR/Cas9 loss of function mutations in transporter genes into iPSCs from patients carrying homozygous <em>GBA1 </em>mutations with and without PD<sup>23</sup> (Fig. 1OQ). After differentiation to DNs and astrocytes, we will evaluate GCase expression and activity, polyamine/GluCer levels, &alpha;syn accumulation and autophagiclysosomal markers. <strong>M27 (ES/VB). </strong><em>In vivo</em>, we will use AAV technology to knockdown the transporters in a mouse model of PD carrying a null <em>Gba1 </em>allele with &alpha;syn overexpression (TJaSYN/WT//<em>Gba1<sup>+/</sup></em>)<sup>18</sup>. <strong>M28 (ES/PV/VB). </strong>We will cross <em>Atp10b </em>KO mice with TJaSYN/WT//<em>Gba1<sup>+/</sup></em>, evaluate motor symptoms, analyze different forms of &alpha;syn, inflammatory markers and DN markers, and evaluate GCase activity and polyamine/sphingolipid levels in brain tissue. <u>Mitigation strategy:</u> If no&nbsp; clear phenotypes are found, we will treat mice with CBE, or cross <em>Atp10b </em>KO with homozygous <em>Gba1</em><em>L444P </em>mice (<em>Gba1<sup>L444P/L444P</sup></em>)<sup>19</sup>.</p>\n<h3>WP6. Role of polyamine/GluCer transporters in PD patients (ES/PV)</h3>\n<p><strong>T11. Analyzing polyamine/GluCer transport in PD patients &ndash; </strong>A minority of <em>GBA1 </em>mutation carriers develop PD<sup>14</sup>, whereas more than 99% of PD cases are polygenic or complex. <strong>M29 (ES/PV). </strong>Via whole genome sequencing, we will identify PDmodifying variants in polyamine/GluCer metabolism/transporter genes in 50 <em>GBA1 </em>mutation carriers with and 70 without PD, which will be confirmed by Sanger sequencing and evaluated using a Genetic Burden test. Transporter mutations will be biochemically evaluated in WP1/2. <strong>M30 (ES). </strong>Changes in polyamine<sup>44</sup> and sphingolipid levels<sup>43</sup> were reported in PD, and will be analyzed in fibroblasts and autopsy samples from <em>GBA1</em>mutation carriers with/without PD.</p>\n<h1>Power Calculations and Statistical Analyses Plan</h1>\n<p>Biochemical and cellular experiments will be independently repeated at least 3 times. Data will be presented as average &plusmn; SEM, and statistical analysis will be performed using GraphPad Prism (One/Two Way Analysis of Variance, Bonferroni/Tuckey posthoc tests). For testing pathological markers including &alpha;syn and GCase in mice, we will use 10 sample replicates for each group (+ 2 spare/group) (T811). It allows 89% statistical power for two independent group ttests assuming a 20% difference in protein and 20% SD with 0.05&alpha; (<a href=\"http://www.stat.ubc.ca/~rollin/stats/ssize/n1.html)\">https://www.stat.ubc.ca</a><u>/~r</u><a href=\"http://www.stat.ubc.ca/~rollin/stats/ssize/n1.html)\">ollin/st</a><u>ats</u><a href=\"http://www.stat.ubc.ca/~rollin/stats/ssize/n1.html)\">/ssize/n</a><u>1.</u><a href=\"http://www.stat.ubc.ca/~rollin/stats/ssize/n1.html)\">html).</a> For screening&nbsp; genetic&nbsp; mutations with a genebased burden test (T11), 50 PD cases and 70 controls allows 88% statistical power (<u>https://andrewhaoyu.shinyapps.io/PAGEANT/</u>), assuming 50% phenotypic explanation by causal variants and 20% proportion of causal variants among total variants in a gene with 0.05&alpha;.</p>\n<h1>Project Timeline and Milestones</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/769c68bc-d299-4a4d-81d2-66d18d8024ef/timeline.jpg\" alt=\"timeline\" /></p>\n<h1>Workflow Schematic</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/cb43d046-edee-4234-bbd0-4e5285b232c9/workflow.jpg\" alt=\"workflow\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Klein, D. &amp; Mazzulli, J. R. Is Parkinson's disease a lysosomal disorder? <em>Brain </em><strong>141</strong>, 22552262 (2018).</li>\n<li>Martin, S. <em>et al. </em>Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. <em>Acta Neuropathol </em>(2020).</li>\n<li>van Veen, S. <em>et al. </em>ATP13A2 deficiency disrupts lysosomal polyamine export. <em>Nature </em>578, 419424, (2020).</li>\n<li>Chang, D. <em>et al. </em>A metaanalysis of genomewide association studies identifies 17 new Parkinson's disease risk loci. <em>Nat Genet </em><strong>49</strong>, 15111516 (2017).</li>\n<li>Nalls, M. A. <em>et al. </em>Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a metaanalysis of genomewide association studies. <em>Lancet Neurol </em><strong>18</strong>, 10911102, (2019).</li>\n<li>Ramirez, A. <em>et al. </em>Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 Ptype ATPase. <em>Nat Genet </em><strong>38</strong>, 11841191 (2006).</li>\n<li>Di Fonzo, A. <em>et al. </em>ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. <em>Neurology </em><strong>68</strong>, 15571562 (2007).</li>\n<li>Ha, H. C. <em>et al. </em>The natural polyamine spermine functions directly as a free radical scavenger. <em>Proc Natl Acad Sci U S A </em><strong>95</strong>, 1114011145 (1998).</li>\n<li>Pegg, A. E. Functions of Polyamines in Mammals. <em>J Biol Chem </em><strong>291</strong>, 1490414912 (2016).</li>\n<li>Madeo, F., Bauer, M. A., CarmonaGutierrez, D. &amp; Kroemer, G. Spermidine: a physiological autophagy inducer acting as an antiaging vitamin in humans? <em>Autophagy </em><strong>15</strong>, 165168, (2019).</li>\n<li>Vrijsen, S. <em>et al. </em>ATP13A2mediated endolysosomal polyamine export provides a mitochondrial antioxidant response. (In Revision PNAS, in appendix).</li>\n<li>Holemans, T. <em>et al. </em>A lipid switch unlocks Parkinson's diseaseassociated ATP13A2. <em>Proc Natl Acad Sci U S A </em><strong>112</strong>, 90409045 (2015).</li>\n<li>Aflaki, E., Westbroek, W. &amp; Sidransky, E. The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease. <em>Neuron </em><strong>93</strong>, 737746 (2017).</li>\n<li>Sidransky, E. <em>et al. </em>Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. <em>N Engl J Med </em><strong>361</strong>, 16511661 (2009).</li>\n<li>Roland, B. P. <em>et al. </em>Yeast and human P4ATPases transport glycosphingolipids using conserved structural motifs. <em>J Biol Chem </em><strong>294</strong>, 17941806 (2019).</li>\n<li>Ahfeldt, T. <em>et al. </em>Pathogenic Pathways in EarlyOnset Autosomal Recessive Parkinson's Disease Discovered Using Isogenic Human Dopaminergic Neurons. <em>Stem Cell Reports </em><strong>14</strong>, 7590 (2020).</li>\n<li>Kett, L. R. <em>et al. </em>alphaSynucleinindependent histopathological and motor deficits in mice lacking the endolysosomal Parkinsonism protein Atp13a2. <em>J Neurosci </em><strong>35</strong>, 57245742 (2015).</li>\n<li>Tayebi, N. <em>et al. </em>Glucocerebrosidase haploinsufficiency in A53T alphasynuclein mice impacts disease onset and course. <em>Mol Genet Metab </em><strong>122</strong>, 198208 (2017).</li>\n<li>Ginns, E. I. <em>et al. </em>Neuroinflammation and alphasynuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. <em>Mol Genet Metab </em><strong>111</strong>, 152162 (2014).</li>\n<li>Thakur, P. <em>et al. </em>Modeling Parkinson's disease pathology by combination of fibril seeds and alpha synuclein overexpression in the rat brain. <em>Proc Natl Acad Sci U S A </em><strong>114</strong>, E8284E8293, (2017).</li>\n<li>Peelaerts, W. <em>et al. </em>alphaSynuclein strains cause distinct synucleinopathies after local and systemic administration. <em>Nature </em><strong>522</strong>, 340344 (2015).</li>\n<li>Van der Perren, A. <em>et al. </em>The structural differences between patientderived &alpha;synuclein strains dictate characteristics of Parkinson&rsquo;s disease, multiple system atrophy and dementia with Lewy bodies. <em>Acta Neuropathol </em>in press (2020).</li>\n<li>Aflaki, E. <em>et al. </em>A New Glucocerebrosidase Chaperone Reduces alphaSynuclein and Glycolipid Levels in iPSCDerived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. <em>J Neurosci </em><strong>36</strong>, 74417452 (2016).</li>\n<li>Timcenko, M. <em>et al. </em>Structure and autoregulation of a P4ATPase lipid flippase. <em>Nature </em><strong>571</strong>, 366370 (2019).</li>\n<li>Lyons, J. A., Shahsavar, A., Paulsen, P. A., Pedersen, B. P. &amp; Nissen, P. Expression strategies for structural studies of eukaryotic membrane proteins. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Curr Opin Struct Biol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">38</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 137144 (2016).</span></li>\n<li>Lyons, J. A., Boggild, A., Nissen, P. &amp; Frauenfeld, J. SaposinLipoprotein Scaffolds for Structure Determination of Membrane Transporters. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Methods Enzymol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">594</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 8599 (2017).</span></li>\n<li>Hiraizumi, M., Yamashita, K., Nishizawa, T. &amp; Nureki, O. CryoEM structures capture the transport cycle of the P4ATPase flippase. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Science </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">365</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 11491155 (2019).</span></li>\n<li>Sitsel, A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Structures of the heart specific SERCA2a Ca(2+)ATPase. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">EMBO J </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">38 </strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019).</span></li>\n<li>Chen, J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">An Nterminal Ca(2+)binding motif regulates the secretory pathway Ca(2+)/Mn(2+) transport ATPase SPCA1. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Biol Chem </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">294</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 78787891 (2019).</span></li>\n<li>Sorensen, D. M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Parkinson disease related ATP13A2 evolved early in animal evolution. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">PLoS One </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">13</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, e0193228 (2018).</span></li>\n<li>Tharkeshwar, A. K. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A novel approach to analyze lysosomal dysfunctions through subcellular proteomics and lipidomics: the case of NPC1 deficiency. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Sci Rep </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">7</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 41408 (2017).</span></li>\n<li>Hung, V. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Spatially resolved proteomic mapping in living cells with the engineered peroxidase </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Protoc </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">11</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 456475 (2016).</span></li>\n<li>Plotegher, &amp; Duchen, M. R. Crosstalk between Lysosomes and Mitochondria in Parkinson's Disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Front Cell Dev Biol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">5</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 110 (2017).</span></li>\n<li>Gusdon, M., Zhu, J., Van Houten, B. &amp; Chu, C. T. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiol Dis </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">45</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 962972 (2012).</span></li>\n<li>Grunewald, A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with KuforRakeb syndrome. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiol Aging </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">33</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1843 e18411847 (2012).</span></li>\n<li>Li, C. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Spermine synthase deficiency causes lysosomal dysfunction and oxidative stress in models of SnyderRobinson syndrome. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Commun </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">8</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1257 (2017).</span></li>\n<li>Plotegher, N., Bubacco, L., Greggio, E. &amp; Civiero, L. Ceramides in Parkinson's Disease: From Recent Evidence to New Hypotheses. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Front Neurosci </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">13</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 330 (2019).</span></li>\n<li>Demirsoy, S. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">ATP13A2/PARK9 regulates endo/lysosomal cargo sorting and proteostasis through a novel PI(3, 5)P2mediated scaffolding function. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Hum Mol Genet </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">26</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 16561669 (2017).</span></li>\n<li>Wong, Y. C., Ysselstein, D. &amp; Krainc, D. Mitochondrialysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">554</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 382386 (2018).</span></li>\n<li>Lam, S. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Directed evolution of APEX2 for electron microscopy and proximity labeling. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Methods </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">12</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 5154 (2015).</span></li>\n<li>Cho, I. T. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Ascorbate peroxidase proximity labeling coupled with biochemical fractionation identifies promoters of endoplasmic reticulummitochondrial contacts. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Biol Chem </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">292</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1638216392, (2017).</span></li>\n<li>Ordureau, A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Dynamics of PARKINDependent Mitochondrial Ubiquitylation in Induced Neurons and Model Systems Revealed by Digital Snapshot Proteomics. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Mol Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">70</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 211227 e218, (2018).</span></li>\n<li>Mielke, M. M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">PLoS One </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">8</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, e73094, (2013).</span></li>\n<li>Saiki, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A metabolic profile of polyamines in parkinson disease: A promising biomarker. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Ann Neurol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">86</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 251263 (2019).</span></li>\n<li>Eisenberg, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cardioprotection and lifespan extension by the natural polyamine spermidine. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Med </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">22 </strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2016).</span></li>\n<li>Rockenstein, E. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Hum Mol Genet </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">25</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 26452660, doi:10.1093/hmg/ddw124 (2016).</span></li>\n<li>Roberts, R. F., BengoaVergniory, N. &amp; AlegreAbarrategui, J. AlphaSynuclein Proximity Ligation Assay (AS PLA) in Brain Sections to Probe for AlphaSynuclein <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Methods Mol Biol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">1948</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 6976 (2019).</span></li>\n<li>Faustini, G. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Synapsin III deficiency hampers alphasynuclein aggregation, striatal synaptic damage and nigral cell loss in an AAVbased mouse model of PD. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Acta Neuropathol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">136</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 621639 (2018).</span></li>\n</ol>\n<p>&nbsp;</p>\n<p>&nbsp;</p>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:39Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:40Z"
    }
  },
  {
    "title": {
      "iv": "Mechanisms of Mitochondrial Damage Control by PINK1 and Parkin"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>PROJECT SUMMARY</h1>\n<p>The integrity of mitochondria is central to the health of neurons<sup>1</sup>. The protein kinase PINK1 and the E3 ubiquitin ligase Parkin are mutated in autosomal recessive PD<sup>2,</sup> <sup>3</sup>, and maintain mitochondrial health by initiating degradation of damaged mitochondria<sup>4</sup>. Some 25% of mitochondria are turned over by Parkin- dependent mitophagy at rest<sup>5</sup>. Mitophagy increases under stresses such as oxidative damage<sup>6</sup>. Failure to clear damaged mitochondria harms the mitochondrial network within neurons<sup>6</sup>, and may initiate systemic inflammation through the release of mitochondrial DNA<sup>7</sup>. This project will reveal in mechanistic detail how mitophagy is executed in neurons at the molecular, organellar, and cellular levels. Mitophagy will be reconstituted from start to finish in vitro, and imaged in neurons.&nbsp; The outcome will be a comprehensive picture of how the mitophagy machinery maintains neuronal health and how deficits in mitophagy may underlie degeneration in PD. This information will guide the future development of mitophagy modulators as PD therapeutics using predictive models and tools.</p>\n<h1>RATIONALE AND PRELIMINARY DATA</h1>\n<h2>Rationale</h2>\n<p>Most factors involved in PINK1/Parkin mitophagy are known (Fig. 1). The great task now is to understand how these factors work with each other, membranes, and the rest of the cell's machinery to execute mitophagy. There is no existing project in the mitophagy field that comes close to the breadth, depth, or degree of integration that is proposed here. Our project will accelerate progress in this area by an order of magnitude compared to waiting for existing piecemeal efforts in individual labs to converge.</p>\n<h2>Preliminary data</h2>\n<p>We already have a great deal of momentum from our existing HFSP-funded collaboration. We have purified the proteins and complexes of Parkin/PINK1-dependent mitophagy in humans (Fig. 2). Lipid conjugation of the ubiquitin-like Atg8 family proteins is a proxy for autophagy. In the presence of polyubiquitin generated by Parkin, the adaptor NDP52 and the ULK1, PI3KC3-C1, and ATG16L1 autophagic complexes conjugate Atg8 family proteins (LC3s and GABARAPs) to synthetic membranes representing the nascent autophagosome, known as the phagophore (Fig. 2). We have reconstituted the seeds of autophagosome biogenesis, ATG9A vesicles (Fig. 3), and purified the human TOM complex (Fig. 4) whose functional state is detected by PINK1. These in vitro studies can be readily compared to live cell imaging of the recruitment of Parkin, mitochondrial ubiquitination, recruitment of the mitophagy adaptors OPTN and NDP52, and generation of an Atg8-positive autophagosome on damaged mitochondria in primary hippocampal neurons (Fig. 5B) or iPSC-derived neurons.</p>\n<h1>RESEARCH TOOLS, MODELS AND RESOURCES</h1>\n<p>We have a collection of nearly all of the purified proteins and complexes required to reconstitute each step in PINK1/Parkin dependent mitophagy. We have a collection of validated probes for imaging the dynamics of every step in PINK1/Parkin dependent mitophagy in cellular assays in HeLa cells, primary hippocampal neurons, and iPSC-derived human neurons, wild type or expressing PD-associated mutations. We have a set of mutant protein complexes which are defective in single interactions with each other, ubiquitin, or membranes, representing about half of those needed. Additional mutant complexes will be made. Cell lines will be generated that have been gene-edited to express labeled components of the mitophagy pathway under their endogenous promoters, therefore a major effort will be invested in genome edited cell line and iPSC cell construction. These protein reagents and cell lines will be critically important tools that will be made available to the community.</p>\n<h1>STUDY PLAN</h1>\n<p>We will employ the most powerful molecular and cellular tools available to study mechanisms of mitophagy in neurons: cryo-EM, <em>in vitro </em>giant unilamellar vesicle (GUV) and proteoliposomes reconstitution, and advanced live cell imaging of primary and genome-engineered iPSC-derived neurons. Continuous feedback between structural biology, in vitro reconstitutions, cellular genome engineering and cell imaging will inform cycles of experimental design and interpretation and radically accelerate progress. We will systematically study <em>all </em>of the major identified factors in PINK1/Parkin mitophagy.</p>\n<h2>Aim 1. Recognition of mitochondrial damage</h2>\n<p><strong>Rationale.&nbsp;</strong>The first decisive step of damage-induced mitophagy is the detection of damaged mitochondria by PINK1. PINK1 accumulates on damaged mitochondria to phosphorylate ubiquitin, which recruits the E3 ligase Parkin to ubiquitinate mitochondrial outer membrane proteins <sup>8-11</sup>. In healthy mitochondria, PINK1 is cleaved and degraded after sequential interactions with the mitochondrial protein translocases TOM and TIM23 complexes. In damaged mitochondria, PINK1 accumulates on the outer membrane by stably associating with TOM because it fails to engage with TIM23 in the inner membrane <sup>12</sup>. This aim will explain how PINK1 associates with TOM, how PINK1 becomes activated on TOM, what triggers the cascade of phosphorylation and polyubiquitination.</p>\n<p><strong>In vitro reconstitution of damage detection in a fully purified system.&nbsp;</strong>We will generate mitochondria-like liposomes, then reconstitute purified TOM complexes and mitochondrial outer membrane proteins that serve as ubiquitination substrates, such as VDAC and Tom70, into proteoliposomes. Currently, it is unknown whether PINK1 peripherally associates with TOM or is partially translocated through the pores of TOM in damaged mitochondria. If necessary, we will incorporate a purified IMS chaperone or a soluble receptor domain for mitochondrial-targeting sequences into the lumen of vesicles to provide a driving force for translocation. PINK1 will be expressed and purified as an MBP fusion protein to prevent it from prematurely engaging with mitochondria. PINK1 recruitment onto TOM-proteoliposomes and its autophosphorylation will be triggered by cleavage of MBP from the N-terminus of PINK1. Parkin will then be added and ubiquitination of Mfn2, CISD1 and VDAC1 <sup>13</sup> detected.</p>\n<p><strong>Structural basis for damage detection by PINK1.&nbsp;</strong>All subunits of the human TOM complex and PINK1 will be overexpressed in insect cells. We will treat cells with CCCP to induce PINK1 engagement with TOM. The assembled complex will be isolated by affinity purification and analyzed by cryo-EM.</p>\n<p><strong>Live cell imaging.&nbsp;</strong>Mitophagy will be imaged live in neurons treated with oxidative stress to induce mitochondrial damage<sup>6,</sup> <sup>14,</sup> <sup>15</sup> and obtain robust quantitative data on the kinetics of PINK1 accumulation, Parkin recruitment, and ubiquitination at the OMM. We will use gene-edited iPSC-derived neurons<sup>15,</sup> <sup>16</sup> stably expressing Halo-tagged PINK1, YFP-Parkin, and/or Halo-OPTN from endogenous promoters. Controls will include expression of catalytically inactive PINK1<sup>K291A/D362A</sup> and Parkin<sup>T240R</sup>. Molecular copy number standards<sup>17</sup> will be used to enable counting of PINK1, Parkin, and OPTN molecules at sites of mitophagy. Direct comparisons of reaction kinetics such as ubiquitination rates from in vitro and cellular experiments will provide quality assurance that our reconstitution experiments are physiologically relevant and to inform integrative modeling as described below.</p>\n<h2>Aim 2. Initiation of mitophagy</h2>\n<p><strong>Rationale.&nbsp;</strong>Ubiquitin chains presented on the surface of damaged mitochondria are recognized by the adaptors NDP52 and OPTN <sup>15</sup>. These adaptors link to the core autophagy machinery. Along with the protein kinase TBK1, adaptors recruit and activate the ULK1 complex <sup>18</sup>. NDP52 binds the FIP200 subunit of the ULK1 complex <sup>18,</sup> <sup>19</sup>, which is sufficient to trigger mitophagy. The NDP52-FIP200 interaction has been mapped, but those of OPTN and TBK1 with the autophagy machinery have not. This is a critical point to address as mutations in both OPTN and TBK1 are sufficient to induce neurodegeneration. Nor is it understood how the other initiating components of autophagy, ATG9A and PI3KC3-C1, are brought into play. It is not known what density of ubiquitin modification on mitochondria is needed to trigger this process, and whether there is a critical threshold level that must be reached as a mechanism to avoid the mitophagy of healthy mitochondria. Any potential therapeutics aimed at restoring or upregulating mitophagy will need to be founded on a quantitative understanding of these parameters, which this aim will yield.</p>\n<p>Atg8 lipidation by ATG16L1 is triggered when WIPI2 binds to the membrane lipid PI(3)P generated by PI3KC3-C1<sup>20</sup> and secondarily by ATG16L1 binding to FIP200. Atg8 proteins binds to LIR (LC3 interacting region) motifs, which are present in autophagy adaptors and core complexes<sup>21,</sup> <sup>22</sup>. The activity of the adaptors and core complexes is reorganized following Atg8 lipidation so as to accelerate mitophagy. Here, we will elucidate how the rate of Atg8 lipidation is governed, and how Atg8 lipidation reciprocally governs the function of core complexes and adaptors in mitophagy.</p>\n<p><strong>Reconstitution of core complex recruitment.&nbsp;</strong>Aim 2 will commence independently of aim 1 by employing beads coated with linear ubiquitin chains as a simple model for ubiquitinated mitochondria. These beads will be added to GUVs composed of a phagophore-based lipid mixture. We have already reconstituted the recruitment of FIP200 to GUV membranes by NDP52 in the presence of linear Ub<sub>4</sub> chains dimerized via GST-fusion (Fig. 3). Moving forward, Ub<sub>4</sub> &ndash;derivatized 1 &mu;m polystyrene beads will be used as a cargo mimetic. Progressively more complex experiments will be carried out with combinations of NDP52, OPTN, and TBK1. The recruitment of FIP200 alone, the full ULK1 complex, ATG9A vesicles, and PI3KC3-C1 will be monitored alone and in combination. Typically, the membrane will be fluorescently labelled along with two autophagy components at a time for three color imaging experiments. All labelled constructs will be validated to verify that the labels are non-perturbing. Experimental series will typically begin with 100-500 nM autophagy adaptors and 50-100 nM of autophagy core complexes, with concentrations decreasing to 10s of nM as we advance to more complex and physiologically realistic mixtures. Known intermolecular interactions will be disrupted as specificity controls. These will include FIP200 <sup>&Delta;ATG13</sup> <sup>23</sup> and FIP200<sup>&Delta;NDP52</sup> <sup>18</sup>, since the FIP200-ATG13 and -NDP52 interactions are known to be essential. All GUV imaging experiments will be quantitated and calibrated against imaging standards of defined concentration, and the molecular densities on the membrane will be estimated. The roles of the TBK1 and ULK1 kinases will be evaluated using kinase-dead variants, kinase inhibitors, and mutations of known phosphosites in OPTN.</p>\n<p>Having piloted the experiments with ubiquitinated beads, we will move on to the recruitment of the autophagy machinery to Parkin-ubiquitinated TOM and VDAC proteoliposomes and cell-free damaged mitochondria ubiquitinated by PINK1/Parkin from aim 1. These experiments, in conjunction with the structural interaction studies, will tell us how autophagy factors are recruited to damaged mitochondria, allow us to probe for any additional signals or binding interactions, and determine whether cargo receptors, ubiquitin, and mitochondrial membrane proteins have synergistic roles in mitophagy initiation.</p>\n<p><strong>Reconstitution of Atg8 lipidation.&nbsp;</strong>Beginning with the Ub<sub>4</sub> &ndash;bead, adaptor complex, TBK1, ULK1, PI3KC3- C1, and ATG9A system developed in Aim 2, we will also incorporate the ATG16L1 complex, WIPI2, the Atg8 protein LC3B, and the E1- and E2-like enzymes of Atg8 conjugation, ATG7 and ATG3. GFP-LC3B will be used to monitor the rate of LC3 lipidation on GUVs as a function of the initial concentrations and structural interactions of the upstream complexes. The mutants ATG16L1 <sup>&Delta;WIPI2</sup> and ATG16L1 <sup>&Delta;FIP200</sup> will be used to test the hypothesis that FIP200 drives the initial recruitment of ATG16L1 while WIPI2 is its main allosteric activator. We will test whether the presence of LC3B affects that activity of core complexes. PI3KC3-C1 will be followed using a GFP-FYVE probe to measure PI(3)P generation <sup>24</sup>. We predict that activity will increase following LC3B lipidation for wild-type but not &Delta;LIR PI3KC3-C1, but it is also possible that the effect will be to allosterically inhibit activity.</p>\n<p><strong>Protein interactions. </strong>Several of the key molecular interactions in this step have been mapped at the residue-by-residue level, including FIP200-NDP52 and the interaction network within the ULK1 complex. Others have yet to be mapped. The ATG9A interactions with ULK1 and PI3KC3-C1 complexes will be mapped. We will map how OPTN engages with the autophagy core complexes using HDX-MS, which probes changes in backbone dynamics of affected regions, can be carried out much faster than other structural biology methods, and has been used extensively by our team on autophagy proteins<sup>23,</sup> <sup>25-28</sup>. Selected interactions will be elucidated by x-ray crystallographic and cryo-EM structure determination. Mutants in interaction sites will be assayed by mitophagy assays and changes in colocalization by cell imaging as described below.</p>\n<p><strong>Cell imaging.&nbsp;</strong>Live cell experiments in neurons will measure the recruitment kinetics of autophagy adaptors and core complexes. We have validated probes for imaging every step, including ATG13, ATG5, ATG9A, WIPI2, TBK1, OPTN, NDP52, and LC3B<sup>6,</sup> <sup>14,</sup> <sup>15,</sup> <sup>29,</sup> <sup>30</sup>. To ensure quantitative accuracy and physiological fidelity, iPSCs will be genomically edited using CRISPR to express fluorescently tagged alleles expressed under their endogenous promoters. The effects of site-specific mutations will be tested using transient knockdown/rescue approaches to avoid inducing compensatory mechanisms. HeLa cells will be used for initial screens for faster throughput, while all key experiments will be performed in iPSC-derived neurons. We currently differentiate i<sup>3</sup>Neurons with high efficiency to cortical neurons <sup>16</sup>and will develop a protocol to differentiate to dopaminergic neurons. PINK1/Parkin mitophagy will be activated in HeLa cells with CCCP and in neurons using oxidative stress<sup>6</sup>. We will also induce focal damage using mito-KillerRed<sup>14</sup>. We will start the FIP200 <sup>&Delta;ATG13</sup> and FIP200<sup>&Delta;NDP52</sup> mutants that disrupt known interactions. We will then examine additional point mutations as defined by the structural work. We will probe the effects of disease-associated mutations in TBK1 and OPTN that disrupt known biochemical activities, including TBK1 dimerization, TBK1 kinase activity, OPTN phosphorylation, and OPTN-LC3/GABARAP binding. All live imaging data will be quantitated, using fluorescent intensities of gene-edited reporters to track rates of binding to mitochondria and dissociation. FRAP will be used to measure turnover. We will ask if mitochondrial clearance is affected by the extent or frequency of damage, to determine whether any steps or components in the pathway become rate-limiting in response to systemic or chronic damage, and we will be able to measure the specific steps disrupted by engineered or disease-associated mutations.</p>\n<p>To complement the live cell imaging above with the highest possible spatial resolution, super- resolution STORM and DNA-PAINT microscopy of endogenous immunostained proteins will be carried out in fixed cells across multiple time points. We will make quantitative measurements of ubiquitination and receptor density using appropriate calibration standard. We will determine the ubiquitin and receptor density thresholds needed to initiate autophagosome formation. Finally, to understand the larger scale 3D organization of mitophagy, 3D focused ion beam- scanning electron microscopy (FIB- SEM) with correlative light-electron microscopy (CLEM) will be used to measure membrane volume, inter-organelle contacts (e.g. with the ER and with vesicles) curvature, surface complexity and mitochondrial engulfment (Fig. 5A) under the different conditions described above.</p>\n<h2>Aim 3. Engulfment of mitochondria</h2>\n<p>We now know that Atg8-lipidated autophagic membranes are generated in situ on a \"just in time\" basis as they are needed<sup>18,</sup> <sup>19,</sup> <sup>31</sup>. Nevertheless, the interactions between the LIR motifs of autophagy adaptors and the LIR binding pockets and the LIR binding pockets of Atg8 proteins contribute to the efficiency of mitochondrial engulfment. The identity of the lipid source for autophagosome growth has been one of the longest running debates in the autophagy field <sup>32</sup>. It now clear that ATG2 is the main lipid transporter that facilitates the growth of the autophagosome<sup>33-35</sup>. ATG2 is targeted to growth sites by WIPI4<sup>36,</sup> <sup>37</sup> and the Atg8 protein GABARAP <sup>38</sup>. WIPI4 is in turn targeted by PI(3)P generated by PI3KC3-C1. The key outstanding question is how to understand how adaptors, Atg8 lipidation, and ATG2-mediated lipid transport work together to grow autophagosomes and engulf mitochondria.</p>\n<p><strong>Reconstitution of mitophagic engulfment.&nbsp;</strong>We will test whether cargo can trigger its own engulfment by activating LC3B lipidation using Ub<sub>4</sub> &ndash;beads prepositioned to contact GUVs with optical tweezers. Proximity between the bead and GUV is predicted to activate LC3B lipidation through the interactions described above. We will test whether a wave of LC3 lipidation spreads from the initial point of contact. We will test whether newly conjugated LC3B interacts autophagy adaptors via their LIR motifs, increasing adhesion between the membrane and bead and leading to its engulfment. Key controls will include NDP52<sup>&Delta;LIR</sup> and OPTN <sup>&Delta;LIR</sup>.</p>\n<p><strong>Reconstitution of autophagosome expansion.&nbsp;</strong>We will recapitulate-lipid transfer driven phagophore growth by asking if we can detect ATG2 mediated lipid transfer into phagophore seeds as formed from ATG9A proteoliposomes. These experiments will include all components used in aim 2, ATG9A, ATG2A, WIPI4 and GABARAP. We will initially employ bulk biochemical assays to assess lipid transfer into, and GABARAP lipidation on ATG9A proteoliposomes. We will then image phagophore elongation by recruiting ATG9 proteoliposomes first to Ub<sub>4</sub> &ndash;beads and then to damaged mitochondria marked by PINK1/Parkin. The sites of key interactions have been mapped<sup>36-38</sup>, and the mutants ATG2<sup>&Delta;WIPI4</sup> and ATG2<sup>&Delta;GABARAP</sup> will be used as controls. Completion of the above two sets of experiments would amount to the reconstitution of the main process of cargo-triggered self-engulfment in mitophagy.</p>\n<p><strong>Imaging of mitochondrial engulfment.&nbsp;</strong>We will use live cell, super-resolution, and FIB-SEM/CLEM microscopy as described in aim 2 to report on the expansion of the phagophore and engulfment of damaged mitochondria, using our validated probes<sup>30</sup>. In neurons, the most likely source of membrane for the phagophore expansion is the ER<sup>39</sup>, which will be tested in iPSC-derived neurons following induction of mitophagy. GFP-LC3B will be used to measure the growth of autophagosomes in 3D image stacks. We expect to see the close apposition of ATG9, WIPI4, and ATG2 during phagophore expansion. Super-resolution and FIB-SEM/CLEM approaches will be used to test ATG2 localization to the juncture between the ER and the expanding autophagosome. We will assay for fusion with lysosomes by scoring for GFP-LC3 co-localization with LAMP1-RFP and acidification of the resulting autolysosome, with the pH sensitive probes Cox8-EGFP-mCherry and mtKeima. PINK1/Parkin mitophagy prevents the release of mtDNA into the cytosol, which leads to inflammation and neuronal cell <sup>7</sup>. GFP-TFAM, LC3B and a mitochondrial marker will be imaged using live cell microscopy of the to determine whether the rate of mitophagy initiation or mitochondrial engulfment influences mtDNA release.</p>\n<p><strong>Integrative modelling.&nbsp;</strong>The goal of this project is to quantitatively describe mitophagy as a basis for targeted intervention. We aim to predict the effects of altering the rate of any event or the activity of any component on the rate of change in mitophagy of damaged mitochondria and to avoid potential spillover to healthy mitochondria. Three-dimensional dynamic simulations of the complete process of autophagosome initiation, expansion, and mitochondrial engulfment will be carried out. Simulations will be informed by experimental molecular copy numbers, interaction affinities, and reaction rates. Modeling will be used to make experimentally testable predictions of the effects on mitophagic flux of enhancing or reducing the rates of specific steps in the pathway.</p>\n<h1>POWER CALCULATIONS AND STATISTICAL ANALYSES PLAN</h1>\n<p>All statistical comparisons will be conducted from three or more biologically independent experimental replicates. For multi-variable and time-course data, statistical comparisons between groups will be performed using two-way ANOVA with post hoc testing by unprotected Fisher&rsquo;s LSD Test. For data representing a single time-point and condition, statistical comparisons between groups will be performed using one-way ANOVA with post hoc testing by unprotected Fisher&rsquo;s LSD Test. <em>P </em>values &lt;0.05 will be considered significant.</p>\n<h1>PROJECT TIMELINE AND MILESTONES</h1>\n<p><strong>0.5Y: </strong>Purify TOM, kinetics of PINK1/Parkin recruitment, quantitation of OMM Ub in cells, map OPTN and ATG9 interactions</p>\n<p><strong>1Y: </strong>Purification of FL PINK1, quantitative imaging of mitophagy initiation in neurons, include OPTN and ATG9 in reconstitutions</p>\n<p><strong>1.5Y: </strong>TOM structure, purify PINK1-TOM, live cell engulfment kinetics and CLEM, cryo-EM of ATG9 liposomes, crystal structure of ATG9-13-101 complex</p>\n<p><strong>2Y: </strong>PINK1-TOM structure, PINK1 engagement of TOM on liposomes, full reconstitution of NDP52- and OPTN- driven autophagy, cryo-EM structure of ATG16L1 complex, model testing with disease mutants</p>\n<p><strong>2.5Y: </strong>PINK1/Parkin Ub&rsquo;d TOM liposomes, model testing of new mutants from structure using imaging, full reconstitution of ATG2-mediated autophagosome growth and engulfment of mitochondria</p>\n<p><strong>3Y: </strong>Imaging of expansion and mitochondrial engulfment using super-res light and 3D EM imaging, measure mitophagy rates, assess mtDNA release and inflammation, integrative model of PINK1/Parkin mitophagy, cryo-ET of reconstituted autophagosome as it engulfs mitochondrion, predictions from integrative modeling</p>\n<h1>WORKFLOW SCHEMATIC</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/2843744d-b720-49cf-bb08-a4de12b4bd09/hurley-workflow-image.png\" alt=\"Hurley_Workflow Image\" width=\"814\" height=\"573\" /></p>\n<h1>ADDITIONAL FIGURE</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/da325f00-70a7-41c0-be77-bc2ef240d44e/hurley-additional-figures.png\" alt=\"Hurley_Additional Figures\" width=\"950\" height=\"1181\" /></p>\n<h1>LITERATURE CITATIONS</h1>\n<ol>\n<li>Pickrell, M. &amp; Youle, R.J. The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson's Disease. Neuron <strong>85</strong>, 257-273 (2015).</li>\n<li>Valente, M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (New York, N.Y.) <strong>304</strong>, 1158-1160 (2004).</li>\n<li>Kitada, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature <strong>392</strong>, 605-608 (1998).</li>\n<li>Narendra, , Tanaka, A., Suen, D.-F. &amp; Youle, R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. Journal of Cell Biology <strong>183</strong>, 795-803 (2008).</li>\n<li>Vincow, S. et al. Autophagy accounts for approximately one-third of mitochondrial protein turnover and is protein selective. Autophagy <strong>15</strong>, 1592-1605 (2019).</li>\n<li>Evans, S. &amp; Holzbaur, E.L. Degradation of engulfed mitochondria is rate-limiting in Optineurin- mediated mitophagy in neurons. eLife <strong>9 </strong>(2020).</li>\n<li>Sliter, A. et al. Parkin and PINK1 mitigate STING-induced inflammation. Nature <strong>561</strong>, 258-262 (2018).</li>\n<li>Kane, A. et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. The Journal of cell biology <strong>205</strong>, 143-153 (2014).</li>\n<li>Koyano, et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature <strong>510</strong>, 162-166 (2014).</li>\n<li>Matsuda, N. et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for The Journal of cell biology <strong>189</strong>, 211-221 (2010).</li>\n<li>Narendra, P. et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS biology <strong>8</strong>, e1000298 (2010).</li>\n<li>Lazarou, , Jin, S.M., Kane, L.A. &amp; Youle, R.J. Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin. Developmental cell <strong>22</strong>, 320-333 (2012).</li>\n<li>Lazarou, et al. PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. The Journal of cell biology <strong>200</strong>, 163-172 (2013).</li>\n<li>Wong, C. &amp; Holzbaur, E.L. Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proceedings of the National Academy of Sciences of the United States of America <strong>111</strong>, E4439-4448 (2014).</li>\n<li>Lazarou, et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature <strong>524</strong>, 309-314 (2015).</li>\n<li>Boecker, A., Olenick, M.A., Gallagher, E.R., Ward, M.E. &amp; Holzbaur, E.L.F. ToolBox: Live Imaging of intracellular organelle transport in induced pluripotent stem cell-derived neurons. Traffic (Copenhagen, Denmark) <strong>21</strong>, 138-155 (2020).</li>\n<li>Sun, et al. Direct comparison of clathrin-mediated endocytosis in budding and fission yeast reveals conserved and evolvable features. Elife pii: e50749 (2019).</li>\n<li>Vargas, N.S. et al. Spatiotemporal Control of ULK1 Activation by NDP52 and TBK1 during Selective Autophagy. Molecular cell <strong>74</strong>, 347-362 e346 (2019).</li>\n<li>Ravenhill, J. et al. The Cargo Receptor NDP52 Initiates Selective Autophagy by Recruiting the ULK Complex to Cytosol-Invading Bacteria. Molecular cell <strong>74</strong>, 320-329 e326 (2019).</li>\n<li>Dooley, C. et al. WIPI2 Links LC3 Conjugation with PI3P, Autophagosome Formation, and Pathogen Clearance by Recruiting Atg12-5-16L1. Molecular cell <strong>55</strong>, 238-252 (2014).</li>\n<li>Zaffagnini, G. &amp; Martens, S. Mechanisms of Selective Autophagy. Journal of Molecular Biology <strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">428</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1714-1724 (2016).</span></li>\n<li>Birgisdottir, B. et al. Members of the autophagy class III phosphatidylinositol 3-kinase complex I interact with GABARAP and GABARAPL1 via LIR motifs. Autophagy <strong>15</strong>, 1333-1355 (2019).</li>\n<li>Shi, et al. ULK complex organization in autophagy by a C-shaped FIP200 N-terminal domain dimer. bioRxiv <strong>758797 </strong>(2020) and J. Cell. Biol. in press.</li>\n<li>Fracchiolla, D., Chang, C., Hurley, J.H. &amp; Martens, S. A PI3K-WIP2 positive feedback loop allosterically activates LC3 lipidation in BioRxiv <strong>10.1101/2019.12.18.880591 </strong>(2019) and J. Cell. Biol. in press.</li>\n<li>Baskaran, et al. Architecture and dynamics of the autophagic phosphatidylinositol 3-kinase complex. eLife <strong>3 </strong>(2014).</li>\n<li>Qi, Q., Kim, D.J., Stjepanovic, G. &amp; Hurley, J.H. Structure of the Human Atg13-Atg101 HORMA Heterodimer: an Interaction Hub within the ULK1 Complex. Structure <strong>23</strong>, 1848-1857 (2015).</li>\n<li>Young, N., Cho, K., Lawrence, R., Zoncu, R. &amp; Hurley, J.H. Dynamics and architecture of the NRBF2-containing phosphatidylinositol 3-kinase complex I of autophagy. Proceedings of the National Academy of Sciences of the United States of America <strong>113</strong>, 8224-8229 (2016).</li>\n<li>Chang, et al. Bidirectional Control of Autophagy by BECN1 BARA Domain Dynamics. Molecular cell <strong>73</strong>, 339-353 e336 (2019).</li>\n<li>Moore, S. &amp; Holzbaur, E.L. Dynamic recruitment and activation of ALS-associated TBK1 with its target optineurin are required for efficient mitophagy. Proceedings of the National Academy of Sciences of the United States of America <strong>113</strong>, E3349-3358 (2016).</li>\n<li>Stavoe, K.H. &amp; Holzbaur, E.L.F. Axonal autophagy: Mini-review for autophagy in the CNS. Neuroscience letters <strong>697</strong>, 17-23 (2019).</li>\n<li>Turco, et al. FIP200 Claw Domain Binding to p62 Promotes Autophagosome Formation at Ubiquitin Condensates. Molecular cell <strong>74</strong>, 330-346 e311 (2019).</li>\n<li>Lamb, A., Yoshimori, T. &amp; Tooze, S.A. The autophagosome: origins unknown, biogenesis complex. Nature Reviews Molecular Cell Biology <strong>14</strong>, 759 (2013).</li>\n<li>Valverde, P. et al. ATG2 transports lipids to promote autophagosome biogenesis. The Journal of cell biology <strong>218</strong>, 1787-1798 (2019).</li>\n<li>Osawa, et al. Atg2 mediates direct lipid transfer between membranes for autophagosome formation. Nat Struct Mol Biol <strong>26</strong>, 281-288 (2019).</li>\n<li>Maeda, , Otomo, C. &amp; Otomo, T. The autophagic membrane tether ATG2A transfers lipids between membranes. eLife <strong>8 </strong>(2019).</li>\n<li>Chowdhury, S. et al. Insights into autophagosome biogenesis from structural and biochemical analyses of the ATG2A-WIPI4 Proceedings of the National Academy of Sciences of the United States of America <strong>115</strong>, E9792-E9801 (2018).</li>\n<li>Zheng, X. et al. Architecture of the ATG2B-WDR45 complex and an aromatic Y/HF motif crucial for complex formation. Autophagy <strong>13</strong>, 1870-1883 (2017).</li>\n<li>Bozic, et al. A conserved ATG2-GABARAP family interaction is critical for phagophore formation. EMBO reports <strong>21</strong>, e48412 (2020).</li>\n<li>Maday, &amp; Holzbaur, E.L. Autophagosome biogenesis in primary neurons follows an ordered and spatially regulated pathway. Developmental cell <strong>30</strong>, 71-85 (2014)</li>\n</ol>\n<p>&nbsp;</p>\n<p>&nbsp;</p>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:39Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:40Z"
    }
  },
  {
    "title": {
      "iv": "The role of PD-related proteins as drivers of disease through modulation of innate and adaptive immunity"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1y37l86X2eImpIpdzJ_AttzelaYkHxceT/view?usp=sharing"
    },
    "adminNotes": {
      "iv": "Michel Desjardins, Samantha Gruenheid, Heidi McBride, Louis-Eric Trudeau, Jo Anne Stratton"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:38Z"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:40Z"
    }
  },
  {
    "title": {
      "iv": "Adaptive Immunity in the Etiology and Progression of Parkinsons disease"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>PROJECT SUMMARY</h1>\n<p>Considerable evidence indicates roles for inflammation in Parkinson&rsquo;s disease (PD) but the mechanisms remain unclear. Our team has demonstrated critical roles for the immune system by establishing gut microbiome and gastrointestinal inflammation (GI) as regulators of PD [1]; the discovery of autoimmune features in PD due to T cell responses toward a-synuclein (a-syn) [2, 3]; the description of antigen presentation by human adult neurons targeted in PD [4]; and demonstration of a role for T cells in mouse PD models caused by a-syn overexpression [5-8]. Together, these results lead to our central hypotheses: <strong>1) <em><u>T cell responses directed towards disease-specific neoantigens, which result from</u> <u>presentation by antigen presenting cells (APCs) in the gut or peripheral lymphoid organs, are critical to</u> <u>the initiation of PD</u>; 2) <u>the responsive T cells and microglia release interferon-</u></em></strong><strong><em><u>g</u></em></strong><strong><em><u> </u></em><u>(</u><em><u>IFN</u></em><em><u><strong>g</strong>)</u></em></strong><strong><em><u> that drives antigen</u> <u>presentation by neurons and further adaptive immune responses that lead to loss of dopamine (DA)-</u> <u>ergic substantia nigra (SN) neurons, norepinephrine (NE)-ergic locus coeruleus (LC) neurons, and</u> <u>catecholaminergic neurons of the enteric nervous system (ENS) in PD</u>. </em></strong>We will investigate how APCs and neurons activate T cells, characterize antigen-specific T cells in blood and the ENS over the course of PD, discover how the gut microbiome regulates antigen-specific T cells, establish the molecular steps by which DA neurons present antigen, and ultimately determine the extent that the cellular and molecular changes we observe in patient blood and animal models are found in PD and age-matched healthy control (HC) donor brain tissue. We expect this unique nexus of microbiology, immunology, and neuroscience to make critical contributions to unraveling PD pathogenesis by defining the role of the adaptive immune system, potentially informing the development of novel therapeutic approaches.</p>\n<h1>RATIONALE AND PRELIMINARY DATA</h1>\n<h2>Hypothesis</h2>\n<p>Our team incorporates expertise from immunology (Sette and Lindestam Arlehamn: LJI), neuroscience (Harms: UAB and Sulzer: CUMC/NYSPI), neuroimmunology (Agalliu: CUMC), the microbiome (Mazmanian: CIT), RNA biology (Sims: CUMC), movement disorders neurology (Standaert and Amara: UAB) and neuropathology (Goldman: CUMC). We outline our <strong>working hypothesis for the role of adaptive immunity in PD </strong>in three steps:</p>\n<p><strong>Step 1:&nbsp;</strong>Altered processing of the nominally cytosolic neuronal protein a-syn [9] and other candidate proteins can occur due to genetic and environmental factors and/or altered immune response in tandem with disruption of normal autophagic/lysosomal processing [10-12], a feature of normal aging [13]. The misprocessing activates APCs such as macrophages, promoting a-syn aggregate formation in the intestine [1, 14, 15]. We hypothesize that <strong><em>APC presentation of </em></strong><strong><em>a-syn-derived neoepitopes in peripheral lymphoid organs and the ENS induces specific T cell proliferation</em>.</strong></p>\n<p><strong>Step 2:&nbsp;</strong><strong>&nbsp;</strong>Peripheral inflammation in the gut, which is directly regulated by the gut microbiome, drives the prodromal enteric symptoms of PD. When ENS APCs including macrophages present a-syn or other PD- related epitopes following spread from other peripheral regions or from disturbed peptide processing, <strong><em>IFN</em></strong><strong><em>g</em></strong><strong><em> -secreting T cell and APC crosstalk further activates APC and T cell proliferation to trigger antigen presentation including by ENS neurons, and consequent T cell-mediated death of these neurons </em></strong>[4].</p>\n<p><strong>Step 3: </strong>The peripheral and ENS steps trigger a cascade through the circulatory system and/or vagus nerve that spreads a-syn aggregates and inflammation to the CNS. The <strong><em>combination of neuronal antigen presentation</em></strong>, particularly in the SN and LC [4] (which may not be limited to a-syn-derived epitopes), <strong><em>and T cells in the CNS that recognize the presented epitope-human leukocyte antigen </em></strong>(HLA: also known as MHC) <strong><em>complex cause specific neuronal death and PD symptoms.</em></strong></p>\n<h2>Scientific Landscape</h2>\n<p>Research from our team has played critical roles in advancing understanding of the role of the adaptive immune system in PD. We reported the presence of a-syn-responsive T cells in human PD, particularly for epitopes containing residue Y39 or phosphorylated S129 (pS129) [2, 3], a component of Lewy bodies. The Y39 peptide is presented by HLA alleles that are associated with PD by GWAS studies [16]. Our finding of a-syn-responsive T cells in PD has been independently replicated [17]. We recently reported that a-syn-reactive T cells are mostly present during prodromal and early PD [3] during the rapid loss of SN DA neurons [18]. To our knowledge, while there are suggestions of additional PD-associated epitopes (e.g., [19]), only our team has assayed this in humans (see also [20]). An important question is whether PD patients exhibit a general change in T cell responses or changes specific to disease-associated proteins (see <strong>Aim 1, 2</strong>). To address this, we will examine if T cells from PD patients exhibit differential responses to common antigenic proteins (e.g., pollens, CMV, EBV, pertussis) and influenza, which may be associated with PD and to which there is nearly universal response due in part to vaccination (<strong>Fig 2</strong>).</p>\n<p>We further reported that a-syn overexpression in the brain activates the infiltration of peripheral APCs into the CNS [6, 8, 21] and triggers neuronal death that is blocked by inhibition of T cells [22]. Consistently, we discovered that adult human SN DA and LC NE neurons display HLA-I (a.k.a. MHC class-I: MHC-I), and that mouse neurons can present antigen by MHC-I. SN DA neuronal MHC-I is induced by IFNg or cytosolic DA oxidative stress ([4]; see also [23-26]) and our pilot data indicate that a-syn-responsive T cells in the CNS release IFNg (<strong>Fig 4</strong>). The combination of neuronal antigen presentation and T cell antigen response leads to neuronal death [4]. In human autopsy material from both PD and the related synucleinopathy multiple system atrophy (MSA), we observed helper (CD4<sup>+</sup>) and cytotoxic (CD8<sup>+</sup>) T cells directly interacting with HLA-I<sup>+</sup> DA and LC neurons [4, 8] (see also [27]). To our knowledge, while there is a reported interaction of Th17<sup>+</sup> T cells with IPSC-derived neurons <em>in vitro </em>[28], no other group has reported interactions between a-syn and MHC in the brain.</p>\n<p>The adaptive immune system relies on APCs to present antigens to T cells to activate T- and B-cell responses. This step is little studied in the nervous system (see reviews including [29, 30]), including the ENS. ENS Lewy bodies have long been noted in PD [31] and our team introduced the hypothesis that the microbiome regulates a-syn aggregation in the gut and brain, as well as neuroinflammation and PD-like motor symptoms in mice [1, 15]; this has promulgated research to explain the Braak &ldquo;spreading hypothesis&rdquo; [32] of PD. Research from many groups shows that the microbiome regulates immune system function and autoimmunity and our preliminary findings indicate that APC activation in the gut of a-syn overexpressing mice requires specific gut bacteria (Harms/Mazmanian, unpublished data).</p>\n<p>Our team realized the potential for collaboration on autoimmunity in PD prior to this proposal, but ASAP support will allow us to perform definitive experiments that cannot be accomplished otherwise.</p>\n<h2>Preliminary Data</h2>\n<p><strong> </strong>In the Preliminary Data page, we show the following unpublished results:</p>\n<p><strong>Fig. 1 </strong>T cell receptor (TCR) repertoires from PD patient PBMCs with reactivity to a-syn peptides. (<strong>Aim 1</strong>)</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/57550c5c-e363-4d1e-9874-d0b38dc9f1d3/sulzer-fig-1.png\" alt=\"Sulzer_Fig 1\" width=\"474\" height=\"337\" />&nbsp;</p>\n<p><strong>Fig. 2 </strong>T cell responses against common antigens in PD patients with T cells who respond to a-syn (PD-R) and those who do not (PD-NR). There may be higher pertussis-specific reactivity for PD-R. (<strong>Aim 2</strong>)</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/6b5f0707-7e09-46bf-8c98-65da7b86f842/sulzer-fig-2.png\" alt=\"Sulzer_Fig 2\" width=\"493\" height=\"350\" /></p>\n<p><strong>Fig. 3 </strong>Loss of ENS DA neurons 4 weeks after immunization with the HLA-DRB1*15:01 restricted Y39 a-syn peptide in a humanized mouse line (HLA15) where WT MHC-II is replaced by HLA-DRB1*15:01 (<strong>Aim 3</strong>)<strong>.</strong></p>\n<p><strong><img src=\"https://cloud.squidex.io/api/assets/asap-hub/0d1c1e43-e199-4667-998e-719fc969fa0d/sulzer-fig-3.png\" alt=\"Sulzer_Fig 3\" width=\"478\" height=\"357\" /></strong></p>\n<p><strong>Fig. 4 </strong>The a-syn-responding T cells following AAV-syn injection in mouse brain are largely CD4<sup>+</sup> and CD8<sup>+</sup> cells that produce IFNg. (<strong>Aim 4</strong>)</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/16b71580-e4b9-4429-9f35-57fbcfe1f6b6/sulzer-fig-4.png\" alt=\"Sulzer_Fig 4\" width=\"482\" height=\"399\" /></p>\n<p><strong>Fig. 5 </strong>Identification of antigen-presentation genes induced by IFNg in SN DA neurons <em>in vivo </em>using translating ribosome affinity purification RNA-seq (RiboTag) and of proteins in SN DA axons using a novel <em>in vivo </em>APEX technique. These approaches will indicate how DA neurons present antigen and reveal how APCs, neurons and astrocytes respond to a-syn peptides. (<strong>Aim 4</strong>)</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/32252a08-31d5-4935-b422-a6f32080264a/sulzer-fig-5.png\" alt=\"Sulzer_Fig 5\" width=\"937\" height=\"359\" /></p>\n<p><strong>Fig. 6 </strong>Single nuclei RNA-seq (snRNAseq) from human brain SN neurons and other cell types indicating that the signals identified in <strong>Aims 1-4 </strong>can now be characterized for specific human brain cells. (<strong>Aim 5</strong>)</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/ce3f456c-3280-40dd-ac66-f5c74cece47c/sulzer-fig-6.png\" alt=\"Sulzer_Fig 6\" width=\"955\" height=\"216\" /></p>\n<h1>RESEARCH TOOLS, MODELS AND RESOURCES</h1>\n<p><strong>HLA humanized mice</strong></p>\n<p>Sulzer/Agalliu developed a line of backcrossed (&gt;7 generations) humanized mice in which native MHC-II genes are replaced by the human allele HLA-DRB1*15:01 under an immune cell promoter (HLA15 mice). This allele displays the Y39 epitope, is present in virtually all ethnic groups at a ratio of ~1/3 of the population, and is linked to PD [16]. This line, but not wild-type (WT) mice, shows loss of ENS DA neurons when immunized subcutaneously with the Y39 a-syn peptide after 4 weeks (<strong>Fig. 3</strong>); we have not yet examined later stages for CNS damage.</p>\n<p><strong>AAV-synuclein</strong></p>\n<p><strong><em> </em></strong>Harms&rsquo; lab developed an rAAV2 model to overexpress &alpha;-syn (AAV-SYN or AAV-GFP control) in mouse SN neurons, in addition to injecting &alpha;-syn fibrils [33]. She finds a critical contribution of MHCII<sup>+</sup> CNS myeloid cells to neuroinflammatory/neurodegenerative phenotypes and demonstrated an influx of IFNg-producing CD4<sup>+</sup> and CD8<sup>+</sup>T cells into the midbrain of &alpha;-syn-overexpressing mice [22] (<strong>Fig 4</strong>).</p>\n<p><strong>PBMCs from PD, RBD, HC</strong></p>\n<p><em>&nbsp;</em>PBMCs are collected from the UAB Movement Disorders Clinic (Drs. Standaert/Amara) and the Sleep Disorders Clinic at McGill University and processed as published [2, 3].</p>\n<p><strong>Mouse tissue</strong></p>\n<p>For changes in mRNA in DA neurons, we use DAT-Cre:RiboTag mice harboring HA-tagged ribosomes in DA neurons and sequence the translating mRNAs (see [34, 35] for methodology). We developed methods to measure a-syn aggregates in mouse gut and to profile gut and brain immune cells by flow cytometry, IHC, RNA-seq, and single-cell RNA-seq (Mazmanian, Harms, Agalliu, Sims).</p>\n<p><strong>Germ-free mice</strong></p>\n<p><strong>&nbsp;</strong>Mazmanian has developed means to specifically manipulate the gut microbiome in any mouse line and to produce germ-free (gnotobiotic) animal models [1, 14].</p>\n<p><strong>APEX proteomic analysis</strong></p>\n<p>To characterize antigen presentation in DA neurons at the protein level, we adapted the use of the engineered ascorbate peroxidase, APEX2 [36, 37], to our knowledge for the first time, to CNS neurons <em>in vivo</em>. Using AAV-driven expression of cytoplasmic APEX2 [38], we have established DA neuron-specific unbiased proteomic analysis (<strong>Fig 5</strong>).</p>\n<p><strong>Human tissue TCR sequencing</strong></p>\n<p>Due to the low abundance of T cells in PD human brain specimens, Sims developed an analysis of the TCR repertoire sequencing (TCR-seq) without T cell isolation using multiplexed PCR amplification of TCR mRNA of a- and b-chains, as published for frozen human specimens of gliomas and non-neoplastic brain tissue [39].</p>\n<p><strong>Human brain pathology and CNS single cell profiling</strong></p>\n<p><strong>&nbsp;</strong>Brain tissue from PD patients and age-matched HC from the New York Brain Bank at CUMC are prepared by Dr. Goldman, a neuropathologist who has examined hundreds of PD cases. The tissue is fresh frozen by a method that prevents ice crystals and is ideal for bulk and single nuclei RNA seq (snRNAseq) and protein detection. Goldman developed methods for snRNAseq, and the lab&rsquo;s initial study focused on the cingulate cortex in patients with Huntington&rsquo;s disease (see [40] for methodology) and they show Preliminary Data on SN from FTD-TAU and HC (<strong>Fig 6)</strong>.</p>\n<h1>STUDY PLAN</h1>\n<h2>Aim 1. Analysis of longitudinal changes in PBMCs to identify autoimmune antigens, epitopes, and TCRs in PD</h2>\n<p>We will determine changes in epitope-specific T cell reactivity against proteins for which processing is known or suspected to be altered in neurodegenerative diseases including PD, such as a-syn (including fibrils, which activate T cells [3]), tau, amyloid-b and amyloid precursor protein, optineurin, GBA, LRRK2, TDP-43, OGHD, dysbindin, and ataxins.&nbsp; Our publications confirm autoimmune T cell responses in individuals with PD against -syn and tau [2, 3, 20], but there are other clear candidates and no studies have been performed on longitudinal samples. As not all PD patients respond to a-syn [2, 3], we will examine if other candidates contribute to autoimmune responses. By studying multiple antigens side-by- side, we will determine if individuals possess polyspecific responses or respond to a unique set of antigens. PD and HC PBMCs will be obtained from Standaert&rsquo;s/Amara&rsquo;s clinic (UAB), and RBD samples from Dr. Ron Postuma&rsquo;s clinic (McGill) and UAB. We will enroll 60 sporadic PD patients, 30 HC, and 40 RBD patients not diagnosed with PD who consent to provide one blood draw/year for 3 years. At the end of 3 years, each RBD subject will be assigned to a confirmed PD or non-PD diagnosis. We will examine magnitude and response quality by measuring proinflammatory (IFNg, IL-5, and TNFa)) and regulatory (IL-10) cytokines. We will determine the antigen-specific TCR repertoire <strong>(Fig 1)</strong> to determine if TCRs promise a PD biomarker. Longitudinal samples will test if antigen-specific reactivity in recently diagnosed PD decreases over time as predicted by our recent study [2], if reactivity predicts PD onset in RBD subjects, and if the proinflammatory/regulatory cytokine ratio changes with a higher proportion of regulatory cytokines over disease duration. We will determine if antigen-specific T cells are present during the prodromal phase in individuals at risk of developing PD and if detection of these cells may provide an early diagnosis of PD.</p>\n<h2>Aim 2. Investigate association of PD with general inflammation</h2>\n<p>It is unknown if T cell changes in PD are specific to a-syn or represent altered general immune functions. Inflammatory features are described in the brain of PD patients [30] and anti-TNF treatment decreases PD incidence [41], suggesting a preclinical heightened TNF response. Our Preliminary Results (<strong>Fig 2</strong>) suggest that PD patients who do not respond to a-syn (which may correspond to later stages) may display a depressed overall immune response. We will characterize antigen-specific responses in the same subjects as above for <strong>Aim 1</strong>. We will record their vaccination history, including seasonal flu vaccination, to investigate if induced vaccine responses differ between the cohorts. T cell reactivity will also be measured against a-syn, fibrils, and epitopes and common antigens due to exposure (pollens, CMV, EBV) and vaccination (pertussis, tetanus, influenza) by Fluorospot and by intracellular cytokine assays for proinflammatory and regulatory cytokines including TNFa. We will investigate basal levels of T cell activation and reactivity by measuring T cell activation markers (OX40, PD-L1, CD137, CD25 and CD69) from unstimulated PBMCs and the response magnitude against polyclonal stimulation (PHA, anti-CD3/CD28 and PMA/IO). Subjects will be analyzed based on reactivity to PD-specific antigens (a-syn and others in <strong>Aim 1</strong>). Subjects associated with neurodegeneration-antigen-specific T cell reactivity will be classified as exhibiting ongoing autoimmunity and compared to non-responsive PD patients (presumably past autoimmune responders and/or patients for whom T cell inflammation does not play a key role). This Aim will determine if PD is associated with general inflammation and altered immune response against frequently encountered foreign antigens.</p>\n<h2>Aim 3. Define gut mucosal adaptive immune response in early PD mouse models</h2>\n<p>Our team has shown that early PD is characterized by GI and microbiome alterations in PD mouse models and that these lead to T cell responses that promote symptoms, a-syn pathology, neuroinflammation ([14] and unpublished data), and in Preliminary Results, ENS DAergic neuronal death (<strong>Fig 3</strong>). To test the hypothesis that immune- mediated PD begins in the gut, we will characterize mucosal and systemic immune changes in mouse models. Sulzer and Agalliu are examining HLA15 mice that express a transgenic human HLA allele which recognizes a-syn epitopes and is associated with PD. At 4 weeks post-Y39 peptide immunization using a modified EAE protocol developed by Agalliu [42], this line exhibits loss of ENS DA neurons. We will examine later time points for PD-like motor symptoms and pathology. We will examine the effects of a-syn overexpression in the CNS as developed by Harms&rsquo; AAV-SYN model [5-8], which activates IFNg secretion by CD4<sup>+</sup> and CD8<sup>+</sup> T cells (<strong>Fig 4</strong>), and IFNg injection, as developed by Sulzer&rsquo;s lab, that induces SN DA neuron expression of MHC-I (<strong>Aim 4, Fig 5</strong>), in conjunction with peripheral a-syn epitope immunization. To determine microbiome involvement, the Mazmanian lab will re-derive HLA15 mice under germ-free conditions and Sulzer/Agalliu will compare changes to outcomes observed in normally colonized mice.</p>\n<p>Mazmanian/Harms are treating the PD mouse models with anti-inflammatory probiotics to determine the impact on mucosal immunity and the effects of alterations in the gut microbiome for inducing antigen- specific tolerance to a-syn protein/peptides, suppressing T cell activation, and blocking a-syn pathology in gut and brain. If specific anti-inflammatory gut bacteria prevent a-syn pathology and motor symptoms, we will determine how this activates regulatory T cells and antigen presentation by ENS/CNS DA neurons in HLA15 and AAV-SYN mice. We will deplete specific APC and T cell subsets to determine their role, and profile immune cell subsets in gut and brain by scRNAseq. We will determine how mucosal immunity and the microbiome affects neuroinflammation in CNS parenchyma, meninges, and CNS draining cervical lymph nodes. The gut-brain connection will be probed by vagotomy to determine how probiotics and mucosal immunity impact the brain and motor symptoms.</p>\n<h2>Aim 4. Elucidate antigen presentation by SN DA neurons</h2>\n<p>Sims/Sulzer have developed methods for DA neuron-specific molecular profiling of both mRNA and protein to unveil the pathways causing neuronal antigen presentation. For changes in RNA, we crossed DAT-Cre mice to RiboTag mice for specific expression of HA-tagged ribosomes in DA neurons [34] and sequenced translating mRNAs from DA neurons following inflammatory insult by SN injection of IFN&gamma;. Preliminary Data confirm our previous report [4], showing that upon stimulation with IFN&gamma;, SN DA neurons massively upregulate a wide range of genes that enable antigen presentation (<strong>Fig 5</strong>). In addition to neuronal expression of canonical MHC-I proteins, peptide transporters and immunoproteasome subunits, we find that SN DA neurons can upregulate MHC-II. This is relevant given the abundance of CD4<sup>+</sup> a-syn reactive T cells in PD patients [2, 3]. To examine the role of neuronal antigen presentation to T cells in the CNS and ENS, we will determine if blocking antigen presentation by selective deletion of IFN&gamma; receptors in DA neurons (already developed by Sulzer/Sims) prevents DA neuronal loss induced by AAV-SYN (from <strong>Aim 3)</strong>. We will determine whether DA neuronal loss is prevented by depleting CD4<sup>+</sup> and CD8<sup>+</sup> T cells using pharmacological and genetic approaches in immunized mice [43]. Immunized HLA15 mice (<strong>Aim 3</strong>) will also be used to analyze ENS and CNS DA neurons. We will confirm these findings at the protein level with a novel proteomic mapping method using the engineered ascorbate peroxidase, APEX2 [36, 37], for protein labeling in acute slices from mouse brain. Combining this protocol with DAT cre-driven expression of cytoplasmic APEX2 [38], we have established DA neuron-specific proteome analysis, which to our knowledge has not been performed previously in the CNS. Our Preliminary Data demonstrate proteomic profiling of DA neuronal soma vs. axons <em>in vivo </em>(<strong>Fig 5</strong>). We will determine the subcellular localization of antigen presentation in DA neurons, including soma, dendrites, and axons; antigen presentation in the highly arborized axons of DA neurons may render them particularly susceptible to autoimmune attack.</p>\n<h2>Aim 5. Determine if PD model and PD patient PBMC associated immune cell types and TCRs are present in PD CNS tissue</h2>\n<p><strong><em> </em></strong>An essential goal to which our entire proposal will contribute is to characterize how the molecular signatures in human blood and mouse models identified in <strong>Aims 1-4 </strong>are expressed in brain tissue of PD patients and healthy controls (HC), including T cells, APCs, and neurons. A minimum of 20 PD and 20 age-matched HC frozen SNs (NY Brain Bank) will be analyzed by Goldman, who will use snRNAseq (<strong>Fig 5</strong>) to define gene expression in microglia, astrocytes, and neuronal subtypes, including SN DA neurons. For TCR analysis in human PD brain, as the cells are in low abundance, we will use a TCR-seq technique introduced by Sims that provides the first means to analyze the TCR repertoire from human brain [39].</p>\n<p>Together, these Aims will test steps that may underlie PD, the specificity of neuronal loss, and determine how the adaptive immune system can be used to elucidate, provide a biomarker, and treat PD.&nbsp;</p>\n<h1>POWER CALCULATIONS AND STATISTICAL ANALYSES PLAN</h1>\n<p>A biostatistician is included in the budget.</p>\n<h2>Human studies</h2>\n<p>The cohort sizes provide sufficient <em>n </em>including for RBD subjects. From the conversion rate of RBD to PD [44], we expect <u>&gt;</u> 4 RBD to convert to PD over 3 years, and 12 to convert afterward. For each antigen, we will rank 4 PD-RBD within the PD (1) to HC (40) reactivity spectrum. The likelihood of all PD- RBD to be ranked within the top 16 is 3% and a p&lt;0.05 of a false-positive result.</p>\n<h2>Mouse studies</h2>\n<p>For HLA15/WT immunolabel, effect size 0.4, p&lt;0.05, power = 0.8 14 mice per group. For AAV-SYN, 50% increase in immune infiltrate compared to control, 95-99% confidence, p&lt;0.05, 10 mice per group, 2 pooled ventral midbrains or striatum per n. For T cells in lymph nodes, 30% increase compared to control, 95-99% confidence, p&lt;0.05, 4 per group. For RiboTag and APEX2 studies, sample size will be based on further data; we typically use 6-10 mice per group. For unbiased stereology, for 30% decrease in DA neurons compared to control, 95% confidence, p&lt;0.05, 12 per group [8].</p>\n<h1>PROJECT TIMELINE AND MILESTONES</h1>\n<p><em>PBMC studies </em><strong>Aims 1,2</strong>: Months 0-12, for UAB Clinic, sample recruitment; 0-12, peptide synthesis/pooling; 7-24, analyze antigen activity (baseline) sample analysis; 25- 20, Y02 samples; 13-36, antigen activity from Y02; 31-36, complete testing and analysis. <em>Mouse studies </em><strong>Aims 3,4</strong>: 0-12, develop mouse lines; 6-18, begin analysis of later time points in the HLA15 line; 13-36, analyze ENS microbiome data; 25-36, T cell depletion analysis; 0-36 RiboTag/APEX2 analysis. <em>Neuropathology </em><strong>Aim 5</strong>: 0-36, We have at present frozen banked SNs (20) from PD subjects with little or no AD pathology and an equivalent number of age-matched HCs for analysis, and plan to examine additional specimens as they arrive: we typically receive 10+ PD brains/year.</p>\n<h1>WORKFLOW SCHEMATIC</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/7fe4e0c3-bcf3-4894-b056-b6934df35129/workflow.jpg\" alt=\"Workflow\" /></p>\n<p>Our proposal is designed to elucidate three steps through which the adaptive immune system plays a role in PD pathogenesis in the periphery (gut) and CNS.</p>\n<p><strong>Step 1: Peripheral immune activation</strong></p>\n<p>Altered processing of a-synuclein (a-syn) and potentially additional disease-related proteins can occur during aging and due to genetic and environmental factors. There may further be overall changes in adaptive responses in subjects who develop PD. In <strong>Aims 1 and 2 (UAB/LJI)</strong>, reactive T cells from subjects with PD, REM sleep behavior disorder (RBD) and from age- matched healthy control (HC) and their responses to activation by antigen presenting cells (APCs) are characterized in a longitudinal design to detect changes in acquired immune responses. In <strong>Aims 3 and 4 (CUMC/NYSPI/CIT/UAB)</strong>, animal models, including a humanized HLA15 mouse model designed to emulate HLA and T cell response to a-syn epitope 32-46 (the Y39 epitope), are used to characterize cellular consequences of specific activation of these processes.</p>\n<p><strong>Step 2: Initiation of gut pathology</strong></p>\n<p>In <strong>Aim 3 (UAB/CIT/CUMC/NYSPI)</strong>, we test how this acquired peripheral immune activation leads to early and prodromal enteric nervous system (ENS) symptoms of PD via T cell crosstalk with APCs, and neuronal death, particularly of dopamine neurons. We will define the effects played by the gut microbiome in PD-relevant ENS neuronal damage, a-syn aggregates, and gut pathology.</p>\n<p><strong>Step 3: Spread of the pathology to the CNS</strong></p>\n<p>In <strong>Aim 3 and 4 (UAB/CIT/CUMC/NYSPI)</strong>, animal models are used to elucidate the spread through the circulatory system and/or vagal nerve to initiate CNS pathology. We analyze changes in CNS APCs, T cells, astrocytes, and neurons and test if interferon-g-secreting T cells in the CNS activate APC proliferation and cytokine signaling to trigger antigen presentation by targeted neurons. CNS cells are characterized by cell type and compartment (axons vs. soma), using new molecular approaches (RiboTAG and APEX2) to reveal how these changes lead to specific neuronal death in PD<strong><em>. </em></strong>In <strong>Aim 5</strong><em>, </em>neuropathologically characterized PD and age-matched HC frozen brain tissue (<strong>CUMC</strong>) are analyzed by new snRNAseq and TCR-seq approaches to determine if the molecular and cellular signatures identified in <strong>Aims 1-4 </strong>(<strong>all components</strong>) are found in human brain at the level of specific T cells, APCs, and targeted neurons.</p>\n<h1>LITERATURE CITATIONS<em>&nbsp; </em></h1>\n<ol>\n<li>Sampson, T.R., et al., <em>Gut microbiota regulatemotor deficits and neuroinflammation in a model of Parkinson's disease. </em>Cell, 2016. <strong>167</strong>(6): p. 1469-1480.e12.</li>\n<li>Lindestam Arlehamn, C.S., et al., <em>alpha-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. </em>Nat Commun, 2020. <strong>11</strong>(1): p.</li>\n<li>Sulzer, D., et al., <em>T cells from patients with Parkinson's disease recognize alpha-synuclein peptides. </em>Nature, 2017. <strong>546</strong>(7660): p. 656-661.</li>\n<li>Cebrian, C., et al., <em>MHC-I expression renders catecholaminergic neurons susceptible to T-cell- mediated degeneration. </em>Nat Commun, 2014. <strong>5</strong>: p.</li>\n<li>Harms, A.S., et al., <em>alpha-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. </em>Acta Neuropathol Commun, 2017. <strong>5</strong>(1): p.</li>\n<li>Harms, A.S., et al., <em>Peripheral monocyte entry is required for alpha-synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. </em>Exp Neurol, 2018. <strong>300</strong>: 179-187.</li>\n<li>Qin, H., et al., <em>Inhibition of the JAK/STAT pathway protects against alpha-synuclein-Induced neuroinflammation and dopaminergic neurodegeneration. </em>J Neurosci, 2016. <strong>36</strong>(18): p. 5144-59.</li>\n<li>Williams, G.P., et al., <em>T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. </em>Acta Neuropathol,</li>\n<li>Sulzer, D. and R.H. Edwards, <em>The physiological role of alpha-synuclein and Its relationship to Parkinson's disease. </em>J Neurochem,</li>\n<li>Cuervo, A.M., et al., <em>Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. </em>Science, 2004. <strong>305</strong>(5688): p. 1292-5.</li>\n<li>Martinez-Vicente, M., et , <em>Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. </em>J Clin Invest, 2008. <strong>118</strong>(2): p. 777-788.</li>\n<li>Orenstein, S.J., et al., <em>Interplay of LRRK2 with chaperone-mediated autophagy. </em>Nat Neurosci, 2013. <strong>16</strong>(4): p. 394-406.</li>\n<li><em> </em>Massey, A.C., C. Zhang, and A.M. Cuervo, <em>Chaperone-mediated autophagy in aging and disease </em>Curr Top Dev Biol, 2006. <strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">73</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: p. 205-35.</span></li>\n<li>Sampson, T.R., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A gut bacterial amyloid promotes alpha-synuclein aggregation and motor impairment in mice. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Elife, 2020. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">9</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">.</span></li>\n<li>Challis, C., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Gut-seeded alpha-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Neurosci,</span></li>\n<li>Wissemann, W.T., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Association of Parkinson disease with structural and regulatory variants in the HLA region. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Am J Hum Genet, 2013. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">93</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(5): p. 984-93.</span></li>\n<li>Lodygin, D., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">beta-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature, 2019. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">566</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(7745): p. 503-508.</span></li>\n<li>Kordower, J.H., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Brain, 2013. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">136</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(Pt 8): p. 2419-31.</span></li>\n<li>Matheoud, D., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Intestinal infection triggers Parkinson's disease-like symptoms in Pink1(-/-) mice. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature, 2019. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">571</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(7766): p. 565-569.</span></li>\n<li>Lindestam Arlehamn, C.S., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Widespread tau-specific CD4 T cell reactivity in the general population. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Immunol, 2019.</span></li>\n<li>Williams, G.P., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Neuroinflammation, 2018. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">15</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(1): p.</span></li>\n<li>Harms, A.S., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Neurosci, 2013. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">33</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(23): p. 9592-600.</span></li>\n<li>Mo, M.S., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Dopaminergic neurons show increased low-molecular-mass protein 7 activity induced by 6-hydroxydopamine in vitro and in </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Transl Neurodegener, 2018. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">7</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: p. 19.</span></li>\n<li>Mosharov, E.V., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Alpha-synuclein overexpression increases cytosolic catecholamine concentration. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Neurosci, 2006. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">26</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(36): p. 9304-11.</span></li>\n<li>Mosharov, E.V., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neuron, 2009. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">62</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2): p. 218-29.</span></li>\n<li>Zhang, W., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurotox Res, 2011. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">19</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(1): p. 63-72.</span></li>\n<li>Brochard, V., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Clin Invest, 2009. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">119</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(1): p. 182-92.</span></li>\n<li>Sommer, A., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson's disease. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Stem Cell, 2018. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">23</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(1): p. 123-131.e6.</span></li>\n<li>Garretti, F., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Autoimmunity in Parkinson's Disease: The role of alpha-Synuclein-Specific T Cells. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Front Immunol, 2019. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">10</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: p.</span></li>\n<li>Lindestam Arlehamn, C.S., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Roles for the adaptive immune system in Parkinson's and Alzheimer's diseases. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Curr Opin Immunol, 2019. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">59</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: p. 115-120.</span></li>\n<li>Sulzer, D. and D.J. Surmeier, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neuronal vulnerability, pathogenesis, and Parkinson's disease. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Mov Disord, 2013. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">28</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(1): p. 41-50.</span></li>\n<li>Braak, H., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Staging of brain pathology related to sporadic Parkinson's disease. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiol Aging, 2003. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">24</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2): p. 197-211.</span></li>\n<li>Volpicelli-Daley, L.A., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">How can rAAV-alpha-synuclein and the fibril alpha-synuclein models advance our understanding of Parkinson's disease? </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Neurochem, </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">139 Suppl 1</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: p. 131-155.</span></li>\n<li>Sanz, E., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell-type-specific isolation of ribosome-associated mRNA from complex </em>Proc Natl Acad Sci U S A, 2009. <strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">106</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(33): p. 13939-44.</span></li>\n<li>Hornstein, N., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Ligation-free ribosome profiling of cell type-specific translation in the </em>Genome Biol, 2016. <strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">17</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(1): p. 149.</span></li>\n<li>Hung, V., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Spatially resolved proteomic mapping in living cells with the engineered peroxidase APEX2. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Protoc, 2016. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">11</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(3): p. 456-75.</span></li>\n<li>Lam, S.S., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Directed evolution of APEX2 for electron microscopy and proximity labeling. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Methods, 2015. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">12</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(1): p. 51-4.</span></li>\n<li>Joesch, M., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Reconstruction of genetically identified neurons imaged by serial-section electron microscopy. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Elife, 2016. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">5</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">.</span></li>\n<li>Sims, J.S., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Diversity and divergence of the glioma-infiltrating T-cell receptor </em>Proc Natl Acad Sci U S A, 2016. <strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">113</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(25): p. E3529-37.</span></li>\n<li>Al-Dalahmah, O., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Single-nucleus RNA-seq identifies Huntington disease astrocyte </em>Acta Neuropathol Commun, 2020. <strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">8</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(1): p. 19.</span></li>\n<li>Peter, I., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">JAMA Neurol, 2018. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">75</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(8): p. 939-946.</span></li>\n<li>Lutz, S.E., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Caveolin1 is required for Th1 cell Infiltration, but not tight junction remodeling, at the blood-brain barrier in autoimmune neuroinflammation. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Rep, 2017. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">21</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(8): p. 2104- 2117.</span></li>\n<li>Brinkmann, V., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">The immune modulator FTY720 targets sphingosine 1-phosphate </em>J Biol Chem, 2002. <strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">277</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(24): p. 21453-7.</span></li>\n<li>Fereshtehnejad, S.M., et al., <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Validation of the MDS research criteria for prodromal Parkinson's disease: longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Mov Disord, 2017. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">32</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(6): p. 865-873.</span></li>\n</ol>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:38Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:40Z"
    }
  },
  {
    "title": {
      "iv": " Adaptive immunity in the etiology and progression of Parkinsons disease"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1WvBJv5JwqzduT_K387IlnnDnZTGF4qWu/view?usp=sharing"
    },
    "adminNotes": {
      "iv": "David Sulzer, Cecilia Arlehamn, Ashley Harms, Sarkis Mazmanian"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:38Z"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:40Z"
    }
  },
  {
    "title": {
      "iv": "From Cancer Associations to Altered Immunity in the Pathogenesis of Parkinson's disease"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>Project Summary</h1>\n<p>Although Parkinson&rsquo;s disease (PD) and cancer are defined pathologically by neuron loss and cell overgrowth, respectively, they have been linked to some of the same gene alterations. <em>LRRK2 </em>mutations, the most common cause of autosomal dominant late-onset PD, are associated with an increased risk of cancer. Mutations of <em>Parkin</em>, a potent tumor suppressor gene, are the most common cause of autosomal recessive early-onset PD. While advances in cancer immunology are revolutionizing the treatment of cancer, there is a growing appreciation of the role of the immune system in PD. Previous and our preliminary studies support that PD and cancer-related <em>LRRK2 </em>and <em>Parkin </em>alterations can lead to dysregulated immune responses. <strong>The overall goal of the </strong><strong>proposed study is to investigate whether and how the genetic connections between PD and cancer alter immune tolerance to dopaminergic neurons and contribute to dopaminergic neurodegeneration </strong>at the cellular, tissue, and systemic levels and in patient samples. Specific aim will be pursued to determine whether <em>LRRK2 </em>and <em>Parkin </em>alterations reprogram immune responses against dopaminergic neurons. Backed by exceptional expertise and resources from cancer research and neuroscience, two major disciplines that rarely crosstalk, the proposed work strikes a balance between high risk and high return to address issues relevant to both &ldquo;Biology of PD-associated Genes&rdquo; and &ldquo;Neuro-immune Interactions&rdquo;. Its findings are expected to advance our understanding of the molecular events in the immune system leading to tumorigenesis in dividing cells and neurodegeneration as part of the systemic disorders in response to the same genetic triggers. These molecular insights would open new avenues for prevention and therapies for PD by offering a range of therapeutic targets, as well as the possibility that immune approaches developed in cancer will find applications in PD.</p>\n<h1>Rationale and Preliminary Data</h1>\n<p>PD and cancer are distinguished by their fundamental features of premature neuronal cell death versus uncontrolled cell proliferation. However, growing evidence suggests that PD and cancer are associated<sup>1,2</sup>.</p>\n<h2>Shared immune dysregulation in PD and cancer</h2>\n<p>Both PD and cancer are increasingly appreciated as systemic disorders. Evidence implicates a common and possibly pivotal role of the immune system in both PD and cancer. While cancer is associated with gradual genomic events that eventually result in malignant transformation, it has become increasingly evident that the immune system has a critical role in all stages of cancer, from initiation to progression, and cancer can in fact be considered a failure of the immune system<sup>3</sup>. Tumor cells develop early on multiple mechanisms of evading the immune system and eventually form an immune suppressed microenvironment that supports and promotes tumor growth. As tumor cells evolve, there is an ongoing war between the immune system and cancer and finally the tumor develops enough virulence to bypass the immune system. Multiple nodes have been identified on which to intervene to break the cycle of immune escape and allow the immune system to control and eliminate cancers. Most notably, immune checkpoint inhibitors have achieved remarkable success leading to revolutionized treatment for many cancers<sup>4,5</sup>. The bidirectional relationship between cancer and the immune system is reflected by recent findings from our team and others showing that the cancer-related pathways not only control tumor cells, but also modulate the immune system and sensitivity of tumors to immune attack<sup>6-7</sup>.</p>\n<p>A potentially essential role of the immune system in dopaminergic neurodegeneration in PD is emerging<sup>8,9</sup>. Persistent microglial activation as well as evidence for changes in peripheral immune cells and their infiltration into the brain support the role of a systemic immune response in PD<sup>8-10</sup>. GWAS analysis identified genetic overlap between PD and autoimmune diseases<sup>11</sup>. PD is associated with MHC II genes, and a polymorphism in a non-coding region may increase MHC II in PD patients<sup>12-14</sup>. T cells from PD&nbsp;patients can generate an autoimmune response to alpha-synuclein (&alpha;Syn)<sup>15</sup>. Moreover, Th17 cells can induce neuronal cell death<sup>16</sup>.</p>\n<h2>Shared genetic factors between PD and cancer and their roles in immune responses</h2>\n<p>Both PD and cancer result from complex interactions between genetic and environmental factors. Common mechanistic foundations for PD and cancer are substantiated by the fact that they share genetic predispositions. The same alterations in several genes are linked to both PD and cancer. In dividing somatic cancer cells, these alterations appear to be oncogenic. When mutated in the germline and manifested in neurons, the same alterations cause neurodegeneration and PD. Our preliminary findings contribute to a pool of emerging evidence for the links of these genetic alterations to altered immune responses (Fig 1-3).</p>\n<p><strong><em>LRRK2</em></strong>: Mutations of <em>LRRK2 </em>are the most common cause of autosomal dominant late onset PD. Pathogenic <em>LRRK2 </em>mutations including predominant G2019S are reported to increase kinase activity resulting in a gain of function. PD patients carrying <em>LRRK2 </em>G2019S have an overall increased risk of cancer<sup>17</sup>. Biologically, LRRK2 regulates cancer-related pathways<sup>18,19</sup>, and <em>LRRK2 </em>G2019S promotes cancer cell proliferation in our study<sup>20</sup>. LRRK2 is highly expressed in immune cells, and it falls within the genetic pathways between PD and autoimmune diseases identified by GWAS analysis<sup>11</sup>. <em>LRRK2 </em>mutation alters type II interferon immune response<sup>21</sup>. LRRK2 also modulates innate immunity and inflammation during microbial infection<sup>22</sup>. We observed reduced regulatory T cells (Treg) in <em>LRRK2 </em>G2019S knockin (<em>LRRK2 </em>KI) mice (Fig 1). When immunized with peptides derived from &alpha;Syn, <em>LRRK2 </em>KI mice displayed significantly increased Ki67<sup>+</sup> B cells in the spleen. &alpha;Syn vaccination increased Ki67<sup>+</sup> CD8<sup>+</sup> cells in both wild type (WT) and <em>LRRK2 </em>KI mice. Ki67 is a proliferation marker. Immunized <em>LRRK2 </em>KI mice exhibited a trend for reduced locomotor activity vs vehicle-treated KI group, which showed presumably compensatory increased locomotor activity vs vehicle-treated WT. WT mice did not show locomotor response to the vaccination (Fig 1). Characterization of dopaminergic phenotypes in these mice has been put on hold due to COVID-19 research closure.</p>\n<p><strong><em>Parkin</em></strong>: is the most common autosomal recessive PD-associated gene causing juvenile PD. The PD- associated <em>Parkin </em>mutations usually lead to a loss of the E3 ubiquitin ligase activity. Our team first identified Parkin as a multisite tumor suppressor<sup>23,24</sup>. Similar to LRRK2, Parkin is expressed in many cell and tissue types and has been implicated in immune regulation. It inhibits inflammatory-related cell death to suppress cancer<sup>25</sup>. Parkin also interacts with other well-established tumor suppressors including P53<sup>26</sup>. In addition, Parkin regulates inflammasome-mediated inflammation in the context of antiviral immunity<sup>27</sup>. Our preliminary transcriptome profiling of cancer cells with <em>Parkin </em>knockdown showed that top scoring pathways are core immune-related processes, including the IFN, VEGF and TGF pathways (Fig 2).</p>\n<p>Taken together, the evidence reviewed above suggests that the pathogenic pathways underlying PD and cancer may converge at the immune system. Further uncovering dysregulated immune function and abnormal immunosurveillance in relation to genetic alterations may hold the key to understand the mechanism of neurodegeneration and to more effective treatment strategies for PD. The proposed study brings together interdisciplinary expertise and resources in cancer immunology, cancer genetics, and neurodegeneration to test <strong>an overall hypothesis that PD and cancer-associated LRRK2 and Parkin and cancer-modified immune system alter immune tolerance to dopaminergic neurons and contribute to dopaminergic neurodegeneration.</strong></p>\n<h1>Research Tools, Models, and Resources</h1>\n<p>Our investigation of altered immunity in relation to PD and cancer-linked genes entails animal models with direct manipulation of the target genes, namely <em>LRRK2 </em>or <em>Parkin</em>, and human iPSCs with <em>LRRK2 </em>or <em>Parkin </em>mutations. For immunologic analysis, we will use a systematic multidimensional approach involving state-of-the-art immunoprofiling, genomic analysis, single cell sequencing, spatial transcriptomics, and&nbsp;proteomics, and functional assays. For dopaminergic phenotypes, we will employ neurobehavioral, neurochemical, and neuropathological approaches.</p>\n<p><u>Existing tools, models, and resources</u> - Mouse models/strains of <em>LRRK2 </em>G2019S KI, &alpha;Syn vaccination,&nbsp;<em>Parkin </em>knockout (KO)<sup>28</sup>, <em>Parkin </em>transgenic (Tg), <em>LRRK2 </em>WT and mutant iPSCs, <em>Parkin </em>WT and mutant iPSCs.</p>\n<p><u>To be obtained commercially or through MJFF or academic collaborations</u> - <em>LRRK2 </em>G2019S Tg, <em>LRRK2 </em>R1441C Tg, <em>LRRK2 </em>KO, PBMC samples from LRRK2 PBMC &amp; Urine Biobank, Blood and CSF samples from LRRK2 Cohort Consortium. <em>OT-I </em>Tg expressing T cell receptor (TCR) recognizing model antigen ovalbumin (OVA) presented by MHC I molecule, and <em>OT-II </em>Tg expressing TCR recognizing OVA present by MHC II molecule (The Jackson Laboratory).</p>\n<p><u>To be generated</u> - To better characterize aSyn-specific T cell epitopes and T cell subsets in dopaminergic neuron immune tolerance, dopaminergic-specific TCR models will be necessary. We will generate Tg mice expressing OVA in dopaminergic neurons with an OVA cDNA under the control of tyrosine hydroxylase (TH) promotor, and cell-specific expression of the transgene will be validated by Western blotting and immunohistochemistry. Together with <em>OT-I </em>and <em>OT-II </em>mice and their crosses to <em>LRRK2 </em>and <em>Parkin </em>strains, we aim to establish experimental models of PD based on the OVA system.</p>\n<h1>Study Plan</h1>\n<p>The genetic associations between PD and cancer present a unique opportunity to better understand the immune mechanisms in PD by bridging the pathobiology of PD and cancer. The overall goal of the proposed study is to investigate whether and how the genetic connections between PD and cancer alter immune tolerance to dopaminergic neurons and contribute to dopaminergic neurodegeneration at the cellular, tissue, and systemic levels using a broad range of preclinical models and clinical samples, with <strong>specific aim </strong>to determine whether <strong><em>LRRK2 </em>and <em>Parkin </em>alterations reprogram immune responses against dopaminergic neurons.</strong></p>\n<h2>A. <em>LRRK2/Parkin</em> mutant iPSC-derived dopaminergic neurons exhibit altered sensitivity to T-cell-induced<u></u> apoptosis.</h2>\n<p>iPSC-derived dopaminergic neurons<sup>29</sup> will be modified to overexpress MART-1 and HLA-A2, which recognize HLA-A2-restricted, MART-1-specific T cells generated in our previous studies<sup>30</sup>. After co- culture with T cells, apoptosis of the modified iPSCs will be determined by a flow cytometry-based cleaved caspase-3 assay. Apoptosis rates of iPSCs with and without genetic alterations in response to T cell killing will be compared. Transcriptomic and proteomic changes in modified iPSCs in responses to T-cell co- culture will be determined by RNAseq and RPPA, respectively. Integrating the Ingenuity Pathway Analysis and Gene Set Enrichment Analysis will identify the key regulators/pathways mediating LRRK2-/Parkin- associated apoptosis of iPSC-derived dopaminergic neurons induced by T cells.</p>\n<h2><em>B. LRRK2</em>/<em>Parkin </em>alterations promote dopaminergic neuron-specific immune responses in &alpha;Syn vaccination.&nbsp;</h2>\n<p>We will characterize immune responses to &alpha;Syn vaccination in mice expressing <em>LRRK2 </em>mutations (G2019S, R1441C) and exhibiting dysregulated immune functions<sup>21,22</sup> or in mice expressing <em>Parkin </em>loss<sup>25,28</sup> using &alpha;Syn-derived peptides<sup>15,31</sup>, which elicit &alpha;Syn-specific immune responses in <em>LRRK2 </em>KI mice in our preliminary study establishing the vaccination model. Complementary <em>LRRK2 </em>KO and P<em>arkin </em>Tg mice and their respective WT littermates will also be characterized. Neurobehavioral tests will be conducted. Blood, spleen and brain samples will be collected over the course of 2 months (a) to determine cytokine/chemokine levels in serum; (b) to stain single cell suspensions from the spleen and the brain (half) with multiple antibody panels for high-dimensional flow cytometry and CyTOF<sup>32</sup> to evaluate abundance and functions of CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, Tregs, natural killer cells, B cells, conventional/plasmacytoid dendritic cells, myeloid-derived suppressor cells, and macrophages/microglia. Single cell RNAseq will be performed to broadly characterize the cellular composition of the peripheral and CNS immune responses. Additionally, isolated splenocytes will be restimulated with &alpha;Syn-derived&nbsp;peptides to determine &alpha;Syn-specific T cells by ELISPOT; (c) to determine integrity of the nigrostriatal dopaminergic system in brain tissues by neurochemical and neuropathological methods. Correlation between the peripheral and CNS immune markers and the neuronal outcomes will be analyzed.</p>\n<h2><em>C. LRRK2</em>/<em>Parkin </em>alterations in T cells enhance induction of immunity against dopaminergic neurons expressing OVA <em>in vivo</em>.</h2>\n<p>As oligodendrocyte cell-specific expression of OVA has been achieved to induce autoimmune encephalomyelitis<sup>33,34</sup>, we will generate TH-driven <em>OVA </em>Tg mice and validate dopaminergic neuron-specific OVA expression. We will also cross <em>LRRK2</em>/<em>Parkin </em>mice with <em>OT-I </em>and <em>OT-II </em>mice to obtain OVA-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells with pathogenic <em>LRRK2 </em>or <em>Parkin </em> TH-<em>OVA </em>mice will then be transferred with naive T cells derived from either <em>OT-I </em>or <em>OT-II </em>mice expressing pathogenic <em>LRRK2</em>/<em>Parkin </em>alterations or their respective littermate controls and vaccinated with OVA peptides<sup>35</sup>. General health and behavior changes will be monitored. Two months after vaccination, blood, spleen and brain samples will be collected to determine their CNS and peripheral immune profiles and dopaminergic integrity. In addition, H-2K<sup>b</sup>/OVA257-264 and H-2A<sup>b</sup>/OVA323-339 MHC tetramers will be used to evaluate dopaminergicneuron-specific CD8<sup>+</sup> (OT-I) and CD4<sup>+</sup> (OT-II) T cells, respectively, in the periphery and CNS.</p>\n<h2>D. Immune cells and biofluids from PD patients with <em>LRRK2 </em>mutations show enhanced immune responses against autoantigens.</h2>\n<p>Immune profiling of PBMCs from patients with or without <em>LRRK2 </em>mutations and healthy subjects from LRRK2 PBMC &amp; Urine Biobank will be characterized by flow &alpha;Syn-specific T cells will be assessed by ELISPOT using pooled peptides containing predicted human &alpha;Syn-specific T cell epitopes. Blood and CSF from the LRRK2 Cohort Consortium will be used to determine levels of autoantibodies against 128 known autoantigens by a high-throughput autoantigen array<sup>36</sup>.</p>\n<p><strong>Impact, pitfalls, and alternatives &ndash; </strong>The proposed study innovatively approaches PD pathogenesis from a novel and unique angle of its association with cancer. The specific experiments take full advantage of the complementary expertise across disciplines from all five groups, three of which will bring fresh perspectives as well as cutting-edge techniques from one of the most transformational fields outside of PD/neuroscience. The lead PI has been showing considerable leadership in bringing together two major disciplines that rarely crosstalk. The PD and Cancer Conference the team organized in 2019 generated infrastructure for the proposed study to achieve its overall goal and specific aim. If the findings substantiate our hypothesis, our efforts here will have an unprecedented conceptual impact on our understanding of genetically triggered molecular events in the immune system leading to tumorigenesis in dividing cells and degeneration of dopaminergic neurons. The resulting molecular insights would open new avenues for prevention and therapies for PD by offering a range of therapeutic targets, as well as the possibility that immune-based therapeutics developed in cancer will find applications in PD.</p>\n<p>We are fully aware of the proposed use of surrogate OVA in our modeling systems elucidating dopaminergic neuron-specific T cells in response to <em>LKKR2</em>/<em>Parkin </em>alterations and their effects on dopaminergic neurodegeneration. If high frequency of &alpha;Syn-specific T cells is identified in our vaccine models, we will consider adoptive transfer of T cells from &alpha;Syn vaccinated mice to validate the results from TH-OVA models. Our team is actively optimizing protocols for multiple immune assays, which will enable us to broadly explore immunomodulatory effects of the genetic alterations and related cancer environment. If new immune measures correlating parkinsonism are identified, we will consider developing new antibody panels for flow cytometry, CyTOF and multiplex IF to include these new factors for further validation.</p>\n<h1>Power Calculations and Statistical Analyses Plan</h1>\n<p>Descriptive statistics will be assessed. We will use t-test and ANOVA for continuous endpoints. If underlying distributional assumptions are not met, non-parametric tests and appropriate data transformation will be employed. For the clinical sample data analysis, the linear model will be used to&nbsp;adjust for demographical and clinical factors. For repeated measures, we will use generalized linear mixed models. The mixed effects will also be used to account for the site-to-site difference. Multi-comparisons will be adjusted. Triplication will be applied for all iPSCs experiments. Ten mice/group will be used in each of the animal experiments, providing at least 80% power to detect a mean difference continuous endpoints of 1.33*standard deviation (SD) between two groups at a significance level of 0.05 based on two-sample t-test. All experiments will be independently repeated at least twice. The sample sizes of the proposed clinical sample cohorts are based on currently available samples. For example, for the cohort of blood from PD, with sample size of 150 in each of the groups, we will have at least 80% power to detect a mean difference of 0.364 comparing PD with LRRK2 mutations vs controls assuming a SD of 1 using two- sample t-test at a significance level of 0.05 (multiple comparisons will be adjusted).</p>\n<h1>Project Timeline and Milestones</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/2dcd465d-61a7-43a9-b249-eb322c330d46/chen-project-timeline-milestones.png\" alt=\"Chen_Project Timeline &amp; Milestones\" width=\"552\" height=\"396\" /></p>\n<h1>Workflow Schematic</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/9b5f4d98-f60e-48c8-91a8-1790944ea45a/chen-workflow-schematic.png\" alt=\"Chen_Workflow Schematic\" width=\"798\" height=\"489\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Feng DD, Cai W, Chen X. The associations between Parkinson's disease and cancer: the plot thickens. Transl Neurodegener. 2015 Oct 26; 4:20. PMID: 26504519</li>\n<li>Morris LG, Veeriah S, Chan Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene. 2010 Jun 17;29(24):3453-64.</li>\n<li>Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018 Oct 1;32(19-20):1267-1284.</li>\n<li>Tawbi HA, Chung C, Margolin K. Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Nov 29;379(22):2178.</li>\n<li>Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, et al., Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med. 2019 Nov;25(11):1715-1720.</li>\n<li>Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic &beta;-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 9;523(7559):231-5.</li>\n<li>Peng W, Chen JQ, Liu C, Malu S, Creasy C, et al., Loss of PTEN Promotes Resistance to T Cell- Mediated Immunotherapy. Cancer Discov. 2016 Feb;6(2):202-16.</li>\n<li>Garretti F, Agalliu D, Lindestam Arlehamn CS, Sette A, Sulzer Autoimmunity in Parkinson's Disease: The Role of &alpha;-Synuclein-Specific T Cells. Front Immunol. 2019 Feb 25; 10:303. PMID: 30858851</li>\n<li>Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J. Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol. 2020 Apr</li>\n<li>Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y.Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis. JAMA Neurol. 2016 Nov 1;73(11):1316- 1324. PMID: 27668667</li>\n<li>Witoelar A, Jansen IE, Wang Y, Desikan RS, Gibbs JR, et , International Parkinson&rsquo;s Disease Genomics Consortium (IPDGC), North American Brain Expression Consortium (NABEC), and United Kingdom Brain Expression Consortium (UKBEC) Investigators. Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases. JAMA Neurol. 2017 Jul 1;74(7):780-792. PMID: 28586827</li>\n<li>Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, et , Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet. 2010 Sep;42(9):781- 5.</li>\n<li>Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG et , Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014 Sep;46(9):989-93.</li>\n<li>Wissemann WT, Hill-Burns EM, Zabetian CP, Factor SA, Patsopoulos et al., Association of Parkinson disease with structural and regulatory variants in the HLA region. Am J Hum Genet. 2013 Nov 7;93(5):984-93.</li>\n<li>Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E et al., T cells from patients with Parkinson's disease recognize &alpha;-synuclein peptides. Nature. 2017 Jun 29;546(7660):656-661.</li>\n<li>Sommer A, Marxreiter F, Krach F, Fadler T, Grosch J et , Th17 Lymphocytes Induce Neuronal Cell Death in a Human iPSC-Based Model of Parkinson's Disease. Cell Stem Cell. 2019 Jun 6;24(6):1006.</li>\n<li>Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B et al., Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. JAMA Neurol. 2015 Jan;72(1):58-65.</li>\n<li>Chen Z, Cao Z, Zhang W, Gu M, Zhou ZD, et al. LRRK2 interacts with ATM and regulates Mdm2-p53 cell proliferation axis in response to genotoxic stress. Hum Mol Genet. 26(22):4494-4505.</li>\n<li>Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ et al., 2011. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) required for oncogenic MET signaling in papillary renaland thyroid carcinomas. Proceedings of the National Academy of Sciences. 108(4):1439-44.</li>\n<li>Cai W, Liu P, Schwarzschild MA, Chen Exploring the Role of LRRK2 in Melanomagenesis. Movement Disorders 2019, 34, pp. S18-S18). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.</li>\n<li>Kozina E, Sadasivan S, Jiao Y, Dou Y, Ma Z et al., Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. Brain. 2018 Jun 1;141(6):1753-1769.</li>\n<li>Shutinoski B, Hakimi M, Harmsen IE, Lunn M, Rocha J et , Lrrk2 alleles modulate inflammation during microbial infection of mice ina sex-dependent manner. Sci Transl Med. 2019 Sep 25;11(511).</li>\n<li>Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E et al., Somatic mutations of the Parkinson's disease- associated gene PARK2 in glioblastoma and other human Nat Genet. 2010 Jan;42(1):77- 82.</li>\n<li>Gong Y, Zack TI, Morris LG, Lin K, Hukkelhoven E et , Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet. 2014 Jun;46(6):588-94.</li>\n<li>Lee SB, Kim JJ, Han SA, Fan Y, Guo LS et al., The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome. Nat Cell Biol. 2019 Aug;21(8):940-951.</li>\n<li>Zhang C, Lin M, Wu R, Wang X, Yang B et al., Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16259-64.</li>\n<li>Li J, Ma C, Long F, Yang D, Liu X et al., Parkin Impairs Antiviral Immunity by Suppressing the Mitochondrial Reactive Oxygen Species-Nlrp3 Axis and Antiviral Inflammation. iScience. 2019 Jun 28; 16:468-484.</li>\n<li>Gong Y, Schumacher SE, Wu WH, Tang F, Beroukhim R et , Pan-Cancer Analysis Links PARK2 to BCL- XL-Dependent Control of Apoptosis. Neoplasia. 2017 Feb;19(2):75-83.</li>\n<li>Jiang H,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ren&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Y,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yuen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EY,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zhong&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ghaedi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; M,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; et , Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induce d pluripotent stem cells. Nat Commun. 2012 Feb 7;3:668.</li>\n<li>Li Y, Liu S, Hernandez J, Vence L, Hwu P, et al., MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol. 2010 Jan 1;184(1):452-65.</li>\n<li>Villadiego J, Labrador-Garrido A, Franco JM, Leal-Lasarte M, De Genst EJ et al., Immunization with &alpha;- synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model. Glia. 2018 Jan;66(1):191-205. PMID: 29024008</li>\n<li>Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA et , Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3K&beta; Inhibition in PTEN Loss Melanoma.Clin Cancer Res. 2019 Nov 1;25(21):6406-6416.</li>\n<li>Cao Y, Toben C, Na SY, Stark K, Nitschke L et al., Induction of experimental autoimmune encephalomyelitis in transgenic mice expressing ovalbumin in Eur J Immunol. 2006 Jan;36(1):207-15.</li>\n<li>Miyagawa F, Gutermuth J, Zhang H, Katz SI. The use of mouse models to better understand mechanisms of autoimmunity and tolerance. J Autoimmun. 2010 Nov;35(3):192-8.</li>\n<li>Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA et al., Persistent antigen at vaccination sites induces tumor-specific CD8 T cell sequestration, dysfunction and deletion. Nat Med. 2013 Apr;19(4):465-72.</li>\n<li>Zhu H, Luo H, Yan M, Zuo X, Li Autoantigen Microarray for High-throughput Autoantibody Profiling in Systemic Lupus Erythematosus. Genomics Proteomics Bioinformatics. 2015 Aug;13(4):210-8.</li>\n</ol>\n<p>&nbsp;</p>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:38Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:40Z"
    }
  },
  {
    "title": {
      "iv": "Mechanisms of mitochondrial damage control by PINK1 and Parkin: How do PINK1 and Parkin govern the sequestration of damaged mitochondria by autophagosomes?"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1yGfbkcxyKhhnThnJmfe8ibyhhnyXJLiR/view?usp=sharing"
    },
    "adminNotes": {
      "iv": "James Hurley, Erika Holzbaur, Michael Lazarou, Sascha Martens, Eunyong Park"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:37Z"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:40Z"
    }
  },
  {
    "title": {
      "iv": "Understanding inherited and acquired genetic variation in Parkinsons disease through single-cell multi-omics analyses: a unique data resource"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/18ElgIkIbsOXrXuHXFzbojir2HBxauROo/view?usp=sharing"
    },
    "adminNotes": {
      "iv": "Thierry Voet, Stein Aerts, Guy Boeckxstaens, Christos Proukakis, Bernard Thienpont"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:37Z"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:40Z"
    }
  },
  {
    "title": {
      "iv": "Cellular Mechanism of LRRK2 in Health and Disease"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1FZShcYLC35VJPP2XEoG3ru2HSgRgw4HV/view?usp=sharing"
    },
    "adminNotes": {
      "iv": "Samara Reck-Peterson, Stefan Knapp, Andres Leschziner, Florian Stengel, Elizabeth Villa"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:37Z"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:40Z"
    }
  },
  {
    "title": {
      "iv": "Parkinsons Disease Proteostasis Consortium: Cellular health depends on an extensive proteostasis machinery"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/13Dkkvb99LibmQqk86cS085exMOLOJs82/view?usp=sharing"
    },
    "adminNotes": {
      "iv": "J. Wade Harper, Ruben Fernandez-Busnadiego, Judith Frydman, Franz-Ulrich Hartl, Brenda Schulman"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:36Z"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:40Z"
    }
  },
  {
    "title": {
      "iv": "Impaired Integration of Organelle Function in Parkinsons disease"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>Project Summary</h1>\n<p>Among the gene mutations that cause, or increase susceptibility for, Parkinson&rsquo;s disease (PD), some are known or thought to impair the function of endo/lysosomes or mitochondria. Although these mutations may promote disease via independent mechanisms, growing evidence points to important cross-talk between endo-lysosomes and mitochondria, with an impact on bioenergetics, mitochondria quality control, and innate immunity. We will use a multidisciplinary approach to investigate the cell biology of selected PD-associated genes that act in the endocytic pathway. We will define how their dysfunction leads to PD with an emphasis on testing the hypothesis that disruption of mechanisms linking the endocytic system to the physiology of mitochondria may have a pathogenetic role. By identifying cellular processes whose dysfunction confers PD vulnerability, our research will support translation of PD genetics into new opportunities for therapeutic interventions.</p>\n<h1>Rationale and Preliminary Data&nbsp;</h1>\n<p>The PD field has been highly successful in identifying genes whose mutations either cause the disease or increase disease risk. In order to develop therapeutics to prevent, stop, or even reverse the course of this devastating disease, we must now build on these valuable genetic insights to elucidate the cellular processes that influence PD risk and their underlying molecular mechanisms. To this end, we will focus on selected PD-associated genes based on the following criteria: 1) clear genetic evidence for their role in PD; 2) our uniquely strong foundation of expertise on the fundamental functions of the proteins encoded by these genes and/or their functional partners; 3) our established record of collaboration in the study of these proteins; 4) opportunities to define new areas of cell biology that may reveal &ldquo;druggable&rdquo; PD- relevant targets. Based on these criteria, we will initially focus on VPS13C (PARK23), Synaptojanin 1 (SJ1, PARK20) and LRRK2 (PARK8). A shared feature of these genes is a role in the endo-lysosomal system. We hypothesize that their disruption initiates a cascade of consequences that result in a negative impact on the physiology of mitochondria with effects on cellular bioenergetics and innate immunity.</p>\n<p><strong><u>VPS13C (PARK23)</u></strong><strong> </strong>is a PD causative gene that was initially reported to regulate mitochondrial function by an unknown mechanism<sup>1</sup>. Our team (PDC, KR) pioneered functional and structural characterization of the VPS13 protein family, revealing that VPS13 proteins mediate lipid fluxes between adjacent membranes by acting as bridges containing a hydrophobic groove along which lipids can slide (Fig. 1A)<sup>2,3</sup>. Surprisingly, given the proposed link to mitochondria function<sup>1</sup>, we found that VPS13C localizes to contacts between the ER and late endosomes/lysosomes (Fig. 1B) and, accordingly, we also found lysosome phenotypes in VPS13C KO cells (unpublished). We hypothesize that mitochondrial defects are a downstream consequence of events that take place at lysosomes, as suggested by recent studies reporting lysosome-to-mitochondria cross-talk<sup>4-6</sup>. The occurrence of such VPS13C-dependent cross-talk is supported by our observations that VPS13C KO cells exhibit an activated innate immune response that depends on mitochondrial DNA leakage (Fig. 1C and unpublished). In view of growing evidence that neuroinflammation may play a role in PD<sup>7</sup>, defining the chain of events linking VPS13C functions at lysosomes to the control of mitochondrial integrity is a top priority.</p>\n<p><strong>S<u>ynaptojanin 1 (SJ1, PARK20)</u></strong>, is a PI(4,5)P2 phosphatase that we (PDC) discovered and extensively investigated (PDC, TR, SF) because of its role in synaptic vesicle (SV) recycling<sup>8-10</sup>. However, a recent study (and our own unpublished results) also suggested an impact of this protein on autophagy in distal axons<sup>1</sup>, a process that could help clearance of damaged mitochondria. SJ1 sequentially dephosphorylates the 5 and 4 positions of phosphatidylinositol via tandemly arranged phosphatase domains. This promotes shedding of endocytic factors, including clathrin, from newly formed endocytic vesicles. Selective impairment (R258Q mutation) of the 4-phosphatase domain (Sac domain) causes early onset PD<sup>11</sup>. We showed that knock-in mice with the patient mutation (SJ<sup>RQ</sup> mice) display PD-like neurological defects including dystrophic changes of nigrostriatal nerve terminals (Fig. 1D) and thus represent a powerful mouse model of dopaminergic neuron selective vulnerability<sup>11</sup>. Additional support for the importance of this defect in PD comes from the partial functional overlap that we (PDC) have observed between the Sac domain of SJ1 and Sac2/INPP5F, an inositol 4-phosphatase whose gene is located in a PD risk locus<sup>3,12</sup>. Furthermore, mutations in auxilin (PARK19), a partner of SJ1 in endocytic clathrin uncoating, also cause early onset PD<sup>13,14</sup>. This genetic data makes a strong argument that endocytic defects arising from impaired clathrin uncoating are highly disease relevant. However, the mechanisms underlying this relationship remain unclear and its role in autophagy needs to be further explored.</p>\n<p><strong>LRRK2 (PARK8)</strong>Mutations that increase LRRK2 kinase activity confer a dramatic increase in PD risk<sup>15</sup>. Multiple lines of evidence link LRRK2 to endo-lysosomal homeostasis<sup>15-19</sup>, with implications for lysosome-mitochondrial cross-talk that intersect with ongoing work and expertise of our team. LRRK2 phosphorylates both SJ1 (TR) and auxilin<sup>14,20</sup>. In addition, it phosphorylates several Rabs and LRRK2- phosphorylated Rab8/Rab10 bind JIP3 and JIP4, two proteins currently investigated in our labs (SF, PDC)(Fig. 1E)<sup>21,22</sup>. LRRK2 is recruited to damaged lysosomes and, together with JIP4, it was reported to mediate membrane tubulation and vesicle sorting<sup>16,19</sup>. LRRK2 also polymerizes into helices around microtubules<sup>23</sup>, but the physiological significance of this finding remains unclear. Interestingly, dynamin was discovered as a protein that polymerizes into helices around MTs<sup>24,25</sup>, but we subsequently showed that the physiological templates for dynamin assembly are membrane tubules (PDC and SF)<sup>26,27</sup>. Dynamin and LRRK2 are distant relatives within the GTPase family which raises the possibility that LRRK2 may directly bind to lipid tubules<sup>28</sup>. Supported by encouraging preliminary results (Fig. 2F), we plan to test this hypothesis. Finally, a recent report of mitochondrial DNA leakage-dependent activation of innate immunity in LRRK2 KO cells<sup>29</sup>, suggested a convergence of LRRK2 and VPS13C dependent processes which we will investigate.</p>\n<p>A special vulnerability of nigrostriatal nerve terminals? Remarkably SJ1, auxilin, and LRRK2 disruptions all lead to a slowing of the SV cycle<sup>11,20,30,31</sup>. We (TR) showed that nerve terminals rely on rapid upregulation of ATP synthesis and that bioenergetic limitations compromise SV recycling<sup>32</sup>. Since Parkin (<em>PARK2</em>) and PINK1 (<em>PARK6</em>) mutations disrupt mitochondrial integrity, this suggests that neuronal bioenergetics is a central locus of dysfunction that may be impacted by multiple PD genes. Our preliminary data (TR) indicates that the vacuolar ATPase (V-ATPase), highly enriched on SVs and lysosomes, represents a significant metabolic burden, and might be central to creating metabolic vulnerabilities in DAergic neurons. Furthermore, enhancing glycolytic activity, by accelerating phosphoglycerate kinase (PGK) function, has an impressive protective effect in several animal PD models and drugs that enhance this activity were retrospectively found to protect against PD<sup>33</sup>. Patients with PGK deficiencies are also frequently diagnosed with PD<sup>34,35</sup>. These considerations motivate our plans to investigate the effects of manipulating PGK activity in the context of PD-linked genetic perturbations.</p>\n<h1>Research tools, Models, and Resources&nbsp;</h1>\n<p>Our cell-based studies will use genome edited human iPSCs that we will differentiate into cortical or DA neurons and microglia via established protocols<sup>36-38</sup>. In vivo studies in mice harboring PD or other relevant gene mutations, reporters and corresponding controls will complement these efforts. <u></u></p>\n<p><u>Models/tools that are already available in our labs</u> include: <u>VPS13C</u>: VPS13C KO mice; VPS13C KO HeLa cells and human iPSCs; KO models of other VPS13 paralogues (mice and cells) to be used as controls. <u>Synaptojanin 1</u>: SJ1 KO mice, SJ1<sup>RQ</sup> mutant mice, auxilin KO mice, and Sac2 KO mice (in addition to KO mice for several other endocytic proteins). <u>LRRK2</u>: Expression vectors and protocols for purification of recombinant LRRK2 and in vitro assays for liposome binding. JIP3 KO, JIP4 KO, and JIP3/JIP4 double KO iPSCs from which we can obtain neurons and microglia. We will further edit these cells to express activating mutations in LRRK2.</p>\n<p><u>Model/tools to be generated or in preparation</u>: VPS13C KO rats, in collaboration with Jon Audhya (Univ. of Wisconsin, in progress). Halo tag knockin mice will be generated for VPS13C, LRRK2, and PGK. VPS13C KO mice crossed to the mutator mouse line, which accumulates mtDNA damage and provokes PD phenotypes when crossed with PINK1 or Parkin deficient mice<sup>39</sup>. Established LRRK2 G2019S knockin mutant mice (B6.Cg-<em>Lrrk2<sup>tm1.1Hlme</sup></em>/J) and DAT bacTRAP mice will be obtained from JAX and crossed with our existing VPS13C, SJ1, and JIP3 mutant mice. All tools will be freely shared with the ASAP network and made publicly available to other researchers upon publication.</p>\n<h1>Study Plan</h1>\n<p>The core leadership team has a productive track record of collaboration on projects at the interfaces between cell biology, neuroscience, and neurodegenerative diseases. This project will focus their expertise on defining cellular pathways radiating from 3 PD genes in order to elucidate how endo- lysosomal dysfunction causes disease either directly or through mitochondrial impairments that compromise cellular bioenergetics and innate immunity. This information is expected to be synergistic with information on PD genes emerging from other labs of the ASAP network.</p>\n<h2>VPS13C</h2>\n<p>We will carry out a comprehensive study of VPS13C function. By analogy with characterized prokaryotic lipid transfer systems, which also feature protein bridges for lipid transport<sup>40</sup>, we hypothesize that VPS13C cooperates with partners at the donor and acceptor organelles, such as membrane proteins that facilitate lipid desorption from the donor membrane, lipid insertion at the acceptor membrane, and scrambling there to distribute arriving lipids between membrane leaflets. To search for such partners, we will use SMA (styrene-maleic acid) based membrane extraction strategies developed by KG to directly extract VPS13C from its native membranes with its molecular neighborhood intact and subsequently use native MS on these SMA lipid particle (SMALP) nanodiscs to identify VPS13C interactors and associated lipids<sup>41,42</sup>. As a complementary approach, we will use proximity biotinylation followed by mass spectrometry (PDC, KG). Cell free systems and cell free quantitative lipidomics will be used to quantitatively test the effects of candidate proteins on lipid transfer by VPS13C (KG, KR, PDC).Leveraging expertise in crystallography and cryo-EM methods (KR), we will establish how interactions of these proteins with VPS13C at the ends of the VPS13C transfer channel influence lipid transfer.</p>\n<p>To understand the cell biological role of VPS13C, we (PDC, TR, SF) will use cellular models, including iPSC-derived neurons and glia to test the hypothesis that VPS13C transfers lipids from the ER to late endosomes/lysosomes, assess the functions of newly identified candidate accessory factors in this process, and determine the impact of VPS13C perturbations on the endo-lysosomal pathway and mitochondria. We (PDC) have evidence for changes in lipid composition of lysosomes purified from VPS13C KO cells and will further investigate both proteomic and metabolic changes within these lysosomes (KG). Interpreting the effects of these changes on lysosomes will be supported by expertise (SF) in the investigation of lysosome homeostasis. We will explore the impact of VPS13C deficiency on mitochondrial function and examine how VPS13C mutations impact synaptic bioenergetics and synaptic function (TR), mitochondrial metabolites, and the proteome and lipidome of immunoisolated mitochondria (KG)<sup>43</sup>. Mitophagy will also be assessed<sup>44</sup>. As VPS13C KO mice do not have an obvious neurological phenotype even after aging, we have started the generation of VPS13C KO rats, which in some cases have been found to be better models of human neurological diseases. Both mouse and rat neurons will be used to assess the efficiency of SV recycling, in particular using protocols that elicit heavy ATP consumption (TR). We will furthermore cross VPS13C KO mice with existing mutant mouse strains with PD relevance (f.e. SJ1, LRRK2) and assess genetic interactions.</p>\n<p>We will also investigate the occurrence of an innate immune response downstream of VPS13C- dependent loss of mitochondrial integrity, similar to what has been proposed with parkin and PINK1<sup>39,45</sup>. Our VPS13C KO cells show an activation of interferon-sensitive genes which is dependent on the cGAS and STING pathway and mitochondrial DNA release (Fig. 1C and unpublished). Intriguingly, STING is expressed only at very low levels in neurons, while it is highly expressed in microglia, raising the possibility that this cell population participates in VPS13C-dependent PD pathogenesis or that vulnerable neurons in PD may engage this pathway. Single cell sequencing approaches will be used in our VPS13C animal models (mice and rats) to identify cell types where interferon genes are activated (collaboration with Le Zhang, key personnel). Further studies will include testing potential synergies of VPS13C and LRRK2 in the activation of a mitochondrial DNA-dependent activation of the innate immunity response, based on evidence that LRRK2 may also regulate such an innate immune response<sup>29</sup></p>\n<h2>Synaptojanin</h2>\n<p>The nigrostriatal axon degeneration in our SJ<sup>RQ</sup> mutant mice (Fig. 1D) makes them a powerful model of PD<sup>11</sup>. We will take advantage of these mice to determine how impaired endocytic traffic resulting from abnormal phosphoinositide metabolism selectively compromises the health of these axons. The onset and progression of these dystrophic changes will be monitored by imaging methods (including 3D reconstruction by FIB-SEM microscopy as well as iDISCO<sup>46</sup>). The impact of the SJ<sup>RQ</sup> mutation on gene expression in the brain will be assessed by single cell (or single nuclei) RNAseq and mass spectrometry-based proteomics to identify genes and pathways linking SJ1 dysfunction to dopaminergic axonal degeneration. The TRAP technique<sup>47</sup>(supported by crossing with DAT bacTRAP mice) will also be used to define protein translation in DA neurons of WT and SJ<sup>RQ</sup> mice over a time course overlapping with the development of axonal pathology. As the abnormal accumulation of endocytic intermediates may enhance ATP consumption by molecular chaperones, parameters of mitochondrial function and ATP production will be examined in control and SJ<sup>RQ</sup> neurons, including iPSC-derived DAergic neurons<sup>32</sup>(TR). We will study the effect of the SJ<sup>RQ</sup> mutation on autophagic mechanisms<sup>48</sup>, which may reveal another intersection between SJ1 and mitochondria via mitophagy. The SJ<sup>RQ</sup> mutation may affect the nucleation of autophagy factors by perturbing their dynamic association with membranes due to ectopic accumulation of phosphoinositides<sup>49-53</sup> that are normally dephosphorylated by the Sac domain of SJ1. Alternatively, the SJ<sup>RQ</sup> mutation may perturb presynaptic endocytic trafficking of ATG9, the only autophagy core factor with transmembrane regions<sup>54-56</sup>. Our preliminary data show that ATG9 undergoes exo-endocytosis and is mislocalized in nerve terminals of SJ1 and dynamin mutant neurons. Further studies of endocytic steps in the regulation of ATG9 function will include: i) use of an ATG9A-pHluorin chimera (fusion of pH-sensitive GFP to a luminal loop of ATG9 to detect cell surface exposure in live cells, TR), ii) use of the RUSH technique<sup>57</sup> for pulse-chase analysis of ATG9 traffic from its site of synthesis in the ER to other destinations including the plasma membrane and nerve terminals; and iii) a comparative analysis of the localization and trafficking of SV markers and ATG9 in control and SJ<sup>RQ</sup> mutant neurons.</p>\n<p>Finally, we will test for genetic interactions between the SJ<sup>RQ</sup> mutation and mutations in other PD genes, as suppressing or synergistic effects will reveal pathways that underlie nigrostriatal degeneration. Most experiments will be carried out in human iPSCs and neurons where multiple genes can be efficiently edited. Selected experiments will be carried out in mice. For example: i) SJ<sup>RQ</sup> and synuclein<sup>A53T</sup> <sup>58</sup> to determine the interplay of two proteins implicated in SV recycling, ii) SJ<sup>RQ</sup> and auxilin KO<sup>31</sup> to determine if these two proteins act sequentially or synergistically,&nbsp; iii) SJ<sup>RQ</sup> and parkin KO<sup>59</sup>, given the many biochemical relationships that have emerged between SJ1 and parkin<sup>11,60,61</sup>, iv) SJ1<sup>RQ</sup> and VPS13C KO, v) SJ1<sup>RQ</sup> and LRRK2 <em>G2019S </em>knockin mice as we have found that SJ1 is a physiological substrate for the kinase activity of LRRK2<sup>20</sup>. These experiments will collectively determine how SJ1 perturbations contribute to PD-relevant vulnerabilities in axonal health.</p>\n<h2>LRRK2</h2>\n<p>We will test the hypothesis that LRRK2 plays a major role in endo-lysosomal function with potential implications for lysosome to mitochondria cross-talk in PD. These studies will build on the extensive expertise of the SF lab in the elucidation of mechanisms that regulate lysosomal homeostasis and signaling and the novel MS approaches developed in KG&rsquo;s lab. We will investigate LRRK2 lysosome recruitment through imaging and biochemical approaches in human cell lines, as well as in both neurons and glia derived from human iPSCs. To establish the mechanism of such recruitment, we will directly extract LRRK2 complexes from endo-lysosomal membranes using SMALP-based nanodiscs followed by MS analysis of these particles (KG). These experiments will reveal the complete identity of membrane bound LRRK2 protein complexes: oligomeric architecture, interacting proteins, post-translational modifications, as well as any associated lipids. We will next use the novel lipid-bilayer native MS approach developed by KG to test the hits arising from cell-based studies through follow-up assays utilizing reconstituted lipid vesicles that mimic lysosomal membranes. We will also directly test the role of Rab29, already implicated in LRRK2 membrane recruitment and activation, and whose importance is potentially supported by PD genetics (PARK16 locus). JIP3 and JIP4 have emerged as major effectors of LRRK2-phosphorylated Rab8/10 GTPases<sup>21</sup>. We (SF, PDC) have established a critical role for JIP3/4 in controlling the intracellular transport of lysosomes<sup>62</sup> (Fig. 1E and our unpublished results). The functional relationship between lysosome stress, LRRK2, and JIP3/4 in controlling lysosome movement and vesicle budding will be explored further via live cell imaging and electron microscopy assays combined with analysis of proteomic and metabolic changes in immunoisolated lysosomes from LRRK2 mutant cells (SF, KG).</p>\n<p>We will build on our extensive past collaborations (PDC, SF, TR) in studies of dynamin GTPase polymers<sup>27,63,64</sup> to test the hypothesis that LRRK2 assembles as a helical polymer on negatively charged bilayers to promote membrane tubulation and vesicle budding from lysosomes via in vitro binding to both synthetic and biological membranes, as well as studies in living cells. KR will provide structural and biochemical expertise, while KG will employ SMALP-based top-down native MS approaches to analyze membrane bound LRRK2 containing complexes. These studies have the potential to deliver new mechanistic insight into functions of LRRK2 at lysosomes and thus provide a foundation for explaining how cell biological changes arising from LRRK2 gain-of-function mutations impinge upon vulnerable cellular pathways in PD. This has immediate relevance for understanding both the risks and opportunities associated with ongoing clinical efforts to test LRRK2 inhibitors for the treatment and prevention of PD<sup>65</sup>.</p>\n<h1>Power Calculations and Statistical Analyses Plan&nbsp;</h1>\n<p>We will adhere to the current standards used for cell biological discovery experiments with respect to statistical analyses, including where appropriate, single or two-sample t-tests, one-way or two-way ANOVA with Tukey-Kramer tests, Wilcoxon Rank-Sum Tests and Wilcoxon Sign- Rank Tests.</p>\n<h1>Project Timeline and Milestones&nbsp;</h1>\n<p>0-6 months: Our major experimental efforts will focus on immediately feasible experiments extending from our preliminary data (such as structure of the C-terminal region of VPS13C; membrane remodeling properties of LRRK2), while developing new mouse and iPSC lines and performing mouse crosses. We will initiate discovery efforts on protein-protein interactions, protein-lipid interactions, and sequencing based approaches. 6-12 months: Completion of the first round of discovery efforts for each project while wrapping up structural elucidation of full length VPS13C; investigation of the activation of innate immunity in VPS13C and LRRK2 mutant cells; studies of autophagy and physiological parameters at SJ<sup>RQ</sup> mutant synapses; complete in vitro assays of LRRK2 membrane interactions; bioenergetic studies in mutant and KO models.</p>\n<p>12-24 months: Development and implementation of assays to test leads arising from discovery efforts; initiation of cell biological and physiological assays on models developed in year 1.</p>\n<p>24-36 months: Individual projects will have matured and yielded new insights arising from each of our PD gene starting points. Our attention will thus turn to integration of discoveries arising from the above studies and other labs of the ASAP network to identify points of convergence between the function of PD genes. Collectively this research will advance the PD field by translating knowledge of single PD genes into a detailed understanding of the cellular processes in which they function and is expected to pave the way for new opportunities for therapeutic interventions.</p>\n<h1>Workflow Schematic</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/8a35224c-233a-44a8-b253-72254c238e78/de-camilli-workflow.jpg\" alt=\"De Camilli workflow\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li class=\"p1\">Lesage, S. et al. 2016. Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. Am J Hum Genet 98, 500-13</li>\n<li class=\"p1\">Kumar, N. et al. 2018. VPS13A and VPS13C are lipid transportproteinsdifferentially localized at ERcontact sites. J Cell Biol217, 3625-39</li>\n<li class=\"p1\"><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cao, M. et al. 2020. Absenceof Sac2/INPP5F enhancesthe phenotype of a Parkinson&rsquo;s disease mutation of synaptojanin 1. bioRxiv,</span>2020.01.21.914317</li>\n<li class=\"p1\">Hughes, C. E. et al. 2020. Cysteine Toxicity Drives Age-Related Mitochondrial Decline by Altering Iron Homeostasis. Cell 180, 296-310 e18</li>\n<li class=\"p1\">Yambire, K. F. et al. 2019. Impaired lysosomal acidification triggers iron deficiency and inflammation in vivo. Elife 8</li>\n<li class=\"p1\">Wong, Y. C., Ysselstein, D.&amp; Krainc, D. 2018. Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis. Nature 554, 382-6</li>\n<li class=\"p1\">Gelders, G., Baekelandt, V. &amp; Van der Perren, A. 2018. Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. J Immunol Res 2018, 4784268</li>\n<li class=\"p1\">McPherson, P. S. et al. 1996. Apresynaptic inositol-5-phosphatase. Nature 379, 353-7</li>\n<li class=\"p1\">Cremona, O. et al. 1999. Essentialrole of phosphoinositide metabolism in synaptic vesicle recycling. Cell99, 179-88</li>\n<li class=\"p1\"><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Hayashi, M. et al. 2008. Cell- and stimulus-dependent heterogeneity ofsynaptic vesicle endocytic recycling mechanisms revealed by </span>studies of dynamin 1-nullneurons. Proc Natl Acad Sci U S A 105, 2175-80</li>\n<li class=\"p1\">Cao, M. et al. 2017. Parkinson Sac Domain Mutation in Synaptojanin 1 Impairs Clathrin Uncoating at Synapsesand Triggers Dystrophic Changes in Dopaminergic Axons.Neuron 93, 882-96 e5</li>\n<li class=\"p1\"><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nakatsu, F. et al. 2015. Sac2/INPP5F is an inositol 4-phosphatase that functions in the endocytic pathway. J Cell Biol209, 85-95</span></li>\n<li class=\"p1\">Nguyen, M.&amp; Krainc, D. 2018. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease. Proc Natl Acad Sci U S A 115, 5576-81</li>\n<li class=\"p1\">Edvardson, S. et al. 2012. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenileparkinsonism. PLoS One 7, e36458</li>\n<li class=\"p1\">Taylor, M.&amp; Alessi, D. R. 2020. Advancesin elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease. Curr Opin Cell Biol 63, 102-13</li>\n<li class=\"p1\">Eguchi, T. et al. 2018. LRRK2 and itssubstrate Rab GTPasesare sequentially targeted onto stressed lysosomesand maintain their homeostasis. Proc Natl Acad Sci U S A115, E9115-E24</li>\n<li class=\"p1\">Fuji, R. N. et al. 2015. Effectofselective LRRK2 kinase inhibition on nonhumanprimate lung. Sci Transl Med7, 273ra15</li>\n<li class=\"p1\">Roosen, D. A.&amp; Cookson, M. R. 2016. LRRK2 at the interface ofautophagosomes, endosomesand lysosomes. Mol Neurodegener11, 73</li>\n<li class=\"p1\">Bonet-Ponce, L. et al. 2020. LRRK2 mediates tubulation andvesicle sorting frommembranedamaged lysosomes. bioRxiv, 2020.01.23.917252</li>\n<li class=\"p1\">Pan, P. Y. et al. 2017. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons. J Neurosci37, 11366-76</li>\n<li class=\"p1\">Steger, M. et al. 2017. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishesa connection to ciliogenesis. Elife6</li>\n<li class=\"p1\">Waschbusch, D. et al. 2020. Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2. Structure 28, 406-17</li>\n<li class=\"p1\">&nbsp;Deniston, C. K. et al. 2020. Parkinson&rsquo;s Disease-linked LRRK2 structure and modelformicrotubule interaction. bioRxiv, 2020.01.06.895367&nbsp;</li>\n<li class=\"p1\">Shpetner, H. S.&amp; Vallee, R. B. 1989. Identification of dynamin, a novel mechanochemical enzyme that mediates interactions between microtubules. Cell 59, 421-32</li>\n<li class=\"p1\">Maeda, K. et al. 1992. Interaction of dynamin with microtubules: itsstructure and GTPaseactivity investigated by using highly purified dynamin. Mol Biol Cell 3, 1181-94</li>\n<li class=\"p1\">Takei, K. et al. 1995. Tubularmembrane invaginationscoated bydynamin rings are inducedby GTP-gamma S innerve terminals. Nature 374, 186-90</li>\n<li class=\"p1\">Ferguson, S. M. et al. 2009. Coordinated actions ofactin and BARproteins upstreamof dynaminatendocytic clathrin-coated pits. Dev Cell 17, 811-22</li>\n<li class=\"p1\">Gasper, R. et al. 2009. It takestwo to tango: regulation of Gproteins bydimerization. Nat Rev Mol Cell Biol 10, 423-9</li>\n<li class=\"p1\">Weindel, C. G. et al. 2020. LRRK2 maintains mitochondrial homeostasisand regulatesinnate immune responsesto Mycobacterium tuberculosis. Elife9</li>\n<li class=\"p1\">Mani, M. et al. 2007. The dualphosphatase activity of synaptojanin1 is requiredforboth efficient synaptic vesicleendocytosis and reavailability at nerve terminals. Neuron56, 1004-18</li>\n<li class=\"p1\">Yim, Y. I. et al. 2010. Endocytosisand clathrin-uncoating defectsat synapsesofauxilin knockoutmice. Proc Natl Acad Sci U S A 107, 4412-7</li>\n<li class=\"p1\">Rangaraju, V., Calloway, N.&amp; Ryan, T. A. 2014. Activity-driven local ATP synthesis is requiredforsynaptic function. Cell 156, 825-35</li>\n<li class=\"p1\">Cai, R. et al. 2019. Enhancing glycolysis attenuates Parkinson'sdisease progression in models andclinicaldatabases. J Clin Invest 129, 4539-49</li>\n<li class=\"p1\">Sakaue, S. et al. 2017. Early-onset parkinsonism in apedigreewith phosphoglycerate kinasedeficiency and a heterozygous carrier: do PGK-1 mutationscontribute to vulnerability to parkinsonism? NPJ Parkinsons Dis 3, 13</li>\n<li class=\"p1\">Sotiriou, E. et al. 2010. Myopathyandparkinsonism in phosphoglycerate kinase deficiency. Muscle Nerve 41, 707-10</li>\n<li class=\"p1\">Fernandopulle, M. S. et al. 2018. Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons. Curr Protoc Cell Biol79, e51</li>\n<li class=\"p1\">Douvaras, P. et al. 2017. Directed Differentiation of Human Pluripotent Stem Cells to Microglia. Stem Cell Reports8, 1516-24</li>\n<li class=\"p1\">Kriks, S. et al. 2011. Dopamine neuronsderived fromhuman EScells efficiently engraft in animal models of Parkinson'sdisease.Nature 480, 547-51</li>\n<li class=\"p1\">Sliter, D. A. et al. 2018. Parkin and PINK1mitigate STING-induced inflammation. Nature561, 258-62</li>\n<li class=\"p1\">Wong, L. H., Gatta, A. T. &amp; Levine, T. P. 2019. Lipid transferproteins: the lipid commute via shuttles, bridges andtubes.Nat Rev Mol Cell Biol 20, 85-101</li>\n<li class=\"p1\">Gupta, K. et al. 2017. The role of interfacial lipids in stabilizing membrane protein oligomers. Nature541, 421-4</li>\n<li class=\"p1\">Esmaili, M.&amp; Overduin, M. 2018. Membrane biology visualized in nanometer-sizeddiscs formed bystyrene maleic acidpolymers. Biochim Biophys Acta Biomembr1860, 257-63</li>\n<li class=\"p1\"><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Chen, W. W., Freinkman, E.&amp; Sabatini, D. M. 2017. Rapid immunopurification ofmitochondria formetabolite profiling andabsolute </span>quantification ofmatrix metabolites. Nat Protoc 12, 2215-31</li>\n<li class=\"p1\">Sargsyan, A. et al. 2015. Rapid parallel measurements of macroautophagy and mitophagy in mammalian cells using a single fluorescent biosensor. Sci Rep5, 12397</li>\n<li class=\"p1\">Newman, L. E.&amp; Shadel, G. S. 2018. Pink1/Parkin link inflammation, mitochondrial stress, andneurodegeneration. J Cell Biol217, 3327-9</li>\n<li class=\"p1\">Renier, N. et al. 2014. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell159, 896-910</li>\n<li class=\"p1\">Brichta, L. et al. 2015. Identification of neurodegenerative factorsusing translatome-regulatory network analysis. Nat Neurosci18, 1325-33</li>\n<li class=\"p1\">Vanhauwaert, R. et al. 2017. The SAC1 domain insynaptojanin is required forautophagosome maturation atpresynaptic terminals. EMBO J 36, 1392-411</li>\n<li class=\"p1\">Wu, Y. et al. 2014. PI3Pphosphatase activity is requiredforautophagosome maturation andautolysosome formation. EMBO Rep15, 973-81</li>\n<li class=\"p1\">Nascimbeni, A. C., Codogno, P.&amp; Morel, E. 2017. Phosphatidylinositol-3-phosphate in the regulation of autophagy membrane dynamics. FEBS J 284, 1267-78</li>\n<li class=\"p1\">Grimmel, M., Backhaus, C.&amp; Proikas-Cezanne, T. 2015. WIPI-Mediated Autophagy and Longevity.Cells 4, 202-17</li>\n<li class=\"p1\">Baba, T. et al. 2019. Phosphatidylinositol4,5-bisphosphate controls Rab7 and PLEKHM1 membrane cycling during autophagosome lysosome fusion. EMBO J 38, e100312</li>\n<li class=\"p1\">Judith, D. et al. 2019. ATG9A shapes the formingautophagosome through Arfaptin 2andphosphatidylinositol 4-kinase IIIbeta. J Cell Biol 218, 1634-52</li>\n<li class=\"p1\">Yamamoto, H. et al. 2012. Atg9vesicles are an important membrane source duringearly stepsof autophagosome formation. J Cell Biol 198, 219-33</li>\n<li class=\"p1\"><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Imai, K. et al. 2016. Atg9A trafficking through the recyclingendosomes is requiredforautophagosome formation. J Cell Sci129, 3781-91</span></li>\n<li class=\"p1\">De Pace, R. et al. 2018. Altered distribution of ATG9A andaccumulationof axonalaggregates inneuronsfroma mouse modelof AP-4 deficiency syndrome. PLoS Genet14, e1007363</li>\n<li class=\"p1\">Boncompain, G. et al. 2012. Synchronization of secretory protein traffic in populationsof cells. Nat Methods9, 493-8</li>\n<li class=\"p1\">Kang, L. et al. 2011. The A53T mutation is keyin defining thedifferencesin the aggregation kinetics ofhumanand mousealpha-synuclein. J Am Chem Soc 133, 13465-70</li>\n<li class=\"p1\">Goldberg, M. S. et al. 2003. Parkin-deficient mice exhibitnigrostriatal deficits butnotlossofdopaminergicneurons. J Biol Chem 278, 43628-35</li>\n<li class=\"p1\">Cao, M. et al. 2014. Upregulation of Parkin in endophilin mutant mice. J Neurosci34, 16544-9</li>\n<li class=\"p1\"><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Trempe, J. F. et al. 2009. SH3 domains from a subset of BAR proteins define a Ubl-binding domain and implicate parkin in synaptic </span>ubiquitination. Mol Cell 36, 1034-47</li>\n<li class=\"p1\">Gowrishankar, S., Wu, Y.&amp; Ferguson, S. M. 2017. Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology. J Cell Biol216, 3291-305</li>\n<li class=\"p1\">Roux, A. et al. 2006. GTP-dependent twisting of dynaminimplicatesconstriction and tension inmembranefission. Nature 441, 528-31</li>\n<li class=\"p1\"><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Ferguson, S. M. et al. 2007. A selective activity-dependent requirementfordynamin 1 in synaptic vesicleendocytosis. Science 316, 570-4</span></li>\n<li class=\"p1\">Baptista, M. A. S. et al. 2020. LRRK2 inhibitors induce reversible changes in non-human primate lungs without measurable pulmonary deficits. Sci Transl Med12</li>\n</ol>\n<p>&nbsp;</p>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:21Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:20Z"
    }
  },
  {
    "title": {
      "iv": "Mapping the LRRK2 signalling pathway and its interplay with other Parkinsons disease components"
    },
    "type": {
      "iv": "Grant Document"
    },
    "link": {
      "iv": null
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "something",
        "test"
      ]
    },
    "labs": {
      "iv": null
    },
    "description": {
      "iv": "<h1>Project Summary</h1>\n<p>Within \"<strong>Biology of PD-associated genes,</strong>\" combining the complementary expertise of our teams and working together, we propose foundational work to transform understanding of LRRK2 kinase&rsquo;s role in PD initiation and progression, with focus on the consequences of Rab GTPase phosphorylation and understanding its effect on the downstream biology of primary cilia, lysosomes, and mitochondria. <strong>(1) </strong>Upstream we will investigate how LRRK2 pathway is regulated by Rab29 [1], VPS35 [2] and PPM1H phosphatase [3]. <strong>(2) </strong>Downstream, we will probe the consequences of phospho-Rab proteins binding to effectors and further study the mechanism by which LRRK2 regulates ciliogenesis including in specific brain cell types. <strong>(3) </strong>Genetic analysis indicates association of variants in mitochondrial and lysosomal genes as susceptibility factors predisposing to sporadic PD [4]. Recent work suggests that LRRK2 plays a major role in regulating lysosome function [5-9]. To uncover the molecular connection between LRRK2 and lysosomes, we will generate LRRK2 wild type and mutant mice containing \"Lyso-Tagged\" lysosomes and study the impact that LRRK2 and VPS35 pathogenic mutations have on proteins, metabolites and lipids in these organelles in brain regions and in select neurons, microglia, oligodendrocytes, and astrocytes. <strong>(4) </strong>Emerging data suggest LRRK2 hyperactivation is also linked to mitochondrial biology [10, 11]. To better define how LRRK2 impacts mitochondria and to explore possible interplay between PINK1 signalling that regulates mitophagy and is linked to PD [12-14], we will generate PINK1 and LRRK2 mutant mice and cells with &ldquo;Mito-tagged&rdquo; mitochondria. This will allow rapid isolation of mitochondria and investigation of how proteins and metabolites are influenced by LRRK2 and PINK1 signalling. We bring together world leaders in kinases and Rab and mitochondrial biology, a practicing neurologist and a new investigator pioneer in rapid organelle isolation to tackle the molecular basis of LRRK2 pathogenesis.</p>\n<h1>Rationale and Preliminary Data</h1>\n<p>Autosomal dominant missense mutations that hyperactivate LRRK2 are a major cause of inherited PD and therapeutic efficacy of LRRK2 inhibitors is currently being tested in clinical trials. The Alessi and Pfeffer labs have collaborated to characterize a subset of Rab GTPases as the physiological substrates of LRRK2 kinase [15, 16]. We identified two upstream pathways regulated by components linked to PD: Rab29 [1] and VPS35 [2]) that activate the LRRK2 pathway, enhancing Rab phosphorylation. We have invested significant effort in generating and sharing tools and methods to study LRRK2 mediated Rab phosphorylation [17-19]. We showed that phosphorylation creates new Rab effector-binding interactions that may mediate LRRK2 pathogenicity: for example, phospho-Rab10 binds with higher affinity to RILPL1, RILPL2 and Myosin Va, blocking ciliogenesis [16, 20, 21]. Elucidation of the roles of these novel, LRRK2-driven interactions is key to our understanding of LRRK2 pathogenesis. We also identified PPM1H as a highly specific phospho-Rab phosphatase, reversing LRRK2-mediated phosphorylation [3]. In Part 1 we propose fundamental work geared towards providing detailed mechanistic understanding of how the LRRK2 pathway is regulated by Rab29, VPS35 and PPM1H. We also plan to define precisely the molecular details by which LRRK2- phosphorylated Rab8A/10 interfere with ciliogenesis, including how LRRK2 regulates ciliogenesis in specific brain cells. We found recently in mouse striatum that astrocytes (in prep) show uniform cilia defects as do cholinergic interneurons [20] and will investigate the consequences of these changes and their cell autonomy. We seek to uncover as yet undiscovered downstream effectors of the LRRK2 pathway that specifically bind LRRK2-phosphorylated Rab proteins. Much recent work has revealed that LRRK2 influences lysosome and mitochondrial biology that aligns with genetic dissection of variants linked to sporadic PD. Our hypothesis is that hyperactivation of LRRK2 upregulates pathways that control lysosomal stress via increased autophagy and/or altered endo-lysosomal trafficking, thereby modulating levels of proteins, metabolites and/or lipids that are toxic; we aim to uncover and characterize these pathways. By incorporating the groups of Abu-Remaileh and Muqit, we introduce new expertise to greatly enhance our collaboration to deploy novel approaches that allow isolation of&nbsp;lysosomes and mitochondria from tissue and cell extracts in a rapid and intact manner. We will determine how pathogenic mutations in LRRK2 influence protein, metabolite and lipid content in cells by mass spectrometry (MS) analysis of these organelles derived from relevant brain cells. For the mitochondrial analysis, we will also compare the combination effect of LRRK2 pathogenic mutations with knock-out of PINK1. We aim to identify novel regulatory pathways relevant to lysosome and mitochondrial biology and PD that are controlled by LRRK2 and PINK1.</p>\n<h1>Research Tools, Models, and Resources</h1>\n<p>Our teams have been working on LRRK2 (Alessi, Pfeffer), PINK1 (Muqit) and lysosome (Abu-Remaileh, Pfeffer) biology for many years and generated a significant resource of cDNAs, antibodies, biochemical assays, recombinant protein and mouse models that will be greatly expanded during this project. We have created a new searchable website, <u>https://</u><a href=\"http://www.lrrk2.bio/\">www.lrrk2.bio </a>that catalogues these resources, providing datasheets and information on how to request these tools. We will continuously update this website with new reagents and mouse models as they are generated. Our labs have access to up-to-date technologies and associated expertise in MS (Orbitrap Lumos and Exploris, Q Exactive HF-X and Bruker timsTOF Pro, ID-X Tribrid, Agilent 6545 Quadrupole Time-of-Flight and Triple Quadrupole LC/MS instruments) for proteomic/lipidomic and metabolomic analysis; confocal microscopy; facilities to breed and analyze knock-out/knock-in mice; and core facilities for cDNA cloning, CRISPR genome editing, antibody generation and protein expression available to all team members. The mouse models we propose are ideal for deciphering the immediate biology surrounding the mechanisms by which endogenous pathogenic LRRK2 and PINK1 kinase mutations influence lysosome, mitochondria and cilia biology, and will provide sufficient material to permit quantitative MS analysis of whole brain as well as microglia, oligodendrocytes, astrocytes and neuron cell subtypes. Tissue-specific conditional LRRK2[R1441G] knock-in mice will permit us to dissect the roles that pathogenic LRRK2 plays in regulating cilia in specific brain cell types. LysoTag and MitoTag mouse models permit rapid organelle isolation from mouse brain extracts and from individual brain cell types, to identify changes in proteins, metabolites and lipids that are controlled by LRRK2 and PINK1 in cells of physiological relevance to PD. We will also isolate lysosome-related lamellar bodies, efficiently tagged in LysoTag model, from lung Type 2 pneumocytes that accumulate in LRRK2 mutant animals; their profiling will help us understand LRRK2's role in regulating organelle biology.</p>\n<h1>Study Plan</h1>\n<h2>How is the LRRK2 pathway influenced by Rab29, VPS35 and PPM1H? (Alessi, Pfeffer)</h2>\n<p>We and others have shown that Golgi-localized Rab29 recruits LRRK2 from the cytoplasm via its N- terminal ARM domain which leads to LRRK2 activation on the Golgi [1, 22, 23]. Rab29 artificially delivered to mitochondria also activates LRRK2, suggesting that membrane association is sufficient [24]. We will delineate the minimal region of the LRRK2 ARM domain that interacts with Rab29, mutagenize conserved residues and aim to co-crystalize this with Rab29 to gain clues regarding how Rab29 activates LRRK2. We will discuss data with the San Diego LRRK2 structural team and work together on this question. We will generate CRISPR knock-in LRRK2 mutations that cannot bind Rab29 in A549 and RPE cells to define the importance of the Rab29 pathway in regulating LRRK2 activity in vivo including cilia formation. We will attempt to reconstitute activation of recombinant LRRK2 by addition of Rab29-decorated liposomes. An even more potent activator of LRRK2 is the pathogenic VPS35 D620N mutant protein [2]. VPS35 is important for normal Rab10- mediated trafficking from the perinuclear region to the plasma membrane; pathogenic VPS35 shows an abnormal cytoplasmic localization [our data &amp; 25]. We aim to characterize the mechanism by which VPS35 mutations promote LRRK2-mediated Rab protein phosphorylation. We will deploy quantitative endogenous immunoprecipitation and MS approaches to identify proteins that differentially co-immunoprecipitate with VPS35, LRRK2 and Rab proteins in wild type, heterozygous and homozygous D620N knock-in MEFs and mouse tissues. Candidates will be prioritized based on the strength of the data, novelty and links to PD biology. Their importance in regulating LRRK2- mediated Rab protein phosphorylation will be validated by generating CRISPR knockout mutations&nbsp;in the VPS35[D620N] mutant knock-in cell lines and testing how this impacts Rab phosphorylation. Proteins found to be important would be further studied and validated to ultimately delineate the mechanism by which they are controlled by VPS35, and impact Rab protein phosphorylation. We aim to better define the importance that the PPM1H protein phosphatase [3] plays in counteracting LRRK2 signalling, and uncover how its Golgi localization and activity are regulated. We have discovered that PPM1H&rsquo;s N-terminal 37 non-catalytic residues drive its Golgi localization. We will test the hypothesis that Golgi localization of PPM1H maintains Rab8/10 dephosphorylated so they can carry out their normal roles on the Golgi in delivery of proteins to the cell surface, while other pools of Rab8/10 (near the centriole) are modulated by LRRK2 [20]. We will deploy CRISPR KI to replace the N-terminus with sequences that artificially anchor all cellular PPM1H either on the mother centriole (PACT motif), the Golgi (TMEM115 fusion) or mitochondria (sequence from monoamine oxidase). We will ask whether phosphatase localization impacts Rab8/10 delivery of proteins from the Golgi to the cell surface as well as ciliogenesis. We aim to explore by endogenous immunoprecipitation MS analysis, whether PPM1H associates with other accessory proteins and if so characterize how these impact PPM1H activity and/or localization. In addition, we will characterize PPM1H knock-out mice that we have recently obtained to define how this impacts Rab protein phosphorylation in the brain where PPM1H is highly expressed. This experiment will provide the first genetic animal model data to support the role that PPM1H plays in Rab regulation. <strong>Backup strategies</strong>: If Rab29 crystallization or reconstitution proves challenging, we will test if other related Rabs that more stably express may interact similarly with the LRRK2 ARM domain. If MS analysis of immunoprecipitates fails to identify relevant targets, we will use crosslinking approaches and/or proximity dependent labelling (BioID). If CRISPR KI approaches to modify localization of PPM1H prove challenging, we will stably express PPM1H mutants in KO cells.</p>\n<h2>Consequences of phospho-Rab binding to novel effectors &amp; LRRK2 regulation of ciliogenesis (Pfeffer, Alessi)</h2>\n<p>We have identified and characterized several Rab effectors, including RILPL1 and RILPL2, that interact with greater affinity with LRRK2-phosphorylated Rab8A and Rab10 [16]. We showed that pRab10-RILPL1 complexes block cilia formation in numerous cell types, including neurons [20]. We have now shown that LRRK2 inhibits cilia formation by blocking TTBK2 kinase recruitment to the mother centriole [26]. We will investigate this in greater detail: does a LRRK2 generated, pRab10- RILPL1 complex block TTBK2 access to its mother centriolar binding partner, CEP164? We will explore whether pRab10-RILPL1/2 or other effector complexes, impact kinases and phosphatases that control phosphoinositide levels around the mother centriole that control interaction of CEP164 with TTBK2 [27]. There are likely other PD-relevant effectors of LRRK2-phosphorylated Rabs to be discovered. We will use overexpression in cell culture and IP from brains of mutant mice to screen for effectors that specifically interact with LRRK2 phosphorylated Rabs 1/3/12/35/43 as we deployed before to identify RILPL1/2 [16]. To define the contribution that pathogenic LRRK2 expression makes to ciliogenesis in specific brain cells, we will create conditional LRRK2[R1441G] mutant knock-in mice and cross these with mice carrying brain cell type-specific Cre drivers (see Aim 3). We will verify that the cell types harboring the KI mutation display increased pRab10 levels. This will enable us to determine whether cilia defects in cholinergic interneurons and striatal astrocytes are cell autonomous and how pathogenic LRRK2 in specific cell types influences Hedgehog signaling (monitoring Gli1 induction with RNAscope in situ hybridization, Figure 1) and dopaminergic dendrite arborization [28] . <strong>Backup strategies</strong>: If we fail to identify novel pRab effectors we will focus on other already discovered, novel pRab effector pairs: EHBP1L1 [16], MYO5A [21], and JIP3/JIP4 [29] to better understand the breadth of phospho-Rab biology and critical molecular events triggered upon LRRK2</p>\n<h2>How LRRK2 impacts lysosome biology (Abu-Remaileh, Alessi, Pfeffer)</h2>\n<p>Human genetics and studies in mice implicate lysosomes in neurodegeneration including LRRK2-associated PD [4]. We aim to provide a global view of the role of LRRK2 regulation of lysosomes using our LysoIP method that allows rapid isolation of lysosomes from cultured cells and tissues [30] (Figure 2). First, we will profile&nbsp;lysosomes from the brain and other organs where LRRK2 is highly expressed including lung and kidney [17]. For this, we will cross our constitutive LysoTag mouse with LRRK2 activating mutants (R1441C &amp; G2019S) and the VPS35 mutant (D620N) to tag their lysosomes. To identify how LRRK2 impacts lysosomes in specific brain cells, we will tag lysosomes in neurons (Syn1-Cre [31]), microglia (CX3CR- Cre [32]), astrocytes (GFAP-Cre [33]) and oligodendrocytes (Olig2-Cre [34]) by crossing our conditional LysoTag mouse (lox-stop-lox-Tmem192-3xHA) (Figure 2) with the indicated Cre models. These models will provide tools to dissect the roles of LRRK2 in regulating lysosome function in relevant tissues and cell types. After rapid purification, we will perform high-resolution, untargeted analysis of the lysosomal proteome including phosphorylation state, lipid, and metabolite contents to identify sets of proteins and lysosomal pathways significantly impacted by LRRK2 and/or VPS35 pathogenic mutations. Our comprehensive datasets may reveal how pathogenic LRRK2 impacts levels or activity of enzymes regulating specific metabolites that may have toxic effects on neurons and/or glia. We will focus on the most robust, 1 or 2 altered pathways for follow up to learn how they lead to neurodegeneration and if they can be reversed by LRRK2 inhibitor administration. <strong>Backup strategies</strong>: To purify lysosomes from specific cell types, we will homogenize whole brains because LysoTag expression is restricted to the cell type of interest. Alternatively, we can enrich these populations or consider using a primary culture system if needed.</p>\n<h2>How LRRK2 and PINK1 signalling impact mitochondrial biology (Muqit, Abu-Remaileh, Alessi)</h2>\n<p>Loss of function mutations in PINK1 is causal for PD [35]. PINK1 is stabilized and activated on depolarized mitochondria where it promotes mitophagy by phosphorylation and activation of the Parkin E3 ligase [12-14]. Pathogenic LRRK2 has been linked to mitochondrial dysfunction [10, 11]. We hypothesize that loss of PINK1 and/or hyperactive LRRK2 lead to disrupted mitochondrial signalling, and will define how PINK1 and LRRK2 each regulate mitochondrial proteins, metabolites and lipids and assess any interplay by exploiting unbiased, rapid isolation of mitochondria tagged with 3XHA-EGFP- OMP25 (MitoTag-IP) [36, 37]. We have crossed LRRK2[R1441G] knock-in mice with PINK1 knockout mice generating primary MEFs from wild-type, homozygous LRRK2[R1441G] KI, homozygous PINK1 KO and double mutant mice lines. We will lentivirally transduce all four genotypes with MitoTag and then stimulate cells with mitochondrial uncouplers and/or LRRK2 inhibitors followed by mitochondrial isolation. We will also cross conditional MitoTag mice (loxp-STOP-loxp-3XHA-EGFP- OMP25) with LRRK2[R1441G], PINK1[KO] and LRRK2[R1441G]/PINK1[KO] mice to isolate mitochondria from brain regions including midbrain and non-CNS tissues including lung in which PINK1 and LRRK2 are expressed. Using MS we will undertake proteomic analysis of mitochondria to identify subsets of proteins whose expression or phosphorylation is altered upon mutant LRRK2 or PINK1 activity or both. In parallel we will perform high resolution untargeted analysis of mitochondrial metabolites and lipids. As in (3), we will verify whether pathogenic LRRK2 induces mitochondrial recruitment of phospho-Rabs and phospho-Rab effectors and whether LRRK2 inhibitors can reverse any changes observed. We will prioritize further analysis of a small subset of mitochondrial proteins whose expression is robustly affected by LRRK2 activity and/or PINK1. We will focus on the most robust, 1 or 2 pathways for follow up to learn how these altered pathways lead to neurodegeneration and if they can be reversed by LRRK2 inhibitor administration. We will investigate how these components are regulated in RPE cells that express both LRRK2 and PINK1 by CRISPR KI. Activation of PINK1 also indirectly induces phosphorylation of Rab8A at Ser111 at the mitochondria through an unknown kinase [38] that may inhibit LRRK2 phosphorylation [39]. We would be particularly interested in assessing if PINK1 induced mitochondrial recruitment of other kinase(s) that are required for Rab8A Ser111 phosphorylation and further explore their regulation and function. <strong>Backup</strong>: If MS analysis fails to identify relevant targets in whole brain tissues/regions we will generate primary neuron (cortical, hippocampal, dopaminergic) and astrocyte cultures from LRRK2 R1441G and PINK1 KO single and double mutant lines crossed with MitoTag mice to perform MitoTag-IP based MS analysis under basal and depolarisation conditions &plusmn; LRRK2 inhibitor to isolate CNS cells under differential states of PINK1 and LRRK2</p>\n<h2>General considerations</h2>\n<p>We have longstanding interactions with leading PD geneticists including T. Gasser (T&uuml;bingen), A. Singleton (NIH), and A. Zimprich (Vienna). For novel components we will consult to seek genetic evidence for PD risk association. For key identified components we will develop antibodies, CRISPR modified cell lines, recombinant proteins and assays required for characterization of their regulation &amp; function and will collaborate with other teams to maximize this opportunity.</p>\n<h1>Power Calculations and Statistical Analyses Plan</h1>\n<p>Power calculations were undertaken using the 2-sample, 2-sided equality (<a href=\"http://powerandsamplesize.com/Calculators/)\">http://powerandsamplesize.com//Calculators/)</a> calculation. We seek to be able to detect a &gt;1.5-fold difference between WT and mutants. Calculations will use power set at 0.8 and type I error at 5%. Tissue samples from each mouse will be analysed in triplicate. Our pilot pRab10 data in mouse brain (the hardest to measure) gives 20% standard deviation. To detect a 50% change with 5% error we would require a sample size of 6/group. We will include a contingency of 3 additional mice/group. Preliminary data indicate no difference in male vs. female mice; we will analyse both and monitor data further to confirm. We will study mice 8 to 16 weeks of age - the cilia phenotype can be seen at 10 weeks (SP+DA).</p>\n<h1>Project Timeline and Milestones</h1>\n<table>\n<tbody>\n<tr>\n<td width=\"42\">\n<p><strong>Aim</strong></p>\n</td>\n<td width=\"71\">\n<p><strong>Month</strong></p>\n</td>\n<td width=\"546\">\n<p><strong>Milestones</strong></p>\n</td>\n</tr>\n<tr>\n<td width=\"42\">\n<p>1</p>\n</td>\n<td width=\"71\">\n<p>0-6; 6-12</p>\n</td>\n<td width=\"546\">\n<p>Define Rab29:LRRK2 ARM interface (DA+SP), interactors that bind differentially to VPS35[D620N] (DA), target PPM1H to different organelles (DA+SP); Impact of Rab29 binding mutants on LRRK2 (DA+SP), prioritize VPS35[D620N] hits (DA+SP), how mis- localization of PPM1H impacts ciliogenesis and pRab8/10 (SP)</p>\n</td>\n</tr>\n<tr>\n<td width=\"42\">\n<p>1</p>\n</td>\n<td width=\"71\">\n<p>12-24</p>\n</td>\n<td width=\"546\">\n<p>Crystallize LRRK2 ARM with Rab29 (DA +SP), characterize VPS35[D620N] hits in regulating LRRK2 biology (DA +SP), characterize PPM1H interactors (DA+SP); reconstitute LRRK2 activation (DA+SP), initiate mechanistic analysis of VPS35[D620N] regulators (DA+SP), study roles of PPM1H regulators (DA+SP)</p>\n</td>\n</tr>\n<tr>\n<td width=\"42\">\n<p>1</p>\n</td>\n<td width=\"71\">\n<p>24-36</p>\n</td>\n<td width=\"546\">\n<p>Characterize factors participating in Rab29 and VPS35[D620N] activation of LRRK2 (DA+SP), finalize mechanistic analysis of PPM1H and its regulators (DA+SP)</p>\n</td>\n</tr>\n<tr>\n<td width=\"42\">\n<p>2</p>\n</td>\n<td width=\"71\">\n<p>0-6; 6-12</p>\n</td>\n<td width=\"546\">\n<p>pRab10 ciliogenesis blockade: does RILPL1/pRab10 block TTBK2 from binding CEP164? What does it bind at the mother centriole? Which phosphoinositides modulate TTBK2 recruitment? (SP), initiate generation of conditional LRRK2[R1441G] KI mice (DA)] ; Cilia loss in striatal astrocytes and ChAT+ interneurons: impact on Hedgehog, GDNF (SP)</p>\n</td>\n</tr>\n<tr>\n<td width=\"42\">\n<p>2</p>\n</td>\n<td width=\"71\">\n<p>12-24</p>\n</td>\n<td width=\"546\">\n<p>Complete analysis of impact of pRab10-RILPL1/2 on effector complexes (SP), cross conditional LRRK2[R1441G] KI mice with brain specific Cre animals (DA+SP); determine if cilia changes are cell autonomous as mouse lines are created (SP+MAR)</p>\n</td>\n</tr>\n<tr>\n<td width=\"42\">\n<p>2</p>\n</td>\n<td width=\"71\">\n<p>24-36</p>\n</td>\n<td width=\"546\">\n<p>Study ciliogenesis in conditional LRRK2[R1441G] KI mice (SP), characterize biochemistry and cell biology of novel pRab effectors (DA+SP)</p>\n</td>\n</tr>\n<tr>\n<td width=\"42\">\n<p>3+4</p>\n</td>\n<td width=\"71\">\n<p>0-6; 6-12</p>\n</td>\n<td width=\"546\">\n<p>Initiate LysoTag (MAR+DA) &amp; MitoTag mouse crosses &amp; generation of MitoTag cell lines (MM+DA); optimize IPs; exchange IP samples between teams &amp; compare results to ensure reproducibility; develop methods for lipidomics of lysosomes and mitochondria; establish MEF lines for all mouse models; Initiate MS analysis in LysoTag mice (MAR+DA) and MitoTag mice + MEFs (MM+MAR+DA): lipidomics and metabolomics (MAR) proteomics (MM+DA)</p>\n</td>\n</tr>\n<tr>\n<td width=\"42\">\n<p>3+4</p>\n</td>\n<td width=\"71\">\n<p>12-24</p>\n</td>\n<td width=\"546\">\n<p>MS analysis in LysoTag and MitoTag mice (MAR+DA), prioritize data for further analysis (MAR+MM+DA+SP)</p>\n</td>\n</tr>\n<tr>\n<td width=\"42\">\n<p>3+4</p>\n</td>\n<td width=\"71\">\n<p>18-36</p>\n</td>\n<td width=\"546\">\n<p>Mechanistic analysis of top lysosome and mitochondrial hits (MAR+MM+DA+SP)</p>\n</td>\n</tr>\n</tbody>\n</table>\n<h1>Workflow Schematic</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/577d5b2f-3fdc-4d39-a7e1-a921409cbd7f/alessi-workflow-image.png\" alt=\"Alessi_workflow image.png\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Purlyte, E., Dhekne, H. S&hellip;.Martinez, T. N., Tonelli, F., <strong>Pfeffer, S. R. </strong>and <strong>Alessi, D. R. </strong>(2018) Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. EMBO J. <strong>37</strong>, 1-18</li>\n<li>Mir, R., Tonelli, F., Lis, P., Macartney, T., Polinski, N. K., Martinez, T. N&hellip;,..Zimprich, A., Sammler, and <strong>Alessi, D. R. </strong>(2018) The Parkinson's disease VPS35[D620N] mutation enhances LRRK2- mediated Rab protein phosphorylation in mouse and human. Biochem J. <strong>475</strong>, 1861-1883</li>\n<li>Berndsen, K., Lis, P., Yeshaw, W. M., Wawro, P. S., Nirujogi, R. S., Wightman, M., Macartney, T., Dorward, M., Knebel, A., Tonelli, F., <strong>Pfeffer, S. R</strong>. and <strong>Alessi, D. R. </strong>(2019) PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. eLife 2019;<strong>8</strong>:e50416</li>\n<li>Wang, C., Telpoukhovskaia, M. A and Gan, L. (2018) Endo-lysosomal dysfunction: a converging mechanism in neurodegenerative diseases. Curr Opin Neurobiol. <strong>48</strong>, 52-58</li>\n<li>Henry, A. G., Aghamohammadzadeh, S., Samaroo, H&hellip;.Needle, E. and Hirst, W. D. (2015) Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. Hum Mol Genet. <strong>24</strong>, 6013-6028</li>\n<li>Schapansky, J., Khasnavis, S., DeAndrade, M. P., &hellip;.Sanderson, J. B., Bartels, T., Melrose, H. L. and LaVoie, M. J. (2018) Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble alpha-synuclein in neurons. Neurobiol Dis. <strong>111</strong>, 26-35</li>\n<li>Eguchi, T., Kuwahara, T., Sakurai, ,.. Harada, A., Fukuda, M., Koike, M. and Iwatsubo, T. (2018) LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc Natl Acad Sci USA. <strong>115</strong>, E9115-E9124</li>\n<li>Wallings, R., Connor, N. and Wade-Martins, R. (2019) LRRK2 interacts with the vacuolar-type H+- ATPase pump a1 subunit to regulate lysosomal function. Hum Mol Genet. <strong>28</strong>, 2696-2710</li>\n<li>Ysselstein, D., Nguyen, M., Young, T. J., Severino, A., Schwake, M., Merchant, K. and Krainc, (2019) LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients. Nat Commun. <strong>10</strong>, 5570</li>\n<li>Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, ,.. R., Carrillo-Reid, L., Xie, Z., Osborn, T., et al. and Isacson, O. (2012) Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med. <strong>4</strong>, 141ra190</li>\n<li>Wauters, F., Cornelissen, T., Imberechts, D., Martin, S., Koentjoro, B., Sue, C., Vangheluwe, P. and Vandenberghe, W. (2020) LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10. Autophagy. <strong>16</strong>, 203-222</li>\n<li>Narendra, D. P., Jin, S. M., Tanaka, ,.. Shen, J., Cookson, M. R. and Youle, R. J. (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. <strong>8</strong>, e1000298</li>\n<li><strong> </strong>Kondapalli, C., Kazlauskaite, A., Zhang, N., Woodroof, I., Knebel, A., <strong>Alessi, D. R. </strong>and <strong>Muqit, M. </strong><strong>M. </strong>(2012) PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. <strong>2</strong>, 120080</li>\n<li>Lazarou, M., Sliter, A.,.. Sideris, D. P., Fogel, A. I. and Youle, R. J. (2015) The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature. <strong>524</strong>, 309-314</li>\n<li>Steger, M., Tonelli, F., Ito, G., Davies, ,.. Baptista, M. A., Fiske, B. K., Fell, M. J., Morrow, J. A., Reith, A. D., <strong>Alessi, D. R. </strong>and Mann, M. (2016) Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. eLife 2016;<strong>5</strong>:e12813</li>\n<li><strong> </strong>Steger, M., Diez, F., Dhekne, H. S., Lis, P., Nirujogi, S., Martinez, T. N., Lorentzen, E., <strong>Pfeffer, S. </strong><strong>R., Alessi, D. R. </strong>and Mann, M. (2017) Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. eLife 2017;6:e31012</li>\n<li>Lis, P., Burel, S., Steger, M., Mann, M., Brown, , Polinski, N. K., Martinez, T. N., Davies, P. and <strong>Alessi, D. R. </strong>(2018) Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase. Biochem J. <strong>475</strong>, 1-22</li>\n<li>Ito, G., Katsemonova, K., Tonelli, F., Lis, P., Baptista, M. A., Shpiro, N., Duddy, G., Wilson, S., Ho, P.&nbsp;W., Ho, S. L., Reith, A. D. and <strong>Alessi, D. R. </strong>(2016) Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors. Biochem J. <strong>473</strong>, 2671- 2685</li>\n<li>Fan, Y., Howden, A. J. M., Sarhan, A. R., Lis, P., Ito, G., Martinez, T. N., Brockmann, K., Gasser, T., <strong>Alessi, D. R. </strong>and Sammler, E. M. (2018) Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem J. <strong>475</strong>, 23-44</li>\n<li>Dhekne, H. S., Yanatori, I., Gomez, R. C., Tonelli, F., Diez, F., Schule, B., Steger, M., <strong>Alessi, D. R. </strong>and <strong>Pfeffer, S. R. </strong>(2018) A pathway for Parkinson's Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain. eLife 2018;7:e40202</li>\n<li>Yanatori, I., Dhekne H,S., et al. and <strong>Pfeffer SR </strong>(2020) LRRK2-phosphorylated Rab10 sequesters Myosin Va with RILPL2 during ciliogenesis blockade. bioRxiv doi.org/10.1101/ 04.28.065664</li>\n<li>Liu, Z., Bryant, N., Kumaran, R., Beilina, A., Abeliovich, A., Cookson, M. R. and West, A. B. (2018) LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Hum Mol Genet. <strong>27</strong>, 385-395</li>\n<li>Kuwahara, T., Inoue, K., D'Agati, V. D., Fujimoto, T., Eguchi, T., Saha, S., Wolozin, B., Iwatsubo, T. and Abeliovich, A. (2016) LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts. Sci Rep. <strong>6</strong>, 29945</li>\n<li>Gomez, R.C., et al., <strong>Alessi, D. R. </strong>and <strong>Pfeffer, S. R. </strong>(2019) Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases. J Cell Biol. <strong>218</strong>, 4157-4170</li>\n<li>Follett, J., Norwood, S. J. et al. and Teasdale, R. D. (2014) The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. Traffic. <strong>15</strong>, 230-244</li>\n<li>Sobu, Y., Wawro, P. S., Dhekne, H. S. and <strong>Pfeffer, S. R. </strong>(2020) Pathogenic LRRK2 regulates ciliation probability upstream of Tau Tubulin kinase 2. bioRxiv, org/10.1101/2020.04.07.029983</li>\n<li>Xu, Q., Zhang, Y et al. and Ling, K. (2016) Phosphatidylinositol phosphate kinase PIPKIgamma and phosphatase INPP5E coordinate initiation of ciliogenesis. Nat Commun. <strong>7</strong>, 10777</li>\n<li>MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K. and Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron. <strong>52</strong>, 587-593</li>\n<li>Waschb&uuml;sch D, Purlyte E, Pal P, McGrath E, <strong>Alessi DR</strong>, Khan AR. (2020) Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2. Structure. 28(4):406-417.</li>\n<li><strong>Abu-Remaileh, M.</strong>, Wyant, G. A., Kim, C., Laqtom, N. N., Abbasi, M., Chan, S. H., Freinkman, E. and Sabatini, D. M. (2017) Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes. Science. <strong>358</strong>, 807-813</li>\n<li>Zhu, Y., Romero, M. I. et al. and Parada, L. F. (2001) Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. <strong>15</strong>, 859-876</li>\n<li>Yona, S., Kim, K. W., Wolf, Y., Mildner, A., et al. and Jung, S. (2013) Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. <strong>38</strong>, 79-91</li>\n<li>Gregorian, C., Nakashima, J. et al. and Wu, H. (2009) Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J Neurosci. <strong>29</strong>, 1874-1886</li>\n<li>Zawadzka, M. Rivers, L.E., Fancy, S.P., Zhao, C., et al.and Franklin, R. J. (2010) CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell. <strong>6</strong>, 578-590</li>\n<li>Valente, E. M., Abou-Sleiman, P. M., Caputo, V., <strong>Muqit, M. M.</strong>, &hellip;. and Wood, N. W. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. <strong>304</strong>, 1158-1160</li>\n<li>Chen, W. W., Freinkman, E., &hellip; and Sabatini, D. M. (2016) Absolute Quantification of Matrix Metabolites Reveals the Dynamics of Mitochondrial Metabolism. Cell. <strong>166</strong>, 1324-1337 e1311</li>\n<li>Bayraktar, E. C., Baudrier, L., Ozerdem, C., Lewis, C. A., Chan, S. H., Kunchok, T., <strong>Abu-Remaileh, M.</strong>, et al. and Chen, W. W. (2019) MitoTag Mice enable rapid isolation and multimodal profiling of mitochondria from specific cell types in vivo. Proc Natl Acad Sci U S A. <strong>116</strong>, 303-312</li>\n<li>Lai, Y. C., Kondapalli, C., &hellip; Trost, M. and <strong>Muqit, M. M</strong>. (2015) Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1. EMBO J. <strong>34</strong>, 2840-2861</li>\n<li>Vieweg, S., Mulholland, K., &hellip; Itzen, A. and <strong>Muqit, M. M. </strong>(2020) PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2 mediated phosphorylation at Threonine72. Biochem J.</li>\n</ol>\n<p>&nbsp;</p>"
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:21Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:20Z"
    }
  },
  {
    "title": {
      "iv": "GP2: The Global Parkinsons Genetics Program"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<div class=\"page\" title=\"Page 1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<h1>Abstract</h1>\n<p>Supported by the Aligning Science Across Parkinson&rsquo;s (ASAP) Initiative, the Global Parkinson&rsquo;s Genetics Program (GP2) is an international collaborative effort aimed at making transformational progress in Parkinson&rsquo;s disease (PD) genetics.</p>\n<p>The aim of GP2 is not simply to improve our understanding of the role genetics plays in PD across World populations, but to also make that understanding actionable. The path to achieving this vision involves the formation of a cohesive group of collaborators, data collection, production, and harmonization at scale, training of analysts around the world, and the development of a portal that democratizes data and analytical resources.</p>\n<p>Bringing together collaborators from Africa, Asia, Central America, the Caribbean, Europe, the Middle East, North America, Oceania, and South America, GP2 will integrate and generate critical clinical and genetic data. Using these data, GP2 will accelerate the identification of novel risk loci and monogenic causes of disease, identify genetic modifiers of disease phenotype and monogenic penetrance, fine map risk loci, and understand population differences in PD genetics.</p>\n<h1>Introduction</h1>\n<p>Fundamentally, the identification of genetic causes and contributors of disease represents the first step in an etiology-based understanding of disease, which, in turn, is a required step in the development of therapeutics targeting the underlying disease process. Genetic understanding serves as a foundation for succeeding functional studies and as a central component of efforts to predict disease risk, onset, and progression, and to understand disease mechanisms in individual patients. Without a reliable and complete foundation of genetic understanding, we limit our ability to develop and deploy treatments.</p>\n<p>A large number of risk loci and causative mutations for PD have been identified; however, it is clear that the majority of genetic risk remains to be found [1,2]. While much can be done with the existing knowledge, moving forward now to expand our genetic understanding will be the foundation that will support the development of a complete view of this network, providing an array of potential therapeutic opportunities. Increasing genetic information can only serve to improve our efforts to treat disease.</p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 2\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Notably, our understanding of the genetic basis of PD has thus far largely been centered on research in individuals of Northern European ancestry. While some genetic discoveries have been made outside of these populations, this work is the exception rather than the norm, and generally focuses on the identification of rare mutations; little has been done in the identification of more common genes or genetic risk discovery [3,4]. Thus, we do not know if our current understanding is generalizable to the rest of the world and how the basis of disease varies across populations. While it is tempting to argue that the genetic basis for the PD will generally be the same across populations, we know that differences in genetic risk exist, and further, there is evidence to suggest that genetic forms of disease can present differently across populations [3,5&ndash;8]. This fundamental limitation of current research creates an inequitable situation for patients.</p>\n<p>To facilitate the rapid expansion of our understanding of the genetic architecture of PD, both in terms of the depth and global context of this knowledge, we have created the Global Parkinson&rsquo;s Genetics Program (GP2, www.gp2.org). GP2 is the first supported resource project of the Aligning Science Across Parkinson&rsquo;s (ASAP) initiative, an audacious effort supporting PD research [9]. GP2 is geared toward creating a worldwide collaborative effort that will first dramatically accelerate the identification of genetic contributors to disease and second establish a network of researchers that can best leverage this understanding to research, diagnose, and treat PD worldwide. Here we describe our mission, the path we have proposed to achieve this, and the core principles of data democratization, transparency, and diversity.</p>\n<h1>Mission and underlying principles</h1>\n<p>The mission of GP2 is to drive transformational progress in our understanding of the genetic architecture of PD and to serve as a useful and actionable resource for the research and therapeutic development community. To fully realize this mission, GP2 will need to engage and mobilize a worldwide community of researchers and participants, generate and analyze genetic data at an extremely large scale, create an infrastructure that removes obstacles to data access, and make data and results accessible and useful to the broader community (Figure 1).</p>\n</div>\n</div>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>There are several underlying principles of GP2 that we believe are central to the overall success of our work and the continued success of the research community.</p>\n</div>\n<div class=\"column\">\n<ol>\n<li>Diversification: We will leverage the power of diversity across each dimension and in both researchers and participants.</li>\n<li>Democratization: We will ensure that the data, its use, compute resources, and results are not only available but usefully accessible to the broader research community. We will democratize GP2 and the use of GP2 data through training for contributing sites to create clinical and data-analytical expertise locally and regionally, growing our own and collaborators&rsquo; capabilities.</li>\n<li>Transparency and reproducibility: The collection, data generation, data cleaning, and analysis will be performed in an open manner. Methods, data, code, and results will be available to the research community in order to facilitate reproducibility, reduce redundancy, and to foster community involvement in and improvement of approaches.</li>\n<li>Collaboration and cooperation: We will promote a high degree of collaboration and cooperation across a global community. To be effective this must be centered on a shared vision, collective opportunities and responsibilities, and ensuring that each member has a voice in the organization.</li>\n<li><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Foundational, actionable resource generation: The data and results we produce will form the foundation of a wealth of scientific and clinical research; therefore they must be both easily available and in a form that is useful for and interpretable by the wider research community.</span></li>\n<li>Safe, responsible data sharing: Data sharing with the research community is key; however this must be done in a manner that ensures participant privacy and is in line with local regulations.</li>\n</ol>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 3\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<h1>Deliverables and path</h1>\n<p>Broadly, there are two scientific arms to GP2, one centered in genetically complex, typical PD, and the other in monogenic disease. Over the initial five-year span of the GP2 program, our path will lead us to a dramatic increase in the number of known genes, disease-causing mutations, and risk loci for both rare monogenic and typical complex PD. Further, this work will be extended, for the first time at scale, to underrepresented populations from around the World. We will generate dense genetic data in more than 150,000 participants, using a genotyping array specifically designed for this purpose. We will also generate whole-genome sequence data from more than 10,000 individuals, to determine the genetic cause in as yet unsolved monogenic cases and to generate much needed reference datasets. Furthermore, we will use long-read DNA sequencing to support the analysis of structural and repeat variability that is relatively resistant to interrogation using traditional genome sequencing methods.</p>\n<p>In order to ensure a functional and efficient structure, we created a series of working groups and hubs that center on achieving specific aims and priorities within GP2. While these groups have clear aims and deliverables, they function as a continuum with shared members (Figure 2).</p>\n<h2>Complex disease genetics</h2>\n<p>The role of this group is to explore the genetic basis of typical, apparently sporadic, PD. The foundation of this work will be the genotyping of 150,000 participants using an array designed by us specifically for this purpose. The Neuro Booster Array is centered on the backbone of the global diversity array (GDA, 1.8+ million variants) (https://www.illumina.com/products/by- type/microarray-kits/infinium-global-diversity.html) but also includes more than 95,000 custom content variants that include neurological disease-oriented content, and population-specific boosters (Manuscript in prep. https://github.com/GP2code/Neuro_Booster_Array). Broadly, we expect to generate data on ~100,000 Northern European ancestry individuals and more than 50,000 subjects from underrepresented populations from around the world. We have established collaborations to collect and assess cases of Black American, East Asian, African, Indian, Caribbean and Central/South American provenance.</p>\n<p>Data from underrepresented populations will be generated from a variety of sources. GP2 has already initiated partnerships with academic research centers in the US to improve respresentation of Black Americans within the project. Samples and data are being collected from East Asia by the International Parkinson&rsquo;s Disease Genomics Consortium (IPDGC) East Asia group, with efforts ongoing in Taiwan, Japan, South Korea, and China. Likewise, IPDGC Africa has initiated collaborations across Africa beginning with patients from Nigeria, Egypt, Ethiopia, Ghana, Mali, Tanzania, Senegal, South Africa, Sudan, and Zambia. The Genetic Epidemiology of Parkinson&rsquo;s disease (GEoPD) Consortium has developed collaborations across underrepresented populations from North and Sub-Saharan Africa, Australia, and Asia. The Luxembourgish- German Indian Alliance on Neurodegenerative diseases and Therapeutics (Lux-GIANT) has <span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">formed a collaborative group to investigate PD patients across India [10]. Lastly, the Latin American Research Consortium on the Genetics of Parkinson&rsquo;s Disease (LARGE-PD) group is a fully active collaborative group collecting and investigating patients from Argentina, Brazil, Chile, Costa Rica, Colombia, Ecuador, Honduras, Mexico, Peru, Puerto Rico, Uruguay, and West Indies [11]. As GP2 continues, there will be room to expand to other countries and populations underserved in our current research.</span></p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 4\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>These data, collectively, will afford the opportunity to rapidly detect novel genetic risk for PD. Critically, the availability of similar data across ancestral groups will allow an assessment of the varied genetic contribution in different ancestries, including the identification of population-specific loci, an understanding of the differences in the heritable component of disease between groups, and the generation of population-specific genetic risk profiles. Notably, these data collectively provide the opportunity to refine association signals, with trans-ethnic fine mapping.</p>\n<p>A crucial step will be integration of clinical phenotype data. We know that there are diverse outcomes of PD including rate of motor and cognitive deterioration, and medication side effects such as levodopa-induced dyskinesias [12]. We believe that these will be in part genetically determined [13,14] and that understanding the associated genes and pathways will lead to new biological insights and importantly personalised treatments. A barrier to this is the harmonisation of data, which is a major goal of the cohort integration group.</p>\n<h2>Monogenic disease genetics</h2>\n<p>While modern genetic methods provide tools for the rapid discovery of rare causal or high-risk mutations, several barriers exist that limit the efficiency of identifying novel causes of disease. First, multiplex families are overall rare and dispersed; second, the generation and analysis of genetic data are specialized and expensive; third, existing genetic data are not harmonized and often not available for sharing; and fourth, penetrance is reduced in dominantly inherited forms and, although high in recessive forms, age-dependent. The latter results in frequent absence of the most prominent red flag for the occurrence of a monogenic form of PD, i.e. positive family history, so that a significant proportion of patients miss out on genetic testing and research because they are not deemed good candidates. Collectively, this means that finding segregating mutations, or mutations in the same putative novel gene is difficult; this in turn has resulted in the publication of a growing number of potentially disease-associated mutations that are preliminary and can be quite misleading or confusing to the field. Importantly, and unlike findings from complex genetic studies of PD, these putative new monogenic causes are often readily implemented in PD gene panels for diagnostic testing by genetic testing companies, posing an additional challenge to patients, unaffected carriers, genetic counselors and physicians in terms of interpretation of the ensuing test results.</p>\n<p>The monogenic disease arm of GP2 aims to address these obstacles and thereby create an efficient infrastructure to accelerate the identification of novel genetic causes of apparently monogenic PD. Leveraging the above-described global network of researchers contributing patient samples to GDA genotyping and including already existing resources from the monogenic field, such as IPDGC [15], the GEoPD and the MJFF Global Genetic Parkinson&rsquo;s Disease Study Group [16], the monogenic arm will collect &gt;5,000 patients and families in whom a monogenic cause may be suspected. Particular emphasis will be placed on families from underrepresented populations. All currently known PD genes have been found in various populations around the globe, however, some occur at highly variable and population-specific frequencies, the most striking examples being the p.G2019S mutation in the LRRK2 gene [17] and GBA mutations including p.N370S [18] and p.K198E [19]. In addition, it is conceivable that population-specific hereditary forms of PD may exist, as exemplified by X-linked dystonia-parkinsonism (XDP), a <span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">condition exclusively present in patients of Filipino ancestry (Pauly et al. Mov Disord, in press), for which the underlying genetic cause has been identified as well as genetic age-at-onset modifiers [20&ndash;22]. This condition has served as an important model for basal ganglia disease [23,24].</span></p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 5\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The monogenic arm will collect families, singleton cases, and patient-parent trios, and prioritize these for WGS or long-range sequencing based on a number of different criteria: family history and availability of samples from several affected (and unaffected) family members, age at onset, ethnicity (with a focus on underrepresented populations), and level of available genetic pre- screening. Importantly, all patients enrolled into the monogenic arm of the project will also undergo Neuro Booster Array genotyping which, based on its PD-related custom content, will result in the identification of a sizable number of patients with mutations in known PD genes. Assuming that an average of ~10-15% of all PD patients carry a mutation in a known PD gene (3- 5%) or a high risk variant in GBA (8-10%) [25], we estimate a total of ~15,000 monogenic or high risk variant carriers to be detected in the total GP2 sample set. It is at this important interface, where the complex genetic and monogenic arms will interact most closely: While the complex genetics arm will identify carriers of known PD-causing mutations that can then be enrolled in various additional investigations, such as genetic modifier studies of age at onset, the monogenic hub will contact all submitters of patients to the monogenic hub to also enroll patient and control cohorts into the complex genetics hub. This interplay will create unprecedented opportunities not only for the discovery of novel genetic causes of PD but also for a better understanding of the known genetic forms of PD.</p>\n<h1>The Democratization of Data Resources</h1>\n<p>Over the last fifteen years, the genetics field has made great strides toward making data available to the research community. However, barriers still exist. Data is typically highly dispersed across silos/portals, there is often considerable administrative burden for data access especially when accessing multiple datasets and data use agreements can be restrictive. In addition, the analytical expertise to interpret results or analyze data can be high, and the cost of data analysis plus curation can be prohibitive. A key stated outcome of GP2 is the generation of data and analyses that can be readily accessed and interpreted by the broad research community. To achieve this, we are taking several steps to consolidate data in one place and provide all analysis scripts with the necessary context in GitHub (https://github.com/GP2code), a public domain.</p>\n<p>We will place as much information as timely and responsibly possible in the public domain, without requiring an extensive data use agreement. While the protection of participant&rsquo;s data must be a priority, a large number of analyses only require summary results and many of these can be shared publicly. De-identified participant level data will be stored securely; however, we will only require a single data use agreement to access these cohorts, streamlining the data access process.</p>\n<p>We will follow a model where researchers analyze data in place, rather than downloading data to local computers. This approach offers several advantages: it means that we can reduce redundancies by capturing standard quality control and analyses and sharing these as a common path. It means we can create collaborative and training opportunities and resources by working across a common, shared workspace. In GP2, we can be both standardized and transparent in our analyses, which can be easily shared with the research community, allowing independent testing, additive analyses, and crowd-sourced improvements to workflows. This approach democratizes the data, tools, and infrastructure, allowing individuals with the skillset but without the compute resources to access and analyze these data. The model of analysts coming to the <span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">data, rather than vice versa, is one being increasingly used or promoted by major national and global genetics and genomics initiatives such as the International Complex Disease Alliance (see whitepaper at https://www.icda.bio/) and the AllOfUs initiative (https://allofus.nih.gov/). To achieve these aims, our current model is centered around Terra (https://terra.bio/) with other platform options possible soon.</span></p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 6\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Terra is a cloud-based, scalable platform developed and actively maintained by the Broad Institute (https://www.broadinstitute.org/) specifically for biomedical research, supporting other initiatives similar to GP2. Terra supports direct access to data stored in Google Cloud Storage and all analysis can be performed on Terra, which eliminates the need for data to be downloaded to local systems and ensures that researchers work from the same data. This is especially important to comply with current GDPR standards and allowing participants to withdraw their information from future analyses. Currently, Terra supports two types of analysis: pipelining with workflows and real-time analysis with Jupyter Notebooks. Workflows allow researchers to perform whole pipelines, such as aligning sequence data per sample and joint-calling across populations. Notebooks follow an intuitive structure and allow for interactive analysis, text that provides appropriate context, and immediate visualization. Terra makes collaboration easy and transparent with the ability to share notebooks and workspaces selectively with other researchers who have similar permissions. Sharing notebooks on a public access workspace allows other researchers to easily use and reproduce your exact workflow. The Terra platform aligns with GP2 goals by creating a secure and easy way to analyze data in the cloud, and enabling collaborative, reproducible, and transparent science.</p>\n<h1>Training and networking</h1>\n<p>It is not enough to just make data available to the wider PD research community. A key part of GP2 is to develop training opportunities that will benefit clinicians and researchers around the world so that they may pursue their own questions using GP2 data.</p>\n<p>These training opportunities aim to establish broad, foundation-level knowledge in genetics, bioinformatics, medical statistics and molecular biology, through a suite of new web-based materials. Our program of web-based training has been brought into sharp focus by the COVID- 19 pandemic and we have accelerated our efforts to deliver educational material in spite of restrictions to travel. We also aim to support clinical training opportunities in regions that would benefit most from this. The increased training would lead to more accurate diagnosis and phenotyping of the participants donating samples for GP2.</p>\n<p>For individuals that demonstrate exceptional drive and talent, whatever their background, we will support a range of individual, formal training opportunities in the form of taught courses (such as Masters degrees), bespoke training visits at centers of excellence, and full PhD studentships. We are committed to serving the needs of clinicians and researchers that have been underrepresented so far in research, and we will enable research training opportunities and build sustainable partnerships through a network of GP2 collaborators.</p>\n<h1>Promoting diversity</h1>\n<p>It is of both scientific and social imperative that research efforts be expanded to diverse populations. We believe that a critical component of expanding research to underserved and underrepresented populations is ensuring ownership of local studies by local researchers, an active voice and role in the global study, and training, development and other infrastructure support for local researchers to build on their expertise.</p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 7\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Within GP2, we aim to address this in several ways. All data are returned to contributing investigators immediately upon completion of harmonization and quality control; further, these data are available to the group within the GP2 Terra compute space, so the individual investigator can access the processing and quality control workspaces that have been used to generate these data. Local investigators can also use GP2 supported cloud computing to perform additional analyses on these data, removing the cost of providing their own infrastructure. A remaining challenge then is ensuring that sufficient expertise exists to perform these analyses. Here, GP2 is providing several layers of support. Within GP2, we have a data analysis core that not only serves to perform study-wide analyses but also to support members in the form of direct analytical services, partners in training, and by providing a data concierge service.</p>\n<h1>Uses of these data</h1>\n<p>The work planned for GP2 will provide foundational data and fundamental insights for PD research. We believe that this work touches almost every aspect of the path from basic biological understanding to therapeutic deployment. It has the potential to inform biology, improve modeling, identify and prioritize targets, inform trial design, increase trial efficiency, and match patients to therapies.</p>\n<p>Most obviously, the work from GP2 will lead to a significant increase in the proportion of the known heritable component of disease. We estimate that our efforts will provide a significant increase in the knowledge that serves as the genesis for our path to functional understanding [1]. This will improve the genetic component of multi-modal risk prediction models and will provide us with greater power to determine whether genetic subtypes of the common disease are present.</p>\n<p>Based on prior experience, the expansion of efforts into traditionally underrepresented populations will also lead to the identification of new loci that are either absent or of weaker effect in the Northern European population [3,5,6]. The underlying genetic data in the underrepresented groups will allow us to determine whether heritability differs substantially across ancestral groups and to construct ancestry-specific risk profiles. Comparisons across all of the ancestral groups will also be incredibly valuable, providing insights into the genetic basis for any potential differences in disease presentation and course, as well as highlighting which groups may be particularly suited to a distinct etiologic-based therapeutic approach. Further, the differences and similarities at individual loci allow us to use trans-ethnic fine-mapping to reduce the critical intervals in which functional risk alleles reside and to identify the functional effector gene.</p>\n<p>Beyond risk, GP2 provides the opportunity to examine the genetic basis of variability in disease. Age at onset, progression, and the range of symptoms and comorbidities are each amenable to genetic discovery. Perhaps more importantly, this work paves the way for the creation of individual risk profiles for onset and trajectories of disease.</p>\n<p>Creating the infrastructure and processes for the identification of mutations underlying rare monogenic forms of disease will accelerate our discovery of novel high-penetrant gene mutations. It will also aid in the efficiency of how the field promotes and tests candidate mutations; a large number of mutations in putative disease-linked genes have been published over the past five years, and the existence of reference variant data in a large and diverse series of PD cases will speed up validation and hopefully reduce the number of false-positives reports of disease-linked genes. Again, these fundamental insights provide the basis for functional investigation of disease and provide immediate targets for therapeutic investigation.</p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 8\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Combining complex genetic approaches with data produced in monogenic cases also allows the identification of genetic modifiers of disease penetrance. Past experience, while of limited power, has shown that this approach is feasible [25,26]. Further, these data suggest that such work may reveal differential effects of the same risk loci in primarily monogenic and complex disease, a potential functional basis for etiologic differences, or at least different etiologic weights between patients. This area is of stated interest to our colleagues in industry who are looking for potential modifiers of the disease process.</p>\n<h2>Broad Applicability</h2>\n<p>There are a wide variety of opportunities provided by the GP2 study that are not part of its most immediate scope. Subject cohorts for GP2 will come from a large range of sources, each with varying ancillary data and future workflows. There is significant potential for additional work made possible through the generation of GP2 data. Our partnership with the PPMI study (https://www.ppmi-info.org/) enables the use of genetic and inferred ancestry data in biomarker development work. This can involve a range of possibilities, including the integration of genetics within multi-modal disease predictions, an examination of the influence of ancestry on biomarkers, and the use of genetics to improve biomarker readouts by adjusting for genetic influence unrelated to disease.</p>\n<p>Like PPMI, many studies have collected additional data (including imaging, phenotype and environmental data) that can be analyzed with genetics. The availability of imaging and neuropathology data provides an opportunity to understand the genetic basis of variance in these measures and may offer insights on disease subtyping. The availability of other data and tissue from samples genotyped in GP2 is also exciting. Combining data from largely unbiased methods such as transcriptomics, epigenomics, metabolomics, and proteomics with genetics provides the opportunity to map quantitative trait loci in both health and disease, an approach that has been used to understand basic etiology and improve biomarker accuracy.</p>\n<p>The sponsorship of GP2 in collecting samples from underrepresented populations also opens up the opportunity to perform ancillary studies in these groups. At the most basic level this may include simple phenotypic characterization of patients from countries or ancestral groups where little has been previously done. It can also include work on attitudes and perspectives on disease and the use of genetics.</p>\n<p>We believe these opportunities, and myriad others in the spaces of environment, epidemiology, epigenetics, and beyond, can and should be prioritized for further research. Our aim in GP2 is not to create an organization that tackles each of these, but rather to create a structure around which such studies can be organized. Our hope is that individual investigators within the GP2 network will propose new lines of investigation and form alliances and collaborations with other investigators to explore these questions. We believe that GP2 and our collective data and structure can serve as an initiator for such work.</p>\n<h2>Cellular context and function</h2>\n<p>The identification of novel PD-linked gene mutations and loci will add considerable insight into the underlying basis and biology of disease. There is excellent evidence from PD and other diseases that integrating these results with other genomic data can provide compelling evidence on the cellular context of genetic risk, a key step in ensuring the relevance of modeling efforts [2,27,28]. Likewise, the more genetic information we possess, the more complete a picture we can construct of the pathogenesis of disease. ASAP has supported a series of ambitious projects within the Collaborative Research Network (https://parkinsonsroadmap.org/research-network/) with a major focus on work to determine the biology of PD-associated genetics. In the relatively short time that we have reliably been able to identify genetic risk factors at scale, the translation to mechanistic <span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">understanding has been challenging. However, recent advances, particularly in the space of single-cell genomics, will elucidate the cellular context, effector gene, and immediate biological effect. Most immediately this will be achieved through the combination of genetic risk loci with human single-cell data on transcription, chromatin accessibility, and physical chromatin interactions. Once defined, the cellular context and disease-relevant effect on expression can be used in traditional reductionist or more recent systems approaches to define disease pathways and networks respectively. Regardless of the path taken, a fundamental understanding of the breadth and depth of genetic influence in PD will at a minimum enhance our ability to understand the disease process but more likely it will form the foundation of that knowledge.</span></p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 9\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<h2>Informing trial design</h2>\n<p>GP2&rsquo;s work can afford us insights into the idea of mechanistic subsetting of disease; whether there are many distinct networks involved in the disease process and the distribution of these mechanisms across a typical PD population. Critically, if we find enriched or divergent mechanisms in subsets of patients, it will be important to match patients with mechanistic personalized therapeutics. This is, in essence, an extension of the rational idea of testing (for example) LRRK2 kinase inhibitors initially in LRRK2 mutation-positive cases. Further, because an outcome of GP2 will be an improved prediction of disease risk and progression, this information will serve to facilitate improved clinical trial design, supporting trials in early (even pre-clinical) patients, and adjusting outcomes based on individualized predictions of progression.</p>\n<h1>The future</h1>\n<p>As discussed above, there are a large number of potential projects and opportunities associated with the GP2 data and collaborative framework. We are clearly at the beginning of our journey but it is certainly difficult to resist the temptation to speculate on what priorities and opportunities may emerge as we continue.</p>\n<p>Clearly, the results of our current work plot the course forward. The efforts of the monogenic group are already providing a clearer understanding of what is left to be found and poised to address key questions in the field. Can we identify modifiers to monogenic disease? How close are we to identifying the majority of these factors? What critical features remain to determine which mutation carriers will express disease, and when? Likewise, data from the complex genetics group will address similar questions. We will be better able to answer the question of whether we have reached biological saturation in common risk loci - the point at which newly identified loci are failing to add new insight into disease biology - perhaps an appropriate stopping point for GWAS. We will also have a good idea of whether scaling up our sequencing efforts in complex disease makes sense; do we see significant additional discoveries or resolution using this method over genotyping?</p>\n<p>At the simplest level, scale is immediately compelling and it is apparent even now that it would be particularly important to scale up our work in underrepresented groups. We know our current efforts in underrepresented groups represent a significant commitment and a major step forward for the field, however, they are just a start. As we show success in these groups it will be important to capitalize on this momentum and continue to invest in research within and by underserved communities so that we can realize the most potential from this work.</p>\n<p>Lastly, we should also be considering the next immediate steps after genetic discovery. In many ways genetics has evolved into a systematic endeavor rather than a scientific one. We have a clear path forward and broad consensus on the road to take. This is also becoming true for the next immediate steps to translate from genetic maps to mechanism, and there may be some <span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">advantage to GP2 tackling some of these problems, particularly around the creation of resources to make this translation efficient. However, regardless of how we get to these next steps, we believe that GP2 will serve as the starting point on this journey and a foundation for the global PD research community. We are excited about the progress we&rsquo;ve made so far, and thrilled to be making this journey with our partners.</span></p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 10\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<h1>Acknowledgements and funding</h1>\n<p>This research was supported by: The Aligning Science Across Parkinson&rsquo;s Initiative. The Intramural Research Program, National Institute on Aging, National Institutes of Health, Department of Health and Human Services; project ZO1 AG000949. The Michael J Fox Foundation for Parkinson&rsquo;s Research.</p>\n<h1>Financial disclosure and conflict of interest</h1>\n<p>Dr. Singleton is supported by the Intramural Research Program of the National Institute on Aging and has received grant support from the Michael J Fox Foundation for Parkinson&rsquo;s Research and the Aligning Science Across Parkinson&rsquo;s Initiative. He has received royalty payments related to a diagnostic for Stroke. He has no conflicts of interest to report.</p>\n<p>Dr. Blauwendraat is supported by the Intramural Research Program of the National Institute on Aging and has received grant support from the Michael J Fox Foundation for Parkinson&rsquo;s Research and the Aligning Science Across Parkinson&rsquo;s Initiative. He has no conflicts of interest to report.</p>\n<h1>References</h1>\n<ol>\n<li>\n<p>Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson&rsquo;s disease. Lancet Neurol 2020;19:170&ndash;8.</p>\n</li>\n<li>\n<p>Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&rsquo;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019;18:1091&ndash;102.</p>\n</li>\n<li>\n<p>Foo JN, Chew EGY, Chung SJ, et al. Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study. JAMA Neurol Published Online First: 20 April 2020. doi:10.1001/jamaneurol.2020.0428</p>\n</li>\n<li>\n<p>Zhao Y, Qin L, Pan H, et al. The role of genetics in Parkinson&rsquo;s disease: a large cohort study in Chinese mainland population. Brain 2020;143:2220&ndash;34.</p>\n</li>\n<li>\n<p>Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson&rsquo;s disease. Nat Genet 2009;41:1308&ndash;12.</p>\n</li>\n<li>\n<p>Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson&rsquo;s disease. Nat Genet 2009;41:1303&ndash;7.</p>\n</li>\n<li>\n<p>Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism in 10 <span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">ethnic Chinese. Neurology 2000;55:800&ndash;5.</span></p>\n</li>\n</ol>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 11\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ol start=\"8\">\n<li>\n<p>Subramony SH, Hernandez D, Adam A, et al. Ethnic differences in the expression of neurodegenerative disease: Machado-Joseph disease in Africans and Caucasians. Mov Disord 2002;17:1068&ndash;71.</p>\n</li>\n<li>\n<p>Schekman R, Riley EA. Coordinating a new approach to basic research into Parkinson&rsquo;s disease. Elife 2019;8. doi:10.7554/eLife.51167</p>\n</li>\n<li>\n<p>Rajan R, Divya KP, Kandadai RM, et al. Genetic Architecture of Parkinson&rsquo;s Disease in the Indian Population: Harnessing Genetic Diversity to Address Critical Gaps in Parkinson's Disease Research. Front Neurol 2020;11:524.</p>\n</li>\n<li>\n<p>Zabetian CP, Mata IF, Latin American Research Consortium on the Genetics of PD (LARGE-PD). LARGE-PD: Examining the genetics of Parkinson&rsquo;s disease in Latin America. Mov Disord 2017;32:1330&ndash;1.</p>\n</li>\n<li>\n<p>Lim S-Y, Tan AH, Ahmad-Annuar A, et al. Parkinson&rsquo;s disease in the Western Pacific Region. Lancet Neurol 2019;18:865&ndash;79.</p>\n</li>\n<li>\n<p>Tan MMX, Lawton MA, Jabbari E, et al. Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson&rsquo;s Disease. Mov Disord Published Online First: 28 October 2020. doi:10.1002/mds.28342</p>\n</li>\n<li>\n<p>Iwaki H, Blauwendraat C, Leonard HL, et al. Genomewide association study of Parkinson&rsquo;s disease clinical biomarkers in 12 longitudinal patients' cohorts. Mov Disord 2019;34:1839&ndash; 50.</p>\n</li>\n<li>\n<p>International Parkinson Disease Genomics Consortium (IPDGC). Ten Years of the International Parkinson Disease Genomics Consortium: Progress and Next Steps. J Parkinsons Dis 2020;10:19&ndash;30.</p>\n</li>\n<li>\n<p>Vollstedt E-J, Kasten M, Klein C, et al. Using global team science to identify genetic parkinson&rsquo;s disease worldwide. Ann Neurol 2019;86:153&ndash;7.</p>\n</li>\n<li>\n<p>Healy DG, Falchi M, O&rsquo;Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson&rsquo;s disease: a case-control study. Lancet Neurol 2008;7:583&ndash;90.</p>\n</li>\n<li>\n<p>Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson&rsquo;s disease. N Engl J Med 2009;361:1651&ndash;61.</p>\n</li>\n<li>\n<p>Velez-Pardo C, Lorenzo-Betancor O, Jimenez-Del-Rio M, et al. The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru. Parkinsonism Relat Disord 2019;63:204&ndash;8.</p>\n</li>\n<li>\n<p>Bragg DC, Mangkalaphiban K, Vaine CA, et al. Disease onset in X-linked dystonia- parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in. Proc Natl Acad Sci U S A 2017;114:E11020&ndash;8.</p>\n</li>\n<li>\n<p>Westenberger A, Reyes CJ, Saranza G, et al. A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism. Ann Neurol 2019;85:812&ndash;22.</p>\n</li>\n</ol>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 12\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ol start=\"22\">\n<li>\n<p>Aneichyk T, Hendriks WT, Yadav R, et al. Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. Cell 2018;172:897&ndash;909.e21.</p>\n</li>\n<li>\n<p>Weissbach A, Baumer T, Rosales R, et al. Neurophysiological fingerprints of X-linked dystonia-parkinsonism: A model basal ganglia disease. Mov Disord 2015;30:873&ndash;5.</p>\n</li>\n<li>\n<p>Hanssen H, Prasuhn J, Heldmann M, et al. Imaging gradual neurodegeneration in a basal ganglia model disease. Ann Neurol 2019;86:517&ndash;26.</p>\n</li>\n<li>\n<p>Blauwendraat C, Reed X, Krohn L, et al. Genetic modifiers of risk and age at onset in GBA associated Parkinson&rsquo;s disease and Lewy body dementia. Brain 2020;143:234&ndash;48.</p>\n</li>\n<li>\n<p>Iwaki H, Blauwendraat C, Makarious MB, et al. Penetrance of Parkinson&rsquo;s Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Mov Disord 2020;35:774&ndash;80.</p>\n</li>\n<li>\n<p>Bryois J, Skene NG, Hansen TF, et al. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson&rsquo;s disease. Nat Genet 2020;52:482&ndash;93.</p>\n</li>\n<li>\n<p>Agarwal D, Sandor C, Volpato V, et al. A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders. Nat Commun 2020;11:4183.</p>\n</li>\n</ol>\n</div>\n</div>\n<div class=\"layoutArea\">&nbsp;</div>\n</div>\n<div class=\"page\" title=\"Page 13\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<h1>Figures</h1>\n<p><strong>Figure 1: The scientific outcomes and underlying structural priorities of GP2</strong></p>\n<p><strong><img src=\"https://cloud.squidex.io/api/assets/asap-hub/450f499f-d1a8-4d06-bedb-fc989b4ea6a4/gp2-figure-1.jpg\" alt=\"GP2 Proposal Figure 1\" width=\"711\" height=\"490\" /></strong></p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 14\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Figure 2: Organizational structure of GP2</strong></p>\n<p><strong><img src=\"https://cloud.squidex.io/api/assets/asap-hub/50c378d3-c599-44b8-82aa-f653602751e7/gp2-figure-2-3-.jpg\" alt=\"GP2 Proposal Figure 2\" width=\"719\" height=\"686\" /></strong></p>\n</div>\n</div>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>&nbsp;</p>\n<p><em>Steering committee:</em> This group oversees the general operation of GP2 and collectively crafts the strategies for achieving our mission and maintaining our core principles.</p>\n<p><em>Operations and compliance:</em> creates and manages the operational workflow for GP2 in addition to ensuring compliance with national and international regulations.</p>\n<p><em>Monogenic hub:</em> designs and manages the collection and prioritization of samples from patients with putative monogenic disease, organizes whole genome sequencing, and performs data analysis.</p>\n<p><em>Sample prioritization: </em>This group will use a scoring system to prioritize cases where a monogenic cause is strongly suspected, with the goal of increasing the likelihood of discovering <span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">new PD genes. Additionally, we hope to gather samples from across the world and include patients from underrepresented populations.</span></p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 15\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><em>Data analyses: </em>To execute and coordinate core analyses to identify the genetic basis of monogenic forms of PD</p>\n<p><em>Portal development: </em>To develop and manage a user-friendly web-based interface through which researchers can contribute data and samples, and obtain results of their patients, as well as aggregated data from other GP2 participating centers.</p>\n<p><em>Complex hub: </em>This group ensures that the complex disease effort operates efficiently, meeting the data generation and analysis milestones laid out in the proposal</p>\n<p><em>Cohort integration:</em> This group liaises with clinical/genetic cohorts to engage them in the overall project, define common clinical datasets, harmonize data for phenotype analysis and help to ensure collaborative clinical-genetic research with investigators working on clinical cohorts around the world.</p>\n<p><em>Data analyses:</em> To design and execute core analyses to identify the basis of genetically complex forms of PD</p>\n<p><em>Underrepresented populations</em><br />This working group has the goal of increasing representation and deciphering the genetic factors that are associated with PD in non-European ancestry populations.</p>\n<p><em>Data and Code Dissemination</em><br />To enable open science by sharing meaningful data, analytical code, and results, balancing participant privacy, regulations, and data security</p>\n<p><em>Training and Networking</em><br />To establish a virtual center-of-excellence to promote training, networking and communication throughout the GP2 project.</p>\n<h2>Appendix</h2>\n<h3>Global Parkinson&rsquo;s Genetics Program:</h3>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/77495ad7-bb49-4902-b118-76a996a68051/screen-shot-2021-01-21-at-2.39.30-pm.png\" alt=\"\" width=\"700\" height=\"219\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/1318c924-dd23-4cec-ba48-96789a5fc8a7/screen-shot-2021-01-21-at-2.39.47-pm.png\" alt=\"\" width=\"700\" height=\"316\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/01311a93-e20b-42da-ada3-69584d99958d/screen-shot-2021-01-21-at-2.39.59-pm.png\" alt=\"\" width=\"700\" height=\"240\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/155fd10d-7b61-4a6b-9b55-78fe3caed94b/screen-shot-2021-01-21-at-2.40.10-pm.png\" alt=\"\" width=\"700\" height=\"289\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/1a485c71-c160-481b-8292-90bc77989609/screen-shot-2021-01-21-at-2.40.17-pm.png\" alt=\"\" width=\"700\" height=\"147\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/3da2869b-63ec-4ad8-9357-878139cb177c/screen-shot-2021-01-21-at-2.40.26-pm.png\" alt=\"\" width=\"700\" height=\"243\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/387a45fb-0967-4751-82b8-3a44a734c5e5/screen-shot-2021-01-21-at-2.40.37-pm.png\" alt=\"\" width=\"700\" height=\"256\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/750dcb94-37a2-413c-977a-c755e98da6e0/screen-shot-2021-01-21-at-2.40.46-pm.png\" alt=\"\" width=\"700\" height=\"302\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/f71da12b-689a-4a50-a5b1-604ca4cd3b02/screen-shot-2021-01-21-at-2.40.54-pm.png\" alt=\"\" width=\"700\" height=\"165\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/dd7e45da-1842-4aa6-987b-649e26a0fff4/screen-shot-2021-01-21-at-2.41.03-pm.png\" alt=\"\" width=\"700\" height=\"247\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/2599d997-c2ec-48a6-8976-099532b63314/screen-shot-2021-01-21-at-2.41.12-pm.png\" alt=\"\" width=\"700\" height=\"307\" /></p>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 18\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>&nbsp;</p>\n</div>\n</div>\n</div>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:20Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:20Z"
    }
  },
  {
    "title": {
      "iv": "Dissecting the Mechanisms Underlying Disease Progression in Parkinsonism"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>Project Summary</h1>\n<p>Genetic analysis has identified many risk genes for Parkinson&rsquo;s disease (PD), giving insight into the mechanisms of initiation<sup>1</sup>. The implicated pathways include mitophagy and lysosomal insufficiency. However, the disease is variable in its rate of progression and spread in the brain<sup>2</sup>. Understanding this variability is our aim and our final goal is to slow this progression. We will shed light on the biology underlying this variability by studying the spread of pathology in the human brain, in mouse and cellular models of disease and by integrating these findings to develop a comprehensive model of the biology of progression. These data will provide the foundations for future drug development efforts. To achieve this vision, we have brought together a world-class interdisciplinary team. Our proposal has 4 themes: i) a <strong>Functional Genetics </strong>theme to identify loci underlying progression ii) a <strong>High Throughput Cell Biology </strong>theme to understand the mechanisms and test therapies, iii) a <strong>Human Molecular Pathology </strong>theme to understand progression in the human disease, and iv) a <strong>Mouse Transgenic Models </strong>theme to understand and manipulate progression in a model of pathology spread.</p>\n<h1>Rationale and Preliminary Data&nbsp;</h1>\n<p>The rationale of this grant is that: i) PD causation and progression have a distinct genetic and molecular architecture, ii) high variability in PD progression suggests that targeting progression would have impact and iii) there is insufficient research into the pathophysiology of progression. This grant addresses this gap through a multi-pronged approach, which should form the basis for novel therapeutic strategies.</p>\n<p>We have generated data across the four themes to demonstrate the utility of this approach. In genetics, we have found that major determinants of progression to dementia in PD are the <em>ApoE4 </em>allele with the second locus being the gene, <em>GBA</em><sup>3,4</sup> (<strong>Fig. 1A</strong>). In Progressive Supranuclear Palsy (PSP), we have identified <em>TRIM11</em><sup>5</sup> and <em>LRRK2</em><sup>6</sup> affecting disease phenotype and progression (<strong>Fig. 1B</strong>). Identification of the <em>LRRK2 </em>locus represents a pathogenic connection between PSP and PD. We will extend these findings to identify more loci that affect progression. We will capitalize on these findings to define, understand and modify the cellular processes driving progression through our <strong>High Throughput Cell Biology </strong>theme. As <strong>Table 1 </strong>demonstrates, we are well placed to interrogate pathways as loci are identified and have already demonstrated our ability to generate and implement cellular assays to dissect loci of interest. For example, we identify <em>KANSL1 </em>as a PD risk locus through our mitophagy screen leading to the suggestion that this, not <em>MAPT</em>, underlies the chromosome 17 PD locus<sup>7</sup>.</p>\n<p>The data generated by themes 1 and 2 needs to be contextualized in human tissues. This will be achieved in the <strong>Human Molecular Pathology </strong>theme. We have already generated paired single nuclear RNA sequences (snRNAseq) and bulk tissue RNAseq from post-mortem cingulate cortex from donors with Lewy body (LB) pathology (<strong>Fig. 2A</strong>). We identify a specific subpopulation of excitatory neurons, which are absent in dementia with LB samples, but not in PD (<strong>Fig. 2B</strong>). We demonstrate the enrichment of genes with high specificity for astrocytes and oligodendrocytes amongst those genes with splicing changes in PD samples, preceding extensive LB pathology and neuronal loss (<strong>Fig. 2B</strong>). However, <em>in vivo </em>models are crucial for understanding the complex spatial and temporal features of PD progression and its possible treatment. In theme 4, <strong>Mouse Transgenic Models</strong>, we will use the Vitras mouse to achieve this. This model, which expresses human 1-120 alpha-synuclein specifically in the gut epithelial cells (<strong>Fig. </strong><strong>3A,B</strong>) showing that some a-syn migrates and collects within neurons of the myenteric plexus (<strong>Fig. 3C,D</strong>) and by 12 months is detected in the dorsal motor nucleus of the vagus when neurodegeneration is also identified (<strong>Fig. 3E,F</strong>).</p>\n<p>Thus, we provide information demonstrating that we can deliver meaningful data across all our themes: on Functional Genetics, we have already found loci that affect rate of progression (<strong>Fig. 1</strong>): in Cell Biology, we identify <em>KANSL1 </em>as a PD risk locus through our mitophagy screen<sup>7</sup>; in Molecular Pathology, we show that we can dissect cell types and cell-specific splicing in human brain expression profiles (<strong>Fig. 2</strong>) and in our mouse work, we show pathological spread from the gut to the brain (<strong>Fig. 3</strong>).</p>\n<h1>Research Tools, Models and Resources&nbsp;</h1>\n<p>To this grant we bring the following resources, models and expertise:-</p>\n<p><strong>Queen Square Brain Bank (QSBB) </strong>specialises in parkinsonian movement disorders and holds &gt;2500 clinically and pathologically characterised brains. Zane Jaunmuktane (ZJ) is the lead neuropathologist for the QSBB (<a href=\"https://tinyurl.com/yck8ee4o\">https://tinyurl.com/yck8ee4o</a>). It houses &gt;700 of cases with a confirmed diagnosis of PD, including cases with <em>GBA </em>mutations (~35 cases), LRRK2 mutations (12 cases) and <em>PRKN </em>mutations (6 cases). Most of these brains have been whole genome genotyped and the rest will have been completed before this grant is initiated under the MD-GAP grant (below).</p>\n<p><strong>MD-GAP </strong>is an MRC funded UK consortium of brain banks led by HM, aimed at collating genetic, clinical and pathological data from all UK brain bank cases of PD to derive predictors of pathology.</p>\n<p><strong>PROBAND </strong>is a longitudinal PDUK programme following the progression of ~2000 incident PD cases (HM and JH co-PI).</p>\n<p>The <strong>Drug Discovery Institute </strong>(Paul Whiting: PW), and the <strong>High Content Biology </strong>group at UCL (Robin Ketteler: RK) have the experience and technology to develop, validate and run phenotypic screens with a variety of endpoints and genetic (siRNA knockdown) and pharmacological (compound libraries) challenges. Relevant to this proposal, together with Helene Plun-Favreau (HPF) they developed a mitophagy screen using quantification of S65 phospho-ubiquitin (a <em>PINK1 </em>mitophagy marker) following mitochondrial depolarization. This was screened using a compound library (unpublished) and an siRNA library and led to the identification of a new signalling pathway linking PD genetics to mitophagy<sup>7</sup>.</p>\n<p><strong>Lysosome Function Assays</strong>. FP&rsquo;s lab has pioneered biochemical assays (glycosphingolipids and lysosomal enzymes, Table 1)<sup>8</sup> that will be applied to this programme of research for monitoring disease progression and understanding the biochemical mechanisms driving it.</p>\n<p><strong>LRRK2 functional assays </strong>are available and routinely used in the Patrick Lewis (PL) group, assessing phosphorylation of Rab8, Rab10, Rab29 and autophosphorylation of <em>LRRK2 </em>at S1292 in murine and human cells. Commercially available antibodies are available for all of these events, alongside specific inhibitors of <em>LRRK2 </em>activity and Lrrk2 knockout cells to allowing calibration of alterations.</p>\n<p><strong>Transcriptomics-related processing pipelines </strong>are publicly available within the RytenLab GitHub (https://github.com/SoniaRuiz/RytenLab_MVC). This includes pipelines for QC, covariate correction, differential expression/splicing and deconvolution of bulk tissue RNAseq data for cell type proportions.</p>\n<p><strong>Data integration pipelines </strong>are publicly available within the RytenLab GitHub. We have implemented pipelines for EWCE, WGCNA, LDscore, SumHer, MAGMA and Coloc as well as machine learning approaches to identify common features amongst disease genes.</p>\n<p><strong>Expertise in the generation of web servers for visualisation of transcriptomic data </strong>as demonstrated by: i) BRAINEAC, an online resource for the visualisation of transcriptomic and eQTL data derived from 10 brain regions dissected from &gt;120 genotyped control human brains (www.braineac.org), ii) vizER, an online resource for visualisation of unannotated expressed regions linked to known genes (https://snca.atica.um.es/browser/app/vizER), and iii) CoExp, an online tool to explore WGNCA-based co-expression data and their functional enrichments (<a href=\"https://snca.atica.um.es/coexp/Run/Catalog/\">https://snca.atica.um.es/coexp/Run/Catalog/</a>)<sup>9</sup>.</p>\n<h1>Study Plan</h1>\n<h2>Theme 1: Functional Genetics&nbsp;</h2>\n<p>We and others had identified Mendelian (synuclein CNV), high-risk (GBA-GD) and common variants (<em>ApoE</em>, <em>LRRK2 </em>locus, <em>TRIM11</em>, <em>GBA </em>E365K) which influence progression and phenotype. These discoveries provide insights into the role of protein loading and proteostasis <em>via </em>the ubiquitin proteasome system and the lysosome in determining progression. Our current sample set comprises `3500 samples from UK studies and PPMI.</p>\n<p>In GP2 we are expanding the collation of genotype/phenotype data towards genotyping 100,000 samples.</p>\n<p><strong>Common variant analysis. </strong>We anticipate that through GP2 ~25,000 samples will have phenotype data which will enable analysis of progression through longitudinal clinical data, survival to motor/cognitive outcomes, mortality and baseline disease severity (trajectory) analysis. We have methods for analysing this data at a genome wide level including mixed effects modelling of principal components, survival analysis to motor and cognitive milestones, and mixed effects linear regression modelling of rate of change in key outcome variables (e.g. MDS-UPDRS).</p>\n<p><strong>Rare variant analysis</strong>. Our work on GBA and synuclein shows that common and rare variants at the same locus influences outcomes. Within ASAP- GP2 and IPDGC we will have access to ~5000 samples with whole exome/genome data and clinical phenotype data. We will use gene-based multi-variant analysis (e.g. SKAT-O) to determine the effects of rare variation on outcomes.</p>\n<p><strong>Integrated pathology analysis: </strong>In a subset of ~3000 PD cases with brain bank genotype data we will identify the genetic drivers of the extent of pathology (based on Braak staging), the rate of spread (annualised rate of Braak stage spread) and the density of pathology (based on semi-quantitative measures of pathology from the MD-GAP study).</p>\n<p>Our initial analysis has identified <em>ApoE4 </em>and <em>GBA </em>(<strong>Fig. 1</strong>) as loci for disease progression, the latter confirming a finding from our colleagues in IPDGC. Progress in this area will come as we increase sample sizes through ongoing GWAS. We will start by meta-analysis of our data with NIH datasets and add additional data from our (PROBAND updates, and MD-GAP) as well as other studies including all those included in AMP-PD and involved in GP2.</p>\n<h2>Theme 2: High Thoughput Cell Biology&nbsp;</h2>\n<p>The aim of the cell biology studies is to understand the disease mechanisms of the loci influencing progression with the intention of intervening in that process.</p>\n<p>A hypothesis of our proposal is that a subset of loci involved in the genetic modification of progression in PD of PD will influence pathways already studied in the context of risk. When new genes are identified in <strong>Theme 1</strong>, they will be tested in a battery of functional screening assays; which are set up within our group to investigate several areas of biology that genetics may lead us, including lysosomal biology, autophagy, mitophagy and neuroinflammation (<strong>Table 1</strong>). Hits identified will undergo a mechanistic analysis. This approach has already led to the identification of new PD GWAS risk genes playing a role in mitophagy<sup>7</sup>.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/acd68f5e-5fe6-477d-ab61-6bad0a3c2b11/hardy-chart.jpg\" alt=\"Hardy Chart\" /></p>\n<p>Initial work (PL) will focus on understanding the mechanistic impact of <em>LRRK2 </em>upon progression across parkinsonian disorders. His group will work with MGS and FP to dissect how <em>LRRK2 </em>kinase activity and GTPase/ scaffolding function act to modulate progression, including measuring changes in glycosphingolipids and lysosomal enzymes. As novel loci are identified, we will focus on testing whether candidate genes interact with <em>LRRK2 </em>activity, using rab8, rab10 and rab29 phosphorylation as the readout, and study the impact on vesicle trafficking/autophagy. As we recognize that genetic localization in GWAS is imperfect, these assays also will inform genetic analysis.</p>\n<h2><em>Theme 3: Human Molecular Pathology&nbsp;</em></h2>\n<p>The aim of this theme is to generate gene expression signatures of PD progression which can serve as testable therapeutic targets. We define signatures of progression as the gene expression features characterising: i) LB pathology propagation across different cortical brain regions and ii) faster disease progression as measured in years from the time of first symptom onset to death from the disease. To identify these signatures, we will analyse RNA expression in non-neurological controls (n=15) and PD patients with cortical LB pathology at Braak stage 5 (short duration n=10, long duration n=10) and Braak stage 6 (short duration n=15 and long duration n=15). Using paired snRNAseq and bulk RNAseq analyses, we will combine the power of snRNAseq to identify cell-specific expression changes with the comprehensiveness of bulk RNAseq for gene and splicing analyses. The gene expression signatures associated with progression will be correlated with glycosphingolipid signatures and lysosomal enzyme levels from these brains to understand the drivers of progression.</p>\n<h3><strong>Molecular signatures of LB pathology propagation across cortical regions</strong></h3>\n<p>We will analyse four cortical regions in each patient donor: anterior cingulate gyrus, middle temporal gyrus, middle frontal gyrus and inferior parietal lobule. These regions were selected because i) of their progressive involvement in PD from Braak stage 4 (anterior cingulate cortex) to Braak stage 6 (inferior parietal lobule), ii) their similar structure, and iii) the availability of public cortical RNAseq data sets to enable partial replication. We will perform snRNAseq analysis on two regions, the most severely and least affected. By focusing the data generation, we will sequence sufficient nuclei to: i) obtain cell-specific gene expression data for rarer cell types/subtypes, including the full diversity of oligodendroglial, microglial and neuronal cell subtypes<sup>9</sup>; <strong>Fig. 2B</strong>), ii) accurately identify significant changes in cell type/subtype diversity<sup>10</sup>, and iii) identify differences in cell-specific expression, focusing on genes highlighted by our progression GWAS. We will use neural network-based deconvolution methods with paired cell-specificity matrices and bulk RNAseq data to: i) analyse cellular diversity, and ii) perform differential gene/splicing analyses, accounting for changes in cell proportions (<strong>Fig. 2C</strong>). The resulting data will be used for intra- and inter- individual analyses to identify reliable signatures of regional LB pathology progression. Based on our findings, we will perform targeted spatial transcriptomic analyses using RNAScope.</p>\n<h3><strong>Molecular features of fast disease progression</strong></h3>\n<p>Using the data set described above, we will identify gene expression signatures associated with the rate of disease progression. Within each Braak stage and for each brain region, we will identify gene expression differences between PD patients who died within 1-7 years of symptom onset and those with disease duration exceeding 25 years. This analysis will include identification of changes in cell type/subtype diversity, gene expression and splicing. It will be complemented by automated, quantitative immunohistochemistry and immunofluorescence-based regional analysis of concomitant misfolded protein (A&beta;, p-tau, TDP43) and vascular pathologies using established machine learning-based digital image analysis tools<sup>11-14</sup>. Preliminary data demonstrating an increase in the proportion of vascular cells and ischaemic lesions amongst PD patients with dementia as compared to those without, already suggests this is an effective approach. In addition, glycosphingolipid signatures and lysosomal enzyme levels will be measured for correlation with gene expression data. Thus, the primary output of this analysis will be gene set/s and the cell types/subtypes in which they operate to promote disease progression along with biochemical changes in the lysosome. This information will inform the analyses in Theme 2 and inform the genomics interpretation in Theme 1.</p>\n<h2><em>Theme 4: Mouse Transgenic Models&nbsp;</em></h2>\n<p>Transgenic mouse models reproducing the neuropathological features of PD and specifically aSyn aggregation can: i) improve our understanding of the mechanisms underlying disease progression, and ii) provide relevant models to test novel therapies.</p>\n<p>Given the increasing evidence from patients and animal models<sup>15-19</sup> suggesting that aSyn aggregation and pathology begins in the gut and progresses to the brain, we will use a transgenic mouse model generated by the lab which expresses truncated aggregation prone aSyn specifically in the gut in the absence of mouse protein (Vitras mice)<sup>18</sup>. The lab has shown that mice expressing aggregation prone 1-120 aSyn (M12 model) more widely develop synaptic dysfunction and dopaminergic neuronal death which can be rescued by an oligomer modifier now in clinical trials<sup>20</sup>. Building on this work, they have shown that: i) at 6 months the Vitras mice have transgenic protein in some neurons of the myenteric plexus, which has migrated from the gut epithelium (also verified by primary neuronal cultures of the myenteric plexus, (<strong>Fig. 3C,D</strong>), but only inconsistently within neurons of the brainstem, and ii) at 12 months transgenic aSyn staining is consistently present in the brainstem (<strong>Fig 3E,F</strong>).</p>\n<p>Using this reliable model of temporal and spatial progression in aSyn aggregation and through the involvement of other PIs (MR, ZJ, FP) we will test hypotheses generated within the other themes. More specifically, using a combination of electron microscopy, RNAseq, immunohistochemistry and lipid biochemistry/lysosomal function assays to characterize gene expression and function (autophagy, lysosomal, mitochondrial and proteasome activity) we will create a molecular data set, which can be queried and compared to sparser human-derived data to understand the molecular features of progression. Informed by our findings across the themes, we will use the mouse model to test if pharmacological targeting of progression modifiers is of benefit. For example, <em>GBA </em>inhibition would be expected to promote progression, whereas <em>LRRK2</em><sup>22</sup> inhibition would be expected to reduce it.</p>\n<p>Our multi-modal approach to progression in PD will provide new insights into disease progression, and identify new drug targets which we hope will be rapidly deployed in clinical trials. We are committed to fast, open science as evidenced by publishing on pre-print servers and development of open access resources (e.g. Braineac). We anticipate rapid sharing of our results with the scientific, industry and lay communities, as guided by the ASAP program.</p>\n<h1>Power Calculations and Statistical Analyses Plan&nbsp;</h1>\n<p><strong>Power calculation for GWAS: </strong>As we exceed 5000 samples, we will be will powered to detect small effects on progression in GWAS based on multiple linear regression. An analysis of 5000 samples including 9 covariates will have a &gt;99% power to detect a small effect (f2=0.02) at a genome wide significance level (p&lt;5e-8).</p>\n<p><strong>Power calculation for mouse experiments: </strong>i) Treatment experiments - For 3 treatments (GBA, LRRK2, vehicle) in two genotypes (Vitras, control), the number of 8 animals per group (48 animals total) was determined by power analysis (G*Power 3.1.9.2 software; effect size = 0.5, significance level = 0.05, correlation among repeated measures = 0.5, power = 0.83); ii) Functional characterisation experiments - For 3 time points (3,6,12 months) and two genotypes (Vitras, control), the number of 10 animals per group (90 animals total) was determined by power analysis (G*Power 3.1.9.2 software; effect size = 0.3, significance level = 0.05, correlation among repeated measures = 0.5, power = 0.83).</p>\n<p><strong>Power calculations for RNAseq experiments: </strong>For bulk RNAseq analyses with 20 experimental subjects per group, we will have 80% power to detect a 2-fold change in expression at FDR 5% (assuming minimum read count over prognostic genes = 10, maximum dispersion = 0.2, total no. of genes tested = is 15,000 &amp; top 300 genes ae prognostic). For snRNAseq analyses with 15 experimental subjects per group, we will have &gt;80% power to detect a subset consisting of 5% of nuclei sampled, at FDR 5% (assuming mapping &gt;90% of reads &amp; classification of &gt;95% of nuclei to one major cell type).</p>\n<h1>Risk Mitigation</h1>\n<p>The principle behind this grant is that PD causation and progression have distinct genetic structures. While there is evidence to suggest this is true, it is possible that we have insufficient power in theme 1 to identify loci. However, all of our analyses will be made available and our previous experience has shown that this will enable sample sizes to be increased through collaboration. In theme 2, although we have expertise in many of the relevant assays, we recognise that we may identify loci that are in new pathways for which we lack know-how. In this circumstance, we will approach our network of colleagues, through IPDGC and more generally, to help understand these pathways and develop assays for them. The main risk associated with theme 3 is access to post-mortem human brain tissue of sufficient quality and quantity to enable generation of robust data. This risk is reduced by our longstanding involvement in the generation of brain transcriptomics, our successful experience in snRNAseq data generation and our direct involvement in PD brain banking (through ZJ) which will enable additional sourcing of samples. In theme 4 we recognise that LRRK2 and GBA inhibition may not have effects on the progression in mice. We think this would be important information since it challenges current views about their mechanisms.</p>\n<p><strong>Our record on ensuring open data access and ASAP&rsquo;s commitment to meaningful access means that the data we generate will be of lasting value to the field. We are confident that we have set out an ambitious but achievable plan to radically improve our understanding of the biology of PD progression and generate new therapeutic approaches.</strong></p>\n<h1><strong>Project Timeline and Milestones and Workflow Schematic&nbsp;</strong></h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/ff87742b-3b01-4444-9d8f-104892aeb0bb/hardy-workflow-and-timeline.jpg\" alt=\"Hardy workflow and timeline\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Singleton A, Hardy J. Progress in the genetic analysis of Parkinson's disease. Hum Mol Genet. 2019 Nov 21;28(R2):R215-R218. doi: 10.1093/hmg/ddz183. PMID: 31518392</li>\n<li>Lawton M, Ben-Shlomo Y, May MT. et Developing and validating Parkinson's disease subtypes and their motor and cognitive progression.J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1279-1287. doi: 10.1136/jnnp-2018-318337.</li>\n<li>Duran R, Mencacci NE, Angeli AV et The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease.Mov Disord. 2013 Feb;28(2):232-236. doi: 10.1002/mds.25248. Epub 2012 Dec 5. PMID: 23225227</li>\n<li>Tan M. et Genome-wide association studies of cognitive and motor progression in Parkinson&rsquo;s disease. MedRxiv/2020/084343</li>\n<li>Jabbari E, Woodside J, Tan MMX et Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Ann Neurol. 2018 Oct;84(4):485-496. doi: 10.1002/ana.25308. Epub 2018 Sep 15. PMID: 30066433</li>\n<li>Jabbari E, Tan MMX, Reynolds RH et Common variation at the LRRK2 locus is associated with survival in the primary tauopathy progressive supranuclear palsy. BioRxiv 2020.02.04.932335; doi:<a href=\"https://doi.org/10.1101/2020.02.04.932335\"> https://doi.org/10.1101/2020.02.04.932335</a></li>\n<li>Soutar M et al . Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1 allele. BioRxiv 01.06.896241</li>\n<li>Hallett, P. J., et (2018). Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. <u>Neurobiol Aging</u> <strong>67</strong>: 189-200.</li>\n<li>Zhang D, Guelfi S, Garcia Ruiz S, Costa B, Reynolds RH, D&rsquo;Sa K, Liu W, Courtin T, Jaffe AE, Hardy J, Botia J, Collado-Torres L, Ryten M. Incomplete annotation of OMIM genes is likely to be limiting the diagnostic yield of genetic testing, particularly for neurogenetic disorders. Science 2020. In press.</li>\n<li>Reynolds RH, Feleke R, Smith A, Tilley B, Hardy J, Matthews P, Gentleman S, Owen D, Johnson M, Srivastava P, Ryten M. Dysregulation of splicing in human brain from individuals with Lewy body disease informs disease mechanisms. ESHG</li>\n<li>Jaunmuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny J, Launchbury F, Linehan J, Richard-Loendt A, Walker AS, Rudge P, Collinge J, Brandner S.Evidence for human transmission of amyloid-&beta; pathology and cerebral amyloid angiopathy. Nature. 2015 Sep 10;525(7568):247-50. doi: 1038/nature15369. Erratum in: Nature. 2015 Oct 22;526(7574):595. PMID: 26354483</li>\n<li>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, Martorell AJ, Ransohoff RM, Hafler BP, Bennett DA, Kellis M, Tsai LH. Nature. 2019 Jun;570(7761):332-337. doi: 1038/s41586-019-1195-2. Epub 2019 May 1. Erratum in: Nature. 2019 Jun 17; Single-cell transcriptomic analysis of Alzheimer's disease. PMID: 31042697</li>\n<li>Bankhead P, Loughrey MB, Fern&aacute;ndez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, James JA, Salto-Tellez M, Hamilton PW. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017 Dec 4;7(1):16878. doi: 1038/s41598-017-17204-5. PMID: 29203879</li>\n<li>Dunning, C., Reyes, J. F., Steiner, J., &amp; Brundin, P. (2012). Can Parkinson's disease pathology be propagated from one neuron to another? Progress in Neurobiology, 97, 205-219. https://doi.org/10.1016/j.pneurobio.2011.11.003</li>\n<li>Braak E, Sandmann-Keil D, R&uuml;b U, Gai WP, de Vos RA, Steur EN, Arai K, alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol. 2001 Mar;101(3):195-201.</li>\n<li>Wood H. New models show gut-brain transmission of Parkinson disease pathology. Nat Rev Neurol. 2019 Sep;15(9):491. doi: 1038/s41582-019-0241-x.</li>\n<li>Pan-Montojo F., Anichtchik O., Dening Y, Knels L., Pursche S., Jung R., Gille G., Spillantini M.G., Reichmann H., Funk R. H.W., Progression of Parkinson&rsquo;s disease pathology is reproduced by intragastric administration of rotenone in Plos one, published 19 Jan 2010\u2028doi:10.1371/journal.pone.0008762</li>\n<li>Ulusoy, et al. Caudo-rostral brain spreading of &alpha;-synuclein through vagal connections. EMBO Mol. Med. 5, 1119&ndash;27 (2013).</li>\n<li>Wegrzynowicz M, Bar-On D, Calo' L, Anichtchik O, Iovino M, Xia J, Ryazanov S, Leonov A, Giese A, Dalley JW, Griesinger C, Ashery U, Spillantini MG. Depopulation of dense &alpha;-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Acta Neuropathol. 2019 Oct;138(4):575-595.</li>\n<li>Kim S. Transneuronal Propagation of Pathologic &alpha;-Synuclein from the Gut to the Brain Models Parkinson's Disease Neuron. 2019 PMID: 31255487</li>\n<li>Bae EJ, Kim DK, Kim C, Mante M, Adame A, Rockenstein E, Ulusoy A, Klinkenberg M, Jeong GR, Bae JR, Lee C, Lee HJ, Lee BD, Di Monte DA, Masliah E, Lee SJ. LRRK2 kinase regulates &alpha;-synuclein propagation via RAB35 phosphorylation. Nat Commun. 2018 Aug 27;9(1):3465.</li>\n</ol>\n<h1>SUPPORTING MATERIALS</h1>\n<h2>TEAM COMMUNICATION PLAN</h2>\n<p>JH has a long history of running successful multi-PI research programmes including the NIH programme project grant which led to the cloning of the tau locus for FTD and the Udall Center grant which led to the identification and clinical characterisation of the SNCA triplication. He will ensure the smooth and collegial operation of the programme and this will include seamless data sharing. This will include a Slack Channel, a listserve and biweekly lab meeting for 1+ hours on Zoom at which there will be updates from all, a single more detailed presentation as well as meeting reports and journal clubs when significant new work is published. These will be organised by the Grant Administrator. We will also have quarterly PI meetings in person and annual &ldquo;whole grant&rdquo; awaydays. UCL has an annual open and video broadcast Movement Disorders Meeting and we will ensure we present our work at that meeting.</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/53e17aa7-d83d-4271-8ed4-2da0bcb2f3e9/image.png\" alt=\"image\" /></p>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:20Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "The Role of PD-related Proteins as Drivers of Disease through Modulation of Innate and Adaptive Immunity"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>PROJECT SUMMARY</h1>\n<p>We demonstrated that gut infection in genetically susceptible mice leads to the development of Parkinson&rsquo;s disease (PD)-like symptoms and engages autoimmune mechanisms driven by the presentation of mitochondrial antigens. Combining the expertise of our established multidisciplinary team, we now seek to decipher the detailed molecular mechanisms by which multiple PD-related proteins act within a mitochondria/lysosome axis to couple innate and adaptive immunity. We will delineate the complex cell biology and signaling pathways from the initial infection in the gut, activation of peripheral immunity and events in the brain resulting in the dysfunction of dopaminergic neurons and motor impairment.</p>\n<h1>RATIONALE AND PRELIMINARY DATA</h1>\n<p>Multiple symptoms of PD, including the hallmark motor impairments, result from the dysfunction of central and peripheral neurons, as strikingly illustrated by the progressive loss of substantia nigra dopamine (DA) neurons. PD research has focused a great deal of its attention on cell-intrinsic mechanisms of neuronal death such as mitochondrial dysfunction<sup>1</sup> and pathological propagation of toxic forms of &alpha;- synuclein<sup>2</sup>. Nevertheless, the molecular mechanisms responsible for DA neuron dysfunction and death are still poorly understood. Mounting evidence, including the high expression of PD proteins in immune cells<sup>3</sup>, points to the immune system as a key contributor to PD pathology. Indeed, markers of inflammation<sup>4&ndash;8</sup>, as well as circulating populations of autoreactive T cells<sup>9,10</sup> are detected in the brain, gut and blood of PD patients, suggesting that autoimmune mechanisms contribute to neuronal dysfunction along a proposed &ldquo;gut-brain&rdquo; axis. Moreover, PD affects both peripheral and central neurons<sup>11</sup>, with prodromal symptoms beginning years before the emergence of the hallmark motor impairments<sup>12</sup>, consistent with the involvement of longer-term adaptive immune responses driving early and late pathologies. In this proposal, we outline a cell and molecular biology approach to integrate these concepts and provide a mechanistic understanding of the immune pathways contributing to PD progression.</p>\n<p>We showed that PINK1 and Parkin, two mitochondria-associated PD proteins, act as repressors of an adaptive immune response activated by infection<sup>13,14</sup>. In their absence, the bacterial endotoxin lipopolysaccharide (LPS) triggers the formation of mitochondria-derived vesicles (MDVs) in antigen- presenting cells (APCs) and a strong induction of mitochondrial antigen presentation (MitAP) (<strong>Fig. 1</strong>). MitAP is also activated in APCs during gut infection with Gram-negative bacteria in PINK1 KO mice, leading to the establishment of autoreactive mitochondria-specific CD8+ T cells, DA neuron die-back, and PD-like motor symptoms reversed by L-DOPA<sup>14</sup>. These observations solved a major paradox since, until now, PINK1 and Parkin KO mice were considered poor models of PD as very few, if any, PD-like symptoms were observed in these animals<sup>15,16</sup>. <u>Our data provide the first mechanistic evidence that autoimmunity directly</u> <u>contributes to PD and establishes a robust mouse model to study the role of the immune system along the</u> <u>gut-brain axis in both early and late stages of the disease.</u></p>\n<p>The cell biological mechanisms of MitAP uncovered in our studies highlight a membrane transport pathway between mitochondria and lysosomes, two organelles in which a host of PD-related proteins are implicated, including LRRK2, VPS35 and GBA<sup>17&ndash;19</sup>. In this context, we extended our studies by showing that LRRK2 and GBA also regulate MitAP (<strong>Fig. 2</strong>). This is consistent with a model where multiple PD proteins act along a common pathway, suggesting that shared pathophysiological processes might account for multiple forms of the disease. The novelty of our discovery is in unravelling a mechanistic pathway where PD proteins regulate <em>adaptive </em>immunity. This is distinct from recent studies indicating that PD protein dysfunction alters <em>innate </em>immune signaling and the release of pro- and anti-inflammatory molecules<sup>20&ndash;22</sup>. Thus, a major challenge is now to unravel how PD proteins link the innate and adaptive immune responses.</p>\n<p>In that context, we observed that loss of PINK1 leads to an increase in IL-6 and IL-23 release in response to infection in APCs <em>in vitro </em>(<strong>Fig. 3</strong>). Moreover, we also found that IL-6 is a strong inducer of MitAP in RAW cells, a process inhibited by a pre-incubation with anti-IL6 receptor antibodies (<strong>Fig. 4</strong>). Remarkably, this is the first indication that IL-6 stimulates antigen presentation, providing a framework by which PD proteins may link innate and adaptive immunity. Along this line, a recent study showed that IL- 6-driven inflammation induced by stress in PINK1 KO mice was rescued by the loss of STING, a component of the cGAS-STING pathway that triggers inflammation in the presence of cytosolic DNA<sup>22</sup>. Interestingly, we observed that the induction of MitAP by LPS was strongly inhibited in STING KO RAW macrophages (<strong>Fig. 5</strong>), suggesting that the regulation of the transition from innate to adaptive immunity by PINK1 requires the cGAS-STING pathway. Mitochondrial DNA (mtDNA) release into the cytosol act as a strong inducer of cGAS/STING<sup>23</sup>. Interestingly, data indicate that a pore-forming protein called GasderminD is highly active upon infection in PINK1 KO cells (<strong>Fig 6</strong>), providing a potential mechanism for mtDNA release<sup>24</sup>. Considering the breadth of evidence linking immunity to PD, <strong>we hypothesize that multiple PD- related proteins act along a common pathway regulating the transition between innate and adaptive immunity during inflammation. We further hypothesize that deregulation of this pathway by the loss/gain of function associated with PD-mutations, triggers autoimmune mechanisms ultimately leading to the recognition and attack of peripheral and central neurons, including DA neurons, by immune cells. </strong>Importantly, in contrast to the short-term nature of innate immunity, activation of adaptive immunity early during PD would impart a long-lasting response, which could explain, in part, why&nbsp;prodromal symptoms begin years before the emergence of the hallmark motor impairments.</p>\n<h1>RESEARCH TOOLS, MODELS AND RESOURCES</h1>\n<p><strong>Cell lines and primary cell models</strong>: We developed series of assays to characterize how PD proteins regulate various steps of the pathological processes linked to PD, usable in immune cells and neurons. These assays measure the expression/release of cytokines, the mechanisms by which PD proteins alter mitochondrial and lysosomal functions, their effect on MitAP and their impact on neuron structure and function.</p>\n<p><strong>Mouse models</strong>: We developed the first mouse model of early onset PD with significant motor impairments by challenging the immune system of PINK1 KO mice with a gut infection<sup>14</sup>. This model will be used to characterize in detail the spatiotemporal engagement of the immune system and its attack on peripheral and central neurons. We will also develop a second PD model of infection in LRRK2G2019S KI mice<sup>25,26</sup> to examine the relevance of our proposed model in a form of familial PD that is later in onset, like sporadic PD, and assess how gain of function might also drive autoimmune mechanisms during PD.</p>\n<p><strong>Additional tools and resources</strong>: Using a high-throughput screen of small molecules, we identified several potent inhibitors and stimulators of MitAP. These compounds will allow us to identify and manipulate key steps of MitAP that can be targeted for therapeutic interventions. We also have expertise in and access to state-of-the-art imaging, single cell sequencing, intestinal organoids, antigen discovery, iPSCs, proteomics, and bioinformatics platforms within our institutes that will be used throughout the project.</p>\n<h1>STUDY PLAN</h1>\n<p>We propose a translational research program taking advantage of newly developed <em>in vitro</em>, <em>ex vivo </em>and <em>in vivo </em>model systems to characterize the molecular mechanisms by which PD proteins engage an autoimmune response in APCs and neurons, how this response promotes the attack of DA neurons by T cells, and how the molecular signature of autoimmune engagement can be used to monitor disease progression in mouse models and PD patients.</p>\n<h2><em>In vitro</em> mapping of PD-related immune pathways</h2>\n<p>First, we will characterize the molecular mechanisms by which 5 PD proteins acting along the mitochondrial/lysosomal axis (PINK1, Parkin, LRRK2, VPS35 and GBA) regulate MitAP and the engagement of the adaptive immune system in inflammatory conditions. To dissect their function, we developed a pipeline of assays and cell biological approaches applicable to APCs, neurons and glial cells in culture<sup>27,28</sup>. These assays measure the role of a protein of interest at multiple steps along the MitAP pathway: 1) assembly of innate signaling complexes; 2) changes in mitochondrial dynamics and signaling leading to MDV formation; 3) expression/release of cytokines; 4) lysosomal function and processing for presentation on MHC molecules and; 5) MitAP. This will be done in primary cells isolated from knock-out (KO) (PINK1, Parkin) and knock-in (KI) mice with relevant PD mutations (LRRK2G2019S and VPS35D620N). KO/KI cell lines will be generated in RAW cells using CRISPR-Cas9 in collaboration with Erwin Schurr, a geneticist who is studying another aspect of the role of PD proteins in immunity, and how some of their mutations influence the susceptibility and resistance to infections<sup>21,29,30</sup>. A second objective of our research program will be to identify substrates of the PINK1, Parkin and&nbsp;LRRK2 enzymes that are critical for response to inflammatory signals and characterize their involvement along the MitAP pathway. A number of proteomics studies have identified substrates for PD proteins under conditions of acute mitochondrial dysfunction, however this has not been done under inflammatory conditions where mitochondrial respiration and function is generally intact. In collaboration with Pierre Thibault, we will employ unbiased biochemical and proteomics approaches to identify the substrates of these enzymes, specifically during inflammatory triggers, within a time course after infection in RAW cells lacking PINK1, Parkin or expressing the LRRK2G2019S mutation. The role of these substrates in MitAP will be characterized in KO RAW cells generated by CRISPR-Cas9, and in our different primary cell models.</p>\n<p>Finally, a unique tool at our disposal to further characterize MitAP is a set of 50 small molecules, identified in a high-throughput screen, that specifically stimulate or inhibit this pathway. Interestingly, some of these compounds are FDA approved and/or known to affect different steps of the MitAP pathway (e.g. inhibitors of cytokine expression; inhibitors of lysosomal proteolysis). Regardless of their potential therapeutic properties, on a purely mechanistic point of view, these molecules will allow us to manipulate the pathway (e.g. focus on key steps; rescue the pathway at different steps; identify proteins involved at different steps). Together, these complementary approaches will provide a high-resolution road map of the MitAP pathway and a thorough understanding of how alteration in PD proteins engages pathological autoimmune mechanisms in both APCs and neurons (see Model in <strong>Fig. 1</strong>).</p>\n<h2><em>Ex-vivo </em>models</h2>\n<p><em>Ex vivo </em>culture systems will be used to characterize how PD proteins regulate the engagement of the immune system along the gut-brain axis in inflammatory conditions following infection.</p>\n<p><strong>The gut: </strong>The first MitAP events occur early, possibly in the gut, following infection in PINK1 KO mice<sup>14</sup>. It is currently unknown whether PD mutations in intestinal epithelial cells (IECs) impact their response to gut infections, local inflammation, as well as the initiation of autoimmune mechanisms. To address this point, we will use organoid-derived polarized primary IEC monolayers, isolated from PD-susceptible mice, in trans-well systems<sup>31</sup>, to characterize how bacterial strains and mutants added to the apical side interact with and activate APCs (with or without T cells) on the basolateral side. Our pipeline of assays in this system will provide key insights into the very early mechanisms of immune induction occurring in the gut during infection and how they may engage an autoimmune response in the PINK1 KO mouse model of PD.</p>\n<p><strong>The brain: </strong>We have shown that MitAP is induced in primary PINK1 KO DA neurons in inflammatory conditions. Understanding how MitAP is triggered in neurons is important to prevent immune recognition. Since neurons are not believed to be major players in the release of cytokines in the brain, we hypothesize that alteration in proteins such as PINK1, Parkin and LRRK2 in microglia and astrocytes dysregulates cytokine secretion, which then impacts neuronal function and survival. Accordingly, the experiments to characterize the role of PD-proteins in APCs above will also be performed in primary DA neurons, microglia and astrocytes isolated from KO and KI PD-susceptible mice. This will allow us, for example, to determine if glial cells isolated from PD-relevant KO or KI mice affect DA neurons from the corresponding animals and WT mice equally. Using such a co-culture system, we showed that DA neurons lacking Parkin only degenerate when cultured with Parkin KO glia but not with WT glia<sup>32</sup>. With Janelle Drouin-Ouellet, we will&nbsp;also characterize the contribution of these PD mutations in co-cultures of iPSC- or fibroblast-derived induced DA neurons, astrocytes and microglia obtained from familial and idiopathic PD patients.</p>\n<p><strong>The peripheral immune system: </strong>We observed that the loss of PINK1 in APCs increases the secretion of IL- 6 and IL-23 (<strong>Fig. 3</strong>), a condition known to promote the differentiation of CD8+ T cells into CD8+ Tc17+ T cells<sup>33</sup>, a subset of cells involved in neuronal attack during PD<sup>34</sup>. In contrast, the secretion of IL-10 (<strong>Fig. 7</strong>), a cytokine involved in the generation of regulatory T cells<sup>35</sup>, is decreased. The modulation of these two cell types would favor autoimmune mechanisms. In collaboration with Martin Richer, a T cell expert, we will systematically characterize how alterations in PD proteins modulate T cell differentiation.</p>\n<p><strong>Identification of autoantigens, autoimmunity and effects on neurons from PD patients: </strong>While we initially focused on one mitochondrial-related antigen (OGDH), the spectrum of autoantigens presented during autoimmunity in PD remains unclear. To address this point, we will perform peptidomics analyses to identify antigen epitopes presented by MHCII at the surface of APCs isolated from WT mice, PINK1 KO mice and LRRK2G2019S KI mice. Our long-time collaborator, Pierre Thibault, has a strong expertise with this approach<sup>36&ndash;38</sup>. Analyses will also be done on stimulated iPSC-derived neurons from idiopathic and familial PD, where antigen epitopes are presented by MHCI. This strategy will allow us to identify epitopes likely to be associated with autoimmune mechanisms in PD. Epitope sequences identified using this unbiased approach will be used to design dextramer screening panels for the detection of T cells specific for these epitopes in blood from both idiopathic and familial PD patients. This will be performed using <em>Immudex </em>technology, a method enabling the discovery of antigen-MHC complexes along with transcriptional information and TCR clonality, all within the same cell. We will use this combined information to determine the transcriptional signatures underlying TCR clones specific for PD-associated epitopes. Jo Anne Stratton and Janelle Drouin-Ouellet have access to blood from PD patients and RBD patients (early PD) via the Quebec Parkinson Network, for this work<sup>39</sup>. Importantly, the antigen-specific T cells discovered using this screen will be expanded and cultured with neurons to determine cytotoxicity. We expect this translational approach will give mechanistic insights into autoimmunity across PD stages and types.</p>\n<h2><em>In vivo </em>models to determine immune cascade from the gut to the targeting of DA neurons</h2>\n<p><strong>Spatiotemporal mapping: </strong>We propose that mitochondria-directed immune activation following infection leads to a progressive and sequential attack of the peripheral and central nervous system, explaining why autonomic dysfunction and associated symptoms such as constipation occur at early stages of PD pathogenesis. We will use a series of flow cytometry (FACS) based and single cell RNA sequencing approaches to precisely map the types of immune cells that become engaged and that may proliferate, and the fate of peripheral and central neurons. In the brain, we will monitor changes in astrocyte, microglia and any infiltrating immune cells throughout disease progression. This will be done first in the infected PINK1 KO mouse model of PD<sup>14</sup>. We will characterize where and when the first MitAP event occurs following gut infection, as well as where and when autoreactive T cells are activated and move along the gut-brain axis at various intervals after infection up to a year. We will do this in the small intestine, colon, the mesenteric/colonic lymph nodes, the spleen, the cervical lymph nodes, the meninges and the brain. Each of these tissues will be treated to dissociate cells that will be sorted by FACS to isolate conventional dendritic cells and cytotoxic T cells (CD8+). The occurrence of MitAP in APCs and the presence of OGDH- specific CD8+ T cells will be determined using established presentation and ELISPOT assays<sup>13,14</sup>.</p>\n<p>An important objective of our research program is to characterize the nature of the engagement of the immune system during PD progression and how this affects the physiology of neuronal cells. To do so, we will use an unbiased approach to systematically profile the transcriptome of enteric, immune, neuronal and glia cell populations along the gut-immune-brain axis throughout the development of autoimmunity in the PINK1 KO and LRRK2G2019S KI infected mouse models. Following initial FACS screening, key timepoints will be selected for each tissue for single cell transcriptomics and TCR repertoire sequencing. These data will be cross-referenced with analyses of epitopes presented by APCs and neurons&nbsp;to determine whether a correlation between datasets exists. Jo Anne Stratton has developed efficient methods to perform these analyses and published extensively in the field<sup>40&ndash;42</sup>. Single cell sequencing approaches have been used recently to identify &ldquo;signatures&rdquo; of immune engagement and neuronal attack<sup>43,44</sup>. Identifying such signatures will allow us to monitor the progression of the disease in animal models and PD patients. Neurons and glial cells will also be collected and profiled for expression of markers of inflammation and oxidative stress to test the hypothesis that neurons in the intestines and peripheral ganglia show evidence of dysfunction prior to neurons of the CNS such as DA neurons. Clearing techniques coupled to light-sheet microscopy will be used to characterize the interaction between immune cells, glial cells and neurons in the peripheral ganglia, intestine wall, striatum and mesencephalon.</p>\n<p><strong>Neuroimmune mechanisms of neuron dysfunction <em>in vivo</em>: </strong>Mitochondrial specific CD8+ T-cell infiltration plays a key role in the early dysfunction and later destruction of DA neurons, however, the relative contribution of PINK1 loss of function in neurons versus peripheral immune cells, in driving neurodegeneration is unknown. We will generate a new line of floxed PINK1 mice and cross them with Cre driver lines (DAT-Cre for DA neurons and CD11c for APCs) to allow the selective removal of Pink1 from DA neurons or APCs. We hypothesize that the selective removal of Pink1 from APCs will be sufficient to induce PD-like phenotype in infected mice. In contrast, the specific removal of Pink1 from DA neurons should not be sufficient to induce PD-like symptoms upon infection, arguing against a cell autonomous mechanism.</p>\n<p><strong>Conclusion: </strong>Inflammation has been recognized as a key contributor to PD pathophysiology. Interestingly, a series of recent observations indicate that inflammation is, at least in part, caused by the impairment of PD proteins. Mechanistically, very little is known about how proteins such as PINK1, Parkin and LRRK2 modulate the innate immune response and how this arm of the immune system contributes to PD. Our data highlight a new role for PD proteins in regulating the transition from innate to adaptive immunity. Deregulation of this process has important impacts on the disease by initiating an autoimmune response that may explain why peripheral and central neurons are progressively targeted in the disease through a protracted period. The finding that PD proteins are key regulators of immunity opens new perspectives for the development of therapeutic approaches based on the modulation of the immune system at both early and late stages of the disease.</p>\n<h1>POWER CALCULATIONS AND STATISTICAL ANALYSES PLAN</h1>\n<p>Our studies will be performed in cells using sets of assays linked to published protocols with established statistical analyses. The <em>in vivo </em>experiments will be performed with sample sizes of 8-10, as described and validated in our recent work<sup>14</sup>.</p>\n<h1>PROJECT TIMELINE AND MILESTONES</h1>\n<p>(The project is divided in 6 periods of 6 months)</p>\n<p><strong>Period 1: </strong>Generate the Pink1 floxed mice; infect the PINK1 KO and the LRRK2G2019S KI mice; train the newly hired personnel; standardize the new protocols to isolate tissues from infected mice. <strong>Period 2</strong>: Cross the Pink1 floxed mice with Cre driver lines; characterize the contribution of the 5 PD proteins along the MitAP pathway; develop the biochemical methods to isolate the PINK1, Parkin and LRRK2 substrates; characterize the engagement of the immune system in infected mice up to 90 days p.i.; establish gut and brain clearing protocols to visualize immune cell interactions with peripheral and central neurons; initiate co-culture experiments. <strong>Period 3</strong>: characterize the effect of the LRRK2 and VPS35 mutations on the MitAP pathway; identify the substrates of the PD proteins; characterize the engagement of the immune system in infected mice up to 180 days p.i. <strong>Period 4: </strong>generate RAW KO cells for selected PD protein substrates by CRISPR; finish the immunopepdidomics in mice; characterize the engagement of the immune system in infected mice up to the final 365 days p.i.; finalize co-culture experiments. <strong>Period 5</strong>: characterize the contribution of selected protein substrates along the MitAP pathway; characterize the effect of selected MitAP inhibitors and stimulators; finalize brain clearing experiments at all key time points; finish the immunopeptidomics in human samples. <strong>Period 6</strong>: finalize data analyses and data dissemination.</p>\n<h1>WORKFLOW SCHEMATIC</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/9073c36f-434c-43c8-96da-b464d1e01cc9/desjardins.jpg\" alt=\"Desjardins\" width=\"1086\" height=\"763\" /></p>\n<p>&nbsp;</p>\n<h1>LITERATURE CITATIONS</h1>\n<ol>\n<li>Ge, P., Dawson, V. L. &amp; Dawson, T. M. PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson&rsquo;s disease. Mol Neurodegener 15, 20 (2020).</li>\n<li>Kalia, L. V. &amp; Kalia, S. K. &alpha;-Synuclein and Lewy pathology in Parkinson&rsquo;s disease. Curr. Opin. Neurol.28, 375&ndash;381 (2015).</li>\n<li>Moehle, M. S. et al. LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 32,1602&ndash;1611 (2012).</li>\n<li>Dzamko, N., Rowe, D. B. &amp; Halliday, G. M. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. Mov. Disord. 31, 889&ndash;897 (2016).</li>\n<li>Kim, R. et al. Peripheral blood inflammatory markers in early Parkinson&rsquo;s disease. J Clin Neurosci 58, 30&ndash;33 (2018).</li>\n<li>Devos, D. et al. Colonic inflammation in Parkinson&rsquo;s disease. Neurobiol. Dis. 50, 42&ndash;48 (2013).</li>\n<li>Schwiertz, A. et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson&rsquo;s disease. Parkinsonism Relat. Disord. 50, 104&ndash;107 (2018).</li>\n<li>Mulak, A., Koszewicz, M., Panek-Jeziorna, M., Koziorowska-Gawron, E. &amp; Budrewicz, S. Fecal Calprotectin as a Marker of the Gut Immune System Activation Is Elevated in Parkinson&rsquo;s Disease. Front Neurosci 13, 992 (2019).</li>\n<li><em> </em>Sulzer, D. <em>et al. </em>T cells from patients with Parkinson&rsquo;s disease recognize &alpha;-synuclein peptides. <em>Nature </em><strong>546</strong>, 656&ndash;661 (2017).</li>\n<li>Lindestam Arlehamn, C. S. <em>et al. </em>&alpha;-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson&rsquo;s disease. <em>Nat Commun </em><strong>11</strong>, 1875 (2020).</li>\n<li>Van Den Berge, N. <em>et al. </em>Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in <em>Acta Neuropathol. </em><strong>138</strong>, 535&ndash;550 (2019).</li>\n<li>Fereshtehnejad, S.-M. <em>et al. </em>Evolution of prodromal Parkinson&rsquo;s disease and dementia with Lewy bodies: a prospective study. <em>Brain </em><strong>142</strong>, 2051&ndash;2067 (2019).</li>\n<li>Matheoud, D. <em>et al. </em>Parkinson&rsquo;s Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. <em>Cell </em><strong>166</strong>, 314&ndash;327 (2016).</li>\n<li>Matheoud, D. <em>et al. </em>Intestinal infection triggers Parkinson&rsquo;s disease-like symptoms in Pink1-/- <em>Nature </em><strong>571</strong>, 565&ndash;569 (2019).</li>\n<li>Kitada, T., Tong, Y., Gautier, C. A. &amp; Shen, J. Absence of nigral degeneration in aged parkin/DJ- 1/PINK1 triple knockout mice. <em>J Neurochem </em><strong>111</strong>, 696&ndash;702 (2009).</li>\n<li>Sanchez, G. <em>et al. </em>Unaltered striatal dopamine release levels in young Parkin knockout, Pink1 knockout, DJ-1 knockout and LRRK2 R1441G transgenic mice. <em>PLoS ONE </em><strong>9</strong>, e94826 (2014).</li>\n<li><em> </em>Sassone, J. <em>et al. </em>The Role of VPS35 in the Pathobiology of Parkinson&rsquo;s Disease. <em> Mol. Neurobiol. </em>(2020) doi:10.1007/s10571-020-00849-8.</li>\n<li>Wallings, R. L. &amp; Tansey, M. G. LRRK2 regulation of immune-pathways and inflammatory <em>Biochem. Soc. Trans. </em><strong>47</strong>, 1581&ndash;1595 (2019).</li>\n<li>Vidyadhara, D. J., Lee, J. E. &amp; Chandra, S. S. Role of the endolysosomal system in Parkinson&rsquo;s <em>J. Neurochem. </em><strong>150</strong>, 487&ndash;506 (2019).</li>\n<li>Sun, L. <em>et al. </em>Lack of PINK1 alters glia innate immune responses and enhances inflammation-induced, nitric oxide-mediated neuron death. <em>Sci Rep </em><strong>8</strong>, 383 (2018).</li>\n<li>Fava, V. M. <em>et al. </em>Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson&rsquo;s disease. <em> Natl. Acad. Sci. U.S.A. </em><strong>116</strong>, 15616&ndash;15624 (2019).</li>\n<li>Sliter, A. <em>et al. </em>Parkin and PINK1 mitigate STING-induced inflammation. <em>Nature </em><strong>561</strong>, 258&ndash;262 (2018).</li>\n<li>Riley, J. S. &amp; Tait, S. W. Mitochondrial DNA in inflammation and immunity. <em>EMBO Rep. </em><strong>21</strong>, e49799 (2020).</li>\n<li>Liu, X. &amp; Lieberman, J. Knocking &rsquo;em Dead: Pore-Forming Proteins in Immune Defense. <em> Rev. Immunol. </em><strong>38</strong>, 455&ndash;485 (2020).</li>\n<li>Yue, M. <em>et al. </em>Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. <em> Dis. </em><strong>78</strong>, 172&ndash;195 (2015).</li>\n<li>Kim, K. S. <em>et al. </em>Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson&rsquo;s disease. <em> Natl. Acad. Sci. U.S.A. </em><strong>115</strong>, E5164&ndash;E5173 (2018).</li>\n<li>Nagashima, <em>et al. </em>Golgi-derived PI(4)P-containing vesicles drive late steps of mitochondrial division. <em>Science </em><strong>367</strong>, 1366&ndash;1371 (2020).</li>\n<li>Sugiura, A., McLelland, G.-L., Fon, E. A. &amp; McBride, H. A new pathway for mitochondrial quality control: mitochondrial-derived vesicles. <em>EMBO J. </em><strong>33</strong>, 2142&ndash;2156 (2014).</li>\n<li>de L&eacute;s&eacute;leuc, L. <em>et al. </em>PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages. <em>PLoS Negl Trop Dis </em><strong>7</strong>, e2015 (2013).</li>\n<li>Mira, T. <em>et al. </em>Susceptibility to leprosy is associated with PARK2 and PACRG. <em>Nature </em><strong>427</strong>, 636&ndash;640 (2004).</li>\n<li>Fernando, E. H. <em>et al. </em>A simple, cost-effective method for generating murine colonic 3D enteroids and 2D monolayers for studies of primary epithelial cell function. <em> J. Physiol. Gastrointest. Liver Physiol. </em><strong>313</strong>, G467&ndash;G475 (2017).</li>\n<li>Gigu&egrave;re, N. <em>et al. </em>Comparative analysis of Parkinson&rsquo;s disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons. <em> Biol. Chem. </em><strong>293</strong>, 9580&ndash; 9593 (2018).</li>\n<li>Zhou, L. <em>et al. </em>IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. <em> Immunol. </em><strong>8</strong>, 967&ndash;974 (2007).</li>\n<li>Sommer, A. <em>et al. </em>Th17 Lymphocytes Induce Neuronal Cell Death in a Human iPSC-Based Model of</li>\n<li>Parkinson&rsquo;s Disease. <em>Cell Stem Cell </em><strong>23</strong>, 123-131.e6 (2018).</li>\n<li>Miyara, M. &amp; Sakaguchi, S. Natural regulatory T cells: mechanisms of suppression. <em>Trends Mol Med </em><strong>13</strong>, 108&ndash;116 (2007).</li>\n<li>Li, <em>et al. </em>Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility. <em>Nat Commun </em><strong>11</strong>, 834 (2020).</li>\n<li>Lamoliatte, , McManus, F. P., Maarifi, G., Chelbi-Alix, M. K. &amp; Thibault, P. Uncovering the SUMOylation and ubiquitylation crosstalk in human cells using sequential peptide immunopurification. <em>Nat Commun </em><strong>8</strong>, 14109 (2017).</li>\n<li>Goyette, G. <em>et al. </em>Proteomic characterization of phagosomal membrane microdomains during phagolysosome biogenesis and evolution. <em> Cell Proteomics </em><strong>11</strong>, 1365&ndash;1377 (2012).</li>\n<li>Gan-Or, Z. <em>et al. </em>The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. <em>J Parkinsons Dis </em><strong>10</strong>, 301&ndash;313 (2020).</li>\n<li>Stratton, J. A. <em>et al. </em>Droplet Barcoding-Based Single Cell Transcriptomics of Adult Mammalian Tissues. <em>J Vis Exp </em>(2019) doi:10.3791/58709.</li>\n<li>Shah, P. T. <em>et al. </em>Single-Cell Transcriptomics and Fate Mapping of Ependymal Cells Reveals an Absence of Neural Stem Cell Function. <em>Cell </em><strong>173</strong>, 1045-1057.e9 (2018).</li>\n<li>Plemel, J. R. <em>et al. </em>Microglia response following acute demyelination is heterogeneous and limits infiltrating macrophage dispersion. <em>Sci Adv </em><strong>6</strong>, eaay6324 (2020).</li>\n<li>Seumois, &amp; Vijayanand, P. Single-cell analysis to understand the diversity of immune cell types that drive disease pathogenesis. <em>J. Allergy Clin. Immunol. </em><strong>144</strong>, 1150&ndash;1153 (2019).</li>\n<li>Hu, <em>et al. </em>Single-cell RNA-seq reveals distinct injury responses in different types of DRG sensory neurons. <em>Sci Rep </em><strong>6</strong>, 31851 (2016).</li>\n</ol>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:20Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": " Co-Pathologies Drive Neuroinflammation and Progression in PD"
    },
    "type": {
      "iv": "Presentation"
    },
    "subtype": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:20Z"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/10KqryfvO0jXvFQyiQ7ISGb9GBwAcEFAP/view?usp=sharing"
    },
    "description": {
      "iv": null
    },
    "tags": {
      "iv": null
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": [
        "f2235d49-af87-4834-8f0f-57cc1a4354a9"
      ]
    },
    "authors": {
      "iv": [
        "b8f0d946-bfef-4673-b1f6-be2e9a97b1b2",
        "3bdfb2ab-4e8a-450a-abf9-4b9bd519a76e",
        "c5937d7b-5e51-4118-ad56-ff6af0c66d66"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": "Jeffrey Kordower, Ashley Harms, Warren Hirst, Alan Landay, Fredric Manfredsson, Vineet Gupta"
    }
  },
  {
    "title": {
      "iv": "Dissecting Genetic Interactions of Parkinsons disease associated Risk Loci (First Year Report)"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Report"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:19Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "<h1>Project Summary</h1>\n<p>This project will address how GWAS-identified risk variants and familial gene mutations contribute to the development and progression of Parkinson&rsquo;s disease (PD). Using state-of-the-art functional genomic approaches including single-cell RNA sequencing, splicing pattern analysis, and Perturb-seq, we will define the biological pathways altered by PD-risk genes and loci in genetically-defined human stem cell-derived brain organoid models. We will use the resulting gene interaction networks to establish the effect of risk genes <em>in vivo </em>and test their impact in preclinical mouse models. Elucidating the biologic effects of PD- associated genes will allow us to nominate novel biomarkers and pharmacological interventions for PD.</p>\n<h1>Rationale and Preliminary Data&nbsp;</h1>\n<p>The discovery of mutations in more than 20 genes linked to rare familial forms of PD have provided vital clues to the underlying pathophysiology<sup>1</sup>. Nevertheless, the molecular mechanisms leading to neuronal cell loss and subsequent circuit-level dysfunction in PD remain largely unknown. The majority (&gt;90%) of PD cases are not familial but sporadic and thought to result from a complex interaction between aging, genetic risk, and environmental factors. Genome-wide association studies (GWAS) have identified common variants with small effect size within 78 genomic regions, implicating more than 300 potential target genes in the etiology of sporadic PD<sup>2,3</sup>. However, there is little mechanistic insight about how these risk variants contribute to the development and progression of PD.</p>\n<p>Four recent technical innovations have fundamentally changed our ability to study human diseases in a culture dish: (i) Reprogramming of somatic cells into human induced pluripotent stem cells (hiPSCs), (ii) the directed differentiation of pluripotent stem cells (hPSCs) into monolayer and 3-dimensional organoids to generate disease-relevant cells, (iii) the development of genome and epigenome engineering approaches such as the CRISRP/Cas9 system and (iv) high throughput single-cell sequencing technologies. <u>Through</u> our expertise in combining these cutting-edge technologies<sup>4-13</sup>, we will decode the genetic liability of PD <u>in a controlled and systematic manner in clinically relevant human cells</u>.</p>\n<p>Here, we propose to establish an integrated model and epistatic interaction map of PD-associated risk loci and genes. Our unique approach will be to systematically dissect the function of all PD-risk loci by combining pooled CRISPR interference/activation perturbation with single-cell sequencing (scRNA-seq) as phenotypic readout in human brain organoids. We hypothesize that the functional analysis of GWAS- risk variants will identify common transcriptional signatures and key biological processes associated with PD. Using this information, we will investigate the pathophysiological relevance of the most significant variants using genetically engineered mouse models and PD post-mortem brain tissue. The proposed experiments will significantly advance our functional understanding of the genetic architecture of PD and allow development of novel diagnostic biomarkers and leads for effective therapeutics.</p>\n<h1>Research Tools, Models and Resources&nbsp;</h1>\n<h2>Genetically engineered human induced pluripotent (hiPSC) and embryonic stem cells (hESCs), collectively hPSCs</h2>\n<p>Expanding on our isogenic hPSC lines carrying familial PD-associated mutations in <em>SNCA</em><sup>7</sup>, we will use well established CRISPR/Cas9 genome engineering approaches in WIBR3 hESCs (NIH registry 0079) or PD hiPSCs<sup>6,7,10</sup> to introduce mutations in high-confidence familial PD-associated genes<sup>1</sup>.</p>\n<h2>Cellular <em>in vitro </em>model systems</h2>\n<p>&nbsp;Cell-type specific monolayer cultures of defined cell types (cortical and dopamine neurons, astrocytes, oligodendrocytes and microglia) and cortical organoids are routinely used in the Bateup, Hockemeyer and Soldner labs<sup>4,6,7,11,14</sup>. Here we will additionally establish midbrain-like organoid cultures according to published protocols<sup>15-17</sup>. Disease relevant cell types know to be absent in organoids (e.g. microglia) will be supplemented with monolayer-derived cells as established previously<sup>18</sup>. <u>Perturb-seq screens:</u> We will genetically engineer hPSC lines to robustly express dCas9 fusion proteins in organoids: dCas9-KRAB for gene interference (CRISPRi), dCas9-VPR (VP64-p65-Rta) for gene activation (CRISPRa), dCas9-p300 as an epigenetic activator, and dCas9-LSD1 as epigenetic repressor. Pooled lentiviral sgRNA libraries targeting the top 300 PD-associated risk genes/risk loci (two sgRNAs/gene or regulatory element) will be constructed as previously described<sup>19</sup>. Similar approaches are currently developed for other cell systems as collaboration between the Gilbert and Hockemeyer labs. <u>Patient post-mortem brain tissue</u>: Flash-frozen tissue samples of the substantia nigra (neurodegeneration already far progressed) and dorsolateral prefrontal cortex (Brodmann Area 9, usually less affected) from PD patients and unaffected controls will be obtained from the NIH-funded NeuroBioBank.</p>\n<h2>CRISPR mice</h2>\n<p>&nbsp;We will generate two mouse lines using CRISPR-mediated gene editing in mouse ESCs that carry either Cre-dependent dCas9-KRAB or dCas9-VPR together with a fluorescent reporter in the Rosa26 locus. In addition, we will generate a Cre-dependent <em>SCNA </em>A53T knock-in overexpression mouse. Combined with transgenic Cre mouse lines and viruses encoding sgRNAs, we will achieve cell type- specific inhibition or activation of any gene of interest. The Bateup and Hockemeyer labs are experienced in generating transgenic mice and recently established a DAT-Flp knock-in mouse line for the intersectional targeting of dopamine neuron subpopulations (publication pending).</p>\n<p>All tools described here (isogenic panel of PD-hPSCs, the Perturb-seq hPSC platform and mice) will be highly useful and flexible research tools, made broadly available to the PD research community.</p>\n<h1>Study Plan&nbsp;</h1>\n<p>The overarching goal of this proposal is to dissect the molecular and cellular effects of PD-associated risk alleles by establishing a comprehensive epistatic interaction map of risk loci and genes in human pluripotent stem cell (hPSC)-derived monolayer and organoid culture systems (see Fig. 1). <strong>Aim 1 </strong>will establish a reference map of cell-type specific changes in gene expression levels and pre-mRNA splicing patterns associated with large effect size mutant alleles linked to familial forms of PD. Building on these reference maps, in <strong>Aim 2</strong>, we will use Perturb-seq approaches to systematically analyze how PD-associated GWAS- identified risk loci and genes impact the transcriptional signatures in PD-relevant cell types. In <strong>Aim 3</strong>, we will confirm the relevance of <em>in vitro </em>identified PD-associated gene signatures in mouse models.</p>\n<h2>Aim 1: Establish a cell-type specific reference map of transcriptional alterations in familial PD</h2>\n<p>Changes in gene expression and RNA-splicing patterns have been directly implicated in the pathology of PD<sup>20</sup>. The identification of a variety of highly penetrant mutations linked to rare familial forms of PD and the spectrum of diverse but overlapping clinical symptoms and pathological changes observed in patients suggest mutation-specific as well as shared molecular features and transcriptional alterations associated with the development of PD<sup>1</sup>. Here, we propose to establish an isogenic panel of genetically engineered hPSCs with familial PD-associated risk alleles and perform bulk and single cell RNA sequencing. The outcome of this Aim will be a comprehensive and cell-type specific reference map of transcriptional alterations and expression signatures associated with familial PD.</p>\n<p><strong>Aim 1-1: Establish isogenic neuronal <em>in vitro </em>models for familial PD</strong></p>\n<p><strong>Genetic engineering of an isogenic panel of hPSCs carrying familial PD-associated mutations</strong></p>\n<p>hPSCs can be differentiated into disease-relevant cell types thereby providing a platform to study complex diseases <em>in vitro</em>. While, in principle, patient-specific hiPSCs carry all disease-relevant genetic alterations, it has been increasingly recognized that effects from genetic modifier loci in patient-derived cells with diverse genetic backgrounds lead to substantial phenotypic variation<sup>21,22</sup>. To overcome this limitation, we have pioneered the use of genome editing technologies such as the CRISPR/Cas9 system to generate isogenic hPSCs to study PD in a genetically controlled manner<sup>4,8,22</sup>. To perform a systematic comparison of PD-associated transcriptional signatures across genotypes, we will build on already existing isogenic <em>SNCA </em>hPSC lines<sup>7</sup> and establish an isogenic panel of hPSCs carrying additional familial PD-associated risk alleles with strong effect size including <em>PRKN</em>, <em>PARK7</em>, <em>LRRK2</em>, <em>PINK1</em>, <em>ATP13A2</em>, <em>FBXO7</em>, <em>GBA</em>, <em>PLA2G6 </em>and <em>VPS35<sup>1</sup></em>.</p>\n<p><strong>Establish robust <em>in vitro </em>monolayer and brain organoid models for PD</strong></p>\n<p>&nbsp;We will establish neuronal <em>in vitro </em>models derived from the hPSC lines generated above. Although PD is characterized by a progressive loss of dopaminergic neurons in the substantia nigra, it is now accepted that PD pathology and neuronal degeneration is widespread throughout the nervous system<sup>23</sup> and that non-neuronal cell types (e.g. astrocytes and microglia) play important roles in the pathogenesis of the disease<sup>24,25</sup>. To capture this wide spectrum of cell types, we propose to analyze midbrain and cortical-specified cultures. First, we will use conventional monolayer cultures (cortical and dopamine neurons, astrocytes, oligodendrocytes and microglia) to profile homogenous cell populations with bulk RNA sequencing approaches and high sequencing depth. As such models do not capture complex non-cell autonomous interactions between different cell types, we will additionally profile cerebral organoids that model complex aspects of human brain development and disease pathology in a more physiological manner<sup>26</sup>. While these models capture greater tissue complexity, the cellular heterogeneity will require us to employ single cell-based approaches.</p>\n<p><strong>Aim 1-2: Establish a reference map of transcriptional changes associated with familial PD mutations </strong></p>\n<p>A central goal of this proposal is to establish gene expression alterations and identify common and mutation- specific transcriptional signatures associated with large effect size alleles in PD. We will use our previously established and novel isogenic PD and control lines (Aim 1-1) and perform scRNA-seq analysis in cortical and midbrain-like organoids at different time points during development using the state-of-the-art deep smart-seq2 method<sup>27</sup>. This analysis will provide cell-type specific reference maps of PD-associated transcriptional signatures and allow us to classify the effects from GWAS-identified risk variants in Aim 2.</p>\n<p><strong>Aim 1-3: Identify changes in pre-mRNA splicing patterns as potential biomarkers for PD</strong></p>\n<p>Splicing pattern changes have been directly implicated in PD<sup>20</sup>. Considering that RNA-splicing is highly variable among cells in the nervous system, we hypothesize that changes in RNA splicing could be more sensitive to identify PD-associated changes compared to gene expression. However, current genome-scale high-throughput scRNA-seq technologies do not provide sufficient sequencing depth to robustly identify pre-mRNA splicing patterns. In a first approach to characterize both gene expression and pre-mRNA splicing patterns, we will perform bulk sequencing (high sequencing depth) on conventional monolayer cultures with defined neuronal and glial cell types that carry PD mutations and their isogenic controls. Here, we will use the Junction Usage Model (JUM) software<sup>28</sup> developed in the Rio lab to find quantitative variations in splicing patterns among these samples. In addition to splicing patterns, this sequencing approach will be used to detect gene expression changes using DES-seq2<sup>29</sup> and provide additional cell-type specific information, which will be integrated with the transcriptional signatures in Aim 1-2. Based on the identified splicing patterns, we will subsequently use a full length ultra-deep scRNA-seq platform (LoopSeq<sup>TM</sup>; www.loopgenomics.com) to confirm similar changes in cortical and midbrain-like organoids. Examining RNA-splicing in PD mutant cell lines has the potential to identify splicing isoform changes that could provide early and highly sensitive biomarkers for disease progression or identify novel drug targets.</p>\n<h2>Aim 2: Develop a genetic interaction map of PD-associated risk loci.</h2>\n<p>GWAS have identified numerous risk variants associated with PD<sup>2,3</sup>. However, the vast majority of risk variants have no established biological function. Advancing from genetic association to causal PD biology has been hindered by a lack of high-resolution functional genomics approaches to dissect the effects of disease-associated risk variants. To overcome this, we will apply Perturb-seq, a novel functional genomics platform that we recently developed, which pairs CRISPR-based screens with scRNA-seq to measure genetic interactions at single cell resolution<sup>19,30</sup>. Perturb-seq analyzes individual cells as independent experiments, connecting a series of genetic perturbations to a transcription phenotype, thereby allowing hundreds of thousands of parallel high-resolution measurements. This technology is ideally suited to dissect the complex effects of GWAS risk loci in human organoids, because it will allow systematic mapping of how risk alleles impact PD-specific genetic interactions and how each perturbation drives a specific form of cellular phenotype in a given cell type. This approach tests the hypothesis that the complexity of PD-risk genes can be reduced and functionally categorized into epistatic gene interaction networks. Together with the gene signatures from Aim 1, these analyses will establish a comprehensive functional interaction map between PD-risk variants, target genes and PD-associated transcriptional signatures.</p>\n<p><strong>Aim 2-1: Identify transcriptional changes associated GWAS-identified risk loci</strong></p>\n<p>We will use Perturb-seq to systematically measure genetic interactions resulting from knock-down (CRISPRi) or activation (CRISPRa) of more than 300 target genes within 78 PD-associated genomic regions (nominated based on latest PD-GWAS<sup>2,3</sup>) in cerebral and midbrain-like organoids. We will use the scRNA-seq profiles associated with the genetic perturbations to define genetic interactions that result from alterations of PD-associated genes. This will enable us to resolve the distinct outcomes underlying genetic interactions in multiple cell types and to model the different ways gene perturbations combine to yield new phenotypes in each cell type within organoid cultures. In particular, comparing and integrating the transcriptional signatures of low effect size GWAS-risk loci with familial PD-associated gene signatures (Aim 1) will allow to identify transcriptional changes most relevant for sporadic PD pathogenesis.</p>\n<p>As the majority of GWAS-identified risk variants are non-protein coding, advancing beyond genetic association to causal biological process remains challenging. There is compelling evidence that disease association in PD is driven by sequence-specific alterations in the function of non-coding regulatory elements, in particular distal enhancers that affect the transcription of target genes. As a follow up of our previous work<sup>4</sup>, we will integrate GWAS summary statistics, linkage disequilibrium (LD) information, epigenomic datasets (e.g. Roadmap Epigenomics Consortium<sup>31</sup>), and eQTL information (e.g. GTEx Consortium<sup>32</sup>) to map putative causal variants associated with PD in regulatory elements. Using the same principle as for Perturb-seq experiments, we will establish a pooled epigenome Perturb-seq screening approach to target CRISPR perturbations (dCas9-p300 as activator, dCas9-LSD1 as repressor<sup>33</sup>) to the top 300 GWAS-identified gene regulatory elements such as distal enhancers to systematically connect non- coding risk variants with the target genes they control<sup>34</sup>. Together, the Perturb-seq analysis of hPSC-derived cortical and midbrain-like organoids will provide a comprehensive, cell-type specific gene-function analysis of PD risk genes and allow us to extract transcriptional signatures associated with sporadic PD.</p>\n<p><strong>Aim 2-2: Identify genetic modifier effects of GWAS risk loci in PD-relevant sensitized backgrounds </strong></p>\n<p>One of the major challenges in functionally dissecting GWAS-identified risk loci/genes remains the small effect size of disease-associated risk variants. This is important in the context of late age of onset diseases such as PD where phenotypes <em>in vitro </em>are expected to be subtle. Based on the concept that familial and sporadic risk variants interact and deregulate a number of overlapping transcriptional disease-associated signatures, we hypothesize that strong effect size PD risk alleles, environmental stress or aging could act as sensitizing backgrounds to facilitate the identification of modifier effects from small effect size variants. This idea is particularly compelling for <em>SNCA</em>, considering its central and overlapping role in the pathogenesis of both sporadic and familial PD<sup>35</sup>. Starting with <em>SNCA</em>, we will perform Perturb-seq experiments as in Aim 2-1 in isogenic cell lines carrying familial PD mutations (Aim 1) as a sensitizer. Environmental factors and aging are thought to play an important role in the pathogenesis of PD<sup>1</sup>. Our previous experiments show that exposure to low level mitochondrial toxins such as environmental pesticides can exacerbate the effect of PD risk alleles in hiPSC-derived neuronal cultures<sup>8</sup>. Similarly, <em>in vitro </em>overexpression of Progerin, a gene associated with the premature aging syndrome Hutchinson-Gilford Progeria, induces aging-associated changes, such as genomic instability, epigenetic dysregulation and mitochondrial dysfunction, and is sufficient to accelerate the appearance of disease-associated phenotypes in a hiPSC model of PD<sup>36</sup>. We will perform Perturb-seq experiments in the presence of low dose mitochondrial toxins or ectopic Progerin as sensitizers to model environmental and age-associated PD risk.</p>\n<p><strong>Aim 2-3: Validate PD-associated transcriptional signatures in post mortem brain tissue</strong></p>\n<p>One advantage of performing functional experiments in human cells is the possibility to directly confirm the <em>in vitro </em>findings in a patient context. We will analyze post mortem brain tissue samples of substantia nigra and dorsolateral prefrontal cortex from PD patients and unaffected controls (see Research Models) to confirm alterations in key PD associated biological processes using quantitative RT-PCR, bulk sequencing, western blot and immunohistochemistry approaches. Together, these experiments enable us to nominate physiologically relevant biomarkers and potential targets for pharmacological interventions.</p>\n<h2>Aim 3: Validate identified transcriptional signatures of PD in mouse models</h2>\n<p>It is well established that <em>in vitro </em>culture systems only partially recapitulate the pathophysiological changes observed in a patient or animal model; especially in the context of a complex neurodegenerative disorder like PD. We hypothesize that the gene interaction networks established in Aims 1 and 2 will allow us to prioritize common key biological effects of PD-risk genes and loci that can be functionally tested in disease- relevant animal models. In this aim, we will use CRISPR/Cas9-mediated genetic manipulation to recreate the biological-modifying effect of the PD-risk genes in mouse models of PD. This will allow us to establish the modulatory effects PD risk genes and ultimately enable identification of biologically relevant biomarkers and potential targets for pharmacological interventions.</p>\n<p>We will use our established expertise in CRISPR/Cas9-mediated gene editing to generate mouse ESCs with Cre-dependent expression of dCas9-KRAB or dCas9-VPR (VP64-p65-Rta) from the Rosa26 locus for CRISPRi or CRISPRa of target genes, respectively. In addition, we will target a Cre-dependent human <em>SCNA </em>gene cassette with the A53T mutation to the collagen locus<sup>37</sup> to allow cell-type specific overexpression of human alpha-synuclein in mice. This panel of mouse lines represents a parallel <em>in vivo </em>platform to the hPSC lines established in Aims 1 and 2. After validating these mouse lines, we will cross the CRISPRi and CRISPRa mice to the <em>SCNA </em>mice. In this context, we will test the <em>in vivo </em>disease modifying effects of up or down-regulation of genes identified in Aims 1 and 2 both in wild-type mice and in the background of a highly penetrant PD mutation.</p>\n<p>To activate the CRISPRi/a system and induce overexpression of alpha-synuclein, we will breed the CRISPRi/a;<em>SCNA </em>mice to established Cre mouse lines that express in cortical (e.g. Emx1-Cre<sup>38</sup>) or dopamine (e.g. DAT-Cre<sup>39</sup>) neurons, or other relevant cell types. We will perform systemic or brain region- targeted intracranial injections with adeno-associated viruses (AAV) expressing sgRNAs against genes of interest, identified in Aims 1 and 2. sgRNAs can be delivered individually or multiplexed in the same AAV to allow simultaneous modulation of 2-3 genes together with expression of a fluorescent marker protein<sup>30,40</sup>. As an alternative approach, Cre can be delivered at the same time as the sgRNAs, allowing for brain region- specific expression of the dCas9-fusion without the requirement of breeding in an additional transgenic mouse line. We propose to test approximately 20 genes from Aims 1 and 2 in this system.</p>\n<p>In adult or aged mice, we will use FACS to isolate cortical pyramidal neurons, dopamine neurons, astrocytes and other cell types of interest. We will use deep bulk RNA-sequencing to measure the transcriptional profiles of cells with different genetic modifications and map them onto the human cell datasets generated in Aims 1 and 2. Alternatively, we can use single cell RNA-sequencing and analyze expression patterns by cell type for whole brain regions. For genetic modifications that cause similar transcriptional changes in human cells and mice or those that produce the greatest changes <em>in vivo</em>, we will further characterize their effects on functional outcomes relevant for PD. The Bateup lab is experienced in the analysis of dopamine and cortical neuron structure, physiology and synaptic output<sup>41,42</sup>, which are cellular properties likely to be altered in the context of PD. In addition, as the primary manifestations of PD are impaired movement and altered cognition, we will test mice in sensitive behavior tasks designed to measure motor and cognitive performance<sup>41-43</sup>. We will determine whether changes in the expression of individual or combinations of PD risk genes affect disease-relevant functional properties. These <em>in vivo </em>experiments provide a powerful complement to the human <em>in vitro </em>culture systems and increase the likelihood of finding bona fide contributors to PD pathophysiology.</p>\n<h1>Power Calculations and Statistical Analyses Plan&nbsp;</h1>\n<p>One of the main outcomes of our experiments will be to establish the effect size of PD-risk alleles on gene expression signatures, making it difficult to perform an <em>a priori </em>power calculation. However, our team has extensive experience with all assays and relevant statistical analysis outlined in this proposal, guiding our experimental design. Bulk sequencing approaches will be performed in triplicates at a sequencing depth of &gt;150x10<sup>6</sup> reads for each cell type and condition<sup>21</sup>. Full-length scRNA-seq from 3 independent brain organoid differentiations will be performed for ~100 cells for each cell-type using full length sequencing methods. Based on our pervious Perturb-seq experiments, we will sequence 250-500 cells for each perturbation (sgRNA) in each cell type. Thus, to assay 300 loci with two sgRNAs<sup>19</sup> we will assay 75,000- 150,000 cells for each cell type. In case we do not reach the required cell numbers for some of the rarer cell types in organoids, we will perform additional experiments in cell-type specific monolayer cultures. For the mouse bulk and scRNA-sequencing experiments, we will collect cells from 4 individual mice (2 male and 2 female) per PD sgRNA and control sgRNA. For behavior experiments we will use 20-24 mice per group (10-12 males and 10-12 females). For physiology experiments we will record from 12-15 neurons from at least 3 mice per group. For voltammetry experiments to measure dopamine release we will use 2 slices from 5 age- and sex-matched pairs of mice from each group. We will compare the effects of each PD sgRNA manipulation with control sgRNA in mice with and without the familial PD mutation (4-way comparison) using a one-way ANOVA followed by Sidak&rsquo;s post-hoc tests. In cases where the data do not pass tests of normality, non-parametric tests will be utilized (e.g. Kruskal-Wallis test for three or more groups). P&lt;0.05 will be considered significant and P values will be corrected for multiple comparisons.</p>\n<h1>Project Timeline and Milestones&nbsp;</h1>\n<p>These are summarized in the workflow schematic below.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/e944a4c4-c6fd-49ef-a9ea-d60a07a8d317/rio-workflow2.jpg\" alt=\"Rio_workflow2\" /></p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/3611c5fb-7b86-4495-b5d5-67ec747dd72e/rio-table.jpg\" alt=\"Rio_Table\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Blauwendraat, , Nalls, M. A. &amp; Singleton, A. B. The genetic architecture of Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">The Lancet Neurology</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, doi:10.1016/s1474-4422(19)30287-x (2019).</span></li>\n<li>Nalls, A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">The Lancet Neurology </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">18</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1091-1102, doi:10.1016/s1474-4422(19)30320-5 (2019).</span></li>\n<li>Chang, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Genet </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">49</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1511-1516, doi:10.1038/ng.3955 (2017).</span></li>\n<li>Soldner, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">533</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 95-99, doi:10.1038/nature17939 (2016).</span></li>\n<li>Soldner, F. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">136</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 964-977, doi:10.1016/j.cell.2009.02.013 (2009).</span></li>\n<li>Hockemeyer, D. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Biotechnol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">27</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 851-857, doi:10.1038/nbt.1562 (2009).</span></li>\n<li>Soldner, F. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">146</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 318-331, doi:10.1016/j.cell.2011.06.019 (2011).</span></li>\n<li>Ryan, S. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">155</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1351-1364, doi:10.1016/j.cell.2013.11.009 (2013).</span></li>\n<li>Chung, C. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Identification and rescue of alpha-synuclein toxicity in Parkinson patient- derived neurons. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Science </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">342</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 983-987, doi:10.1126/science.1245296 (2013).</span></li>\n<li>Hockemeyer, D. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genetic engineering of human pluripotent cells using TALE nucleases. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Biotechnol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">29</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 731-734, doi:10.1038/nbt.1927 (2011).</span></li>\n<li>Blair, D., Hockemeyer, D. &amp; Bateup, H. S. Genetically engineered human cortical spheroid models of tuberous sclerosis. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Med </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">24</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1568-1578, doi:10.1038/s41591-018-0139-y (2018).</span></li>\n<li>Gilbert, A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">154</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 442-451, doi:10.1016/j.cell.2013.06.044 (2013).</span></li>\n<li>Gilbert, A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">159</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 647-661, doi:10.1016/j.cell.2014.09.029 (2014).</span></li>\n<li>Blair, D., Hockemeyer, D., Doudna, J. A., Bateup, H. S. &amp; Floor, S. N. Widespread Translational Remodeling during Human Neuronal Differentiation. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Rep </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">21</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 2005-2016, doi:10.1016/j.celrep.2017.10.095 (2017).</span></li>\n<li>Smits, M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Modeling Parkinson's disease in midbrain-like organoids. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">NPJ Parkinsons Dis </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">5</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 5, doi:10.1038/s41531-019-0078-4 (2019).</span></li>\n<li>Jo, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Stem Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">19</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 248-257, doi:10.1016/j.stem.2016.07.005 (2016).</span></li>\n<li>Kwak, T. H. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Generation of homogeneous midbrain organoids with in vivo-like cellular composition facilitates neurotoxin-based Parkinson's disease modeling. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Stem Cells</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, doi:10.1002/stem.3163 (2020).</span></li>\n<li>Li, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genome-wide CRISPR screen for Zika virus resistance in human neural cells. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Proc Natl Acad Sci U S A </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">116</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 9527-9532, doi:10.1073/pnas.1900867116 (2019).</span></li>\n<li>Norman, M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Exploring genetic interaction manifolds constructed from rich single-cell phenotypes. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Science </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">365</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 786-793, doi:10.1126/science.aax4438 (2019).</span></li>\n<li>Gaweda-Walerych, K., Mohagheghi, F., Zekanowski, C. &amp; Buratti, Parkinson's disease-related gene variants influence pre-mRNA splicing processes. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiol Aging </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">47</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 127-138, doi:10.1016/j.neurobiolaging.2016.07.014 (2016).</span></li>\n<li>Liang, &amp; Zhang, Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Stem Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">13</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 149-159, doi:10.1016/j.stem.2013.07.001 (2013).</span></li>\n<li>Soldner, &amp; Jaenisch, R. Stem Cells, Genome Editing, and the Path to Translational Medicine. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">175</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 615-632, doi:10.1016/j.cell.2018.09.010 (2018).</span></li>\n<li>Braak, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Staging of brain pathology related to sporadic Parkinson's disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiol Aging </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">24</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 197-211, doi:10.1016/s0197-4580(02)00065-9 (2003).</span></li>\n<li>Booth, H. E., Hirst, W. D. &amp; Wade-Martins, R. The Role of Astrocyte Dysfunction in Parkinson's Disease Pathogenesis. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Trends Neurosci </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">40</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 358-370, doi:10.1016/j.tins.2017.04.001 (2017).</span></li>\n<li>Schapansky, J., Nardozzi, D. &amp; LaVoie, M. J. The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neuroscience </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">302</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 74-88, doi:10.1016/j.neuroscience.2014.09.049 (2015).</span></li>\n<li>Chen, I., Song, H. &amp; Ming, G. L. Applications of Human Brain Organoids to Clinical Problems. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Dev Dyn </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">248</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 53-64, doi:10.1002/dvdy.24662 (2019).</span></li>\n<li>Picelli, S. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Smart-seq2 for sensitive full-length transcriptome profiling in single cells. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Methods </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">10</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1096-1098, doi:10.1038/nmeth.2639 (2013).</span></li>\n<li>Wang, &amp; Rio, D. C. JUM is a computational method for comprehensive annotation-free analysis of alternative pre-mRNA splicing patterns. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Proc Natl Acad Sci U S A </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">115</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, E8181-E8190, doi:10.1073/pnas.1806018115 (2018).</span></li>\n<li>Love, I., Huber, W. &amp; Anders, S. Moderated estimation of fold change and dispersion for RNA- seq data with DESeq2. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genome Biol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">15</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 550, doi:10.1186/s13059-014-0550-8 (2014).</span></li>\n<li>Adamson, B. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">167</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1867-1882 e1821, doi:10.1016/j.cell.2016.11.048 (2016).</span></li>\n<li>Roadmap Epigenomics, C. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Integrative analysis of 111 reference human epigenomes. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">518</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 317-330, doi:10.1038/nature14248 (2015).</span></li>\n<li>Consortium, T. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genetic effects on gene expression across human tissues. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">550</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 204- 213, doi:10.1038/nature24277 (2017)</span></li>\n<li>Tycko, J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al.</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, doi:10.1101/520569 (2019).</span></li>\n<li>Gasperini, M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">176</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 377-390 e319, doi:10.1016/j.cell.2018.11.029 (2019).</span></li>\n<li>Devine, J., Gwinn, K., Singleton, A. &amp; Hardy, J. Parkinson's disease and alpha-synuclein expression. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Mov Disord </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">26</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 2160-2168, doi:10.1002/mds.23948 (2011).</span></li>\n<li>Miller, J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Human iPSC-based modeling of late-onset disease via progerin-induced aging. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Stem Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">13</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 691-705, doi:10.1016/j.stem.2013.11.006 (2013).</span></li>\n<li>Beard, , Hochedlinger, K., Plath, K., Wutz, A. &amp; Jaenisch, R. Efficient method to generate single- copy transgenic mice by site-specific integration in embryonic stem cells. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genesis </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">44</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 23-28, doi:10.1002/gene.20180 (2006).</span></li>\n<li>Gorski, A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Neurosci </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">22</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 6309-6314, doi:20026564 (2002).</span></li>\n<li>Backman, C. M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Characterization of a mouse strain expressing Cre recombinase from the 3' untranslated region of the dopamine transporter locus. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genesis </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">44</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 383-390, doi:10.1002/dvg.20228 (2006).</span></li>\n<li>Zhou, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">509</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 487-491, doi:10.1038/nature13166 (2014).</span></li>\n<li>Kramer, D. J., Risso, D., Kosillo, P., Ngai, &amp; Bateup, H. S. Combinatorial Expression of Grp and Neurod6 Defines Dopamine Neuron Populations with Distinct Projection Patterns and Disease Vulnerability. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">eNeuro </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">5</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, doi:10.1523/ENEURO.0152-18.2018 (2018).</span></li>\n<li>Kosillo, P. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Tsc1-mTORC1 signaling controls striatal dopamine release and cognitive flexibility. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Commun </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">10</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 5426, doi:10.1038/s41467-019-13396-8 (2019).</span></li>\n<li>Benthall, N., Ong, S. L. &amp; Bateup, H. S. Corticostriatal Transmission Is Selectively Enhanced in Striatonigral Neurons with Postnatal Loss of Tsc1. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Rep </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">23</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 3197-3208, doi:10.1016/j.celrep.2018.05.037 (2018).</span></li>\n</ol>\n<p>&nbsp;</p>"
    },
    "tags": {
      "iv": [
        "GWAS",
        "invivo",
        "Year 1"
      ]
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": [
        "f2235d49-af87-4834-8f0f-57cc1a4354a9",
        "a61a6e09-29f3-46f4-99db-b03e50dce6b3",
        "859bd247-1e49-4c88-a2c0-585b6e13ad05"
      ]
    },
    "authors": {
      "iv": [
        "0f3f3478-9af0-497f-a6e7-896bc801ff7b",
        "f21fb988-cb68-4889-a444-6161006dff67",
        "29f03856-fff9-4312-938c-de07ada412f0",
        "9912c4d4-58cb-4e10-9f93-44f4eb5f1e7b"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": " Activation of transposable elements as a trigger of neuroinflammation in Parkinsons disease"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1yH03IpjFO7Vti622Vij50vjonEyRPbYA/view?usp=sharing"
    },
    "adminNotes": {
      "iv": " Johan Jakobsson, Molly Hammel, Agnete Kirkeby, Roger Barker"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:19Z"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "Understanding Inherited and Acquired Genetic Variation in Parkinsons disease through Single-cell Multi-omics Analyses: a Unique Data Resource"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>PROJECT SUMMARY</h1>\n<p>The functional roles of inherited and acquired genetic variation in the pathogenesis of Parkinson's disease (PD) remain largely unknown. Here, we will first study how germline genetic variants at PD-risk loci, which were identified by genome-wide association study (GWAS), perturb the expression of genes in specific cell (sub)populations of the brain and gut (Figure 1). To this aim, we will apply single-cell gene-expression and open-chromatin quantitative trait locus (QTL) analyses, enabling identification of PD-relevant genes and cell (sub)types. We will deliver the mechanisms of PD-candidate gene expression (dys)regulation in the normal condition, with ageing and in PD, as well as a unique single-cell multi-omic resource for the community. Second, we will study the nature and role of somatic mutations in brain and gut cells in PD- etiopathology. Finally, we will characterize biochemical and phenotypic effects of loss- or gain-of-function QTLs and somatic mutations of candidate genes in <em>in vitro </em>and <em>in vivo </em>model systems, including their impact on the neuro-immune axis. This project thus aligns with both ASAP-themes.</p>\n<h1>RATIONALE AND PRELIMINARY DATA</h1>\n<p>Although 90 GWAS PD-risk loci have been identified<sup>1</sup>, the genes and biological pathways affected, their mode of perturbation (e.g. loss- or gain-of-function) and the cell (sub)types of relevance remain incompletely understood. Expression of potential PD-risk genes is enriched in substantia nigra (SN) dopaminergic (DA) neurons<sup>1</sup>, but also other cell types have been implicated, including immune cells<sup>2&ndash;5</sup>. PD has heterogeneous motor phenotypes, and is not purely a brain disorder, with gastrointestinal dysfunction often preceding motor symptoms. PD may indeed be seen as &ldquo;brain-first&rdquo; or &ldquo;gut-first&rdquo;<sup>6</sup>. The biological basis for this is however not clear. Finally, ageing is the biggest risk factor for PD, though we still cannot answer the fundamental question of what age-related factors predispose to it.</p>\n<p>Recent developments in sequencing the RNA of single cells<sup>7</sup> revolutionized (i) the discovery of novel cell types and subtypes based on their molecular signature, (ii) profiling the heterogeneity in functional and phenotypic cell states in normal and diseased tissues, (iii) studying individual cell responses to external signals and (iv) constructing roadmaps of cell state transitions or differentiation by pseudo-time ordering of single-cell transcriptomes. In fact, single-cell technology enabled a new world-wide project &ndash;the Human Cell Atlas<sup>8</sup> (HCA)&ndash; aiming to create comprehensive reference maps of all human cells as a basis for both understanding human health and diagnosing, monitoring and treating disease. As part of HCA, PIs T. Voet and G. Boeckxstaens are actively contributing to the Gut Cell Atlas<sup>9</sup>.</p>\n<h4>We hypothesize that single-cell gene-expression quantitative trait locus (sc-eQTL) analyses performed on human brain and gut tissues in normal ageing and PD will allow identifying the disease-relevant genes and cells, and that supplementing this with single-cell epigenomic and <em>in situ </em>data will provide unprecedented mechanistic understanding of PD-candidate gene-expression regulation in PD-relevant cell (sub)types in normal individuals, and of their putative further disturbance with ageing and in PD. Our project is supported by the single-cell eQTLGen Consortium<sup>10</sup>.</h4>\n<p>Somatic mutations, acquired with development or ageing, are prominent in brain neurons<sup>11&ndash;13</sup>. Defects in DNA repair have been associated with human PD-pathogenesis<sup>14</sup>, two genes in GWAS PD-risk loci are involved in DNA repair (<em>NUCKS1</em><sup>15</sup>; <em>ARID2</em><sup>16</sup>), and prediction of brain-disorder risk genes using chromatin interaction profiles found enrichment of DNA damage/repair in all studied brain disorders<sup>2</sup>. We hypothesize that somatic DNA mutations, copy number variants (CNVs) in <em>SNCA </em>and other genes in particular, (co-)determine the risk of developing PD, regional or cellular vulnerability, and variation in the phenotype<sup>17,18</sup>. PI C. Proukakis identified somatic DNA copy number gains of <em>SNCA </em>in synucleinopathy brains, more frequent in PD than control neurons, correlating with clinical features, and with the presence of inclusions in the same cells in Lewy body cases<sup>19,20</sup> (Figure 2A).</p>\n<p>Microglia, the resident macrophages of the brain, clear apoptotic cells, extracellular proteins as &alpha;- synuclein released by neurons<sup>5</sup>, and cellular debris. Dysfunction of these neuroprotective roles plays a major role in the pathogenesis of neurodegenerative disorders, including PD<sup>5</sup>. PI G. Boeckxstaens discovered a macrophage population in the colon with microglia-like properties, which when removed lead to neuronal loss and constipation<sup>21</sup>. These macrophages lose their neuro-supportive phenotype in ageing mice, a finding associated with constipation and the appearance of protein aggregates. <strong>We hypothesize that dysfunction of such neuron-associated macrophages in the human gut, as a result of inherited or acquired genetic variation, contributes to impaired clearance of extracellular debris, &alpha;- synuclein aggregation, neuronal distress and constipation. </strong>PD-risk genes are expressed in enteric neurons<sup>22</sup>, and <em>LRRK2</em>, a major PD-risk gene, is highly expressed in the macrophages associated with myenteric neurons<sup>9</sup>. Our acquired insights may shed new light on the brain-gut connection in PD, and the potential retrograde spread of &alpha;-synuclein from the gut to the brain via the vagus nerve.</p>\n<h1>RESEARCH TOOLS, MODELS AND RESOURCES</h1>\n<h2>Human tissue collection</h2>\n<p>Brain and colon samples of PD and control donors are available and will be obtained from various biobanks, while additional colon tissue will be collected prospectively (Table 1). PD and control donors will be age-, gender- and ethnicity-matched. Two brain regions will be studied: the <strong>substantia nigra (SN)</strong>, where pathology is most pronounced, and the <strong>cingulate cortex (CingC)</strong>, where there is widespread aggregation but limited cell loss. In both SN and CingC somatic <em>SNCA </em>CNVs have been demonstrated<sup>19,20</sup>. Full thickness specimens of the <strong>right colon (RC) </strong>will be collected, to enrich for myenteric neurons and macrophages from the muscularis propria. RC is chosen as the vagal innervation reaches to the transverse colon.</p>\n<h2>Single-cell analysis</h2>\n<p><strong> </strong>A state-of-the-art Single Cell Analysis platform is available at KU Leuven and VIB, including custom and commercial microfluidics systems<sup>23,24</sup>, a fleet of liquid handling robots and Illumina HiSeq4000 and NovaSeq6000 (n=3) sequencing devices for high-throughput automated single-cell sequencing. High resolution microscopy for <em>in situ </em>sequencing<sup>25</sup> and seqFISH<sup>26,27</sup> is available, allowing profiling transcriptional states of cells at spatial resolution. A bioinformatics and data storage platform integrated with the Flemish SuperComputing Center (VSC) is installed.</p>\n<h2>Functional validation of eQTLs</h2>\n<p>Gene expression reporter systems, Drosophila model systems, iPSC lines and <em>in vitro </em>co-culture systems are available at KU Leuven and VIB and further detailed in WP3.</p>\n<h1>STUDY PLAN</h1>\n<h2>WP 1: Understanding gene expression perturbation by inherited genetic variants at GWAS PD-risk loci</h2>\n<h3><strong>1.1 Single-cell e/caQTL analyses</strong></h3>\n<p>To identify the genes and cells that are affected by PD-associated SNPs and thus are most relevant for PD-etiology, we will first investigate how inherited SNP-haplotypes in PD- risk loci perturb gene expression in brain and colon cells of normal control To this aim, we will first perform single-cell gene expression and chromatin accessibility quantitative trait locus (sc-eQTL and sc-caQTL respectively) analyses on over 200 normal control brain (SN and CingC regions per brain) and 200 colon samples across an age range (40-95 years old). Linked-read whole-genome sequencing (WGS) of each donor will provide SNP-allele haplotype structures, enabling to link PD-risk SNP-variant alleles to allele-specific expression of genes on the same haplotype (Figure 2B), thus increasing power for cis-eQTL detection. To profile open chromatin DNA loci and mRNA-transcripts of the same single cell, state-of-the-art single-nucleus ATAC-plus-RNA sequencing<sup>28,29</sup> (scAR-seq) will be performed on the frozen tissues. This also circumvents cell-sampling and -stressing biases inherent to fresh tissue disaggregation protocols. Samples from 5 individuals will be hashed together in scAR-seq library pools of 25,000 cells to reduce cost, with sequencing data being error-robustly deconvoluted<sup>30</sup> by genotype analysis of donor-specific SNP profiles in the scAR-seq data. The phased WGS will then be integrated with the snRNA-seq data to measure cis- (and potentially trans-) eQTLs as well as dispersion QTLs. In addition, integration with snATAC-seq data will allow to disclose DNA-accessible sites correlating with those eQTLs to elucidate changes in regulatory element and transcription factor usage<sup>31,32</sup>, and whether genes are affected by loss- of-function, gain-of-function or dispersion traits. Importantly, these data will also reveal if sc-e/caQTLs emerge or change upon ageing in the brain and colon. Computational pipelines to predict eQTLs and caQTLs have been established<sup>33,34</sup>. These pipelines combine generalized linear models with motif enrichment and deep learning. Our methods will be benchmarked against other methods of the single- cell eQTLGen Consortium, and further adapted to include additional factors, namely normal versus PD, and young versus old. Next, phased WGS and scAR-seq will be repeated for brain and colon samples of 100 PD donors, to assess whether some sc-e/caQTLs are exacerbated or attenuated along the disease spectrum and duration in PD brain and colon. These data will also reveal if particular cellular phenotypic states arise &ndash;including gene expression perturbation for any genes outside the PD-risk loci&ndash; in comparison to normal age-, gender- and ethnicity-matched control samples, and disclose cellular mechanisms and responses relating to disease progression or phenotypic variation across patients. This delivers a unique multi-omic &gt;4,500,000 cell atlas and resource of brain plus colon in health and PD.</p>\n<h3><strong>1.2 eQTL validation and intercellular eQTLs</strong></h3>\n<p>Sequential fluorescence <em>in situ </em>hybridization (seqFISH) techniques for gene transcripts (&plusmn;proteins)<sup>27,35</sup> (Figure 2C) will first confirm identified eQTLs to near- absolute quantitative precision <em>in situ</em>, together with marker gene transcripts for the cell (sub)types of interest in a highly multiplexed fashion. Additionally, seqFISH methods enable to rapidly query eQTLs in other brain/ colon regions, and in more individuals if needed. Second, we will computationally infer cell- cell or cell- microenvironment interactions from the above snRNA-seq data using CelPhoneDB<sup>36</sup> and Niche-Net<sup>37</sup>, to assess if QTLs in one cell also affect expression of genes and phenotypes of neighboring cells. g, a SNP perturbing expression of a ligand in one cell type may affect cognate receptor signaling in a neighboring cell type. Such inter-cellular eQTL interactions will be validated by seqFISH. Third, the cellular architecture and phenotypic states within tissues may alter significantly with ageing, including emergence of phenotypic drift and of senescent cells secreting 'senescence-associated secretory phenotype or SASP'-factors as chemokines, inflammatory cytokines and other factors. Communication between senescent cells and neighboring cells is suspected to contribute to age-related diseases<sup>38</sup>. SeqFISH will allow us to study these altered cell ecosystems and their relevance in PD-pathogenesis.</p>\n<h3><strong>1.3 Single-nucleus nucleosome, methylation and transcription sequencing (snNMT-seq) analyses</strong></h3>\n<p><strong> </strong>To further investigate gene expression regulation across ageing and in disease, and to validate gene- regulatory element usage, snNMT-seq<sup>39</sup> will be performed (Figure 2D) on 4,600 cells of interest selected from WP1.1. It enables integration of allele-specific open chromatin, DNA methylation and gene expression in the same cell. It will thus reveal chromatin dynamics, in particular open chromatin alterations during ageing of cells instigated by g. histone depletion. Genome-wide DNA methylomes will simultaneously capture changes in heterogeneity and ageing-associated drift<sup>40</sup>, and how such epimutations differ amongst cell types across ageing and in PD. Finally, RNA-sequences from the same single cells will reveal how acquired epimutations derail transcriptional programs and gene regulatory networks of brain/colon cells, and thus assay the epigenome&rsquo;s impact on cell function during ageing. To integrate data across these different omics layers for each cell, we will use a hierarchical Bayesian modeling framework. This allows that as data accumulates, weakly-informative prior distributions of unknown parameters can be updated and learned across datasets, thus significantly increasing power.</p>\n<h3><strong>Risks and mitigation</strong></h3>\n<p><strong> </strong>As fallback for scAR-seq from 10X Genomics (available this year<sup>28,29</sup> - personal communication attached), we have SNARE-seq<sup>41</sup> in house. In case tissues are of low RNA-quality, we will contact more biobanks. Borderline significant QTLs due to technical noise from snRNA-seq will be validated with allele-specific seqFISH/MERFISH assays, which deliver near 100% transcript sensitivity<sup>27,35</sup>.</p>\n<h2>WP 2: Identifying nature and roles of somatic CNVs in PD-etiopathology</h2>\n<p>Somatic CNVs could play etiological or modifier role(s) e.g. by sparking &alpha;-synuclein aggregation in mutant neurons, providing a &ldquo;seed&rdquo; from which pathology spreads to non-mutant cells, or making mutant neurons prone to other phenotypic alterations, stress responses or cellular vulnerability<sup>42</sup>.</p>\n<h3><strong>2.1 Inference of CNVs</strong></h3>\n<p><strong> </strong>We will use the brain and colon cell atlas (WP1) to computationally infer somatic CNVs in these cells, and scrutinize their nature, frequency and recurrence in PD and controls across PI T. Voet has expertise in detecting CNVs from single-cell RNA data (Figure 2E), and will also devise an algorithm to determine CNVs from sn-ATAC and -methylation data, reinforcing CNV detection in the same cells. This data will allow selecting PD and control brain and colon samples, and the cell types of interest, to further investigate and eventually validate the role of somatic CNVs in PD.</p>\n<h3><strong>2.2 Validation and impact of CNVs</strong></h3>\n<p><strong> </strong>We will use laser capture microdissection (LCM) combined with immunohistochemistry (IHC) to select cells based on location, morphology, &alpha;-synuclein or other cell pathology/marker, and neuromelanin in the SN, and perform low coverage single-cell WGS (scWGS). We will optimize section thickness and IHC-LCM-scWGS using a PD brain with <em>SNCA </em>duplication<sup>20</sup>. Further characterization of somatic CNVs in those and other brain regions will be done with deep bulk long-read WGS, to detect smaller/other structural variants, and ddPCR to detect low-level subclones. To study cell phenotypic impacts, we will use single-nucleus genome-plus-transcriptome sequence<sup>43</sup> (Figure 2E) and immuno-FISH assays, and determine pathways enriched for CNVs, as well as clonality<sup>20</sup>.</p>\n<h3><strong>Risks and mitigation</strong></h3>\n<p><strong> </strong>We have already performed LCM-scWGS for SN DA neurons (Figure 2F). In the unlikely case of inadequate scWGS quality after IHC-LCM, we will use a nuclear isolation plus scWGS protocol, proven to work with immunostaining in multiple system atrophy (MSA) brains<sup>20</sup>.</p>\n<h2>WP 3: Functional characterization of eQTL and somatically mutated genes</h2>\n<p>WP3 will study the causative role in PD of genes found dysregulated by germline or acquired genetic variation in the brain using a validated <em>Drosophila </em>model as well as in the gut on the intestinal neuro- immune interaction between macrophages and enteric neurons.</p>\n<h3><strong>3.1<em> In vitro </em>functional screening of dysregulated PD </strong></h3>\n<p>The impact of significant PD-associated SNPs on eQTL-based target gene expression will be first evaluated using an established <em>in vitro </em>reporter system<sup>44</sup>. Enhancers or promoters with non-coding SNPs are cloned <em>en masse, </em>upstream of a minimal promoter controlling a barcoded mRNA reporter. The plasmids will then be transfected in different commercially available cell lines, depending on the cell type(s) identified from WP1. The functional impact of the different SNP-alleles will be determined by evaluating altered expression of the reporter mRNA using next-generation sequencing. This system enables high-throughput validation of putative eQTL SNPs that may deregulate candidate PD-risk genes and pathways.</p>\n<h3><strong>3.2 </strong><strong>Assessment of the causative role in PD of identified dysregulated genes in the brain</strong></h3>\n<p><strong> </strong>Next, we will functionally assess the top candidate eQTLs selected in 3.1 using <em>Drosophila</em>. We will use available genome-wide RNAi and cDNA collections to knockdown or over-express the top 100 candidate genes throughout the nervous system and use video-tracking for automated behavioral analyses (i.e. walking, flying, sleeping, micromovements ) to assess the neurological defects and define candidate genes that phenocopy our established PD models. Next, to define which cell type(s) cause(s) the behavioral defects, we will select ~20 different Gal4 lines, based on complementary expression in the fly brain (covering neurons and glia) to specifically knockdown or over-express our 5 best candidate genes.</p>\n<h3><strong>3.3 Evaluation of immune cell neuro-supportive pathway in the gut</strong></h3>\n<p><strong> </strong>In parallel, we will study how dysregulation of the candidate genes affects intestinal macrophage function, both with respect to their ability to clear &alpha;-synuclein aggregates<sup>5</sup> but also their supportive role towards enteric neurons<sup>45</sup>. We will make use of an <em>in vitro </em>screening platform, comprising human iPSC-derived macrophages and enteric neurons<sup>46,47</sup>. iPSCs differentiated to enteric neurons and macrophages will be studied separately as well as in co-culture to study their bidirectional interaction. The top 5 dysregulated genes will be edited in either cell types using CRISPR/Cas9. The impact on neuronal health and function will be assessed by neurite outgrowth, Ca<sup>2+</sup> signaling activity, mitochondrial transport and morphology, HuC/D localization and activation of apoptosis. Macrophage phenotype and function will be judged by phagocytosis of damaged neurons (by multiphoton approaches), protein aggregates and apoptotic bodies, degradation of &alpha;-synuclein aggregates by autophagy, expression of polarization markers, secretion of inflammatory mediators, cytokines and growth</p>\n<h3><strong>Risk and mitigation plan</strong></h3>\n<p><strong> </strong>The reporter system and <em>Drosophila </em>models are routinely used, also for the discovery of cell types affecting behavior and thus do not contain risk. The co-culture of iPSC-derived enteric neurons and macrophages is complex, but validated in our Stem Cell Institute of KU Leuven.</p>\n<h1>POWER CALCULATIONS AND STATISTICAL ANALYSES PLAN</h1>\n<p>Power for eQTL tests was calculated<sup>48</sup> (Figure 2G), assuming testing up to 10 cell types from 3 different tissues (30 cell types in total). Sample numbers were chosen to maximize power for detecting eQTLs for 87 of the 107 SNPs previously associated with PD that have minor allele frequencies &gt;10%<sup>1</sup>. Specifically, we aimed for 80% power to significantly (FDR&lt;0.05) link allele-specific expression levels of SNP-flanking genes to the PD-associated SNP genotype with effect sizes (<em>delta/sigma</em>) exceeding 1. To achieve this, 200 samples are needed. The standard deviation of expression in single-cell analyses is on average 0.3 (own data), indicating a 30% increased or decreased expression is detectable for these 87 SNPs. Similarly, half of all 107 SNPs in the latest GWAS analysis<sup>1</sup> have minor allele frequencies exceeding 23%; for these, effect sizes of 0.7 (21% changes in expression) will be detectable. Note that, due to the cell-type-specific nature of sc-eQTLs and the proposed haplotype phasing, we will likely uncover larger effect sizes than bulk unphased eQTL analyses, where effect sizes are lowered by admixture of non-contributing cells and heterozygous alleles. Power estimates are hence conservative.</p>\n<h1>PROJECT TIMELINE AND MILESTONES&nbsp;</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/20765d84-955a-4cad-ba19-8a7a7b21e3df/timeline.jpg\" alt=\"Timeline\" /></p>\n<h1>WORKFLOW SCHEMATIC</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/00d57786-fd60-49ec-950d-b1cb2bd2b4d0/workflow.jpg\" alt=\"Workflow\" /></p>\n<h1>LITERATURE CITATIONS</h1>\n<ol>\n<li>Nalls, M. A. <em>et al. </em>(2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson&rsquo;s disease: a meta-analysis of genome-wide association studies. <em>Lancet Neurol. </em>18, 1091&ndash;1102.</li>\n<li>Sey, N. Y. A. <em>et al. </em>(2020) A computational tool (H-MAGMA) for improved prediction of brain-disorder risk genes by incorporating brain chromatin interaction profiles. <em> Neurosci. </em>23, 583&ndash;593.</li>\n<li>Reynolds, R. H. <em>et al. </em>(2019) Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson&rsquo;s disease heritability. <em>Npj Park. Dis. </em>5, 1&ndash;14.</li>\n<li>Keo, A. <em>et al. </em>(2020) Transcriptomic signatures of brain regional vulnerability to Parkinson&rsquo;s disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Commun. Biol. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">3, 1&ndash;12.</span></li>\n<li>Choi, I. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2020) Microglia clear neuron-released &alpha;-synuclein via selective autophagy and prevent neurodegeneration. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Commun. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">11, 1&ndash;14.</span></li>\n<li>Borghammer, &amp; Van Den Berge, N. (2019) Brain-First versus Gut-First Parkinson&rsquo;s Disease: A Hypothesis. <em>Park. Dis. </em>9, S281&ndash;S295.</li>\n<li>Svensson, V. <em>et al. </em>(2017) Power analysis of single-cell RNA-sequencing experiments. <em> Methods </em>14, 381&ndash;387.</li>\n<li>Regev, A. <em>et al. </em>(2018) The Human Cell Atlas White Paper. <em>ArXiv181005192 Q-Bio</em>.</li>\n<li>Drokhlyansky, E. <em>et al. </em>(2019) The enteric nervous system of the human and mouse colon at a single-cell resolution. <em>bioRxiv </em></li>\n<li>van der Wijst, M. <em>et </em>(2020) The single-cell eQTLGen consortium. <em>eLife </em>9, e52155.</li>\n<li>McConnell, J. <em>et al. </em>(2017) Intersection of diverse neuronal genomes and neuropsychiatric disease: The Brain Somatic Mosaicism Network. <em>Science </em>356, eaal1641.</li>\n<li>Rohrback, <em>et al. </em>(2018) Genomic mosaicism in the developing and adult brain. <em>Dev. Neurobiol. </em>78, 1026&ndash; 1048.</li>\n<li>Lodato, A. &amp; Walsh, C. A. (2019) Genome aging: somatic mutation in the brain links age-related decline with disease and nominates pathogenic mechanisms. <em>Hum. Mol. Genet. </em>28, R197&ndash;R206.</li>\n<li><em> </em>Sepe, S. <em>et al. </em>(2016) Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson&rsquo;s Disease. <em>Cell </em>15, 1866&ndash;1875.</li>\n<li>Parplys, C. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2015) NUCKS1 is a novel RAD51AP1 paralog important for homologous recombination and genome stability. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nucleic Acids Res. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">43, 9817&ndash;9834.</span></li>\n<li>Castro, O. de <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2017) The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J. Biol. Chem. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">292, 8459&ndash;8471.</span></li>\n<li>Leija-Salazar, M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2018) Review: Somatic mutations in neurodegeneration. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Appl. Neurobiol. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">44, 267&ndash;285.</span></li>\n<li>Proukakis, C. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2013) Somatic alpha-synuclein mutations in Parkinson&rsquo;s disease: Hypothesis and preliminary data. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Disord. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">28, 705&ndash;712.</span></li>\n<li>Mokretar, K. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2018) Somatic copy number gains of &alpha;-synuclein (SNCA) in Parkinson&rsquo;s disease and multiple system atrophy brains. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Brain </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">141, 2419&ndash;2431.</span></li>\n<li>Perez-Rodriguez, D. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019) Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Acta Neuropathol. Commun. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">7,</span></li>\n<li>Prinz, M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019) Microglia Biology: One Century of Evolving Concepts. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">179, 292&ndash;311.</span></li>\n<li>Bryois, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2020) Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson&rsquo;s disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat. Genet. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">1&ndash;12.</span></li>\n<li>Lambrechts, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2018) Phenotype molding of stromal cells in the lung tumor microenvironment. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat. Med. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">24, 1277&ndash;1289.</span></li>\n<li>Davie, K. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2018) A Single-Cell Transcriptome Atlas of the Aging Drosophila Brain. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">174, 982- 998.e20.</span></li>\n<li>Ke, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2013) In situ sequencing for RNA analysis in preserved tissue and cells. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat. Methods </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">10, 857&ndash;</span>860.</li>\n<li>Shah, S. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2016) In Situ Transcription Profiling of Single Cells Reveals Spatial Organization of Cells in the Mouse Hippocampus. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neuron </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">92, 342&ndash;357.</span></li>\n<li>Wang, G. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2018) Multiplexed imaging of high-density libraries of RNAs with MERFISH and expansion microscopy. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Rep. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">8, 4847.</span></li>\n<li>http://web.archive.org/web/20200505132929/https://<a style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\" href=\"http://www.10xgenomics.com/product-updates/\">10xgenomics.com/product-updates/</a><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Product Updates - 10x Genomics.</span></li>\n<li>http://web.archive.org/web/20200505133358/https://investors.10xgenomics.com/news-releases/news- release-details/10x-genomics-debuts-range-new-products-agbt (2020) 10x Genomics Debuts Range of New Products at AGBT - 10x</li>\n<li>Kang, M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2018) Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat. Biotechnol. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">36, 89&ndash;94.</span></li>\n<li>Gonz&aacute;lez-Blas, B. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019) cisTopic: cis-regulatory topic modeling on single-cell ATAC-seq data. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat. Methods </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">16, 397&ndash;400.</span></li>\n<li>Aibar, S. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2017) SCENIC: single-cell regulatory network inference and clustering. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Methods </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">14, 1083&ndash;1086.</span></li>\n<li>Jacobs, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2018) The transcription factor Grainy head primes epithelial enhancers for spatiotemporal activation by displacing nucleosomes. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat. Genet. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">50, 1011&ndash;1020.</span></li>\n<li>Atak, Z. K. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019) Prioritization of enhancer mutations by combining allele-specific chromatin accessibility with deep learning. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">bioRxiv </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">12.21.885806.</span></li>\n<li>Xia, C. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019) Spatial transcriptome profiling by MERFISH reveals subcellular RNA compartmentalization and cell cycle-dependent gene expression. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Proc. Natl. Acad. Sci. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">116, 19490&ndash;19499.</span></li>\n<li>Efremova, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019) CellPhoneDB v2.0: Inferring cell-cell communication from combined expression of multi-subunit receptor-ligand complexes. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">bioRxiv </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">680926.</span></li>\n<li>Browaeys, R. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2020) NicheNet: modeling intercellular communication by linking ligands to target genes. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat. Methods </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">17, 159&ndash;162.</span></li>\n<li>L&oacute;pez-Ot&iacute;n, C. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2013) The Hallmarks of Aging. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">153, 1194&ndash;1217.</span></li>\n<li>Clark, S. J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2018) scNMT-seq enables joint profiling of chromatin accessibility DNA methylation and transcription in single cells. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Commun. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">9, 1&ndash;9.</span></li>\n<li>Veitia, R. A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2017) Aging: Somatic Mutations, Epigenetic Drift and Gene Dosage Imbalance. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Trends Cell Biol. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">27, 299&ndash;310.</span></li>\n<li>Chen, S. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019) High-throughput sequencing of the transcriptome and chromatin accessibility in the same cell. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Biotechnol. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">37, 1452&ndash;1457.</span></li>\n<li>Santaguida, S. &amp; Amon, A. (2015) Short- and long-term effects of chromosome mis-segregation and aneuploidy. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Rev. Mol. Cell Biol. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">16, 473&ndash;485.</span></li>\n<li>Macaulay, I. C. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2015) G&amp;T-seq: parallel sequencing of single-cell genomes and transcriptomes. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Methods </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">12, 519&ndash;522.</span></li>\n<li>Verfaillie, A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2016) Multiplex enhancer-reporter assays uncover unsophisticated TP53 enhancer logic. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genome Res. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">26, 882&ndash;895.</span></li>\n<li>Schepper, D. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2018) Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">175, 400-415.e13.</span></li>\n<li>Barber, K. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019) Derivation of enteric neuron lineages from human pluripotent stem cells. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Protoc. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">14, 1261&ndash;1279.</span></li>\n<li>Mancuso, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019) Stem-cell-derived human microglia transplanted in mouse brain to study human disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat. Neurosci. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">22, 2111&ndash;2116.</span></li>\n<li>Lonsdale, J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2013) The Genotype-Tissue Expression (GTEx) project. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Genet. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">45, 580&ndash;585.</span></li>\n</ol>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:18Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "Mechanisms Overwhelming Protein and Organelle Quality Control in Parkinsons disease"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>Project Summary</h1>\n<p>Abnormal protein aggregation and prion-like aggregate spreading are hallmarks of the degenerative cascades associated with sporadic and familial Parkinson&rsquo;s Disease (PD) [1]. Deposition of &alpha;-Synuclein (&alpha;- Syn) inclusions (Lewy bodies and Lewy neurites), along with the death of dopaminergic (DA) neurons within the Substantia nigra, are pathognomonic of PD [2, 3]. Multiple mechanisms of aggregate toxicity have been implicated in cellular PD pathology, including damage to membranes and synapses as well as aberrant interactions with key proteins. However, no single defect has emerged as a central intermediate in PD initiation or progression. Protein aggregation is controlled by an extensive proteostasis network (chaperones and proteolytic clearance systems), regulated by stress response pathways that interface with environmental factors. <strong><em>A central tenet of this proposal is that PD phenotypes, at the molecular level, result from the failure of quality control (QC) mechanisms and that finding ways to maintain or augment QC capacity will provide access to new therapeutic strategies for PD and possibly other neurodegenerative disorders.</em></strong></p>\n<p>Research in model organisms suggests that QC capacity declines during aging, particularly in non- dividing cells such as neurons [4], thereby facilitating neurodegeneration. Pathological aggregates overwhelm the dwindling QC capacity and undermine cellular defense mechanisms. Specifically, PD phenotypes are considered to be the result of: 1) loss of chaperone and proteasome capacity due to accumulation of misfolded proteins and aggregates that sequester specific chaperone factors, 2) defective ubiquitin and protein kinase signaling, which impinge on organelle dynamics and removal, and 3) defective autophagy and lysosomal degradation capacity. These adverse effects &ndash; independently or combined, in parallel or synergistically - likely unleash a vicious cycle, accelerating QC decline and eventually leading to the collapse of protein homeostasis. In this context, familial mutations that predispose to early onset disease may disable or impair underlying QC mechanisms with accelerated kinetics.</p>\n<h1>Rationale and Preliminary Data</h1>\n<p>Through an integrative approach employing cell biology, biochemistry, genetic screening, <em>in situ </em>structural analysis by cryo-ET, and proteomics, our team aims to address the key questions (Fig 1a):</p>\n<ol>\n<li>What are the cellular and extracellular chaperone machineries that normally prevent the formation of PD associated protein aggregates and Lewy bodies and whose decline through aging or impairment by other causes facilitates aggregate formation and spreading with ensuing cytotoxicity?</li>\n<li>Are there distinct aggregate structural forms derived from dominant mutations of &alpha;-Syn? To what extent do these mutations impact aggregate biochemical properties or exert effects on cellular QC? Do different cell types (e.g. neurons vs. glia cells) react differently to aggregation?</li>\n<li>What are the key properties of damaged organelles and proteins that elicit requirements for specific QC functions genetically linked with PD?</li>\n<li>Can understanding the underlying trafficking and quality control defects in PD at a molecular level suggest new therapeutic approaches?</li>\n</ol>\n<p>Answering these questions will require systematic examination of individual and combinatorial PD- associated defects, the development of bold new assays that couple direct molecular observation of QC systems for organelles, protein machines, and toxic aggregates spatially and within single cells with mechanistic elucidation via reconstitution of key QC steps <em>in vitro</em>, and testing cross-pathway synergies. Using enabling technologies pioneered by our team (Fig. 1b-f), we propose to integrate advanced quantitative measurements of protein and organelle QC pathways with cryo-ET and single particle cryo-EM approaches that allow direct observation of specific cellular structures, organelles, molecular machines, and aggregates at sub-nanometer resolution. We expect to define how PD mutations affect QC systems at protein domain or higher resolution in intact neurons. We also will determine how defects in individual and/or multiple QC pathways impair other pathways either in specific subcellular compartments, or globally throughout cells within the context of neuronal systems and PD mutations in patient-derived cells.</p>\n<p>Our team has synergistic expertise in dissecting complex cellular pathways and molecular mechanisms, including defining chaperone functions from organisms to cells to structures (JF, UH) and ubiquitin-proteasome and autophagy systems (BS, WH); and pioneering use of cryo-ET for analyzing cellular macromolecular machines and aggregates <em>in situ </em>(RFB, our consortium junior investigator, with W. Baumeister as collaborator). Members of this group have collaborated extensively over &gt;2 decades, with 42 total joint publications (19 &ndash; WH,BS; 3 &ndash; RFB,UH; 12 &ndash; RFB,WB; 9 &ndash; UH,WB; 2 &ndash; JF,UH; 1 &ndash; BS,WB submitted), and other team efforts such as conference co-organization. We believe our long-established working relationships, our culture of highly collaborative science, and an extensive plan for effective communication will build on our existing productive collaborations to create exceptionally strong synergies. Previous work from our groups defined roles of many chaperone systems in preventing amyloidogenic protein aggregation [5-8], demonstrated that aggregates engage in aberrant interactions with endogenous proteins involved in key cellular pathways [9-11], determined structures and functions of various ubiquitin ligase assemblies and the 26S proteasome &ndash; even <em>in situ </em>in neurons [12-15], and systematically analyzed organelle QC by ubiquitin and autophagy systems [16-18]. Importantly, we also visualized aggregate inclusions <em>in situ </em>at unprecedented resolution by cryo-ET, for both huntingtin and C9orf72 dipeptide repeat proteins [19-21], providing the first molecular snapshots of how aggregates interfere with QC functions within cells [20].</p>\n<p>In ongoing work relevant to this proposal, we have analyzed how the QC network changes during differentiation of neural stem and progenitor cells (NSPCs) to neuronal cells and found that differentiation rewires multiple aspects of the chaperone and clearance systems ([22]; WH, unpublished). Moreover, using a previously published protocol [23], we have established a model of &alpha;-Syn aggregate seeding in SH- SY5Y reporter cells expressing GFP-&alpha;-Syn as well as in murine primary neurons (UH, unpublished). These cells form Lewy body-like inclusions that sequester membrane trafficking components including CHMP2b and display an accumulation of autophagosomes (Fig. 1e,d). We employed correlative cryo-light microscopy and cryo-ET to analyze the molecular architecture of &alpha;-Syn inclusions. Interestingly, the overall architecture of the inclusion bodies and the &alpha;-Syn fibrils therein was comparable, irrespective of whether <em>in vitro </em>pre-formed fibrils (PFFs) or &alpha;-Syn aggregates purified from patient brain were used for seeding. &alpha;-Syn-GFP forms fibrils very similar to &alpha;-Syn, with a distance between fluorescent protein domains generally below ~6 nm, and thus suitable for FRET. We could directly visualize the seeding process by cryo-ET using gold-labeled PFFs (Fig 1e). We prepared the extracellular chaperone clusterin, a risk factor for early onset Alzheimer&rsquo;s, and are now in a position to analyze its effects on &alpha;-Syn aggregation and seeding.</p>\n<h1>Research Tools, Models and Resources</h1>\n<p>Understanding the underlying molecular basis of PD will require mechanistic dissection using cellular and <em>in vitro </em>systems that, in turn, allow specific hypotheses to be tested with genetic clarity and in appropriate contexts. The majority of tools have been painstakingly optimized and primed for maximum exploitation precisely for this project, based on decades of our work as individuals or within pairs. This award would provide a unique opportunity for merging this know-how for experimental synergy in attacking the fundamental problems outlined above (see Fig. 1a and Workflow Schematic).</p>\n<p><strong><u>Cell systems</u> </strong>&ndash; We will employ several cell systems to examine neuronal and glial phenotypes: 1) iNeurons and iGlia cells from patient-derived iPSCs and fibroblasts, including trans-differentiation approaches, 2) mouse primary neurons, 3) NSPCs which can be differentiated to neurons, and 4) hES cells that can be&nbsp;differentiated to induced iNeurons or iGlia. NSPCs and hESCs have been exploited to create numerous disease and pathway-relevant mutations (Fig. 1b) and this will be expanded upon in this study. We also employ KBM-7 derived haploid (HAP1) cells to facilitate genetic analysis of QC pathways.</p>\n<p><strong><u>QC Reporter systems</u> </strong>&ndash; We have developed multiple types of reporters to measure QC systems, protein/organelle turnover via proteasome/autophagy (flux reporters), transcriptional responses, and &alpha;- Syn aggregation (GFP-&alpha;-Syn and FRET reporters), including their incorporation into iNeurons, facilitating analysis of QC pathway defects under endogenous conditions and in relevant cell types.</p>\n<p><strong><u>Resources for genetic and proteomic analysis</u> </strong>&ndash; we have developed various CRISPR-Cas9 libraries with deep coverage of proteostasis/trafficking pathways [17] and many quantitative proteomics approaches.</p>\n<p><strong><u>Biochemical reconstitution</u> </strong>&ndash; We developed methods for reconstituting multi-component assemblies within the ubiquitin-proteasome, autophagy, and chaperone systems, and have innovative assays for assessing their activities, including expertise and infrastructure for single particle analysis of complexes and intermediates by cryo-EM, crystallography, and single turnover biochemical measurements. We also have methods for creation of &alpha;-Syn aggregates and their amplification from patient material.</p>\n<p><strong><em><u>In situ </u></em><u>structural biology</u> </strong>&ndash; We have pioneered the analysis of aggregates by cryo-ET in neurons, as well as computational approaches to identify macromolecules <em>in situ</em>. Necessary infrastructure and expertise is available at MPI (and will be available from Q2 2021 in G&ouml;ttingen) to perform the proposed studies.&nbsp;</p>\n<h1>Study Plan</h1>\n<p>The questions we plan to address are organized into 3 collaborative work packages (WP). All WPs will be initiated simultaneously, thereby integrating knowledge gained from the 3 arms contemporaneously. The <strong><em>Workflow Schematic </em></strong>shows the major elements of each WP, illustrating how they feed into each other and emphasizing interactive roles of team members. <strong><em>We view this research program as a full-force attack on the mechanisms of cellular disturbances caused by &alpha;-Syn aggregation in PD</em></strong>.</p>\n<h2>WP1 &ndash; In situ analysis of aggregate architecture and seeding mechanisms.</h2>\n<p>The prion-like spreading of &alpha;-Syn aggregates can be reproduced in cellular models. Importantly, the seeded aggregation of endogenous &alpha;-Syn is associated with pronounced cytotoxicity. <strong><em>Here, using powerful molecular visualization, analytical discovery, and biochemical tools in iNeuron and iGlial systems, we will elucidate how individual aggregate strains (including patient derived aggregates) and mutations in &alpha;-Syn contribute to aggregate architecture in situ and the extent to which distinct aggregate types alter proteostasis machineries through sequestration or other mechanisms. </em></strong>We will employ correlative cryo- ET to perform detailed <em>in situ </em>analyses of seeded &alpha;-Syn inclusions in SH-SY5Y reporter cells, iNeurons (including patient derived iNeurons derived from iPSCs, and iNeurons from fibroblasts of individuals of different ages), iGlia, and mouse cortical neurons (UH,JF,RFB,WB). Cells will be grown on EM grids and aggregate formation induced by addition of PFFs (WT or mutant &alpha;-Syn) or &alpha;-Syn aggregates isolated from patient brain material (Neurobiobank Munich). If necessary, aggregates from brain tissue will be amplified by protein misfolding cyclic amplification (PMCA) [24]. Seeds will be generated from WT and dominant &alpha;- Syn mutants (A30P, E46K, H50Q, G51D, A53T). We feel these experiments will be mechanistically impactful in several ways. First, by systematically comparing the seeding capacity and ensuing cytotoxicity of different aggregates in the cellular models and through their analysis by cryo-ET, we will elucidate genetic determinants of molecular pathology, including large-scale alterations in membranes and organelles (UH,RFB,BS,WB). Second, a central feature of aggregates is their ability to sequester molecular machines to reduce proteostasis capacity, but whether distinctive aggregates or seeding mechanisms preferentially affect different QC machineries is poorly understood. We will employ cryo-ET to visualize and classify the propensity of aggregate types to sequester molecular machines, and will relate this to both the activity status via biochemical reconstruction and available structural data (UH,RFB,BS,WB). Third, in parallel, we will discover new proteins (and their modification states) that selectively associate with &alpha;-Syn at different stages of aggregation in iNeurons and iGlia of various types using &alpha;-Syn-enrichment approaches in combination with quantitative proteomics (UH,JF,WH). Fourth, we will integrate WP1 with&nbsp;WP2 and WP3 in order to dissect mechanisms by which modifiers of aggregation and seeding affect specific steps in the process, taking advantage of bottom-up approaches to elucidate the biochemical mechanisms underlying aggregate modification (BS,UH,JF). Armed with knowledge from these experiments, we will be in a position to interrogate how aggregate form affects spreading between glia and neurons, a key question in the field (UH, JF, RFB).</p>\n<p>Optogenetic aggregate induction [25] using fusions of &alpha;-Syn with plant cryptochrome 2 (Cry2, Opto- &alpha;-Syn) will be employed to induce aggregation without external seeding. This approach will allow distinguishing toxic effects of the seeding process itself from those of endogenous &alpha;-Syn oligomer and fibril formation. We (UH) recently set up this system to nucleate polyQ protein aggregation. Opto-&alpha;-Syn aggregates will be characterized by cryo-ET, interactome analyses and toxicity measurements (UH, JF,RFB,WB,WH). Biochemical reconstitutions will provide mechanistic and structural insights (BS, UH).</p>\n<h2>WP2 &ndash; Disturbance of QC and transport processes by aggregate pathology.</h2>\n<p>An emerging theme in PD and other neurodegenerative diseases is aggregate interference with chaperones, proteasome function and selective autophagy (e.g. mitophagy). Indeed, our preliminary data (RFB, WB) indicate close association of autophagosomes with &alpha;-Syn aggregates (Fig 1e). However, we do not understand what specific events or combination(s) of events generate cellular sensitivities and how these events are normally controlled by trafficking and QC activities. In WP2, we will apply a highly integrated approach to systematically dissect dysfunctions of QC machineries in response to: 1) diverse types of aggregates, but with a primary focus on &alpha;-Syn, and 2) mutations in PD-related genes that may alter cellular responses to the aggregates, including distinct QC machinery, membrane, and organelle interactions and sequestration by <em>a</em>-Syn aggregates. <strong><em>We will do this by creating genetically precise perturbations or &ldquo;pathologies&rdquo; within iNeurons harboring PD risk alleles and by then defining &ldquo;pathological intermediates&rdquo; in situ using cryo-ET (UH,RFB,BS,WB), and reconstitution approaches in vitro (BS,WH,UH,JF).</em></strong></p>\n<p>We will use engineered iNeurons expressing reporters for proteasome function, autophagic flux and proteostasis maintenance to investigate how &alpha;-Syn aggregates alter these parameters, and how such changes may be linked to toxicity mechanisms. We (WH &amp; R. Kopito) found that proteasomes are modified by UBE3C-dependent ubiquitylation immediately upon protein aggregation [26]. These modifications are proteasome subunit specific, suggesting that there might be an underlying &ldquo;code&rdquo; that depends upon the identity and the properties of the upstream misfolding event. We will test this hypothesis with &alpha;-Syn and other aggregates (Huntingtin, Tau, C9orf72 dipeptide repeats) as well as by exposing cells to forms of stress (temperature, oxidative stress) that trigger misfolding (UH,WH,BS,JF).</p>\n<p>Innovative biophysical techniques, including single molecule FRET to identify the earliest QC steps with regard to chaperone recognition, ubiquitin modification and proteasome interaction, will be used in reconstitution experiments (BS,UH,JF,WH), with subsequent single particle cryo-EM structure determination of high priority assemblies, revealing underlying mechanisms (BS,WB,RFB). As aggregate seed material may be released from cells in modified (ubiquitylated and/or phosphorylated) form, it will be of specific interest to reproduce the ubiquitination patterns and other modifications identified <em>in situ.</em></p>\n<p>Mutations linked with neurodegeneration often affect organelle and protein trafficking in axons or dendrites [27]. A plausible hypothesis is that loss of coordination of molecular and organelle trafficking in neurons is a consequence (or by-product) of loss of QC capacity. Using iNeurons with tagged organelles and proteostasis regulators, we will examine the effects of aggregates and selected patient mutations on trafficking to understand any common defects and will interrogate pathological intermediates by cryo-ET to understand mechanistic defects at nanometer resolution (BS,RFB,WB,JF,WH).</p>\n<h2>WP3 &ndash; Genetic modifiers of aggregate formation, seeding and cytotoxicity. To understand which cellular functions are critical to the ability of aggregates both to expand and to induce toxicity, we will use newly developed cellular reporter systems coupled with CRISPR-Cas9 technology and gene-trap mutagenesis in HAP1 cells to identity modifiers (enhancers and suppressors) of aggregate formation, seeding, and cytotoxicity, and will interrogate these modifiers using assays developed in WP1 and WP2.</h2>\n<p>For screening, we will employ three complementary strategies: 1) We will conduct unbiased genome-scale knockout screens using ultra-deep mutagenesis in HAP1 cells [28] (UH,JF,WH). HAP1 sensor cells co- expressing mVenus-&alpha;-Syn (donor) and mScarlet-&alpha;-Syn (acceptor) will be engineered, with BFP expression for abundance control. The ratio of red:blue will report &alpha;-Syn abundance and FRET and pulse shape analysis [29] will report oligomer and aggregate formation. Sorted populations will be deep sequenced to provide a ranked gene list of enhancers and suppressors of aggregate formation. We will establish a HAP1 based regimen to measure toxicity upon &alpha;-Syn aggregate seeding with PFFs to identify gene knockouts which either sensitize or reduce cell death. 2) Using iNeurons from hESCs with or without PD patient mutants (e.g. VPS35<sup>D620N</sup>) (Fig. 1b) and proteostasis-focused CRISPR libraries [17], we (WH,UH,JF) will perform a toxicity screen [30] using distinct &alpha;-Syn aggregate strains with the goal of understanding the importance of individual proteostasis components on neuronal viability. 3) GWAS derived PD risk variant causality will be assessed on H9 hESC derived iNeurons in a multiplexed format. A modified CROP-seq [3] library consisting of barcoded HDR repair templates linked to each gene-specific sgRNA will be transduced into H9 cells (expressing inducible SpCas9) (UH,WH). RNAseq will be performed on <em>in vitro </em>differentiated neurons [22]. Variant causality pertaining to each cell type will be ranked using transcriptome divergence and shortlisted candidates will be analyzed in detail in WP1 &amp; WP2. We expect that these screens will reveal genes that modify &alpha;-Syn abundance, aggregation, or trafficking. We will integrate the findings from these screens with the functional experiments (bottom-up and top-down) described in WP1 and WP2.</p>\n<h1>Power Calculations and Statistical Analyses Plan</h1>\n<p>Highly quantitative assays with multiple replicates across several physiologically relevant cell lines will be used in this project. Power calculations are not relevant to the types of studies to be performed.&nbsp;</p>\n<h1>Project Timeline and Milestones</h1>\n<p><strong>Months 1-6</strong>: WP1: Complete cryo-ET analysis of &alpha;-Syn aggregates <em>in situ </em>in SH-SY5Y cells and mouse cortical neurons; initiate Opto-&alpha;-Syn and UBE3C-reconstitution. WP2: Generate &alpha;-Syn aggregates in iNeurons engineered to express QC reporters. Initiate biochemical reconstitutions for mechanistic and structural studies. WP3: Establish HAP1 sensor cells for monitoring &alpha;-Syn aggregation by FRET and pulse shape analysis in flow cytometry. <strong>Months 7-12</strong>: WP1: Complete interactome analysis of &alpha;-Syn aggregates by proteomics. WP2: Complete analysis of effects of &alpha;-Syn aggregates on QC functions in iNeurons and iGlia cells. WP3: Establish iNeurons expressing &alpha;-Syn for pooled CRISPR-Cas9 KO screening. <strong>Months 13- 18</strong>: WP1: Establish aggregate seeding protocols for patient derived iNeurons and iGlia cells. WP2: Analysis of aggregate effects on proteostasis reporters and toxicity upon modulation of QC factors identified in WP1 and WP3; initiate proteasome trafficking analysis biochemically and <em>in situ</em>. WP3: Complete first screen in HAP1 cells for factors that modulate aggregate toxicity and initiate iNeuron screen. <strong>Months 19- 24</strong>: WP1: Continue Opto-&alpha;-Syn aggregation and complete analysis of Opto-aggregates by cryo-ET and proteomics. WP2: Complete analysis of and begin biochemical reconstitution of post-translational modifications (ubiqitylation and phosphorylation) of QC factors upon formation of &alpha;-Syn aggregates (and other disease protein aggregates) with a specific focus on modifications of the proteasome. WP3: Complete screen in HAP1 cells for factors that modulate seeding/aggregate formation. <strong>Months 25-30</strong>: WP1: Complete cryo-ET analysis of &alpha;-Syn aggregates <em>in situ </em>generated in patient derived iNeurons derived from iPSCs, iNeurons from individuals of different age, and iGlia cells. WP2: Establish &alpha;-Syn aggregate formation in iNeurons with tagged organelles/ proteostasis regulators and analysis of effects on organellar trafficking and autophagic function; complete UBE3C and initiate proteasome trafficking structural mechanisms. WP3: Complete CRISPR-Cas9 knockout screen in iNeurons for factors that modulate viability in the presence of &alpha;-Syn aggregates. <strong>Months 31-36</strong>: WP1: Reconstitute &alpha;-Syn aggregation (seeded and non-seeded) <em>in vitro </em>and analyze interaction of aggregates with QC factors from WP2 and WP3. WP2: Finish <em>a</em>-Syn and QC factor reconstitution and proteasome trafficking assays. WP3: Finish analysis of iNeuron modifiers in WP1/WP2.</p>\n<h1>Workflow Schematic</h1>\n<p>Our proposal involves the integration of 5 components (Cell Systems, Functional Analysis Tools, Molecular Visualization methods, Quantitative Analysis Modules, and tools for the production of protein aggregates) (top panel). Primary team members expertise is indicated (initials), and reagents/expertise will be transferred between the 6 groups. These components will be used to execute 3 integrated work packages (WPs), starting immediately upon proposal initiation (lower panel), and the integration of components across each WP indicates the extensive synergy that will be created. Approximate milestones are indicated by year (<strong>Y</strong>) &amp; quarter (<strong>Q</strong>) (also see <strong>MILESTONES </strong>section). <strong>WP1 </strong>focuses on in situ analysis of aggregate architecture and seeding, and seeks to develop rules for aggregate assembly and interactions. Various forms of <em>a</em>-Syn aggregates (UH,JF) will be introduced into iNeurons derived from stem/iPS cells (WH,JF), facilitating analysis of toxicity, aggregate structure by cryo-ET, aggregate interactions with proteins and organelles by cryo-ET and proteomics (RFB,WB,UH, BS, WH,JF). Candidate genetic modifiers from <strong>WP3 </strong>will be examined using assays developed in <strong>WP1</strong>. Interactions of components with aggregates will be independently reconstituted using either preformed aggregates (not shown) or Opto-aggregates to facilitate a structural and functional understanding of how distinct forms of <em>a</em>-Syn aggregates affect QC pathways (BS,UH,JF,WH). <strong>WP2 </strong>focuses on disturbances of QC and transport processes by aggregates and in the context of PD gene mutations. Module 1 is the cell line creation module (also see Fig 1a), while Module 2 is the assay module examining autophagic or proteasomal flux, organelle trafficking, and aggregation. The effect of PD gene mutations (LRRK2, VPS35, PARKIN, PINK1, FBXO7/PARK15) (WH,JF) on aggregate biology and the proteasomal trafficking complex will be systematically examined as in <strong>WP1 </strong>using cryo-ET (RFB,WB,BS,UH), and imaging approaches to understand impact on trafficking and autophagic flux using organelle-specific flux reporters (UH,WH,JF). Focused biochemical reconstitution and single particle cryo-EM analysis of two major QC pathways &ndash; proteasomal trafficking on microtubules via a FBXO7-PI31-proteasome-motor complex and an aggregate-dependent proteasomal ubiquitylation pathway involving UBE3C &ndash; will be performed and the information used to facilitate in situ cryo-ET analysis of the cognate structures (BS). <strong>WP3 </strong>focuses on the identification of genetic modifiers using gene trap-based mutagenesis or CRISPR-Cas9 library screening of various reporter cell lines for aggregate toxicity, formation or seeding in HAP1 cells or iNeurons (UH,JF,WH). Candidate modifiers will be examined using assays developed in <strong>WP1 </strong>and <strong>WP2</strong>.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/d5b1c737-2a2c-46fb-9d4c-27367023c204/harper-workflow-schematic.png\" alt=\"Harper_Workflow Schematic\" width=\"976\" height=\"1073\" />&nbsp;</p>\n<h1>Additional Figure</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/09fbe3f7-1583-4cf0-b18e-2a06aa8cf685/harper-additional-figure.png\" alt=\"Harper_Additional Figure\" width=\"977\" height=\"718\" /></p>\n<p>Fig 1. Overview of enabling technologies. (A) Inter-relationship between UPS (ubiquitin-proteasome system), autophagy, and chaperone systems as they relate to organelle/aggregate QC. A subset of genes linked with PD patients and specific pathways are shown. We will employ multiple approaches (grey ovals), including trans-differentiated patient fibroblasts and engineered iNeurons, multiple SCNA aggregate mouse models, biochemical reconstitutions, and cryo-ET in iNeurons, to elucidate mechanisms of pathogenesis. (B) hES and iPS cell transdifferentiation systems we have developed to study PD and related neurodegenerative diseases. Gene editing has been used to create ES cells harboring epitope-tagged proteins or patient/structure-based mutations. (C) Structural biology and biochemical reconstitution of a variety of multi-subunit ubiquitin ligase systems has been achieved using multi-bac approaches and used to both biochemical reconstitution of biological systems but also for analysis by single molecule cryo-EM and crystallographic approaches. (D) Several systems have been developed for cellular analysis of protein/organelle QC pathways, and various systems for production of <em>a</em>-Syn aggregates <em>in vitro </em>and in cells has been created. We have found that <em>a</em>-Syn aggregates created by either expression of GFP- <em>a</em>-Syn or the use of PPFs to initiate aggregate formation sequester much of the ESCRT-III complex protein CHMP2b within the cell, suggesting one potential cellular factor whose depletion may alter the formation of multi-vesicular body and endocytosis. (E) Tools (top left panel) and preliminary data depicting cryo-ET to examine the sociology of <em>a</em>-Syn fibrils in neurons. Large right panel: (top) Neurons expressing GFP-<em>a</em>-Syn were treated with pre-formed <em>a</em>-Syn fibrils in the culture media. <em>a</em>-Syn aggregates were localized by correlative light microscopy. Cryo-focused ion beam milling of the region of interest allowed cryo-ET imaging (raw tomogram, left panel, 3D rendering: right panel). Fibrils (magnified on the right panels) are detected in the cytoplasm and are surrounded by multiple organelles, such as autophagosomal structures. Large right panel: (bottom left) Poly-GA aggregates (red) in neurons visualized by cryo-ET. Aggregates accumulate numerous proteasome particles in close proximity with poly-GA ribbons while ribosomes are excluded from entering the aggregate (left panel). Resolution (11-15 A) was sufficient to detect both ground state and substrate engaged proteasome (right panel). Aggregate-bound proteasomes preferentially adopted substrate- processing states. Large right panel: (bottom right) Poly-Gln aggregates modeling Htt in neurons were analyzed by cryo-ET. Fibrils (blue) largely exclude molecular machines such as the proteasome. Poly-Gln fibrils frequently contacted membrane structures within the cell (ER membranes, red), and in some cases appear to deform membranes. Bottom left panel: <em>a</em>-Syn fibrils in SH-SY5Y cells seeded by gold-labeled PFFs. Gold particles (yellow) decorate the seed while the portion of the expanding fibril within the cell is indicated by the black arrow. Scale bar: 40 nm. (F) Several proteomics tools have been generated, including 16-plex tandem mass tagging approaches, which can routinely quantify around 9K proteins/condition.</p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Wong YC, Krainc D (2017). &alpha;-Synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 23, 1-13.</li>\n<li>Braak H, Del Tredici K, Rub U, de Vos RAI, Steur E, Braak E (2003). Staging of brain pathology related to sporadic Parkinson&rsquo;s disease. Neurobiol Aging 24, 197&ndash;211.</li>\n<li>Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I. (2009). Neuropathological assessment of Parkinson&rsquo;s disease: refining the diagnostic criteria. Lancet Neurol 8, 1150&ndash;7.</li>\n<li>Hipp MS, Kasturi P, Hartl FU (2019). The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol. 20, 421-35.</li>\n<li>Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU (2000). Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like Proc Natl Acad Sci U S A. 97, 7841-6.</li>\n<li>Behrends C, Langer CA, Boteva R, B&ouml;ttcher UM, Stemp MJ, Schaffar G, Rao BV, Giese A, Kretzschmar H, Siegers K, Hartl FU (2006). Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell 23, 887-97.</li>\n<li>Tam S, Geller R, Spiess C, Frydman J (2006). The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol 8, 1155-62.</li>\n<li>Shen K, Calamini B, Fauerbach JA, Ma B, Shahmoradian SH, Serrano Lachapel IL, Chiu W, Lo DC, Frydman J (2016). Control of the structural landscape and neuronal proteotoxicity of mutant Huntingtin by domains flanking the polyQ Elife. 2016 Oct 18;5. pii: e18065. doi: 10.7554/eLife.18065.</li>\n<li>Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM (2011). Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67-78.</li>\n<li>Woerner AC, Frottin F, Hornburg D, Feng LR, Meissner F, Patra M, Tatzelt J, Mann M, Winklhofer KF, Hartl FU, Hipp MS (2016). Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. Science 351, 173-6.</li>\n<li>Frottin F, Schueder F, Tiwary S, Gupta R, K&ouml;rner R, Schlichthaerle T, Cox J, Jungmann R, Hartl FU, Hipp MS (2019). The nucleolus functions as a phase-separated protein quality control compartment. Science 365, 342-7.</li>\n<li>Brown NG, VanderLinden R, Watson ER, Weissmann F, Ordureau A, Wu KP, Zhang W, Yu S, Mercredi PY, Harrison JS, Davidson IF, Qiao R, Lu Y, Dube P, Brunner MR, Grace CRR, Miller DJ, Haselbach D, Jarvis MA, Yamaguchi M, Yanishevski D, Petzold G, Sidhu SS, Kuhlman B, Kirschner MW, Harper JW, Peters JM, Stark H, Schulman BA (2016). Dual RING E3 architectures regulate multiubiquitination and ubiquitin chain elongation by APC/C. Cell 165, 1440-53.</li>\n<li>Qiao S, Langlois CR, Chrustowicz J, Sherpa D, Karayel O, Hansen FM, Beier V, von Gronau S, Bollschweiler D, Sch&auml;fer T, Alpi AF, Mann M, Prabu JR, Schulman BA (2020). Interconversion between anticipatory and active GID E3 Ubiquitin ligase conformations via metabolically driven substrate receptor assembly. Mol Cell 77, 150-63.</li>\n<li>Baek K, Krist DT, Prabu JR, Hill S, Kl&uuml;gel M, Neumaier LM, von Gronau S, Kleiger G, Schulman BA (2020). NEDD8 nucleates a multivalent cullin-RING-UBE2D ubiquitin ligation Nature 578, 461-6.</li>\n<li>Asano S, Fukuda Y, Beck F, Aufderheide A, F&ouml;rster F, Danev R, Baumeister W. (2015). Proteasomes. A molecular census of 26S proteasomes in intact neurons. Science 347, 439-42.</li>\n<li>Heo JM, Ordureau A, Paulo JA, Rinehart J, Harper JW (2015). The PINK1-PARKIN mitochondrial ubiquitylation pathway drives a program of OPTN/NDP52 recruitment and TBK1 activation to promote mitophagy. Mol Cell 60, 7-20.</li>\n<li>Heo JM, Harper NJ, Paulo JA, Li M, Xu Q, Coughlin M, Elledge SJ, Harper JW (2019). Integrated proteogenetic analysis reveals the landscape of a mitochondrial-autophagosome synapse during PARK2-dependent Sci Adv. 2019 Nov 6;5(11):eaay4624. doi: 10.1126/sciadv.aay4624.</li>\n<li>Ordureau A, Paulo JA, Zhang J, An H, Swatek KN, Cannon JR, Wan Q, Komander D, Harper JW (2020). Global landscape and dynamics of Parkin and USP30-dependent ubiquitylomes in iNeurons during mitophagic signaling. Mol Cell 77, 1124-42.</li>\n<li>B&auml;uerlein FJB, Saha I, Mishra A, Kalemanov M, Mart&iacute;nez-S&aacute;nchez A, Klein R, Dudanova I, Hipp MS, Hartl FU, Baumeister W, Fern&aacute;ndez-Busnadiego R (2017). In Situ architecture and cellular interactions of polyQ inclusions. Cell. 171, 179-87.</li>\n<li>Guo Q, Lehmer C, Mart&iacute;nez-S&aacute;nchez A, Rudack T, Beck F, Hartmann H, P&eacute;rez-Berlanga M, Frottin F, Hipp MS, Hartl F<strong>U</strong>, Edbauer D, Baumeister W, Fern&aacute;ndez-Busnadiego R (2018). In situ structure of neuronal C9orf72 poly-GA aggregates reveals proteasome recruitment. Cell 172, 696-705.</li>\n<li>Schaefer T, Riera-Tur I, Hornburg D, Mishra A, Fern&aacute;ndezMosquera L, Raimundo N , Mann M , Baumeister W , Klein R , Meissner F , Fern&aacute;ndez-Busnadiego, Dudanova I. (2020). Amyloid-like aggregates cause lysosomal defects in neurons via gain-of function toxicity. bioRxiv<u> https://doi.org/10.1101/2019.12.16.877431</u>.</li>\n<li>Vonk WIM, Rainbolt TK, Dolan PT, Webb AE, Brunet A, Frydman J. (2020). Differentiation drives widespread rewiring of the neural stem cell chaperone network. Mol Cell 78, 329-45.</li>\n<li>Volpicelli-Daley LA, Luk KC, Lee VM (2014). Addition of exogenous &alpha;-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous &alpha;-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc. 9, 2135-46.</li>\n<li>Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, Hu B, Schmeichel A, Singer W, Wu G, Tsai AL, Shirani H, Nilsson KPR, Low PA, Soto C. (2020). Discriminating &alpha;-synuclein strains in Parkinson's disease and multiple system atrophy. Nature 578, 273-7.</li>\n<li>Shin Y, Berry J, Pannucci N, Haataja MP, Toettcher JE, Brangwynne CP (2017). Spatiotemporal control of intracellular phase transitions using light-activated opto droplets. Cell 168, 159-71.</li>\n<li>Gottlieb CD, Thompson ACS, Ordureau A, Harper JW, Kopito RR (2019). Acute unfolding of a single protein immediately stimulates recruitment of ubiquitin protein ligase E3C (UBE3C) to 26S proteasomes. J Biol Chem 294, 16511-24.</li>\n<li>Abeliovich A, Gitler AD (2016). Defects in trafficking bridge Parkinson's disease pathology and Abeliovich A, Gitler AD. Nature 539, 207-16.</li>\n<li>Carette JE, Guimaraes CP, Wuethrich I, Blomen VA, Varadarajan M, Sun C, Bell G, Yuan B, Muellner MK, Nijman SM, Ploegh HL, Brummelkamp TR (2011). Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat Biotechnol 29, 542-6.</li>\n<li>Ramdzan YM, Wood R, Hatters DM (2013). Pulse shape analysis (PulSA) to track protein translocalization in cells by flow cytometry: applications for polyglutamine Methods Mol Biol. 2013;1017:85-93. doi: 10.1007/978-1-62703-438-8_6.</li>\n<li>Tian R, Gachechiladze MA, Ludwig CH, Laurie MT, Hong JY, Nathaniel D, Prabhu AV, Fernandopulle MS, Patel R, Abshari M, Ward ME, Kampmann M (2019). CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. Neuron 104, 239-55.</li>\n</ol>\n<p>&nbsp;</p>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:18Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "Cellular Mechanism of LRRK2 in Health and Disease"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>Project Summary</h1>\n<p><strong>L</strong>eucine <strong>R</strong>ich <strong>R</strong>epeat <strong>K</strong>inase <strong>2 </strong>(<em>LRRK2</em>) is the most commonly mutated gene in familial Parkinson&rsquo;s Disease (PD)<sup>1</sup> and is also deregulated in the sporadic form<sup>1,2</sup>. LRRK2 is proposed to function in membrane trafficking<sup>3</sup> and co-localizes with microtubules (MTs) in cells<sup>4,5</sup>, but its cellular function remains largely unknown. <strong>Our overall goal is to map the structural states of LRRK2 and their consequences on its cellular interaction landscape. This will allow us to understand LRRK2&rsquo;s function in normal and diseased cells. </strong>Our preliminary data includes the long sought-after high-resolution structure of the catalytic half of LRRK2<sup>6</sup> (Fig.1A,B) and the first structure of LRRK2 in cells bound to MTs as ordered filaments<sup>7</sup> (Fig.1C,D). We also discovered that MT-associated LRRK2 blocks the motility of the MT-based motors dynein and kinesin<sup>6</sup>. In addition to its association with MTs, LRRK2 exists in cytosolic and membrane-associated pools<sup>8,9</sup> (Fig.1E-G). We will solve structures of multiple conformations and variants of LRRK2 (<strong>Goal 1</strong>) to manipulate these different pools of LRRK2 and understand their cellular functions. We will determine how LRRK2 binds to MTs and affects MT-based motors (<strong>Goal 2</strong>); identify the protein interaction landscape of LRRK2 (<strong>Goal 3</strong>); and test cellular hypotheses we develop based on the experiments in Goals 1-3, including whether LRRK2 regulates the transport of MT-based cargos (<strong>Goal 4</strong>). Our collaborative team includes experts in Cryo-electron microscopy (Cryo-EM), Cryo-electron tomography (Cryo-ET), small molecule synthesis, proteomics, and single-molecule and live-cell imaging. <strong>Our work on LRRK2 will provide a comprehensive understanding of the structure and conformation- dependent association with cellular partners of this key target for the development of PD therapeutics.&nbsp;</strong></p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/5d881ba3-8668-4d43-a91f-82c16485e9df/reck-peterson-figure-1.jpg\" alt=\"Reck-Peterson_Figure 1\" /></p>\n<h1>Background</h1>\n<p>Leucine-Rich Repeat Kinase 2 (LRRK2). LRRK2 is a large (288 kDa) multi-domain protein (Fig.1A). Its N-terminal half contains repetitive protein interaction motifs (Armadillo, Ankyrin, and Leucine- Rich Repeats), while its C-terminal half harbors its catalytic activities&mdash;a Ras-like GTPase (RoC domain) and a kinase domain, interspersed with C-terminal Of Roc (COR) and WD40 domains (Fig.1A). <em>In vitro </em>data suggest there is crosstalk between the kinase and GTPase<sup>10&ndash;12</sup>. All five major PD-linked mutations are found in LRRK2&rsquo;s C-terminal half (Fig.1A). In cells, LRRK2 phosphorylates Rab GTPases, which are central regulators of membrane trafficking<sup>13,14</sup>, and co-localization of LRRK2 and Rabs on membranes enhances this phosphorylation<sup>15</sup>. All five major PD-causing mutations increase Rab phosphorylation<sup>13,14</sup>. LRRK2 function and/or pathology has also been linked to MTs as LRRK2 partially co-localizes with MTs in cells<sup>4</sup> and most PD-causing mutations enhance LRRK2&rsquo;s association with MTs<sup>5</sup>. Long-distance transport of Rab- marked membranes occurs along MTs and is driven by the MT-based motors dynein and kinesin<sup>16,17</sup>.</p>\n<h1>Preliminary Data</h1>\n<p>See Figure 2.</p>\n<p><strong>Cryo-EM structure of LRRK2<sup>RCKW</sup></strong></p>\n<p><em>We solved the first high-resolution (3.5&Aring;) structure of the C-terminal half of LRRK2 (&ldquo;LRRK2<sup>RCKW</sup>&rdquo;) using Cryo-EM </em>(Figs.1B and 2A)<sup>6</sup>. The kinase is in an open (inactive) conformation. The structure is J-shaped, bringing the GTPase and kinase into close contact despite their separation along the sequence (Fig.2A), and providing a structural explanation for their reported crosstalk<sup>10&ndash;12</sup>.</p>\n<p><strong>Structures of MT-associated LRRK2(I2020T) filaments</strong></p>\n<p><em>We solved a 14&Aring; structure of MT-associated filaments of LRRK2 with the I2020T PD mutation in cells using Cryo-ET </em>(Figs.1C,D,2B)<sup>7</sup><em>. </em>LRRK2(I2020T) forms double-helical, right-handed filaments around the (left-handed) MT<sup>7</sup>. We combined the Cryo-ET and Cryo- EM structures to build an atomic model of the filament (Figs.1D,2C). The interfaces that mediate formation of the filament&mdash;COR-COR and WD40-WD40&mdash;are the same ones that mediate dimer formation in solution (Fig.2D). We reconstituted filaments <em>in vitro </em>with purified MTs and LRRK2<sup>RCKW</sup>(I2020T)<sup>6</sup>; a preliminary structure shows that these filaments are similar to those seen in cells (Fig.2B,C,E).</p>\n<p><strong>LRRK2<sup>RCKW</sup> acts as a roadblock to MT-based motors</strong></p>\n<p><strong> </strong>Using single-molecule assays we showed that <em>low nanomolar </em>concentrations of LRRK2<sup>RCKW</sup> inhibit the motility of dynein and kinesin, suggesting that <em>LRRK2 acts as a roadblock for MT-based transport </em>(Fig.2F)<sup>6</sup>.</p>\n<p><strong>A structural and mechanistic model for LRRK2&rsquo;s binding to MTs</strong></p>\n<p><strong> </strong>Our structural modeling suggested that <em>only a closed conformation of LRRK2&rsquo;s kinase is compatible with oligomerization on MTs (Fig.2A-C,G)</em><sup>6</sup>. Indeed, Type-2 inhibitors (which stabilize an open/inactive kinase) rescued LRRK2<sup>RCKW</sup>-dependent inhibition of dynein and kinesin, while Type-1 inhibitors (which stabilize a closed/active kinase) did not (Fig.2F)<sup>6</sup>. We observed similar trends on LRRK2 filament formation in cells (Fig.2H)<sup>6</sup>. Our data suggest that the LRRK2-MT interaction is electrostatic and not stereospecific<sup>6</sup> (Fig.2I).</p>\n<p><strong>LRRK<u>1</u><sup>RCKW</sup> and LRRK<u>2</u><sup>RCKW</sup> are structurally similar</strong></p>\n<p><strong> </strong>LRRK1 is the closest homolog of LRRK2. Unlike LRRK2, LRRK1 has not been linked to PD and does not bind to MTs (data not shown). Our preliminary ~8&Aring; Cryo- EM structure of LRRK1<sup>RCKW</sup> shows that <em>the two are similar </em>(Fig.2J). We also have promising preliminary data for the full-length forms of both LRRK1 and LRRK2 (Fig. 2L).</p>\n<h1>Study Plan</h1>\n<p>See Figure 3.</p>\n<h2>OVERALL STRATEGY</h2>\n<p><strong> </strong>Little is known about LRRK2&rsquo;s cellular functions, and even less about how these may change depending on LRRK2&rsquo;s cellular localization&mdash;cytosol, membranes, or MTs. <em>We will selectively perturb these pools of LRRK2 in cells and determine the functional consequences of those perturbations and how they are altered by PD mutations</em>. We believe that only an integrative approach, where a structure-guided interpretation of cellular phenotypes drives the testing of functional hypotheses, will uncover the molecular basis of LRRK2&rsquo;s involvement in such a complex disease as PD.</p>\n<h2>GOAL 1: The structural states of LRRK2</h2>\n<p><strong>IMPACT</strong></p>\n<p><strong> </strong><em>This work will provide a broad structural understanding of LRRK2. </em>We will determine the conformational space of LRRK2 and how it is altered by PD-linked mutations, drug binding and the nucleotide state of LRRK2&rsquo;s GTPase. We will also compare LRRK1 and LRRK2 to understand the structural basis of the latter&rsquo;s pathogenicity. Finally, we will design conformation-specific LRRK2 ligands as tracers for cellular imaging and for probing LRRK2 function in cells.</p>\n<p><strong>RATIONALE</strong></p>\n<p>&nbsp;Until our recent work<sup>6,7</sup>, high-resolution structural information on LRRK2 was limited<sup>18&ndash;22</sup>. Our structures of the catalytic half of LRRK2 (LRRK2<sup>RCKW</sup>)<sup>6</sup> (Fig.2A) and of MT-associated LRRK2(I2020T) filaments in cells<sup>7</sup> (Fig.2B) allowed us to propose and test a structural and mechanistic hypothesis for how the conformation of LRRK2&rsquo;s kinase controls its ability to oligomerize on MTs (Fig.2C,G). <em>We will expand our structural characterization of LRRK2 to selectively manipulate LRRK2&rsquo;s ability to dimerize, oligomerize, and bind MTs to probe the cellular functions of the cytosolic, membrane- and MT-associated pools of LRRK2 and how PD-linked mutations alter them. </em>We will develop conformation-specific, structure-based probes to track LRRK2 in cells, as following endogenous LRRK2 in cells has remained elusive.</p>\n<p><strong>STRATEGY: (1) Structural tools to selectively manipulate LRRK2</strong></p>\n<p><strong>Manipulating LRRK2&rsquo;s cellular pools</strong></p>\n<p><strong>Microtubules. </strong>Our preliminary data provided significant insight into how LRRK2 binds to MTs (Fig.2A-H)<sup>6</sup>. To manipulate this interaction and eliminate/diminish the MT-bound pool we will break the interfaces required for oligomerization and introduce mutations that directly abolish MT binding (Fig.3A). We will solve high-resolution structures of soluble dimers (Figs.2D and 3A) and MT-associated filaments (Figs.2E and 3A). Importantly, disrupting LRRK2 dimerization interfaces will help us determine the functional importance of monomers <em>vs. </em>dimers in each pool. We have already identified loops in LRRK2&rsquo;s RoC domain necessary for MT binding (Fig.2I); we will continue characterizing these to tune LRRK2&rsquo;s affinity for MTs (Fig.3A,F).</p>\n<p><strong>Membranes</strong>. Although co-localization of LRRK2 and Rabs has been shown to be important for efficient Rab phosphorylation<sup>15</sup>, little is known about how LRRK2 interacts with membranes. We will solve structures (Cryo-EM/Cryo-ET) of LRRK2 on membranes using liposomes, nanodiscs<sup>23</sup>, and cellular membranes <em>in situ </em>to identify ways of disrupting that interaction (Fig.3B).</p>\n<p><strong>Cytosol</strong>. We will manipulate the cytosolic pool indirectly, by reducing/depleting the other two. Disruption of dimer interfaces will also establish which species play a functional role in the cytosol.</p>\n<h4><strong>Manipulating LRRK2&rsquo;s substrate specificity</strong></h4>\n<p>Rabs have been identified as physiological substrates of LRRK2<sup>13,14</sup>. We aim to disrupt the interaction between LRRK2 and Rabs, ideally in a Rab-specific manner. We will solve structures of LRRK2:Rab complexes to determine the molecular basis of Rab recognition and specificity (Fig.3C).</p>\n<h4><strong>The conformational space of LRRK2</strong></h4>\n<p>Our data highlights the central role of LRRK2&rsquo;s kinase as a conformational switch with functional consequences that go beyond its canonical enzymatic activity. Because LRRK2&rsquo;s conformation is likely to affect its cellular distribution we will use Cryo-EM to establish how PD-linked mutations and the nucleotide state of the GTPase domain alter LRRK2&rsquo;s structure/conformation (Figs.3A and 2J).</p>\n<p><strong>STRATEGY: (2) Structural &ldquo;comparative anatomy&rdquo; of LRRK1 and LRRK2</strong></p>\n<p>LRRK1 and LRRK2 share a common domain architecture, with LRRK1 missing only the ARM repeats. Our preliminary data show that LRRK<u>1</u><sup>RCKW</sup> and LRRK<u>2</u><sup>RCKW</sup> have similar structures (Fig.2J). <em>Why is LRRK1 not linked to PD pathogenesis? What features of LRRK2 underlie its pathogenic role? </em>We will compare structures of LRRK1 and LRRK2 to develop and test models to understand the functional consequences of their differences (Fig.3D).</p>\n<p><strong>STRATEGY: (3) Conformation-specific small-molecule tools</strong></p>\n<p>The highly selective Type-1 (active-state selective) LRRK2 inhibitor MLi-2<sup>24,25</sup> has been a versatile cellular tool to study the active form of LRRK2&rsquo;s kinase. Other potent Type-1 inhibitors have been developed, albeit with lower selectivity for LRRK2<sup>26</sup>. We will use these inhibitors and MLi-2 to develop two types of conformation-specific reagents: (1) Fluorescently labeled chemical probes for imaging LRRK2 in cells; and (2) Biotin-adducts to pull down LRRK2-containing species in cross-linking/mass-spectrometry (XL-MS) experiments (Fig.3E) (Goal 3). Unfortunately, no selective Type-2 inhibitor (inactive-state (DFG-out) selective) is available to date. To fill this gap, we have initiated synthetic efforts using known Type-1 inhibitors such as PF-06447475<sup>27</sup> to develop a selective Type-2 inhibitor. We have developed a tracer for cellular BRET (Bioluminescence Resonance Energy Transfer) assays<sup>28</sup>. We will confirm the Type-2 binding mode of any inhibitors we design using our MT-based motor assays (Fig.2F)<sup>6</sup>. We will also develop LRRK2-specific small molecules to target oligomerization interfaces and other sites where LRRK2&rsquo;s conformation can be manipulated allosterically.</p>\n<p><strong>ENABLING OUTCOMES/TOOLS</strong></p>\n<p><strong> </strong>This goal will provide the structural information and conformationally- sensitive probes (fluorescent or biotin-tagged) necessary to manipulate and visualize the different cellular pools of LRRK2 and their interactions with signaling or other cellular partners. These tools will be shared with the community and may serve as proof of concept molecules for studying LRRK2 in disease models.</p>\n<h2>GOAL 2: How does LRRK2 bind microtubules and act as a roadblock for motors?</h2>\n<p><strong>IMPACT</strong></p>\n<p>We will determine how LRRK2 binds to MTs, how it blocks dynein and kinesin movement, and how these processes are altered by PD-linked mutations.</p>\n<p><strong>RATIONALE</strong></p>\n<p><strong> </strong>Our recent work showed that LRRK2<sup>RCKW</sup> associates with MTs at low nanomolar concentrations and can act as a roadblock for dynein and kinesin <em>in vitro </em>(Fig.2F)<sup>6</sup>. Oligomerization of LRRK2 on MTs is likely a complex process involving an initial binding of LRRK2 (monomers and/or dimers) to the MT, followed by oligomerization into longer chains. We will use biochemistry, single-molecule biophysics and Cryo-ET to determine how LRRK2 binds to MTs and how it inhibits dynein and kinesin.</p>\n<p><strong>STRATEGY</strong></p>\n<h4><strong>How does LRRK2 bind to and oligomerize on microtubules? </strong></h4>\n<p>We will use fluorescently labeled LRRK2/LRRK2<sup>RCKW</sup> constructs and single-molecule assays to dissect MT binding (Fig.3F). Constructs will include: mutants that prevent dimerization at the WD40-WD40, COR-COR, or both interfaces (Fig.2D); mutations in the basic loops identified as candidates for MT binding (Fig.2I); and PD mutations.</p>\n<h4><strong>Do microtubule associated proteins (MAPS) and tubulin modifications alter LRRK2 microtubule- binding? </strong></h4>\n<p>We will determine the impact of MAPs and tubulin modifications on LRRK2&rsquo;s ability to bind to MTs using <em>in vitro </em>reconstitutions, cell-based assays, and Cryo-ET of LRRK2 in cells (Fig.3F-H).</p>\n<h4><strong>How does LRRK2 block movement of dynein and kinesin? </strong></h4>\n<p>We will combine the constructs described above with our ability to reconstitute dynein and kinesin motility <em>in vitro</em><sup>29&ndash;34</sup> to determine which structural states of LRRK2 are responsible for blocking the motors, and how they do it (Fig.3F,G).</p>\n<h4><strong>Cryo-ET of LRRK2 roadblocks</strong></h4>\n<p><strong> </strong>We will use Cryo-ET and sub-tomogram averaging to solve structures of motors paused at LRRK2 roadblocks on MTs reconstituted <em>in vitro </em>(Fig.3H)<em>.</em></p>\n<p><strong>ENABLING OUTCOMES/TOOLS</strong></p>\n<p>This Goal will provide a <em>structural and mechanistic understanding of the MT-bound pool of LRRK2</em>. With Goal 1, this will guide experiments probing the protein interactomes of the different LRRK2 pools in cells (Goal 3) and test the hypothesis that LRRK2 acts as a roadblock for motors to regulate transport, with malfunction leading to defects in membrane trafficking (Goal 4).</p>\n<h2>GOAL 3: What is the cellular interaction landscape of LRRK2?</h2>\n<p><strong>IMPACT</strong></p>\n<p><strong> </strong><em>The work in this Goal will reveal the protein interactomes of LRRK2 in normal and disease states. </em>We will selectively manipulate the different cellular pools of LRRK2 to identify their interaction partners, including likely substrates for its kinase, and how these interactions are altered by PD-linked mutations.</p>\n<p><strong>RATIONALE</strong></p>\n<p>The existence of different LRRK2 pools&mdash;cytosolic, membrane- and MT-bound&mdash;raises two important questions: <em>(1) Do different pools have different functions? (2) Are they differently altered by PD- linked mutations? </em>We will set out to answer these questions by <em>characterizing the protein interactomes and phosphoproteomes of the different pools of LRRK2 </em>using MS-based proteomics.</p>\n<p><strong>STRATEGY</strong></p>\n<h4><strong>Protein interactomes of the MT-bound and -free pools of LRRK2</strong></h4>\n<p><strong> </strong>We will use proximity-dependent biotinylation (BioID), as we have previously<sup>34,35</sup>, to identify LRRK2&rsquo;s cellular partners (Fig.3I). We will do so while selectively manipulating the MT-bound and -free pools of LRRK2, as well as LRRK2&rsquo;s monomer/dimer state, using our structural and mechanistic insights and data from Goals 1 and 2.</p>\n<h4><strong>XL-MS to identify direct interactions</strong></h4>\n<p><strong> </strong>As a complementary approach we will use XL-MS to determine direct interaction partners of and binding sites on LRRK2<sup>36</sup> (Fig.3J). We will also combine BioID with our existing proteome-wide crosslinking<sup>37</sup> approaches to determine which BioID &ldquo;hits&rdquo; are direct interaction partners. We will use the biotinylated Type-1 and 2 inhibitors from Goal 1 to specifically pull down interactors bound to LRRK2 in closed or open conformations and will correlate these data with cellular localizations determined by using fluorescently labeled versions of the same inhibitors (Goal 4). XL-MS will also be used to guide integrative modeling of <em>in situ </em>Cryo-ET structures of the different LRRK2 pools.</p>\n<h4><strong>Phosphoproteomics of the MT-bound and -free pools of LRRK2</strong></h4>\n<p><strong> </strong>The same strategies used to look at the LRRK2 interactomes will be used to characterize their phosphoproteomes (Fig.3K).</p>\n<h4><strong>Alterations of LRRK2&rsquo;s interactome/phosphoproteome by PD-linked mutations</strong></h4>\n<p>We will determine how PD-linked mutations affect LRRK2&rsquo;s cellular interaction landscape (Fig.3I-K).</p>\n<p><strong>ENABLING OUTCOMES/TOOLS</strong></p>\n<p>This Goal will apply and critically extend established MS-based proteomic workflows, identify the interactomes of each LRRK2 cellular pool, and determine how PD-linked mutations alter those interactions. It will provide new targets for structural studies of LRRK2 bound to kinase substrates and other interaction partners (Fig.3L) and generate specific mechanistic hypothesis about LRRK2&rsquo;s functions in cells to be tested in Goal 4 (Fig.3M-O).</p>\n<h2>GOAL 4: <em>What are the cellular functions of LRRK2?</em></h2>\n<p><em> </em><strong>IMPACT</strong></p>\n<p><em>Our ultimate goal is to determine the cellular basis for why mutations in LRRK2 are linked to PD. </em>We will use the outcomes and tools from Goals 1-3 to test hypotheses about LRRK2&rsquo;s cellular functions.</p>\n<p><strong>RATIONALE</strong></p>\n<p>We will take two complementary approaches: (1) We will use the small-molecule probes generated in Goal 1 and our ability to selectively perturb the different pools of LRRK2 to probe their cellular localization and that of their interaction partners identified in Goal 3; and (2) We will test specific hypotheses by introducing structure-guided LRRK2 mutants into LRRK2 knock-out (KO) cell lines (Fig.2K).</p>\n<p><strong>STRATEGY</strong></p>\n<h4><strong> (1) Discovery-based approach. Imaging LRRK2 with conformation-specific probes</strong></h4>\n<p>We will use the fluorescently labeled, conformation-specific probes developed in Goal 1 to image LRRK2 in live- cells and in flash-frozen cells for correlative light and Cryo-ET. This will establish how LRRK2&rsquo;s kinase conformation regulates its cellular localization (Fig.3M). This spatial information will be correlated with the proteomics data from Goal 3 obtained using the biotinylated versions of the same probes. We will also image LRRK2 carrying interface and PD mutants using light microscopy and Cryo-ET.</p>\n<p><strong> (2) Hypothesis-testing<em>. </em>Does LRRK2 regulate the transport of MT-based cargos? </strong></p>\n<p>We showed that LRRK2 blocks the motility of dynein and kinesin <em>in vitro </em>(Fig.2F)<sup>6</sup>. Both motors bind to membranous cargos either directly or indirectly via Rab effector proteins, which are phosphorylated by LRRK2 on their interaction interface<sup>13</sup>. We hypothesize that LRRK2 phosphorylates Rabs and thereby disrupts Rab-motor interactions. This could either (1) prevent initiation of cargo transport or (2) lead to cargo release. We propose that mutations in LRRK2 or changes in its expression levels could alter the normal balance of cargo transport. Indeed, numerous membranous cargos show abnormal motility and localization upon LRRK2 perturbation<sup>3,38</sup>. We will test this hypothesis using:</p>\n<p>(1) <strong><em>In vitro </em>reconstitution. </strong>We will reconstitute transport of Rab-marked cargos by motors on MTs in the presence of LRRK2 (Fig.3N) and use single- molecule imaging and Cryo-ET to visualize the consequences of Rab phosphorylation by LRRK2 (Fig.3O).</p>\n<p>(2) <strong>Cellular imaging: </strong>We will use live-cell spinning-disk confocal and lattice-light-sheet microscopy to image the movement of Rab-marked cargos in cells (Fig.3M). We will manipulate the LRRK2 expressed in these experiments, including testing dimerization interface and PD mutants (Fig.2K). Image analysis will reveal the motility parameters and distribution of LRRK2, Rabs and associated cargos. We will also use correlative light and Cryo-ET to reveal the structure of a LRRK2 roadblock <em>in situ </em>(Fig.3M,O). Additional hypotheses developed from our work and the ASAP community will be tested using similar methods.</p>\n<p><strong>ENABLING OUTCOMES/TOOLS</strong></p>\n<p>Work in this Goal will determine the cellular basis for why mutations in LRRK2 are linked to PD. This will lead to new avenues for drug discovery and the development of better animal models of PD.</p>\n<h1>Statistical Analyses Plan&nbsp;</h1>\n<p>Single-molecule and cellular data will be collected from three technical replicates. To assess statistical significance, a Mann Whitney test or a Kruskal-Wallis test with Dunn&rsquo;s posthoc for multiple comparisons will be used. A power calculation will be done whenever appropriate.</p>\n<h1>Additional Figure</h1>\n<p><strong>Figure 2. </strong>ADDITIONAL FIGURE. <strong>Preliminary Data. </strong>The figure is divided into four panels, corresponding to the four Goals in the proposal. The contents are summarized here but see proposal for more details: <strong>(A) </strong>3.5&Aring; Cryo-EM structure of the C-terminal half of LRRK2 (LRRK2RCKW). <strong>(B) </strong>14&Aring; Cryo-ET structure of LRRK2(I2020T) filaments in cells. <strong>(C) </strong>Docking of LRRK2RCKW into the Cryo- ET structure revealed that only the closed conformation of LRRK2&rsquo;s kinase is compatible with the filaments. <strong>(D) </strong>Cryo-EM maps of soluble LRRK2RCKW dimers mediated by either of the two interfaces seen in the filaments with the LRRK2RCKW structure docked in.&nbsp;<strong>(E) </strong>Preliminary structure of LRRK2RCKW(I2020T) filaments reconstituted <em>in vitro</em>. <strong>(F) </strong>LRRK2RCKW acts as a roadblock for the microtubule-based motors dynein and kinesin. As predicted by our model <strong>(G)</strong>, Type-2 kinase inhibitors that stabilize the open/inactive conformation of the kinase relieve the inhibition, while Type-1, which stabilize the closed/active form, do not <strong>(F)</strong>.&nbsp;<strong>(H) </strong>Type-2 inhibitors also reduce the formation of LRRK2 filaments in cells. <strong>(I) </strong>Single-molecule microtubule-binding assay of LRRK2RCKW. <strong>(J) </strong>Cryo-EM maps of LRRK<strong><u>2</u></strong>RCKW and LRRK<strong><u>1</u></strong>RCKW. <strong>(K) </strong>Western blot showing the knocking out of LRRK2 in A549 cells. <strong>(L) </strong>Negative stain structure of full-length LRRK2 and 2D Cryo-EM class average of full-length LRRK1.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/d59b016f-993e-4ded-8fbd-52acf100cc40/reck-peterson-additional-figure.png\" alt=\"Reck-Peterson_Additional Figure\" width=\"812\" height=\"892\" /></p>\n<h1>Workflow Schematic, Project Timeline, and Milestones&nbsp;</h1>\n<p>Figure 3 (below) includes our timeline and illustrates key milestones.&nbsp;</p>\n<p><strong>Figure 3. </strong>WORKFLOW SCHEMATIC and PROJECT TIMELINE AND MILESTONES. This figure has the same overall structure as Figure 2. Letters indicate experiments discussed in the proposal and referred to in the Goals. The arrows linking lettered panels highlight how results from a set of experiments will enable/guide others. Numbered diamonds refer to milestones and are also annotated in the timeline. The colors and letters in the timeline at the bottom refer to those in Fig.3.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/348c43f1-73a9-4903-b1b5-7eb48c91c3a1/reck-peterson-workflow-timeline-milesones.png\" alt=\"Reck-Peterson_Workflow, Timeline &amp; Milesones\" width=\"818\" height=\"1005\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Monfrini, &amp; Di Fonzo, A. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson&rsquo;s Disease. <em>Adv. Neurobiol. </em><strong>14</strong>, 3&ndash;30 (2017).</li>\n<li>Di Maio, R. <em>et al. </em>LRRK2 activation in idiopathic Parkinson&rsquo;s disease. <em> Transl. Med. </em><strong>10</strong>, eaar5429 (2018).</li>\n<li>Abeliovich, A. &amp; Gitler, A. D. Defects in trafficking bridge Parkinson&rsquo;s disease pathology and <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">539</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 207&ndash;216 (2016).</span></li>\n<li>Gloeckner, C. J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Mol. Genet. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">15</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 223&ndash;232 (2006).</span></li>\n<li>Kett, L. R. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">LRRK2 Parkinson disease mutations enhance its microtubule association. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Mol. Genet. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">21</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 890&ndash;899 (2012).</span></li>\n<li>Deniston, C. K. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Parkinson&rsquo;s Disease-linked LRRK2 structure and model for microtubule interaction. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">bioRxiv </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">5</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 809&ndash;11 (2020).</span></li>\n<li>Watanabe, R. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">The in situstructure of Parkinson&rsquo;s disease-linked LRRK2. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">7</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 8667&ndash;22 (2019).</span></li>\n<li>Berger, Z., Smith, K. A. &amp; LaVoie, M. J. Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Biochemistry </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">49</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 5511&ndash;5523 (2010).</span></li>\n<li>Purlyte, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Rab29 activation of the Parkinson&rsquo;s disease-associated LRRK2 kinase. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">EMBO J. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">37</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1&ndash; 18 (2018).</span></li>\n<li>Ito, G. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson&rsquo;s disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Biochemistry </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">46</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1380&ndash;1388 (2007).</span></li>\n<li>West, A. B. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Parkinson&rsquo;s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Mol. Genet. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">16</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 223&ndash;232 (2007).</span></li>\n<li>Terheyden, , Nederveen-Schippers, L. M. &amp; Kortholt, A. The unconventional G-protein cycle of LRRK2 and Roco proteins. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Biochem. Soc. Trans. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">44</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1611&ndash;1616 (2016).</span></li>\n<li>Steger, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Phosphoproteomics reveals that Parkinson&rsquo;s disease kinase LRRK2 regulates a subset of Rab GTPases. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">eLife </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">5</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 809 (2016).</span></li>\n<li>Steger, M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">eLife </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">6</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, e80705 (2017).</span></li>\n<li>Gomez, R. C., Wawro, P., Lis, P., Alessi, D. R. &amp; Pfeffer, S. R. Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Cell Biol. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2019).</span></li>\n<li>Reck-Peterson, S. L., Redwine, W. B., Vale, R. D. &amp; Carter, A. P. The cytoplasmic dynein transport machinery and its many cargoes. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Rev. Mol. Cell Biol. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">149</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1&ndash;17 (2018).</span></li>\n<li>Guedes-Dias, P. &amp; Holzbaur, E. L. F. Axonal transport: Driving synaptic function. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Science </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">366</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, (2019).</span></li>\n<li>Deng, J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Structure of the ROC domain from the Parkinson&rsquo;s disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">105</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1499&ndash;1504 (2008).</span></li>\n<li>Zhang, P. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Crystal structure of the WD40 domain dimer of LRRK2. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">116</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1579&ndash;1584 (2019).</span></li>\n<li>Gotthardt, , Weyand, M., Kortholt, A., Van Haastert, P. J. M. &amp; Wittinghofer, A. Structure of the Roc- COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">EMBO J. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">27</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 2239&ndash;2249 (2008).</span></li>\n<li>Deyaert, E. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Structure and nucleotide-induced conformational dynamics of the Chlorobium tepidum Roco protein. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> J. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">476</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 51&ndash;66 (2019).</span></li>\n<li>Gilsbach, B. K. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Roco kinase structures give insights into the mechanism of Parkinson disease- related leucine-rich-repeat kinase 2 mutations. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">109</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 10322&ndash;10327 (2012).</span></li>\n<li>Denisov, G. &amp; Sligar, S. G. Nanodiscs for structural and functional studies of membrane proteins. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat. Struct. Mol. Biol. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">23</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 481&ndash;486 (2016).</span></li>\n<li>Fell, M. J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Pharmacol. Exp. Ther. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">355</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 397&ndash;409 (2015).</span></li>\n<li>Scott, J. D. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Med. Chem. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">60</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 2983&ndash;2992 (2017).</span></li>\n<li>Hatcher, J. M., Choi, H. G., Alessi, D. R. &amp; Gray, N. S. Small-Molecule Inhibitors of LRRK2. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Neurobiol. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">14</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 241&ndash;264 (2017).</span></li>\n<li>Henderson, J. L. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Med. Chem. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">58</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 419&ndash;432 (2015).</span></li>\n<li>Dale, N. C., Johnstone, E. K. M., White, C. W. &amp; Pfleger, K. D. G. NanoBRET: The Bright Future of Proximity-Based Assays. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Bioeng. Biotechnol. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">7</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 56 (2019).</span></li>\n<li>Roberts, A. J., Goodman, B. S. &amp; Reck-Peterson, S. L. Reconstitution of dynein transport to the microtubule plus end by kinesin. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">eLife </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">3</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, e02641&ndash;16 (2014).</span></li>\n<li>Derr, D. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Tug-of-war in motor protein ensembles revealed with a programmable DNA origami scaffold. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">338</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 662&ndash;665 (2012).</span></li>\n<li>Qiu, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Dynein achieves processive motion using both stochastic and coordinated stepping. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat. Struct. Mol. Biol. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">19</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 193&ndash;200 (2012).</span></li>\n<li>Huang, J., Roberts, A. J., Leschziner, A. E. &amp; Reck-Peterson, S. L. Lis1 acts as a &lsquo;clutch&rsquo; between the ATPase and microtubule-binding domains of the dynein motor. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">150</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 975&ndash;986 (2012).</span></li>\n<li>DeSantis, E. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Lis1 Has Two Opposing Modes of Regulating Cytoplasmic Dynein. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">170</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1197&ndash; 1201.e13 (2017).</span></li>\n<li>Redwine, B. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">The human cytoplasmic dynein interactome reveals novel activators of motility. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">eLife </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">6</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 379 (2017).</span></li>\n<li>Kendrick, A. A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Hook3 is a scaffold for the opposite-polarity microtubule-based motors cytoplasmic dynein-1 and KIF1C. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Cell Biol. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">218</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 2982&ndash;3001 (2019).</span></li>\n<li>Sailer, C. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Structural dynamics of the E6AP/UBE3A-E6-p53 enzyme-substrate complex. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> Commun. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">9</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 4441 (2018).</span></li>\n<li>F&uuml;rsch, J., Kammer, K.-M., Kreft, S. G., Beck, M. &amp; Stengel, F. Proteome-Wide Structural Probing of Low-Abundant Protein Interactions by Cross-Linking Mass <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Anal. Chem. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">92</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 4016&ndash;4022 (2020).</span></li>\n<li>Kluss, H., Mamais, A. &amp; Cookson, M. R. LRRK2 links genetic and sporadic Parkinson&rsquo;s disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Biochem. Soc. Trans. </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">47</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 651&ndash;661 (2019).</span></li>\n</ol>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:17Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "Senescence in Parkinsons disease and Related Disorders"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>PROJECT SUMMARY</h1>\n<p>Aging is by far the greatest risk factor for the development of Parkinson&rsquo;s disease (PD). However, how aging promotes PD is not fully understood. Examining the role of cellular senescence, a major driver of aging, in PD represents a completely novel approach to understanding disease pathophysiology. Herein, we propose to combine genetic mouse models of accelerated senescence/aging with PD models to determine if and how PD-linked genes/PD pathology are mechanistically linked to senescence and whether senescence can directly contribute to cause and/or drive progression of PD. Our results will lead to deeper understanding of PD pathogenesis, novel biomarkers of disease, and novel targets for disease-modifying therapies.</p>\n<h1>RATIONALE AND PRELIMINARY DATA</h1>\n<p>Aging is associated with dramatic increases in the incidence of neurodegenerative diseases, including PD. Aging is driven by cellular senescence, which promotes chronic inflammation, loss of regenerative capacity, and abnormal cellular bioenergetics<sup>1-3</sup>. While these senescence-associated phenotypes are individually implicated in the pathogenesis of PD and other neurodegenerative diseases, it is unknown whether the cellular senescence is involved in the etiology of PD. In Alzheimer&rsquo;s disease (AD), emerging evidence suggests that neuronal abnormalities in mouse models of tauopathy<sup>4</sup> and Ab pathology<sup>5</sup> are associated with increased cellular senescence; and reducing the senescent cell burden can attenuate the neuropathology. Significantly, increased senescence occurs in microglia for tauopathy<sup>4</sup> and oligodendrocytes for Ab models<sup>5</sup>, indicating distinct cellular vulnerability with different types of neuropathology. While there is some indirect evidence for involvement of senescence in PD<sup>3</sup>, the mechanistic link between senescence and PD has not been subject of systematic analysis. Because novel therapies targeting senescent cells, some of which are in phase II clinical trials, are under development, identifying interactions between senescence and PD will lead to deeper understanding of PD pathogenesis and lead to novel therapies for PD. We propose to establish a collaborative effort between experts in the biology of aging, neurobiology and molecular genetics to identify the neuropathological interaction between senescence, PD-associated genes, and PD pathology.</p>\n<p><strong>Project 1. Is cellular senescence in particular cell populations in the brain sufficient to cause PD-relevant neuropathology? (PI: Laura Niedernhofer).&nbsp;</strong>The Niedernhofer lab developed a genetic approach to drive senescence, achieved by deleting the DNA repair endonuclease ERCC1-XPF (ERX), in a cell type-specific manner in mice<sup>2,6,7</sup>. We observe that selective postnatal deletion of ERX in forebrain neurons lead to profound adult-onset neurodegeneration (Fig. 1), modeling neurodegeneration associated with aging. In addition, reduced ERX function in mice, via constitutive expression of an <em>Ercc1 </em>hypermorphic allele, shows progressive neurodegeneration<sup>8</sup>. Importantly, loss of ERX function accelerates senescence normally seen in the CNS of aged wild-type mice<sup>2</sup> and is associated with increased oxidative stress and mitochondrial dysfunction<sup>9</sup>, which are relevant to PD pathology. Significantly, our preliminary observations indicate that these mice may exhibit loss of dopaminergic (DA) neurons and glial activation in the SNpc (Fig. 2). Thus, we will determine whether premature senescence in different brain cell types driven by <em>Ercc1 </em>deletion lead to PD-relevant neurodegeneration. Finally, we observed that a-synuclein (aS) expression is required for memory deficits and senescence- associated phenotypes in AD models <sup>10,11</sup>; and the loss of LRRK2 function has been linked to attenuation of CNS inflammation and aS pathology<sup>12,13</sup>. Thus, we will examine if the endogenous expression of genes linked to PD pathogenesis impacts neuropathology in the ERX model of premature senescence.</p>\n<p><strong>Project 2. Are there bidirectional pathological interactions between senescence and a- synucleinopathy? (PI: Michael Lee).</strong></p>\n<p><strong>Project 3. Are there bidirectional pathological interactions between senescence and LRRK2/VPS35 models of PD? (PI: Darren Moore).&nbsp;</strong>Mutations in aS (<em>SNCA</em>), <em>LRRK2 </em>and <em>VPS35 </em>genes cause late-onset, autosomal dominant forms of familial PD that are clinically indistinguishable from sporadic PD<sup>14</sup>. In addition, <em>SNCA </em>and <em>LRRK2 </em>gene polymorphisms are associated with sporadic PD risk<sup>14</sup>. The late disease-onset with these PD-linked genes suggest that interactions with age-related pathways are critical for manifesting or unmasking their pathogenic actions. Studies in experimental models further suggest that PD-linked aS (or a- synucleinopathy), <em>LRRK2 </em>and <em>VPS35 </em>mutations can induce abnormal mitochondrial function, lysosomal activity, autophagy, proteostasis and inflammatory processes, pathways that are dysregulated by cellular senescence <sup>15-20</sup>.</p>\n<p>We hypothesize that senescence promotes pathological onset and spreading of aS aggregation and mediate aS-dependent neurodegeneration. LRRK2 and VPS35 are studied together as they have overlapping functions within the endolysosomal pathway<sup>19-22</sup>. Further, recent data demonstrate that LRRK2 and VPS35 interact in a common pathway culminating in LRRK2 hyperactivation<sup>23</sup>. Our studies reveal that PD-linked <em>LRRK2 </em>mutations can induce nuclear envelope abnormalities with advancing age in mice<sup>24</sup> and genetic lifespan extension is neuroprotective in mutant LRRK2 worm models<sup>25</sup>.</p>\n<p><strong>Project 4. Is senescence a component of human PD and does experimental senescence lead to alterations in PD-related gene expression? (PI: Jose Bras).&nbsp;</strong>Single-cell RNAseq (scRNAseq) approaches provide unparalleled opportunities to characterize gene expression at the cellular level. This is particularly important for PD as the brain is a complex mixture of diverse cell types. Using scRNAseq data from human cases and animal models, we can determine if increased senescence is associated with PD as a function of disease severity (Braak stages), provide comparative analysis of gene expression changes between human PD cases and various mouse models, and determine if altered expression of PD-associated genes (from familial PD and GWAS) are associated with premature senescence in humans and various models of senescence developed in Projects 1-3.</p>\n<h1>RESEARCH TOOLS, MODELS AND RESOURCES</h1>\n<p><strong>Models/reagents relevant to Senescence: </strong><em>Ercc1<sup>-/&Delta;</sup> </em>and <em>Ercc1</em>-flox<sup>8</sup> (combined with Cre drivers; Nestin-Cre, TH-Cre, Cx3cr1-Cre). INK-ATTAC Tg line <sup>4</sup> to selectively remove senescent cell.</p>\n<p><strong>Models relevant to PD: </strong>aS Tg mice (TgA53T)<sup>15,26</sup>; aS PFF inoculation model<sup>15,27</sup>; SNCA KO mice. mutant LRRK2 and VPS35 knock-in mice; Ad5-LRRK2 rat model; LRRK2-KO and BAC-LRRK2 mice.</p>\n<p><strong>Brain tissues </strong>of individuals diagnosed with PD from Brain Banks across the US and Europe.</p>\n<h1>STUDY PLAN</h1>\n<h2>Core Methods common to projects 1-3.</h2>\n<p><strong>Mouse Behavioral Phenotyping</strong></p>\n<p>Behavioral testing will be supported by the Mouse Behavior Cores at University of Minnesota or at Van Andel Institute. General motor behavior includes, open field activity monitoring, rotarod<sup>26,28,29</sup>, gait analysis<sup>24</sup>, and pole test<sup>30</sup> to reveal striatal motoric abnormalities. Cognitive tests will include delayed fear conditioning<sup>31</sup>, Y maze test (Spontaneous alternation and Spatial recognition memory) and Barnes Maze to define spatial memory deficits in the Tg mouse models<sup>31</sup> .</p>\n<p><strong>Senescence markers</strong></p>\n<p><strong><em> </em></strong>We will perform a spatiotemporal analysis to detect increased p16<sup>Ink4a</sup> and p21<sup>Cip1</sup> and senescence-associated secretory phenotype (SASP) mRNA expression<sup>1,2</sup> using RNAscope-ISH (ACD Bio) in brain sections. We will also monitor increased senescence-associated &beta;-gal, DNA damage (using &gamma;H2AX) and reduced levels of the nuclear envelope marker, Lamin-B1, by immunofluorescence analysis. Images will be quantified using Halo analysis software (Indica Labs) or MBF stereology system. We will focus on the substantia nigra (particularly colocalization of senescent markers with DA neurons and glial cell types), striatum, cortex and hippocampus, all regions that are affected in PD. Because neuron-specific neuropathology can lead to senescence in microglia<sup>4</sup>, we will identify relevant cell types undergoing senescence (using NeuN, GFAP, Iba1, etc.) and distinct subpopulations within each brain region (RNAseq). Micro-dissected fresh brain regions will be prepared for analysis of SASP factors by qPCR analysis (Niedernhofer) and MSD MESO Scale Biomarker discovery (Butterick/Lee), and by Western blot analysis of p16<sup>Ink4a</sup>, p21<sup>Cip1</sup> and LMNB1. Fresh brain tissue will also be used for evaluation of&nbsp; endoplasmic reticulum stress (ERS), autolysosomal system (Lee/Karim) and LRRK2 kinase activity (Moore). <em>These measures (e.g. SASP via MESO scale analysis) may identify potential biomarkers for evaluation of senescence/senolytic target engagement in PD cases.</em></p>\n<p><strong>Markers &nbsp;of &nbsp;PD-relevant &nbsp;neuropathology</strong></p>\n<p><strong><em>&nbsp;</em></strong>Neurodegeneration &nbsp;and &nbsp;neuropathology &nbsp;will &nbsp;be evaluated using unbiased stereological analysis (StereoInvestigator, MBF) of immunostained brain sections<sup>31,32</sup>. In particular, we will determine the integrity of the nigro-striatal DA system by defining the density &nbsp;of &nbsp;DAergic &nbsp;terminals &nbsp;in &nbsp;the &nbsp;striatum &nbsp;and &nbsp;the &nbsp;number &nbsp;of &nbsp;TH+ &nbsp;DA &nbsp;neurons &nbsp;in &nbsp;the &nbsp;SNpc. Neuroinflammation will be evaluated by immunostaining for GFAP (astrocytes) and Iba1/CD68 (microglia). We will also use various anti-aS, anti-LRRK2 and anti-VPS35 antibodies to evaluate aggregation and cellular expression of these proteins. &nbsp;Biochemical analysis will include expression of aS, LRRK2, VPS35, tau and other related proteins.&nbsp; We will also determine if soluble oligomers of aS and tau are altered by senescence status (Lee/Lesne)<sup>11,33</sup>.</p>\n<p><strong>Single-cell RNAseq (scRNAseq)</strong></p>\n<p>We will provide high-resolution gene expression analysis of mouse brains (Cortex, Hippocampus, Striatum, Ventral Midbrain) using two platforms. Single-cell gene expression profiling (Chromium, 10X Genomics) will provide cell type-specific gene expression associated with senescence and PD-related pathology. Visium Gene Expression Solution (10X Genomics) will spatially resolve gene expression changes in brain tissue of each mouse model. The results will be integrated in Project 4 (Bras).</p>\n<h2>Project 1. Is cellular senescence in particular cell populations in the brain sufficient to cause PD-relevant neuropathology? (PI: Laura Niedernhofer).</h2>\n<p><strong>Specific Aims</strong></p>\n<p>We will test our hypothesis that <em>cellular senescence is sufficient to cause PD-relevant neurodegeneration </em>by determining whether: (1) CNS-specific deletion of <em>Ercc1</em>, via Nestin-Cre driver, leads to pathology and progressive neurodegeneration relevant to PD; (2) selective loss of ERX in DA neurons, via TH-Cre driver, causes progressive DAergic neurodegeneration, (3) selective loss of <em>Ercc1 </em>expression in microglia, via Cx3cr1-Cre driver, leads to PD-relevant neurodegeneration, and (4) aS or LRRK2 is involved in the neuropathology associated with the loss of ERX function.</p>\n<p><strong>Experimental Strategy</strong></p>\n<p>We will use <em>Ercc1</em>-flox mice combined with various Cre-driver mice to selectively induce premature senescence, via accumulation of DNA damage, oxidative stress and mitochondrial dysfunction in various neural cell population. Because tamoxifen causes DNA damage, we are not able to use CreERT lines. In <strong>Aim 1</strong>, <em>Ercc1 </em>expression will be deleted throughout the nervous system by&nbsp; mating <em>Ercc1</em>-flox mice to Nestin-Cre driver mice (Jax:003771)<sup>34</sup>. In <strong>Aims 2 and 3</strong>, we will remove <em>Ercc1 </em>expression from DA neurons or microglia by mating <em>Ercc1</em>-flox mice to <em>TH-Cre</em>(Jax:008601)<sup>35</sup> or <em>Cx3cr1</em>- Cre (MMRRC:036395-UCD)<sup>36</sup> mice, respectively. In <strong>Aim 4</strong>, we will use the progeria model, <em>Ercc1<sup>-/&Delta;</sup> </em>mice. These mice exhibit neurodegeneration by 6 months of age. The <em>Ercc1<sup>-/&Delta;</sup> </em>mice will be successively bred to either <em>Snca</em><sup>-/-</sup> (Jax: 016123) or <em>Lrrk2</em><sup>-/-</sup> (Jax: 016121) background. If the results of Aim 1 show that the <em>Nestin-Cre </em>based model shows robust neurodegeneration without significant peripheral tissue involvement, we will use the <em>Ercc1</em><sup>-/fl</sup>:Nestin-Cre for this aim. The cohorts of mice will be evaluated at 12 and 24 weeks of age for behavior, neuropathology, and gene expression as described (Core Methods). We expect to show that premature senescence is sufficient to drive PD-relevant neurodegeneration.</p>\n<h2>Project 2. Are there bidirectional pathological interactions between senescence and a-synucleinopathy? (PI: Michael Lee).</h2>\n<p><strong>Specific Aims</strong></p>\n<p>We will test our hypothesis that <em>cellular senescence is induced by </em><em>a</em><em>-synucleinopathy and blocking senescence can attenuate the pathogenic effects of </em><em>a</em><em>-synucleinopathy </em>by determining whether:</p>\n<p>(1) Onset and progression of a-synucleinopathy induces cellular senescence in the rodent brain, (2) accelerated aging can exacerbate progression of a-synucleinopathy and neurodegeneration in mouse models, and (3) if removing senescent cells will provide neuroprotection from a-synucleinopathy in rodent models.</p>\n<p><strong>Experimental Strategy</strong></p>\n<p><strong> </strong>We will use aS-preformed fibril (PFF) inoculation model and a transgenic mouse model expressing human A53TaS (<em>TgA53T</em>). These models are well established in the lab and combinatorial use of these models allows us to study the effects of aS pathology in a variety of brain regions with different time course. Specifically, mouse aS-PFF inoculation (dorsal striatum) on wild-type C57BL/6 mice induces cortical and subcortical a-synucleinopathy with loss of SNpc DA neurons by 6 mos following inoculation<sup>27</sup>. <em>TgA53T </em>mouse model naturally develop a-synucleinopathy and motor dysfunction with aging (~13 mo of age). <em>TgA53T </em>mouse model inoculated (intramuscular) with human aS PFF develops end-stage disease within 90 days post-inoculation<sup>15</sup>.</p>\n<p>In <strong>Aim 1</strong>, we will determine if aS pathology causes cellular senescence and which cell types exhibit premature senescence. For WT/PFF and <em>TgA53T</em>/PFF, 2 month-old animals will be inoculated with aS monomer (Control) or PFF. Animals analyzed (Core Methods) at 1, 3, and 6 months following inoculation. Naturally aging <em>TgA53T </em>mice will be analyzed at 6 and 12 months of age. Based on the results with the mutant tau Tg model, we expect that a-synucleinopathy will be associated with increased senescence. While aS pathology is restricted to &nbsp;neurons &nbsp;in &nbsp;these &nbsp;models, &nbsp;we &nbsp;may &nbsp;also &nbsp;find &nbsp;that &nbsp;neuronal &nbsp;abnormalities &nbsp;are &nbsp;associated &nbsp;with premature senescence in glial cells, as seen with AD models<sup>4,5</sup>.</p>\n<p>In <strong>Aim 2</strong>, we will determine if senescence can contribute to the onset/progression of a-synucleinopathy and subsequent neurodegeneration. We will put <em>TgA53T </em>mice in the progeria model, <em>Ercc1<sup>-/&Delta;</sup> </em>mice, to generate 4 key genotypes (i.e. <em>WT</em>, <em>TgA53T</em>, <em>Ercc1<sup>-/&Delta;</sup> </em>and <em>TgA53T/Ercc1<sup>-/&Delta;</sup></em>). These mice will be inoculated with aS-PFF and analyzed at 1, 3 and 6 months of age (see Core Methods).</p>\n<p>Finally, in <strong>Aim 3</strong>, we will evaluate whether senescent cells directly contribute to neurodegeneration in aS-PFF and <em>TgA53T </em>models of a- synucleinopathy. These robust models of a-synucleinopathy will be treated pharmacologically with the senolytic combination, Dasatinib (12 mg/kg) and Quercetin (50 mg/kg) (D+Q)<sup>5</sup>, or vehicle, by oral gavage, once a week. For the aS-PFF model, we will start D+Q treatment at 1 month following inoculation and neuropathology will be analyzed at 1, 3, and 6 months post-inoculation (Core Methods). For the <em>TgA53T </em>model, D/Q treatment will be initiated at ~10 months of age, prior to the onset of disease, until all of the vehicle treated controls develop progressive motor dysfunction. As an additional test, we will cross <em>TgA53T </em>model with <em>INK-ATTAC </em>Tg mice to selectively eliminate <em>p16<sup>Ink4a</sup></em>-expressing senescent cells via the twice-weekly administration of AP20187 from weaning age<sup>4</sup>. Aims 2 and 3 will show that senescence directly participates in the onset/progression of a-synucleinopathy.</p>\n<h2>Project 3. Are there bidirectional pathological interactions between senescence and LRRK2/VPS35 models of PD? (PI: Darren Moore).</h2>\n<p><strong>Specific Aims</strong></p>\n<p>We will test the hypothesis that <em>PD-linked LRRK2 and VPS35 mutants cause cellular&nbsp; senescence and blocking senescence will provide neuroprotection </em>by determining whether: (1) PD-linked mutations in LRRK2 or VPS35 induce cellular senescence in the rodent brain, (2) increased senescence can exacerbate or unmask PD-like neurodegenerative phenotypes in LRRK2 or VPS35 mouse models, and (3) if removing senescent cells will provide neuroprotection in LRRK2 or VPS35 rodent models of PD.</p>\n<p><strong>Experimental Strategy</strong></p>\n<p><strong> </strong>Our primary model systems include LRRK2 models (<em>G2019S LRRK2 </em>knock-in and human <em>BAC-LRRK2-G2019S </em>transgenic mice; and <em>Ad5-LRRK2 </em>vector delivery in rats) and <em>D620N VPS35 </em>knock-in mice<sup>32,37-39</sup>. All of these models are established in our lab. Given the biological link between LRRK2 and VPS35, we will compare these two genetic PD models in all studies.</p>\n<p>In <strong>Aim 1</strong>, we will evaluate whether LRRK2 and VPS35 models induce cellular senescence in the brain with advancing age. We will compare heterozygous and homozygous <em>G2019S LRRK2 </em>knock-in or <em>D620N VPS35 </em>knock-in mice with their wild-type littermates at 6, 12 and 18 months of age as described in the Core Methods. As LRRK2 and VPS35 are expressed in neurons and glia, it will be of interest to determine if glial cells, particularly microglia and astrocytes, exhibit aberrant senescence. These studies will provide a detailed spatiotemporal analysis of age-related cellular senescence in genetic models of late-onset PD.</p>\n<p>In <strong>Aim 2</strong>, we will evaluate whether inducing cellular senescence and accelerated aging is sufficient to unmask or exacerbate PD-like neurodegenerative phenotypes in existing LRRK2 and VPS35 models. <em>G2019S LRRK2 </em>knock-in, BAC-LRRK2-G2019S transgenic, and <em>D620N VPS35 </em>knock-in mice will be crossed into the <em>Ercc1<sup>-</sup></em><em><sup>/&Delta;</sup></em><em> &nbsp;</em>background. &nbsp;For &nbsp;each &nbsp;cross, &nbsp;we &nbsp;will &nbsp;generate &nbsp;4 &nbsp;key &nbsp;genotypes &nbsp;(i.e. &nbsp;<em>WT</em>, &nbsp;<em>LRRK2<sup>KI/KI</sup></em>, &nbsp;<em>Ercc1<sup>-/&Delta;</sup> &nbsp;</em>and <em>LRRK2<sup>KI/KI</sup>/Ercc1<sup>-/&Delta;</sup></em>) that will be analyzed at 1, 3 and 6 months of age (see Core Methods<strong>)</strong>.</p>\n<p>Finally, in <strong>Aim 3</strong>, we will evaluate whether removal of senescent cells in LRRK2 and VPS35 PD models is neuroprotective. We will use two models with robust, age-dependent DAergic neurodegeneration: i) adult Wistar rats with intra-striatal delivery of recombinant <em>Ad5-LRRK2-G2019S </em>vectors that develop acute neuronal loss at 6 weeks<sup>40</sup>, and ii) <em>D620N VPS35 </em>knock-in mice that display chronic neuronal loss, and widespread axonal damage and tau pathology, by 12 months<sup>32</sup>. <em>Ad5-LRRK2 </em>rats will be treated with D/Q from 1-6 weeks post-viral delivery, with neurodegeneration evaluated at 3, 6 and 12 weeks. <em>D620N VPS35 </em>knock-in mice will be crossed with <em>INK-ATTAC </em>transgenic mice to selectively eliminate <em>p16<sup>Ink4a</sup></em>- expressing senescent cells. Quantitative analysis of nigrostriatal pathway neurodegeneration and neuropathology (Core Methods) will be monitored at 6, 12 and 18 months of age. Aims 2 and 3 will establish whether cellular senescence directly participates in the PD-like neurodegeneration induced by LRRK2 and VPS35 mutations <em>in vivo</em>.</p>\n<p><strong>Alternatives, Projects 1-3: </strong>Based on collective expertise of the investigators, we do not expect problems in completing studies proposed in Projects 1-3. However, if we encounter unexpected lethality with any of our proposed matings (e.g. <em>TgA53T</em>/<em>Ercc1<sup>-/&Delta;</sup></em>), we will use conditional <em>Ercc1-KO </em>(e.g. <em>Ercc1</em><sup>-/fl</sup>:<em>Nestin-Cre</em>). We will continually fine-tune our experiments (e.g. time course, cohort size, outcome measures) based on our intermediate results and transcriptomic analysis (Project 4).</p>\n<h2>Project 4. Is senescence a component of human PD and does experimental senescence lead to alterations in PD-related gene expression? (PI: Jose Bras).</h2>\n<p><strong>Specific Aims</strong></p>\n<p>We hypothesize that <em>cellular senescence plays a role in the progression of neuropathological events in the human PD brain</em>. This project will: 1) Characterize the neuropathological progression of PD with single-cell resolution; 2) Determine the levels of senescence, as captured by a transcriptome signature, at each Braak stage; and 3) Integrate the rodent model transcriptomic data with the human scRNA-Seq.</p>\n<p><strong>Experimental Strategy</strong></p>\n<p>We will perform scRNA-Seq in 3 brain regions (frontal cortex, substantia nigra and hippocampus) of 5 controls and 5 PD cases at each of the six Braak stages for a total of 105 experiments using 10X Genomics technology. We will ensure that all samples were diagnosed according to the same clinico-pathological criteria. To identify transcriptomic differences at the cell type level between Braak stages, differential expression will be performed as described for AD brains<sup>41,42</sup> Furthermore, we will apply MTGO-SC<sup>43</sup> to each cluster identified by Seurat, together with the Gene Ontology (GO) database as a source of gene labels, to identify gene and functional module networks that are different between each stage. We will follow recent data that shows a transcriptomic signature of senescence to identify genes that are expected to have different expression levels in senescence<sup>44</sup> and compare these levels at each Braak stage in age-matched PD cases. To integrate the model with the human data we will use gene set enrichment analyses, using <em>limma</em>, across the aging mice and determine overlap of genes with those derived from PD cases with higher expression of senescence- associated genes. We have performed several scRNA-seq experiments using human tissue (<em>manuscripts in preparation</em>), so we do not foresee technical problems. However, it is plausible that transcriptional differences across Braak stages may reside in rare cell subsets that are not captured with our depth of sequencing. In this unlikely case, we would turn to more sophisticated analyses methods, such as CellCnn, a representation learning approach to detect rare cell subsets associated with disease using high-dimensional single-cell measurements. The results will establish the presence of senescence in PD brains as well as provide the community with high-resolution transcriptomic analysis of PD. Further, we will provide novel comparative analysis of gene expression changes in human PD and mouse models. In addition to our proximal goal to study senescence in PD, our efforts will provide a database that will likely provide novel mechanistic insights about PD pathogenesis and the relevance of rodent models.</p>\n<h1>POWER CALCULATIONS AND STATISTICAL ANALYSES PLAN</h1>\n<p>For animal studies (<strong><em>Projects 1-3</em></strong>), we will perform power analysis to detect 20% difference with 80% power based on our historical experiences with the mouse strains. In most cases, difference between means will be defined using ANOVA, followed by Newman-Keuls post-test (Prism, Graph Pad). We will use equal number of males and females. For genomic studies <strong><em>(Project 4)</em></strong>, statistical analysis is an integral component of the analysis<sup>41,42,44</sup>.</p>\n<h1>PROJECT TIMELINE AND MILESTONES</h1>\n<p><strong>Months 1-6: </strong>Generate mouse strains and cohorts needed for the projects. Obtain brain tissue from postmortem human PD cases and start the generation of scRNA-seq data.</p>\n<p><strong>Months 7-12: </strong>Collection of brains for Projects 1 (nestin-cre/ <em>Ercc1<sup>fl/fl</sup></em>, Aim 1) and 2 (PFF models, Aim 1). Perform scRNA-Seq and preliminary analysis in the first 45 samples.</p>\n<p><strong>Months 13-18: </strong>Complete the analysis of nestin-cre/ <em>Ercc1<sup>fl/fl</sup> </em>(Project 1, Aim 1) and PFF models (Project 2, Aim 1). Collect TgA53T mice (Project 2, Aim 1) and <em>G2019S LRRK2 </em>knock-in or <em>D620N VPS35 </em>knock-in mice (Project 3, Aim 1).</p>\n<p><strong>Months 19-24: </strong>Complete the analysis of TgA53T mice (Project 2, Aim 1) and <em>G2019S LRRK2 </em>knock-in or <em>D620N VPS35 </em>knock-in mice (Project 3, Aim 1). Collect mouse for Project 1 (TH-cre/ <em>Ercc<sup>-/fl</sup></em>, Cx3cr1-cre/ <em>Ercc1<sup>-/fl</sup> </em>Aim 2/3) and Projects 2/3 (PD-model/<em>Ercc1<sup>--/&Delta;</sup> </em>cohorts, Aim 2). Complete the scRNA-Seq in human tissue (Project 4)</p>\n<p><strong>Months 25-30: </strong>Complete the analysis of TH-cre/<em>Ercc1<sup>-/fl</sup> </em>and Cx3cr1-cre/<em>Ercc1<sup>-/fl</sup> </em>(Project 1, Aim 2/3). Complete the analysis of PD-model/<em>Ercc1-<sup>-/&Delta;</sup> </em>cohorts (Projects 2 and 3; Aim 2). Integrate the model scRNA-Seq with the data generated in human samples. Start Aim 3 for Project 2 and 3 (D/Q treatment, INK-ATTAC mice). Collect <em>Ercc1<sup>-/&Delta;</sup> </em>mice lacking aS or LRRK2 expression (Aim 4, Project 1)</p>\n<p><strong>Months 31-36: </strong>Complete all proposed studies.</p>\n<h1>WORKFLOW SCHEMATIC</h1>\n<p>The ASAP Collaborative Research Program in Senescence in Parkinson&rsquo;s disease is a collaborative effort between investigators at University of Minnesota (UMN; Lee and Niedernhofer) and Van Andel Research Institute (VARI; Bras and Moore). In addition, Dr. Tammy Butterick (VAMC) will provide MSD Meso scale analysis of SASP-associated cytokines/biomarkers. Below schematic outlines the collaborative and multidisciplinary nature of the program. Filled arrows indicate the flow of materials (mouse models, samples) while open arrows indicate the flow of information. Asterisks (*) are items that will be provided to the entire program. Dr. Niedernhofer (Project 1) will provide the expertise in senescence and provide senescence relevant mouse models to Projects 2 and 3. Dr. Lee (Project 2) will provide expertise in a-synuclenopathy, analysis of proteostasis, and neuropathology for Project 1 and 3. Dr. Moore (Project 3) will provide expertise in LRRK2/VPS35 biology and models. Dr. Bras (Project 4) will provide expertise in transcriptomic analysis and bioinformatics of PD brain and models. All data will be discussed during regular group meetings (Administration/Coordination) and execution of studies will be discussed according to emerging data. For example, if results from conditional <em>Ercc1-KO </em>models indicate that use of <em>Nestin-Cre:Ercc1<sup>fl/fl</sup> </em>mice would be superior to the use of <em>Ercc1<sup>-/</sup></em><em>&Auml;, </em>we will modify our experimental approach. Similarly, we will be informed by transcriptomic analysis to fine-tune our analysis of mouse models.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/039686ae-a58f-43fe-9d97-8a7f846accd3/lee-workflow.jpg\" alt=\"Lee workflow\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Hernandez-Segura, , Nehme, J. &amp; Demaria, M. Hallmarks of Cellular Senescence. <em>Trends Cell Biol </em><strong>28</strong>, 436-453 (2018).</li>\n<li><em> </em>Yousefzadeh, M.J. <em>et al. </em>Mouse Models of Accelerated Cellular Senescence. <em>Methods Mol Biol </em><strong>1896</strong>, 203-230 (2019).</li>\n</ol>\n<ol start=\"3\">\n<li>Baker, J. &amp; Petersen, R.C. Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. <em>J Clin Invest </em><strong>128</strong>, 1208-1216 (2018).</li>\n<li>Bussian, J. <em>et al. </em>Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. <em>Nature </em><strong>562</strong>, 578-582 (2018).</li>\n<li>Zhang, <em>et al. </em>Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model. <em>Nat Neurosci </em><strong>22</strong>, 719-728 (2019).</li>\n<li>Yousefzadeh, J. <em>et al. </em>Tissue specificity of senescent cell accumulation during physiologic and accelerated aging of mice. <em>Aging Cell </em><strong>19</strong>, e13094 (2020).</li>\n<li>Wang, J., Clauson, C.L., Robbins, P.D., Niedernhofer, L.J. &amp; Wang, Y. The oxidative DNA lesions 8,5'-cyclopurines accumulate with aging in a tissue-specific <em>Aging Cell </em><strong>11</strong>, 714-6 (2012).</li>\n<li>Borgesius, Z. <em>et al. </em>Accelerated age-related cognitive decline and neurodegeneration, caused by deficient DNA repair. <em>J Neurosci </em><strong>31</strong>, 12543-53 (2011).</li>\n<li>Robinson, R. <em>et al. </em>Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging. <em>Redox Biol </em><strong>17</strong>, 259-273 (2018).</li>\n<li>Khan, S. <em>et al. </em>Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons. <em>Acta Neuropathol </em>(2018).</li>\n<li>Larson, E. <em>et al. </em>Soluble alpha-synuclein is a novel modulator of Alzheimer's disease pathophysiology. <em>J Neurosci </em><strong>32</strong>, 10253-66 (2012).</li>\n<li>Zhao, H.T. <em>et al. </em>LRRK2 Antisense Oligonucleotides Ameliorate alpha-Synuclein Inclusion Formation in a Parkinson's Disease Mouse <em>Mol Ther Nucleic Acids </em><strong>8</strong>, 508-519 (2017).</li>\n<li>Daher, P., Volpicelli-Daley, L.A., Blackburn, J.P., Moehle, M.S. &amp; West, A.B. Abrogation of alpha- synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. <em>Proc Natl Acad Sci U S A </em><strong>111</strong>, 9289-94 (2014).</li>\n<li>Blauwendraat, C., Nalls, M.A. &amp; Singleton, A.B. The genetic architecture of Parkinson's <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Lancet Neurol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">19</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 170-178 (2020).</span></li>\n<li>Karim, R. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">alpha-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Mol Neurodegener </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">15</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 27 (2020).</span></li>\n<li>Colla, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Endoplasmic Reticulum Stress Is Important for the Manifestations of alpha- Synucleinopathy In Vivo. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Neurosci </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">32</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 3306-20 (2012).</span></li>\n<li>Martin, J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Neurosci </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">26</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 41-50 (2006).</span></li>\n<li>Koprich, B., Kalia, L.V. &amp; Brotchie, J.M. Animal models of alpha-synucleinopathy for Parkinson disease drug development. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Rev Neurosci </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">18</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 515-529 (2017).</span></li>\n<li>Williams, E.T. &amp; Moore, D.J. Deciphering the role of VPS35 in Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Neurosci Res </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">96</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1339-1340 (2018).</span></li>\n<li>Nguyen, P. &amp; Moore, D.J. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Adv Neurobiol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">14</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 71-88 (2017).</span></li>\n<li>Cunningham, A. &amp; Moore, D.J. Endosomal sorting pathways in the pathogenesis of Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Prog Brain Res </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">252</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 271-306 (2020).</span></li>\n<li>Williams, T., Chen, X. &amp; Moore, D.J. VPS35, the Retromer Complex and Parkinson's Disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Parkinsons Dis </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">7</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 219-233 (2017).</span></li>\n<li>Mir, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Biochem J </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">475</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1861-1883 (2018).</span></li>\n<li>Tsika, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiol Dis </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">71</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 345-58 (2014).</span></li>\n<li>Cooper, J.F. <em>et al. </em>Delaying aging is neuroprotective in Parkinson's disease: a genetic analysis in elegans models. <em>NPJ Parkinsons Dis </em><strong>1</strong>, 15022 (2015).</li>\n<li>Lee, M.K. <em>et al. </em>Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --&gt; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. <em>Proc Natl Acad Sci U S A </em><strong>99</strong>, 8968-73 (2002).</li>\n<li>Henderson, M.X. <em>et al. </em>Spread of alpha-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network <em>Nat Neurosci </em><strong>22</strong>, 1248- 1257 (2019).</li>\n<li>von Coelln, <em>et al. </em>Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. <em>J Neurosci </em><strong>26</strong>, 3685-96 (2006).</li>\n<li>Unger, E.L. <em>et al. </em>Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in <em>Neurobiol Dis </em><strong>21</strong>, 431-43 (2006).</li>\n<li>Matsuura, , Kabuto, H., Makino, H. &amp; Ogawa, N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. <em>J Neurosci Methods </em><strong>73</strong>, 45-8 (1997).</li>\n<li>Singh, <em>et al. </em>Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of alpha-synucleinopathy. <em>Acta Neuropathol </em>(2019).</li>\n<li>Chen, X. <em>et al. </em>Parkinson's disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic <em>Proc Natl Acad Sci U S A </em><strong>116</strong>, 5765-5774 (2019).</li>\n<li>Larson, E. <em>et al. </em>Selective lowering of synapsins induced by oligomeric alpha-synuclein exacerbates memory deficits. <em>Proc Natl Acad Sci U S A </em><strong>114</strong>, E4648-E4657 (2017).</li>\n<li>Tronche, <em>et al. </em>Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. <em>Nat Genet </em><strong>23</strong>, 99-103 (1999).</li>\n<li>Savitt, M., Jang, S.S., Mu, W., Dawson, V.L. &amp; Dawson, T.M. Bcl-x is required for proper development of the mouse substantia nigra. <em>J Neurosci </em><strong>25</strong>, 6721-8 (2005).</li>\n<li>Zhao, F. <em>et al. </em>Targeting Microglia Using Cx3cr1-Cre Lines: Revisiting the Specificity. <em>eNeuro</em></li>\n<li>Yue, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiol Dis </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">78</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 172-95 (2015).</span></li>\n<li>Melrose, L. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiol Dis </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">40</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 503-17 (2010).</span></li>\n<li>Tsika, E. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiol Dis </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">77</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 49-61 (2015).</span></li>\n<li>Dusonchet, J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Neurosci </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">31</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 907-12 (2011).</span></li>\n<li>Mathys, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Single-cell transcriptomic analysis of Alzheimer's disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">570</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 332-337 (2019).</span></li>\n<li>Grubman, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A single-cell atlas of entorhinal cortex from individuals with Alzheimer's disease reveals cell-type-specific gene expression regulation. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Neurosci </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">22</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 2087-2097 (2019).</span></li>\n<li>Nazzicari, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">MTGO-SC, A Tool to Explore Gene Modules in Single-Cell RNA Sequencing Data. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Front Genet </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">10</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 953 (2019).</span></li>\n<li>Casella, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Transcriptome signature of cellular senescence. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nucleic Acids Res </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">47</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 11476 (2019).</span></li>\n</ol>\n<p>&nbsp;</p>\n<p>&nbsp;</p>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:17Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "Co-Pathologies Drive Neuroinflammation and Progression in PD"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>Project Summary</h1>\n<p>While PD is considered a synucleinopathy, clinical progression of PD is driven by neuroinflammation elicited by co-pathologies such as misfolded Tau, beta amyloid, TDP-43, and stroke.<sup>1</sup> Indeed, it has become increasingly evident that CNS and peripheral immune cell mediated inflammation plays a key role in PD neurodegeneration <sup>2,3</sup> In post-mortem PD brains, &alpha;-synuclein (&alpha;-syn) pathology and other co-pathologies are accompanied by HLA-DR (MHCII) expression on myeloid cells such as microglia, increased pro-inflammatory cytokine expression in blood and CSF<sup>3,4</sup>, and infiltration of T lymphocytes<sup>5,6</sup>. To deliver effective therapies, a better understanding of the basic biology of PD inflammation and immune system involvement requires the creation of relevant models based upon co-pathologies. <em>The overall hypothesis will be tested utilizing three inter-related goals/projects:</em></p>\n<p><strong><em>Goal 1: </em></strong>Determine the role of age and the immune system in co-pathology-mediated inflammation and neurodegeneration in mouse models of PD (Led by Ashley Harms, UAB).</p>\n<p><strong><em>Goal 2: </em></strong>Determine the role of age and co-pathology-mediated inflammation and neurodegeneration in nonhuman primate (NHP) models of PD (Led by Jeffrey Kordower, Rush).</p>\n<p><strong><em>Goal 3: </em></strong>Validate the role of neuroinflammation as <strong><em>causative </em></strong>in neurodegeneration and associated behavioral outcomes, using immunomodulatory compounds. We will use unique antibody tools to characterize the co-pathology mechanisms and temporal independencies (Led by Warren Hirst, Biogen and in collaboration with Jeffrey Kordower and Ashley Harms).</p>\n<h1>Rationale and Preliminary Data</h1>\n<p>One of the most exciting and novel theories in neurodegenerative disease research over the last two decades is that aggregated/pathological proteins have the capacity to progressively spread throughout the organism. This is accomplished by the transfer and induction of protein aggregation in previously healthy cells, resulting in progression of pathology and clinical signs and symptoms. Inflammation precedes this propagation by years,<sup>7</sup> indicating that inflammation can be a driver of this process. We have also shown that misfolded proteins can propagate and induce degeneration in murine and NHP models of PD following injections of a single pathological species of preformed &alpha;-syn fibrils (PFF) into the striatum<sup>8,9</sup>. A number of preclinical and clinical trials are underway that are mechanistically aimed at removing extracellular species using active and passive immunotherapeutic approaches but they suffer from the fact that<u> <strong><em>PD is initiated by &alpha;-syn but clinical progression is associated</em></strong></u><strong><em> <u>with the co-pathologies Tau and Abeta</u></em><u>.</u> </strong>To our knowledge, no group is currently investigating such co- pathologies and this shortcoming in the field may be <strong><em><u>a significant barrier to achieving successful clinical</u> <u>outcomes as only one form of pathology is typically addressed</u></em><u>.</u> </strong>We are uniquely positioned to successfully overcome such barriers since we have developed robust and faithful models of misfolded proteins in rodents and NHPs of &alpha;-syn pathology<sup>8,9</sup> tau pathology (<strong>Fig panels A-H top and bottom</strong>), and amyloid pathology<sup>10</sup>.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/cbad6fe1-1df7-4c89-bd21-4ee4a3222717/kordower-panel-images-a-h.png\" alt=\"Kordower_Panel Images A-H\" width=\"889\" height=\"908\" /></p>\n<h1>Research Tools, Models, and Resources</h1>\n<p><em>To be shared collaboratively to ensure reproducibility.</em></p>\n<ul>\n<li>AAV vectors expressing tau<sup>mut/mut</sup>. (Generated and validated by Fredric Manfredsson, BNI)</li>\n<li>&alpha;-syn PFFs. (Generated for rodents/monkey models of PD by Ashley Harms, UAB)</li>\n<li>sVCAM-1 measurement in CSF, plasma and brain (Hirst, Biogen)</li>\n<li>VLA-4 (including Tysabri), &alpha;-syn, tau, beta- amyloid antibodies and potentially &alpha;-syn, tau and APP ASOs (Hirst, Biogen)</li>\n<li>CSF and serum neurofilament light chain assays (Hirst, Biogen)</li>\n<li>Antibodies that have been modified to bind specifically to mouse VLA-4, &alpha;-syn, Tau, Abeta &amp; the corresponding human antibodies, from current clinical trials for the mouse and NHP studies (Hirst, Biogen)</li>\n</ul>\n<p><strong><em>Methodologies for all goals: </em></strong>For all goals, similar endpoint measures will be obtained as detailed in <strong>Table 1. </strong>Immunophenotyping utilizing flow cytometry multiplex ELISA immunohistochemistry, and flow cytometry are described below and detailed in <strong>Table 2</strong>. Using a novel and innovative multiplex imaging platform, SeqStain Spatialomics, (collaboration Drs. Gupta and Landay, RUSH) we will directly evaluate cellular markers of CD4 T cell subsets, M1 macrophages, and microglia inflammasome (NLRP3) formation and activation in brain This technology can visualize over 100 proteins on the same section through sequential staining, unstaining, and then re-staining, <u>without any loss of sensitivity or tissue integrity</u>. Fluorescently tagged antibodies will be used to directly evaluate the spatial distribution of T cell subsets (<strong>Table 2</strong>) in relation to neurons or dopaminergic neurons in brain tissue. In addition, we will stain for M1 or myeloid cells, (NLRP3) formation (caspase-1+) and activation using fluorescently tagged antibodies to determine their contribution to neuro-inflammation in both NHP and mouse models of PD.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/91fcd9ff-39a1-41db-995d-2c2441f542c0/kordower-table-1.png\" alt=\"Kordower_Table 1\" width=\"678\" height=\"230\" /><img src=\"https://cloud.squidex.io/api/assets/asap-hub/d07f559e-ccc8-44ad-be8f-4bb657650057/kordower-tabe-2.png\" alt=\"Kordower_Tabe 2\" width=\"473\" height=\"629\" /></p>\n<h1>Study Plan</h1>\n<h2 style=\"text-align: left;\"><u>Project Goal 1:</u> Determine the role of the immune system in co-pathology-mediated inflammation and neurodegeneration in mice</h2>\n<p style=\"text-align: left;\"><strong><em>(Led by Ashley Harms, UAB) </em></strong>The major histocompatibility complex II (MHCII) (HLA DR, DP, DQ in humans) is a crucial regulator of the cellular&nbsp;immune response. In response to foreign proteins, MHCII expressed on myeloid cells presents antigen to T lymphocytes, a process that is important for linking the innate and adaptive immune responses. In response to antigen presentation, patrolling CNS T cells secrete pro-inflammatory cytokines and chemokines such as TNFa, IFN&iexcl;, CCL2, RANTES <sup>3,4</sup> leads to CNS invasion of peripheral immune cells including monocytes, macrophages, and T cells <sup>11</sup>. Infiltration of CD4 and CD8 T cells into the CNS, and T cells reactive to &alpha;-syn peptides have been identified in PD patients indicating a critical role of adaptive immunity in PD<sup>12,13</sup>. In &alpha;-syn models of PD, our group has shown that antigen presentation via MHCII+ myeloid cells to CD4+ T cells is required for &alpha;-syn- mediated neuroinflammation and&nbsp;neurodegeneration<sup>14,18</sup>. <strong>These data suggest that blocking CNS antigen presentation via MHCII or entry of CD4 T cells via knockout can greatly attenuate brain inflammatory responses such as expression of pro-inflammatory cytokines and chemokines, and neurodegeneration.</strong></p>\n<p>Currently, the role of the immune system in co-pathology-mediated neurodegeneration is unknown. One challenge to studying age-related&nbsp;co-pathologies in PD is the lack of an animal model as discussed above. Based on preliminary data from our novel co-pathology NHP model, <strong><em>we hypothesize that initial innate immune response to co-pathologies is mediated by MHCII expression on CNS resident (TMEM119+) microglia</em></strong><em><sup>19</sup><strong>. These cells in turn trigger the entry and activation of and CD4+ T cells, leading to enhanced deleterious inflammation and neurodegeneration. </strong></em>In Goal 1 we will exploit genetic models, technologies such as SeqStain Spatialomics, multiplex ELISA, and a novel mouse model of co-pathologies to dissect the mechanisms of toxicity. Results from these studies will not only show what specific immune subsets are required for co-pathology-driven neuroinflammation, but will demonstrate the importance of specific targets by using therapeutics to reverse the inflammation (Goal 3).</p>\n<h3>Specific Aim 1</h3>\n<p><strong>We will test the hypothesis that selective deletion of <em>MHCII </em>from CNS resident microglia is protective against &alpha;-syn-co-pathology induced monocyte and T cell invasion, neuroinflammation, and neurodegeneration in a novel mouse model of PD.</strong></p>\n<p>Microglia act as the resident immune cells of the brain, and are the first to respond to neural insult<sup>20,21</sup> Global knockout of MHCII proteins<sup>22</sup>, as well as blockade of the upstream transcriptional co-activator CIITA, are protective against &alpha;-syn-induced inflammation and neurodegeneration<sup>18</sup>. These results indicate a central role for microglial MHCII in the activation of both the innate and adaptive immune responses to &alpha;-syn in PD, and suggest that <strong>MHCII and antigen presentation to patrolling T cells may be a target of neuroprotective therapies. </strong>Understanding the role of resident microglia in initiating the neuroinflammatory response is critical to understanding mechanisms of neurodegeneration in a novel co-pathology mouse model of PD.</p>\n<p><strong>Aim 1 approach</strong>: MHCII knockout and mice in which MHCII (MHCII <sup>loxP/loxP</sup>) can be deleted in CNS resident microglia (TMEM119-CreERT2), will be used to determine the contribution of resident vs peripheral antigen presenting cells to disease phenotypes and if deletion of MHCII attenuates &alpha;-syn-co-pathology induced pro- inflammation (cytokine and chemokine expression), monocyte and T cell infiltration, and neurodegeneration. <strong>Mice: </strong>MHCII knockout<sup>23</sup>, TMEM119-CreERT2<sup>24</sup>, and MHCII <sup>loxP/loxP</sup> and/or non-motor/cognitive deficits on a congenic (C56BL/6) background. Male and female mice will be used and experimental groups will mirror project goal 2&nbsp;(below). To generate conditional MHCII knockout mice that bypass developmental effects of MHCII deficiency, TMEM119-CreERT2<sup>+/+</sup> mice will be bred to IA-B-floxed (MHCII <sup>loxP/loxP</sup>) mice. To completely delete MHCII from TMEM119+ resident microglia, TMEM119-CreERT2<sup>+/-</sup> x MHCII <sup>loxp/+</sup> animals will be bred to littermates to generate TMEM119-CreERT2<sup>+/-</sup>x MHCII <sup>loxP/loxP</sup> mice. TMEM119<sup>+/-</sup>x MHCII <sup>loxP/loxP</sup> mice will be injected twice subcutaneously (48 hours between doses) with 4mg Tamoxifen dissolved in 200uL corn oil or corn oil control and aged 30 days prior to viral transduction and &alpha;-syn preformed fibril injection. Unlike the NHP co-pathology model<sup>10</sup>, mice do not develop endogenous beta amyloid pathology, therefore we have chosen to combine our genetic knockout approaches with the human APP &ldquo;J20&rdquo; transgenic mouse line on the C57BL6/J background (MMRRC Stock No: 34836-JAX) that develops progressive beta-amyloid deposition with age, closely mimicking the aged NHP studies. This cohort of mice will be tested in tandem with mice on the C57BL6/J (WT) background.(<strong>Table 3</strong>).</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/8da63ec9-f82d-4413-8061-24384b22f2cb/kordower-table-3.png\" alt=\"Kordower_Table 3\" width=\"412\" height=\"288\" /></p>\n<p><strong>Co-Pathologies mouse model: </strong>C57B6/J (WT background) or J20 (beta-amyloid) mice approximately 8-10 weeks of age will receive stereotaxic injections of 5ug of &alpha;-syn fibrils into the right striatum. Thirty days later, mice will receive an ipsilateral intranigral injection (2 uL) of AAV 9 expressing tau<sup>mut/mut</sup> or a GFP control. The timepoints for each endpoint are in <strong>Table 1</strong>.</p>\n<p><strong>Multiplex ELISA, neurofilament light chain, and sVCAM1</strong><em>: </em>Brain lysates collected on cells FAC sorted from the striatum and SNpc and/or CSF collected from AAV/PFF transduced mice (n=6/group) will be analyzed for mouse cytokine and chemokine production in a 32 analyte assay at 1 and 3 months post-surgery. (MILLIPLEX-MAP-Mouse-CytokineChemokine-Magnetic-Bead-Panel). A power calculation was performed and is based on pilot data for TNF-alpha detection in a lipopolysaccharide injection&nbsp;model. CSF will be collected and passed to Dr. Hirst to measure sVCAM1 and neurofilament light chain levels.</p>\n<p><strong>IHC: </strong>Mice (n=10/group) will be sacrificed 1 month and 3 months post AAV/PFF transduction, perfused, and processed for immunohistochemistry (IHC) according to previously published protocols <sup>22,25,26</sup>. To assay inflammation via IHC, we will utilize antibodies detailed in <strong>Table 2</strong>.</p>\n<p><strong>Behavioral assessment: </strong>Mice (n=12/group) will be assessed for motor phenotype and/or non- motor/cognitive deficits 6 months post-AAV/PFF transduction. We will use a battery of tests including open field, rotarod, pole test, and challenging beamwalk <sup>31</sup>, Y-maze and fear conditioning.</p>\n<p><strong>Neurodegeneration: </strong>Mice (n=12/group) will be sacrificed 6 months post-AAV/PFF transduction, according to previously published protocols<sup>22,25,26</sup>. Unbiased stereology will be performed for both TH+ and Nissl- stained neurons in the SNpc and NeuN+ neurons in the dorsal-lateral striatum.</p>\n<p><strong>Power analysis: </strong>Based on previous work with the AAV-&alpha;-syn model<sup>22,25,26,27,28</sup> we expect a 30% decrease in TH+ neurons in as compared to control with 95% confidence and p&lt;0.05, we will need n=12 per group.</p>\n<p><strong>Flow Cytometry (Immune cell infiltrate and characterization): </strong>Phenotypic characterization of infiltrating immune cells in the CNS and draining cervical lymph nodes (dCLNs), will be performed on dissected dCLNs, striatum, and SNpc tissues of AAV/PFF injected mice and isolated mononuclear cells by flow cytometry. Labeled resident microglia (CD45, TMEM119+), peripheral monocyte, and T cell populations will be analyzed for percent of parent population and mean fluorescent intensity (MFI) for MHCII expression<sup>17</sup>using an Attune Nxt or a BDFacs Symphony flow cytometer and Flow Jo software. To observe a 50% increase in peripheral immune infiltrate in AAV transduced mice when compared to control with 95-99% confidence and p&lt;0.05, we need n=5 for each group. (10 mice total per group, 2 pooled ventral midbrains or striatum per n). For dCLNs, to observe a 30% increase in immune cell numbers in AAV transduced mice when compared to control with 95-99% confidence and p&lt;0.05, we need n=4/group.</p>\n<h3>Specific Aim 2</h3>\n<p><strong>We will test the hypothesis that inhibition of CD4+ T cell entry into the CNS attenuates &alpha;-syn-co-pathology induced monocyte entry, and neurodegeneration in a novel mouse model of PD.</strong></p>\n<p>Using global knockout strategies (MHCII, CIITA) we showed that blocking CD4 T cell responses is neuroprotective in an &alpha;-syn model of PD<sup>14,18</sup>. However, a major caveat to these finding is that mice that are deficient in MHCII and CIITA lack functional CD4 T cells, as APC MHCII expression is critical for CD4 T cell maturation in the thymus<sup>23</sup>. <em>These studies raise the question of whether the &alpha;-syn-induced inflammation and neurodegeneration is mediated by resident microglia, CD4 T cells, or both in combination </em>as the interaction between APCs and T cells is required for the production of pro- inflammatory cytokines and chemokines needed to mount an adaptive immune response. Functionally, it has been shown that CD4 and CD8 T cells derived from PD patient peripheral blood mononuclear cells (PBMCs) compared to age matched controls produce more cytokines in response to &alpha;-syn peptides<sup>15</sup> In post-mortem PD brain, &alpha;-syn pathology as well as other co-pathologies are accompanied by HLA-DR expression<sup>1</sup>, increased pro-inflammatory cytokine expression<sup>3,4</sup>, and infiltration of peripheral lymphocytes (CD4 and CD8+)<sup>5,6</sup>. Based on the role of &alpha;-syn in initiating an adaptive immune response in our mouse model of PD and other synucleinopathy models, <em>it is critical to <strong>determine whether CD4+ T cells are required for co-pathology-induced expression of damaging cytokines/chemokines, peripheral monocyte entry, and neurodegeneration as they can be targeted via FDA-approved therapies in use.</strong></em></p>\n<p><strong>Aim 2 approach: </strong>We will determine if deletion of CD4+ T cells attenuates &alpha;-syn-induced inflammation, monocyte and T cell infiltration and neurodegeneration. We will assay pro-inflammatory cytokine/chemokine expression, peripheral immune cell infiltration, and neurodegeneration as in Aim 1, <strong>Mice: </strong>CD4 knockout<sup>29</sup>, and C57BL/6 mice have been obtained from Jackson Labs and maintained/bred on a congenic (C56BL/6) background. Both male and female mice 8-12 weeks of age will be used. <strong>Table 3</strong>.</p>\n<p><strong>Timepoints: </strong>Mice will be sacrificed for the various outcomes as indicated in SA1.</p>\n<p><strong>Outcomes: Flow cytometry (Immune cell infiltrate</strong>), <strong>multiplex ELISA, neurofilament light chain, and sVCAM1</strong><em>, </em><strong>immunohistochemistry and imaging</strong>, <strong>behavioral assessment, histopathology- </strong>will be executed exactly as described for Aim 1, and the same power calculations apply.</p>\n<h2>Project Goal 2: Determine the role of age and co-pathology-mediated inflammation on structural and functional decline in monkey models of PD</h2>\n<p><strong>(Led by Jeffrey Kordower, Rush)</strong>. The creation of NHP models of co-pathologies is critical they are genetically and structurally more similar to humans and in many cases have a higher validity for human pathology than rodents.</p>\n<h3>Specific Aim 1</h3>\n<p><strong>We will test the hypothesis that &alpha;-syn and tau co-pathologies will exacerbate inflammation and functional decline in young NHPs.</strong></p>\n<p>Four groups of monkeys will be employed.</p>\n<ul>\n<li>Group 1: Young adult monkeys injected with both controls (AAV9-GFP and &alpha;-syn monomer; n=5).</li>\n<li>Group 2: Young adult monkeys injected with PFFs and AAV9-GFP; (n=5).</li>\n<li>Group 3: Young adult monkeys injected with PFFs plus AAV9- tau<sup>mut/mut</sup>; (n=5)</li>\n<li>Group 4 Young adult monkeys injected with &alpha;-syn monomer plus AAV9-tau<sup>mut/mut</sup>; (n=5).</li>\n</ul>\n<p><strong>Aim 1 Approach: </strong>All subjects will be trained on a hand reach task, get baseline general activity data, and be rated on a clinical rating scale. Based upon hand reach data, subjects will be assigned into groups outlined above. We will then deliver bilateral injections of: PFFs (or control) into the putamen as described before (3x40&micro;l;)<sup>8</sup> and (AAV-tau<sup>mut/mut</sup> (or control) into the SN (2x 20&micro;l), an area where we have demonstrated the presence of neurofibrillary tangles in aged patients and patients with PD<sup>1,30</sup> All injections are performed using a Medtronics Stealth Surgical Navigation System. Beginning one month following surgery, subjects will be tested on the same battery of tests for up to 6 months. Additionally, preoperatively and each month post-operatively, CSF and serum will be taken for measurements of neurofilament light chain which is increased in our NHP models to a level seen in patients with neurodegenerative diseases (<strong>Fig panel I</strong>) and this will allow us to assess the use of this molecule as potential biomarker for progression in the co-pathology model. Six months following surgery, all subjects will be perfused with ice cold saline, the brain removed and punched for neurochemistry. A battery of quantitative neuroanatomical neurochemical, and molecular biological endpoints will be evaluated to assess the role of co-pathologies on inflammatory processes, brain pathology, and neural degeneration as described below and in <strong>Table 2</strong>.</p>\n<h3>Specific Aim 2</h3>\n<p><strong>We will test the hypothesis that &alpha;-syn and tau co-pathologies will exacerbate inflammation and decline in aged NHPs</strong></p>\n<p><strong>Approach: </strong>Aging is the number one risk factor for PD. Aged NHPs<sup>10</sup>, like aged humans <sup>1,30</sup> and PD patients<sup>1</sup>, display beta amyloid plaques. Indeed, the failure to use&nbsp;aged animals in most preclinical studies may explain the generally poor clinical translation of therapies. In this aim, aged NHPs (&gt;22 years of age), will receive PFFs and AAV-tau<sup>mut/mut</sup> exactly as described in SA1, effectively creating a NHP model with <u>three</u> clinically relevant co-pathologies. Thus, in SA2 we will determine the added role of beta amyloid on the inflammatory processes, as well as structural and functional progression of motor deficits and neuropathology (see letter of support for aged monkeys). For both Aims 1 and 2, we will assess the dependent measures (see <strong>Table 1</strong>): <strong>1</strong>) Hand-reach, general activity, and clinical rating scale measures that have motor and non-motor components will be compared across groups (both Aim 1 young animals and aim 2 aged animals. <strong>2</strong>) Stereological counts of TH-immunoreactive neurons (similar to goal 1). <strong>3</strong>) Optical density of striatal TH. <strong>4</strong>) HPLC of striatal dopamine. <strong>5</strong>) Monthly serum and CSF samples to measure neurofilament light chain. <strong>6</strong>) Multiple Immunophenotyping assessments using the, SeqStain Spatialomics platform and the markers listed in <strong>Table 2</strong>.</p>\n<p><strong>Statistics</strong>: Clinical rating scale data will be analyzed by a non-parametric repeated measures ANOVA. Hand reach and general activity will be analyzed by a repeated measures ANOVA. With significant interaction effects, appropriate post-hoc tests that control for multiple comparisons will be employed. Correlations between specific neuroanatomical parameters and behavior across groups will be employed.</p>\n<h2>Project Goal 3: Validate the role of neuroinflammation as <em>causative </em>in neurodegeneration and associated behavioral outcomes, using immunomodulatory compounds</h2>\n<p><strong>(Led by Dr. Warren Hirst, Biogen). </strong>The goals of this project are three-fold:</p>\n<p><strong><em>First</em></strong>, we will test the hypothesis that pathogenic levels of lymphocyte trafficking occurs in the PD brain. To this end, brain samples from Dr. Kordower&rsquo;s brain bank will be utilized to measure sVCAM1 (marker of endothelial cell activation) levels in 10 aged-matched controls, 10 PD&rsquo;s. In order to establish the specificity of this effect, we will also compare these data to samples from 10 MSA patients and 10 AD patients. We will also employ a detailed spatialomics approach as described above using a series of markers described in <strong>Table 2</strong>.</p>\n<p><strong><em>Second</em></strong>, we will further validate the hypothesis that immune and inflammatory processes are integral to the etiopathology of our co-pathology model. We will <strong>a</strong>) Assess sVCAM1 levels in samples provided from the murine and nonhuman primate models (Projects 1 &amp; 2). <strong>b</strong>) Determine whether anti-integrin alpha 4 antibodies, (i.e. murine version of Tysabri) which block T-cell entry, attenuate the loss of TH-ir neurons. Groups of C57B6/J (WT) mice (n=12/group detailed <strong>Table 3</strong>) will receive the following:</p>\n<p>Group1: Co-pathology model (PFF&rsquo;s plus AAV9- tau<sup>mut/mut</sup> , Aim 1) + control antibody. Group 2: Co-pathology model + murine anti-VLA4 antibody.&nbsp;Details of the measures of inflammation, immune response, TH-positive neuron counts, as well behavior are as described both above (Goal 1) and in <strong>Table 1</strong>.</p>\n<p><strong><em>Third</em></strong>, we will address the mechanistic question of which pathology / pathological species, &alpha;-syn, Tau or Abeta is the upstream mechanistic driver. This will be addressed using antibodies, to test the hypothesis of extracellular propagation. Groups of mice (n=12/group; 6 male and 6 female of the co-pathology model (PFF&rsquo;s plus AAV9-tau<sup>mut/mut</sup> in J20 mice) will receive either of the following: <strong>1</strong>) Control Abs, <strong>2</strong>) &alpha;-syn Ab + veh/anti-VLA4 Ab, <strong>3</strong>) Abeta Ab + veh/anti- VLA4 Ab, <strong>4</strong>) Tau Ab + veh/anti-VLA4 Ab, <strong>5</strong>) &alpha;-syn Ab + Abeta Ab + veh/anti-VLA4 Ab, <strong>6</strong>) &alpha;-syn Ab + Tau Ab&nbsp;+ veh/anti-VLA4 Ab, <strong>7</strong>) aSyn Ab + Abeta Ab + Tau Ab + veh/anti-VLA4 Ab.&rdquo;</p>\n<p>The Ab will be administered from months 3-6, i.e. after some pathology has developed to resemble human PD and assess the potential for reversal as well as progression. Based upon these data, the best result will then be tested in the further combination with murine anti-VLA4 Ab, e.g.: <strong>1</strong>) &alpha;-syn Ab + Abeta Ab + murine anti-VLA4 Ab, <strong>2</strong>) &alpha;-syn Ab + Tau Ab + murine anti-VLA4 Ab, <strong>3</strong>) &alpha;-syn Ab + Abeta Ab + Tau Ab + murine anti- VLA4 Ab. Based upon these data, the best combinations (up to 4 groups + control) will then be tested in the nonhuman primate model of co-pathologies, as described in Goal 2, above.</p>\n<h1>Power Calculations and Statistical Analyses Plan</h1>\n<p>Integrated in specific aims above.</p>\n<h1>Project Timeline and Milestones</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/4519f748-9716-4d23-8167-0be350b65f87/kordower-study-milestones.png\" alt=\"Kordower_Study Milestones\" width=\"927\" height=\"268\" /></p>\n<h1>Workflow Schematic</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/2ceb4935-2a17-4b2e-84ce-2743c8796c6b/kordower-workflow-schematic.png\" alt=\"Kordower_Workflow Schematic\" width=\"591\" height=\"716\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Buchman, A.S., Yu L., Wilson, R.S., Leurgans, S.E. Nag, S, Shulman, J.M., Barnes, .LL., Schneider, J.A., Bennett, D.A. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30894446\">Progressive parkinsonism in older adults is related to the burden of mixed</a><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30894446\"> brain pathologies. </a> 16, 92, e1821-e1830. doi: (2019).</li>\n<li>McGeer, P. L., Itagaki, S., Boyes, B. E. &amp; McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. <em>Neurology </em>38, 1285-1291, doi:10.1212/wnl.38.8.1285 (1988).</li>\n<li>Qin, X. Y., Zhang, S. P., Cao, C., Loh, Y. P. &amp; Cheng, Y. Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis. <em>JAMA Neurol </em>73, 1316-1324, doi:10.1001/jamaneurol.2016.2742 (2016).</li>\n<li>Reale, M. <em>et al. </em>Peripheral cytokines profile in Parkinson's disease. <em>Brain Behav Immun </em>23, 55-63, doi:10.1016/j.bbi.2008.07.003 (2009).</li>\n<li>Brochard, V. <em>et al. </em>Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. <em>J Clin Invest </em>119, 182-192, doi:10.1172/JCI36470 (2009).</li>\n<li>Sommer, A. <em>et al. </em>Th17 Lymphocytes Induce Neuronal Cell Death in a Human iPSC-Based Model of Parkinson's <em>Cell Stem Cell </em>23, 123-131 e126, doi:10.1016/j.stem.2018.06.015 (2018).</li>\n<li>Olanow, C.W., Savolainen, M., Chu, Y., Halliday, G.M., Kordower, J.H. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/31056668\">Temporal evolution of</a><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/31056668\"> microglia and &alpha;-synuclein accumulation following foetal grafting in Parkinson's disease.</a> 1,1690-1700, doi: 10.1093/brain/awz104. PMID: 31056668 (2019).</li>\n<li>Chu, Y., Muller, S., Tavares, A., Barret, O., Alagille, D., Seibyl, J., Tamagnan, G., Marek, K., Luk, K.C., Trojanowski, J.Q., Lee,V.M.Y., Kordower, J.H. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/31580415\">Intrastriatal alpha-synuclein fibrils in</a><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/31580415\"> monkeys: spreading, imaging and neuropathological changes. </a> 1, 3565-357, doi: 10.1093/brain/awz296.PMID: 31580415 (2019).</li>\n<li>Williams, G.P., Schonhoff, A.M, Jurkuvenaite, A., Thome, A.D., Standaert, D.G, Harms, A.S. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease J Neuroinflammation. 15, 244, doi: 10.1186/s12974-018-1286-2 (2018).</li>\n<li>Mufson, E.J., Benzing, W.C., Cole, G.M., Wang, H., Emerich, D.F., Sladek, J.R. Jr, Morrison, J.H., Kordower, J.H. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/7824054\">Apolipoprotein E-immunoreactivity in aged rhesus monkey cortex: colocalization</a><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/7824054\"> with amyloid plaques. </a>Neurobiol Aging. 15, 621-7.PMID: 7824054 (1994).</li>\n<li>Schonhoff, A. M., Williams, G. P., Wallen, Z. D., Standaert, D. G. &amp; Harms, A. S. Innate and adaptive immune responses in Parkinson's disease. <em>Prog Brain Res </em>252, 169-216, doi:10.1016/bs.pbr.2019.10.006 (2020).</li>\n<li>Lindestam Arlehamn, C. S. <em>et al. </em>alpha-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. <em>Nat Commun </em>11, 1875, doi:10.1038/s41467-020- 15626-w (2020).</li>\n<li>Sulzer, D. <em>et al. </em>T cells from patients with Parkinson's disease recognize alpha-synuclein peptides. <em>Nature </em>546, 656-661, doi:10.1038/nature22815 (2017).</li>\n<li>Harms, A. S. <em>et al. </em>MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. <em>J Neurosci </em>33, 9592-9600, doi:10.1523/JNEUROSCI.5610-12.2013 (2013).</li>\n<li>Harms, A. S. <em>et al. </em>alpha-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. <em>Acta Neuropathol Commun </em>5, 85, doi:10.1186/s40478-017-0494-9 (2017).</li>\n<li>Harms, A. S. <em>et al. </em>Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. <em>Exp Neurol </em>300, 179-187, doi:10.1016/j.expneurol.2017.11.010 (2018).&nbsp;</li>\n<li>Williams, G. P. <em>et al. </em>T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. <em>Acta Neuropathol</em>, doi:10.1007/s00401-020-02126-w (2020).</li>\n<li>Williams, G. P. <em>et al. </em>Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease. <em>J Neuroinflammation </em>15, 244, doi:10.1186/s12974-018-1286-2 (2018).</li>\n<li>Bennett, M. L. <em>et al. </em>New tools for studying microglia in the mouse and human CNS. <em>Proc Natl Acad Sci U S A </em>113, E1738-1746, doi:10.1073/pnas.1525528113 (2016).</li>\n<li>Ransohoff, R. M. Microglia and monocytes: 'tis plain the twain meet in the brain. <em>Nature neuroscience </em>14, 1098-1100, doi:10.1038/nn.2917 (2011).</li>\n<li>Ransohoff, R. M. &amp; Cardona, A. E. The myeloid cells of the central nervous system parenchyma. <em>Nature </em>468, 253-262, doi:10.1038/nature09615 (2010).</li>\n<li>Harms, A. S. <em>et al. </em>MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. <em>J Neurosci </em>33, 9592-9600, doi:10.1523/JNEUROSCI.5610-12.2013 (2013).</li>\n<li>Madsen, L. <em>et al. </em>Mice lacking all conventional MHC class II genes. <em>Proc Natl Acad Sci U S A </em>96, 10338-10343, doi:10.1073/pnas.96.18.10338 (1999).</li>\n<li>Yona, S. <em>et al. </em>Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. <em>Immunity </em>38, 79-91, doi:10.1016/j.immuni.2012.12.001 (2013).</li>\n<li>Thome, A. D., Harms, A. S., Volpicelli-Daley, L. A. &amp; Standaert, D. G. microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. <em>J Neurosci </em>36, 2383-2390, doi:10.1523/JNEUROSCI.3900-15.2016 (2016).</li>\n<li>Thome, A. D., Standaert, D. G. &amp; Harms, A. S. Fractalkine Signaling Regulates the Inflammatory Response in an alpha-Synuclein Model of Parkinson Disease. <em>PloS one </em>10, e0140566, doi:10.1371/journal.pone.0140566 (2015).</li>\n<li>Fleming, S. M. <em>et al. </em>Early and progressive sensorimotor anomalies in mice overexpressing wild- type human alpha-synuclein. <em>J Neurosci </em>24, 9434-9440, doi:10.1523/JNEUROSCI.3080-04.2004 (2004).</li>\n<li>Bassil, F. <em>et al. </em>Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy. <em>Movement disorders : official journal of the Movement Disorder Society </em>32, 1230-1239, doi:10.1002/mds.27041 (2017).</li>\n<li>Rahemtulla, A. <em>et al. </em>Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. <em>Nature </em>353, 180-184, doi:10.1038/353180a0 (1991).</li>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Schneider%20JA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16374822\">Schneider, J.A</a>., <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20JL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16374822\">Li, J.L</a>., <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16374822\">Li, Y</a>., <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Wilson%20RS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16374822\">Wilson, R.S</a>., <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Kordower%20JH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16374822\">Kordower, J.H</a>., <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Bennett%20DA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16374822\">Bennett, D.A. </a>Substantia nigra tangles are related to gait impairment in older persons. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Kordower%2C%2BSchneider%2C%2BTangles\">Ann Neurol. </a>59,166-73 (2006).</li>\n</ol>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:16Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "Dissecting the mechanisms underlying disease progression in parkinsonism"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1esbDdpKlcJVkvhUFu2wewByL_24HXowY/view?usp=sharing"
    },
    "adminNotes": {
      "iv": "John Hardy, Frances Platt, Mina Ryten, Maria Grazia Spillantini, Zane Jaunmuktane"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:16Z"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "An in vivo Approach to Elucidate the Pathobiology of PD-associated Genes using Human Diseased Neurons"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>Project Summary&nbsp;</h1>\n<p>Mutations and/or deletions in specific genes result in a high probability of developing PD, suggesting a critical role for these genes in the health and survival of specific cells. Curiously, it is not yet clear how specific types of brain cells are functionally impacted by genetic mutations to generate neuronal loss that defines PD. This project is built on the premise that patient-derived cells from genetic forms of PD, studied in the environment of a living brain, will provide a unique paradigm to reveal temporal, spatial and cellular components of PD pathobiology.</p>\n<h1>Rationale and Preliminary Data</h1>\n<p>We will use iPSCs derived from patients with three known genetic causes of PD &ndash; namely cells generated from patients with loss of parkin function (<em>PRKN </em>KO iPSCs; Partners&rsquo; own cell collection) and those that have been obtained from patients with disease-causing mutations in <em>SNCA </em>and <em>LRRK2 </em>(from the PPMI collection). Notably, these genetic forms have distinctly different presentations. Complete loss of parkin function causes an autosomal recessive parkinsonism &ndash; early onset PD with benign, motor-dominant clinical course and&nbsp; neurodegeneration restricted to catecholaminergic brain cells that lack protein aggregates [1]. At the cellular level, we know that parkin deficiency causes mitochondrial defects with severe consequences to cell survival [2,3]. In contrast, point mutations in <em>SNCA </em>cause autosomal dominant disease, have wide-spread pathology&nbsp; with high aggregate burden, involve not only monoaminergic cells but also other neuronal systems e.g., the cortex, and often times present with non-motor symptoms such as dementia, although the phenotype can be variable between mutation carriers [4]. Available neuropathological data from <em>LRRK2 </em>mutation cases suggests that while aSyn pathology is found in some cases, they invariably contain tau aggregates, otherwise typically seen in Alzheimer&rsquo;s disease [5]. These data suggest that while the two latter mutations promote protein aggregation, the precise mechanism of disease could be different favoring different types of aggregates to be formed by different proteins.</p>\n<p>Whereas neuronal pathology in PD is well documented and widely recognized, an equally important but less well studied aspect of the pathology involves the astrocytes, which accumulate aSyn in PD [6,7]. Importantly, emerging data from recent studies highlight that astrocytic pathology in PD can be replicated in iPSC-derived astrocytes <em>in vitro </em>and that the presence of abnormal astrocytes could be a key factor determining the fate of neurons affected by the disease process [8]. We have therefore designed our work to demonstrate not only regional and neuronal sub-type specific impacts of the 3 genetic forms of PD but also how these mutations influence the health and survival of astrocytes, as well as the interplay between these two key cell types in the brain.</p>\n<p>In order to provide greater mechanistic insights into the key determinants of disease pathogenesis and progression, our work will not only study the cells with their native mutations but also incorporate isogenic lines generated from them. We will take advantage of gene editing strategies to replace one mutated PD causative gene with another, giving us a unique paradigm to explore whether the mutations are irreplaceable drivers of the neuropathology seen in these sub-groups of patients. For example, would replacement of <em>LRRK2 </em>mutation with that of <em>SNCA </em>switch the tau dominant protein aggregation phenotype to that of aSyn? Alternatively, would the insertion of <em>PRKN </em>mutation in a corrected <em>SNCA </em>isogenic line spare cortical cells and lead to a more selective loss of dopaminergic neurons as seen in cases with <em>PRKN </em>mutations? This effort will also yield isogenic corrected lines from the same parental patient lines, which will serve as control cells in this experimental setting.</p>\n<p>Finally, here we propose to study the patient-derived iPSCs in an <em>in vivo </em>grafting paradigm in nude-mice (essentially creating a human-mouse chimera model). Unlike <em>in vitro </em>culture systems, this system has the unique capability to follow the maturation and integration of the human cells over extended timeframes in living brain circuitry where the metabolic demands, substrate availability and elimination of end-products are tightly controlled. Importantly, this will model pathological features that manifest over longer time frames than feasible <em>in vitro</em>, and those that depend exclusively on <em>in vivo </em>features, e.g., the establishment of an extensive functional terminal network in a complex, physiological environment.</p>\n<h1>Research Tools, Models and Resources&nbsp;</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/ca23017c-3bd8-4812-83b3-92c2c520ac55/kirik-table-1.jpg\" alt=\"Kirik Table 1\" /></p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/d5671516-a474-486b-9f54-90afa9bfa123/kirik-table-2.jpg\" alt=\"Kirik Table 2\" /></p>\n<h1>Study Plan</h1>\n<h2>Specific Aim 1:&nbsp; <em>In vitro </em>characterization and differentiation of the critical tools for use in grafting studies, iPSC lines with PD-mutations of the desired cell types and distinctive cell pathologies</h2>\n<p>Necessary for the generation of donor cells suitable for transplantation is confirmation that patient-derived iPSCs can differentiate into neural populations known to be affected in PD. iPSCs from <em>SNCA </em>and <em>LRRK2 </em>mutation carriers are available from PPMI (Table 1). As <em>PRKN </em>mutation carriers are not part of PPMI, we will use fibroblast lines from <em>PRKN </em>mutation carriers with extensive clinical records and mitophagy-related biomarkers (n=9) [3] from Johnston/NysnoBio and Sue to generate iPSCs.<sup>1</sup></p>\n<p>iPSCs will then be differentiated into both midbrain and cortical cells (neurons and astrocytes) using protocols established in the consortium (Parish Lab) or based on published protocols, with adaptations [9] (Fig. 1). In brief, <em>dorsal forebrain cortical progenitors </em>will be generated on Laminin-521, exposed to dual-SMAD inhibition (SB/LDN) to promote neural induction, expanded in the presence of FGF2, prior to transitioning into &lsquo;maturation media&rsquo; containing GDNF, BDNF, TGF&beta;3, DAPT, ascorbic acid and cAMP. <em>Ventral midbrain dopaminergic (vmDA) progenitors </em>will be generated using our previously developed and fully characterized protocol [10]. Following neural induction (SB/LDN), exposure to ventralizing cues SHH and Purmorphamine (PM) in addition to caudalizing signals via the Wnt agonist, CHIR 99021, promotes regional specification. Cultures are similarly transitioned to the same &lsquo;maturation media&rsquo; as cortical progenitors. Prolonged culturing (&gt;65 days) in maturation media generates regionally patterned cortical and VM astroglia. Generation of appropriate lineage and cell types will be confirmed by immunocytochemistry and qPCR at various points in the differentiation &ndash; to confirm early neural specification, regional identity of neuronal progenitors at the time of transplantation (VM day 20: FOXA2, OTX2, NURR1, LMX1A, Cortex, day30: PAX6, SOX2), and their capacity to generate mature neuronal cell types (e.g. MAP2, NEUN; VM: PITX3, TH; Cortex: CTIP2, TBR1, BRN2, vGLUT). Regionally specified astrocytes will be confirmed by expression of GFAP, s100&beta; together with FOXA2, OTX2,&nbsp; NURR1 (VM) or FoxG1, Lhx2 (Cortex). Cell lines demonstrating robust regional specification will be differentiated on large scale for cryopreservation at a stage in the differentiation amenable to transplantation.<sup>2</sup> A single vial from large cell batches will be thawed and grafted into 3 animals/line to confirm survival and maintained regional identity of progenitors at 6 weeks after grafting, prior to shipment for 1) WGS and disease phenotyping (Sue Lab; further detailed under SA2) and 2) large-scale transplantation studies at FINMH (Thompson Lab) and Lund, Sweden (Kirik Lab) for SA3.</p>\n<p><sup>1</sup> We contacted 3 professional service providers to generate 6 disease lines (3 clones/line) as well as screening for sterility, viability, stemness and validation for tri-germinal potential. Optimal clones showing robust pluripotency and tri lineage potential will be selected for generation of working cell banks &ndash; with the target of obtaining 2 clones from at least 4 lines.</p>\n<p><sup>2</sup> Single T175 flask of undifferentiated iPSCs can produce &gt;60 million neural progenitors (12 vials at 5 million cells/vial).</p>\n<h2>Specific Aim 2. Generation of the isogenic iPSCs and analysis of WGS data from all lines used in the study to test hypothesis that distinct PD mutations cause different cellular disease states</h2>\n<p>Generation of isogenic disease lines for Specific Aim 4 is necessary to test whether replacing an endogenous mutation with another PD-associated mutation will alter the cell phenotype to that of the inserted gene proving that the disease process is solely driven by the causative mutations. Such cells are currently unavailable, and our strategy is to take advantage of any ASAP efforts to generate isogenic iPSC lines, if possible, or to use one of two professional commercial service providers (Horizon Discovery or CensoBio) or a non-profit facility (StemCore) to ensure feasibility. While no prior work, to our knowledge, has tested this hypothesis, there is some evidence that removing a mutation in a genetic iPSC line alters the presence of abnormal proteins found in the diseased parental line [11,12].</p>\n<p>The genes we propose to change in these iPCSs (i.e., correct one gene and insert a mutation in another) are based on their robust neuropathological presentation and on careful consideration of the feasibility of the gene editing work. The editing strategy for <em>PRKN </em>(two alleles affected commonly with gene segment deletions) is more complex than for <em>SNCA </em>or <em>LRRK2 </em>(single allele point mutations), and gene editing for two allele correction intrinsically bares more risks and has lower success. We will therefore, correct a <em>PRKN </em>allele with only a point mutation and insert a second copy of <em>PRKN </em>cDNA after a 2A peptide in the same allele, leaving the other <em>PRKN </em>allele unaltered. This gives a reasonably high chance of generating iPSCs with a normal <em>PRKN </em>gene dosage, as confirmed by two professional CRO&rsquo;s specialized on this technology. Isogenic control and disease IPSCs will be differentiated into both midbrain and cortex types (neurons and astrocytes) using SA1 protocols (Fig. 1) and phenotyped using Table 2 readouts.</p>\n<p><em>SNCA</em>-to-<em>PRKN </em>and <em>LRRK2</em>-to-<em>PRKN </em>editing will give us the possibility to show that the respective protein aggregation phenotype (aSyn and Tau) as well as spread of pathology to cortical cell types will be avoided, while the neuron loss phenotype will be retained. <em>LRRK2</em>-to-<em>SNCA</em><em> </em>mutation editing will probe whether a tau dominant pathology can be replaced with an aSyn dominant feature &ndash; a relevant readout for both cortical and DA neuron types. Finally, <em>PRKN</em>-to-<em>SNCA </em>editing should induce protein aggregation in cells that would not have this presentation and extend the pathology to a cell type that would otherwise be spared. All cell lines will undergo WGS using our published protocols on total genomic DNA to verify that no PD gene specific abnormalities have been introduced during reprogramming, mitigating against the risk of unintended off-target alterations [13]<sup>3</sup>.</p>\n<p>The third activity in SA2 will be to generate a unified, interactive database for all data we will generate in the course of this project on the cell lines, including their WGS data (with annotations for all known PD- associated genes), <em>in vitro </em>and <em>in vivo </em>characterization. This task will be a unique contribution by Johnston/NysnoBio with the objective of establishing an interactive user interface with an artificial intelligence learning algorithm based on the oncology database CanSar (cansarblack.icr.ac.uk) which has successfully amassed multi-dimensional data from hundreds of cancer cells lines to obtain detailed information about specific cell line activity. The database will be built in two stages, where Stage 1 is the implementation of the framework of the database and user interface along with the AI algorithm for data analysis. In Stage 2, we will input the yearly clinical progression information as UPDRS (actual video assessment will remain anonymous), genomic sequence, biomarker data, 3D structural analysis, and mutational analysis for each cell line. Our larger goal would be to assemble data not only on the lines we select to study here but on all commonly used cell lines from the PPMI and other repositories.</p>\n<p><sup>3</sup> Through the PPMI and AMP-PD web portals, we have access to WGS data for the <em>SNCA </em>and <em>LRRK2 </em>lines performed on DNA extracted from PBMCs but will generate WGS data for our PRKN fibroblast lines for comparison. All WGS for iPSC lines will be done as part of the present project.</p>\n<h2>Specific Aim 3. An <em>in vivo </em>xeno-grafting approach to model and test the specificity of dopamine and cortical neuron pathologies related to PD clinical cohorts with distinct genetic mutations</h2>\n<p>Cryopreserved preparations of either 1) vmDA or 2) cortical progenitors (detailed in Fig. 1) will be thawed and prepared for grafting as previously described [10]. Single deposits will be implanted as 100,000 cells in 1ul into either the striatum (vmDA progenitors) or cortex (cortical progenitors) of adult athymic mice. We have extensive experience in the specific housing requirements for long-term experimentation using immune- compromised rodents [14,15,16] (see e.g. in Fig 2 of SNCA triplication iPSC-derived vmDA neurons 6 months after transplantation in athymic mice). To reduce the total number of animals as well as the workload for post- mortem analysis, animals will be grafted bilaterally, receiving a cortical graft in one hemisphere and vmDA graft in the contralateral striatum.</p>\n<p>For each of the three PD-associated genetic backgrounds, separate cohorts of 10 animals each will be grafted in Melbourne for histology (FINMH) and Lund for biochemical (LU) readouts (Table 2) using the same cryopreserved batch of the corresponding cell line following QC validation in SA1 (n=3). Each of these experimental &lsquo;disease&rsquo; cohorts will consist of 3 iPSC lines from 3 separate clinical cases representing the PD- associated genetic mutation (e.g. <em>SNCA</em>_A53T) and 2 wild-type control lines (5 groups in total) generating 72 mice per cohort for each of 3 genetic backgrounds investigated in each of the two locations (432 total) performed over approx. 18 months period, assuming a 10% attrition rate. To allow for extensive synaptic integration and functional maturation of grafted neurons <em>in </em><em>vivo </em>[17], which we hypothesize will reveal aspects of pathology not attainable in conventional <em>in vitro </em>approaches, grafted animals will be taken out to 6 months and disease cohorts will be staggered to facilitate capacities for housing and tissue processing as shown in the Gantt Chart (see Project Timelines and Milestones on page 6 for a Flow Chart and inter-dependencies between tasks). Neuronal subtypes will be verified in the Thompson Lab using phenotypic markers (Table 2). Pathological readouts will include abnormal protein biochemistry (established protocols [18,19,20]) and histology as well as markers for cell death and inflammation (Table 2). To identify single cell transcriptome changes we will use NanoString nCounter barcoding technology on the histological sections. This technology enables spatially resolved, digital readout of &gt;1000 RNA targets in a multiplexed assay and with single cell resolution giving us a unique ability to map the transcriptional signature of the grafted mature human cells.</p>\n<h2>Specific Aim 4. An <em>in vivo </em>xeno-grafting approach to model and test the replacement of one PD mutation for another to alter the specific disease phenotypes to those of the inserted gene mutations</h2>\n<p>Work under SA3 will provide us with the first insights into key neuropathological readouts of the 3 PD-associated gene mutations. The next step will be to assess the gene edited iPSC lines (generated as part of SA2 above) for cell phenotype conversion in the xeno-grafts. Before the end of year 2, we expect to have obtained at least 1 successful edited line for each condition defined above (4 lines in total) and potentially also isogenic controls (3 lines in total). To establish cell phenotype conversion <em>in </em><em>vivo</em>, grafting experiments following the SA3 protocols will be performed in Lund with Table 2 readouts.</p>\n<h2>Specific Aim 5. An <em>in vivo </em>xeno-grafting approach to model and test the expression of PD causing mutations in astrocytes as contributors to neuronal PD pathologies</h2>\n<p>Even though more astrocytes have increased aSyn in PD affected regions than neurons, and a single type of astrocyte is involved [6,7], there is limited data on the pathobiology of different types of astrocytes with causal PD mutations and whether the type of astrocyte involved contributes to the neuronal disease phenotypes described. To establish astrocyte subtype and PD-mutation specific phenotypes, astrocyte precursors (generated as part of SA1) will be matured to undergo Table 2 readouts. To test whether astrocyte-derived proteins are sufficient to cause neuronal PD pathology, 3 sets of grafting experiments will be performed in FINMH using the SA3 transplant system. The astrocytes and neuronal cell lines identified in culture that have the most significant PD cell pathology will be used (see Fig 3 for a mixed neuron-astrocyte grafts generated <em>in vivo </em>from human iPSCs). For these experiments, our objective is to co-graft neuroblasts and astrocytes at the same site in the mouse brain to obtain equivalent numbers of mature astrocytes and neurons at 6 months. We will first show that grafted PD-affected astrocytes are sufficient to cause neuronal PD pathology in co-grafted isogenic control neurons. Second, we will determine whether grafted PD-affected astrocytes accelerate PD pathology in co-grafted PD-affected neurons and, if necessary, perform additional experiments to find out if the onset of pathology is earlier or the time course remains unaltered, but the severity is increased. While in the first instance, we can test the same gene mutation in both cell types and look for acceleration of the neuronal pathology in the grafts, based on the results we obtain up to this point, we will be able to judge if we can derive conclusive data from any combination of mutations as well (e.g., <em>SNCA </em>mutation carrying astrocytes co-grafted with <em>PRKN </em>KO neurons or vice versa). Finally, the reverse experimental design will determine whether grafting isogenic control astrocytes will rescue PD pathology in co-grafted PD-affected neurons and, if at all possible extend the survival period of the experiment to 9-12 months to show robustness (although this would inevitably go beyond the project period for this grant).</p>\n<h1>Power Calculations and Statistical Analyses&nbsp;</h1>\n<p>The total number of cells surviving in each graft varies considerably within groups (typical range for graft volumes could be from 2 &ndash; 12 mm<sup>3</sup>) however the cell numbers (e.g., TH-positive neurons defined as % of total neurons in the graft) is more tightly controlled (consistently between 5-8% of all grafted cells) and is a better measure to demonstrate the effect we are studying. Using this parameter, we have sufficient power (0.9) to show differences between groups for an effect size of 0.23 at an alpha level of 0.05 in an experiment with 5 groups and 2 response variables analyzed by MANOVA.</p>\n<h1>Project Timeline and Milestones&nbsp;</h1>\n<p>Please see workflow schematic for details.&nbsp;</p>\n<p>M1. Database creation and testing completed (Year 1)</p>\n<p>M2. <em>In vitro </em>differentiation capacity of all lines completed, lines for grafting selected and banked (Year 1)</p>\n<p>M3. WGS analysis of all iPSC and gene-edited lines are completed (Year 2)</p>\n<p>M4. Level 1 analysis of WGS, clinical data and <em>in vitro </em>characterization work completed</p>\n<p>M5. <em>In vivo </em>assessment of SNCA, LRRK2 and PRKN iPSC-derived neuronal pathology completed (Year 2)</p>\n<p>M6. Characterization of pathological signatures in gene-edited iPSC derived neurons and astrocytes (Year 3)</p>\n<p>M7. Effect of PD-associated gene expression in astrocytes on neuronal pathology characterized (Year 3)&nbsp;</p>\n<p>M8. Level 2 analysis including all <em>in </em><em>vivo </em>outcomes completed</p>\n<h1>Workflow Schematic&nbsp;</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/562cc6bc-ec8e-4778-8d66-f6f52f8560f3/kirik-wf-image-pt-2.png\" alt=\"Kirik_WF Image pt 2\" width=\"1011\" height=\"248\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Doherty KM, Silveira-Moriyama L, Parkkinen L, Healy DG, Farrell M, Mencacci NE, Ahmed Z, Brett FM, Hardy J, Quinn N, Counihan TJ, Lynch T, Fox ZV, Revesz T, Lees AJ, Holton Parkin disease: a clinicopathologic entity? JAMA Neurol. 2013 May;70(5):571-9. doi: 10.1001/jamaneurol.2013.172.</li>\n<li>Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4078-83. doi: 10.1073/pnas.0737556100.</li>\n<li>Narendra D, Tanaka A, Suen DF, Youle Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008 Dec 1;183(5):795-803. doi: 10.1083/jcb.200809125.</li>\n<li>Nussbaum RL. Genetics of Synucleinopathies. Cold Spring Harb Perspect Med. 2018 Jun 1;8(6):a024109. doi: 10.1101/cshperspect.a024109.</li>\n<li>Henderson MX, Sengupta M, Trojanowski JQ, Lee VMY. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's Acta Neuropathol Commun. 2019 Nov 16;7(1):183. doi: 10.1186/s40478-019-0836-x.</li>\n<li>Braak H, Sastre M, Del Tredici Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol. 2007 Sep;114(3):231-41. doi: 10.1007/s00401-007-0244-3.</li>\n<li>Song YJ, Halliday GM, Holton JL, Lashley T, O'Sullivan SS, McCann H, Lees AJ, Ozawa T, Williams DR, Lockhart PJ, Revesz TR. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein J Neuropathol Exp Neurol. 2009 Oct;68(10):1073-83. doi:10.1097/NEN.0b013e3181b66f1b.</li>\n<li>di Domenico A, Carola G, Calatayud C, Pons-Espinal M, Mu&ntilde;oz JP, Richaud-Patin Y, Fernandez-Carasa I, Gut M, Faella A, Parameswaran J, Soriano J, Ferrer I, Tolosa E, Zorzano A, Cuervo AM, Raya A, Consiglio Patient-Specific iPSC- Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease. Stem Cell Reports. 2019 Feb 12;12(2):213-229. doi: 10.1016/j.stemcr.2018.12.011.</li>\n<li>Shi, , Kirwan, P., Smith, J., Robinson, H.P., and Livesey, F.J. (2012). Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci 15, 477-486, S471.</li>\n<li>Niclis JC, Gantner CW, Alsanie WF, McDougall SJ, Bye CR, Elefanty AG, Stanley EG, Haynes JM, Pouton CW, Thompson LH, Parish Efficiently Specified Ventral Midbrain Dopamine Neurons from Human Pluripotent Stem Cells Under Xeno-Free Conditions Restore Motor Deficits in Parkinsonian Rodents. Stem Cells Transl Med. 2017a Mar;6(3):937- 948. doi: 10.5966/sctm.2016-0073.</li>\n<li>Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE, Muffat J, Mitalipova M, Pluth MD, Jui NT, Sch&uuml;le B, Lippard SJ, Tsai LH, Krainc D, Buchwald SL, Jaenisch R, Lindquist Identification and rescue of &alpha;-synuclein toxicity in Parkinson patient-derived neurons. Science. 2013 Nov 22;342(6161):983-7. doi: 10.1126/science.1245296.</li>\n<li>Ryan SD, Dolatabadi N, Chan SF, Zhang X, Akhtar MW, Parker J, Soldner F, Sunico CR, Nagar S, Talantova M, Lee B, Lopez K, Nutter A, Shan B, Molokanova E, Zhang Y, Han X, Nakamura T, Masliah E, Yates JR 3rd, Nakanishi N, Andreyev AY, Okamoto S, Jaenisch R, Ambasudhan R, Lipton SA. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1&alpha; transcription. Cell. 2013 Dec 5;155(6):1351-64. doi: 1016/j.cell.2013.11.009.</li>\n<li>Kumar KR, Davis RL, Tchan MC, Wali GM, Mahant N, Ng K, Kotschet K, Siow SF, Gu J, Walls Z, Kang C, Wali G, Levy S, Phua CS, Yiannikas C, Darveniza P, Chang FCF, Morales-Brice&ntilde;o H, Rowe DB, Drew A, Gayevskiy V, Cowley MJ, Minoche AE, Tisch S, Hayes M, Kummerfeld S, Fung VSC, Sue CM. Whole genome sequencing for the genetic diagnosis of heterogenous dystonia Parkinsonism Relat Disord. 2019 Dec;69:111-118.</li>\n<li>Somaa FA, Wang TY, Niclis JC, Bruggeman KF, Kauhausen JA, Guo H, McDougall S, Williams RJ, Nisbet DR, Thompson LH, Parish Peptide-Based Scaffolds Support Human Cortical Progenitor Graft Integration to Reduce Atrophy and Promote Functional Repair in a Model of Stroke. Cell Rep. 2017 Aug 22;20(8):1964-1977. doi: 10.1016/j.celrep.2017.07.069.</li>\n<li>Niclis JC, Gantner CW, Hunt CPJ, Kauhausen JA, Durnall JC, Haynes JM, Pouton CW, Parish CL, Thompson A PITX3- EGFP Reporter Line Reveals Connectivity of Dopamine and Non-dopamine Neuronal Subtypes in Grafts Generated from Human Embryonic Stem Cells. Stem Cell Reports. 2017b Sep 12;9(3):868-882. doi:10.1016/j.stemcr.2017.08.002.</li>\n<li>Gantner CW, de Luzy IR, Kauhausen JA, Moriarty N, Niclis JC, Bye CR, Penna V, Hunt CPJ, Ermine CM, Pouton CW, Kirik D, Thompson LH, Parish CL. Viral Delivery of GDNF Promotes Functional Integration of Human Stem Cell Grafts in Parkinson's Disease. Cell Stem Cell. 2020 Apr 2;26(4):511-526.e5. doi:10.1016/j.stem.2020.01.010.</li>\n<li>Niclis JC, Turner C, Durnall J, McDougal S, Kauhausen JA, Leaw B, Dottori M, Parish CL, Thompson Long-Distance Axonal Growth and Protracted Functional Maturation of Neurons Derived from Human Induced Pluripotent Stem Cells After Intracerebral Transplantation. Stem Cells Transl Med. 2017c Jun;6(6):1547-1556. doi: 10.1002/sctm.16- 0198.</li>\n<li>Landeck N, Hall H, Ardah MT, Majbour NK, El-Agnaf OM, Halliday G, Kirik A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Mol Neurodegener. 2016 Aug 22;11(1):61. doi: 10.1186/s13024-016-0125-0.</li>\n<li>Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, Montezinho LP, Poole S, Safieh- Garabedian B, Tokuda T, Teunissen CE, Berendse HW, van de Berg WD, El-Agnaf Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Mol Neurodegener. 2016 Jan 19;11:7. doi: 10.1186/s13024-016-0072-9.</li>\n<li>Kang UJ, Boehme AK, Fairfoul G, Shahnawaz M, Ma TC, Hutten SJ, Green A, Soto Comparative study of cerebrospinal fluid &alpha;-synuclein seeding aggregation assays for diagnosis of Parkinson's disease. Mov Disord. 2019 Apr;34(4):536- 544. doi: 10.1002/mds.27646.</li>\n</ol>\n<p>&nbsp;</p>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:16Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "Parkinson5D: Deconstructing Proximal Disease Mechanisms across Cells, Space, and Progression"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>PROJECT SUMMARY</h1>\n<p><strong> </strong>Genome-wide association studies (GWAS) have unequivocally linked thousands of noncoding variants to Parkinson&rsquo;s disease (PD). Why have these breakthroughs not uncovered the mechanism(s) of common, genetically complex PD? <strong>We do not know <em>how </em>GWAS variants cause neurodegeneration, <em>which </em>variants are causal, and <em>why </em>they impair some brain cells but not others. </strong>Overwhelming evidence shows that <em>cis</em>-regulation of transcription is the most likely mediator of disease risk, and that it is finely tuned by cellular and dynamic context. Here we will pinpoint the <em>causal gene(s) </em>(Fig. 1a- g, eGene) through which GWAS loci function in spatially barcoded, single brain cells (a-b) and, dynamically, over pseudotime (c, Stage) using single-nucleus expression Quantitative Trait Locus (eQTL) analysis. Putative causal genes will be tested mechanistically in cell- and stage-specific analyses <em>in vivo </em>in <em>Drosophila </em>avatars (f) and <em>in vitro </em>in human pluripotent stem cells (g). Moreover, we will identify the corresponding <em>causal </em>GWAS <em>variants </em>(eSNP; h-i) through allele-specific expression and CRISPR/Cas9-variant editing in single brain cells. Our collaborative and highly integrated project will begin to reveal the complex human genetics of PD through a dynamic, five-dimensional view of proximal cellular mechanisms across brain cells (1D), brain space (3D), and disease stage (1D).</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/51ca861f-f212-485b-8737-c0d1ec5dcfac/workflow-schematic.jpg\" alt=\"workflow schematic\" /></p>\n<h1>RATIONALE</h1>\n<p>Thousands of noncoding variants in ninety independent GWAS signals are linked to susceptibility for common, genetically complex PD<sup>1</sup>, which affects more than 7 million people around the world. The vast majority of these PD variants --- 98% --- are <em>noncoding</em>: located in introns and intergenic regions of genomic DNA that do not code for protein sequences. Very few GWAS signals coincide with Mendelian genes (e.g. <em>SNCA</em>, <em>LRRK2</em>). GWAS peaks for PD are broad (e.g. up to 2 million bp) with on average 34 genes <em>physically </em>localized under <em>each </em>peak, implicating a total of 3,104 genes. <strong>Regulation of transcription is the most likely proximal mechanism of noncoding disease variants</strong>. GWAS variants modulate transcription in preferential cell-types<sup>2,3</sup> through nearby or distal enhancer elements<sup>4,5</sup>, transcription factor binding sites, and alternative splicing. Therefore, variants manifest their effects more strongly in the cell type and state most relevant to a specific disease phenotype<sup>6</sup>. PD evolves dynamically through cellular, spatial, and temporal dimensions: from preferentially vulnerable catecholaminergic neurons in the brainstem to cortical neurons that are massively affected during advanced stages; with important roles emerging for astrocytes<sup>7,8</sup> and microglia<sup>9,10</sup>. It may take a decade from the onset of PD neuropathology until patients develop clinical symptoms and are finally diagnosed with PD<sup>11</sup>, but most prior work has been limited to patients with advanced neuropathology and massive nigral dopamine loss. Based on emerging evidence from our (<strong>Fig. 2</strong>; Nature Neuroscience, 2018<sup>12</sup> --- attached; <em>Science, </em>2017<sup>13</sup>; <em>Science Translational Medicine</em>, 2010<sup>14</sup>) and other groups<sup>4,5</sup> <strong>we hypothesize that most PD GWAS variants function through cell-, space-, and stage-dependent gene-regulatory mechanisms</strong><em>. </em>Our research will tackle the critical task of clarifying the precise mechanisms through which this recently identified wealth of genetic variation regulates onset and progression of PD.</p>\n<h1>PRELIMINARY STUDIES</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/66979d60-2d9b-4fec-9218-745e5f9ba352/figure2.jpg\" alt=\"Figure2\" /></p>\n<p>Fig.&nbsp; 2&nbsp; &amp;&nbsp; 3;&nbsp; and S1-S5 indicate pervasive <em>cis</em>-regulatory and cell type- specific mechanisms of PD GWAS variants using bulk RNAseq-based expression Quantitative Trait Locus (eQTL) analysis and <em>Drosophila </em>genetics. In 1,171 human brains expression of 185 Genes (eGenes) was <em>cis</em>-regulated by ninety PD-linked GWAS signals<sup>1</sup> with genome-wide significance and <em>P </em>values as low as 10<sup>-150</sup> (<strong>Fig. 2a</strong>). We confirmed <em>cis</em>- regulatory effects on <em>LRRK2 </em>and implicated a natural <em>SNCA </em>antisense transcript (<em>SNCA-AS</em>). We assigned novel gene-regulatory functions to 46.7% of the GWAS signals (42 of 90) indicating, that for many loci, the true causal gene may differ from the gene previously nominated chiefly based on physical proximity to the lead GWAS variant. Moreover, susceptibility loci were functionally much more complex than previously imagined with 36.7% affecting multiple coding and noncoding genes (<strong>Fig. 2a</strong>). In complementary functional analyses in a new, cell type-specific <em>Drosophila </em>model of <em>a</em>- synucleinopathy (<strong>Fig. S2</strong>) knockdown (KD) of the eGene&nbsp;&nbsp;&nbsp; <em>Gch1&nbsp;&nbsp;&nbsp; </em>(<strong>Fig.&nbsp;&nbsp;&nbsp; 2a</strong>)&nbsp;&nbsp;&nbsp; with&nbsp;&nbsp;&nbsp; transgenic RNAi specifically in neurons altered locomotion (Fig. 2b) and metabolism (2c), while knockdown of <em>Gch1 </em>in glia had no effect on <em>a</em>-synuclein (<em>a</em>-Syn) toxicity (1d). By contrast, glial-specific knockdown of the eGene <em>Rit2 </em>(<strong>Fig. 3</strong>) significantly impaired locomotion (Fig. 3b), enhanced <em>a</em>-Syn-induced degeneration of TH-positive neurons in a non-cell autonomous manner (3c), increased the number of <em>a</em>-Syn aggregates (3d).</p>\n<h1>STUDY PLAN, RESOURCES, RESEARCH TOOLS, AND MODELS</h1>\n<p>&nbsp;</p>\n<h2>1 - Systematically delineating the precise genetic mechanism of complex genetic variation in human PD across brain cells, brain space, onset and progression (Fig. 1a-e)</h2>\n<p>Gene expression is the most proximal function of the genome. We will reveal the precise proximal mechanisms of genetic disease variants at unprecedented scale and resolution in 645,000 single human brain cells from 100 midbrains and 100 temporal cortices --- representing more than sixteen highly distinct types of neurons, astrocytes, and microglia --- from healthy controls, from patients at the earliest, subclinical stages of PD neuropathology (henceforth prodromal PD; see below), and from patients with clinical PD. The <em>cis</em>-regulatory effects of GWAS variants associated with susceptibility from ninety independent GWAS signals<sup>1</sup> and emerging disease-variants linked to progression<sup>15,16</sup> will be assessed across cell types, brain space, and disease stages.</p>\n<p><strong>Cell types </strong></p>\n<p><strong>(Fig. 1a; Project 1 Scherzer)</strong></p>\n<p><strong> </strong>Single-nucleus RNAseq (snRNAseq) will be performed using experimental<sup>17,18</sup> and computational methods (e.g. Seurat<sup>19</sup>), which were co-invented by the Broad team<sup>20</sup>; and optimized for frozen human brains on the 10x Genomics Chromium platform in the Scherzer lab based on Refs.<sup>17,21,22</sup>. Our Preliminary Studies of cortex and midbrain (<strong>Fig. S1</strong>) of six controls and PD cases revealed 16 and 10 cell types, respectively, and a surprising diversity of dopamine neurons: We identified two fundamentally distinct types of dopamine neuron transcriptomes --- which likely represent preferentially PD-vulnerable substantia nigra pars compacta (SNpc; type 1) vs. more resistant ventral tegmental area (VTA) DA neurons --- with striking differences in expression modules including heat shock proteins<sup>23</sup> (Fig. S1a-c). Human midbrain glutamatergic and GABAergic neurons that are physiologically characterized in rodent midbrain<sup>24</sup>, but largely unstudied in humans were confidently detected (Fig. S1a-b). We will genotype PD GWAS variants in the brain samples <strong>using whole genome sequencing </strong>and the GATK pipeline<sup>25</sup>.</p>\n<p><strong>Space </strong></p>\n<p><strong>(Fig. 1b; Project 2 Levin, collaborator Regev with letter)</strong></p>\n<p><strong> </strong>Charting the spatial organization of cells along with their molecular features provides a powerful lens into tissue function and is a cornerstone of disease pathology. For example, determining whether these diverse types of midbrain neurons spatially localize to the most vulnerable subregions (e.g. SNpc) vs. more resistant subregions (e.g. VTA) in the midbrain is of critical interest. Moreover, the spatial connections between glia and neurons are critical for understanding the pathophysiology of PD. Furthermore, Lewy body-positive and -negative neurons are expected to differ and this will be determined by including anti-<em>a</em>-Syn immunostaining into our spatial analyses. We will use High-definition spatial transcriptomics (HDST)<sup>26</sup> as reported by the Broad team in Nature Methods, 2019<sup>26</sup> ( --- attached) with 2,893,865 fluorescently barcoded beads in an array of &gt;1.4 million wells on slides to achieve 2 &mu;m spatial resolution<sup>26</sup> --- higher than previous methods and not limited to pre- selected targets<sup>5&ndash;10</sup>. While HDST data per cell are relatively sparse, signals are highly specific, and this is overcome by computational integration with snRNAseq<sup>26</sup>.</p>\n<p><strong>Stage </strong></p>\n<p><strong>(Fig. 1c; collaborator Beach</strong>). 100 human midbrains (with vulnerable substantia nigra (SN) and more resistant ventral tegmental area (VTA)) and 100 temporal cortices each from 100 individuals spanning the entire spectrum of prodromal (<em>N </em>= 34) and symptomatic PD-Lewy body neuropathology (<em>N </em>= 33) as well as age-, sex-, PMI-, and RIN-matched controls (<em>N </em>= 33) will be assayed. This will be the first transcriptome-wide study of incipient, prodromal PD --- hard-to-find neurologically normal individuals, whose brain autopsy revealed hallmark PD neuropathology with <em>a</em>-Synuclein (<em>a</em>-Syn)-positive Lewy body Braak stages I-III<sup>27</sup> and reduction of dopamine markers<sup>28,29</sup> (also known as incidental Lewy body cases)<sup>28,29</sup>, although this is not without controversy<sup>30</sup>. The 100 brains with detailed ante-mortem (e.g. cognitive and motor scales) and postmortem neuropathology (e.g. a-positive Lewy body burden) are already available in the Banner brain bank with excellent RNA quality (median RNA Integrity Number of 8.9) and post-mortem intervals (PMI; median 3.0 hours). Rigorous inclusion/exclusion criteria as we reported in Ref.<sup>31</sup> include PMI &lt; 24 hours; high RIN &ge; 6; absence of brain tumor etc. Cases will be free of other neurologic diseases,e.g. without AD by NIA-Reagan criteria<sup>32</sup>; controls will be free of Lewy body neuropathology and any neurologic diagnosis.</p>\n<p><strong>Statistical analysis </strong></p>\n<p><strong>(Fig. 1d-e; Project 3 Dong, statistician Locascio)</strong></p>\n<p><strong><img src=\"https://cloud.squidex.io/api/assets/asap-hub/d8bcabc0-8fff-48c9-89b6-7e87d3251db1/table1.jpg\" alt=\"Table1\" /></strong></p>\n<p>The <em>cis</em>-regulatory effects on single-nucleus gene expression of 5,694 PD GWAS variants (with 20,364 proxy variants and emerging progression variants will be modeled for each cell type (<strong>Fig. 1d</strong>), spatially (<strong>Fig. 1e</strong>), and dynamically across disease stages (<strong>Fig. 1d</strong>) using a hierarchical, random and fixed effects model with zero-inflated Poisson distribution (5D-eQTL). Each nucleus will be indexed to a cell type <em>ct </em>(from snRNAseq as in <strong>Fig. S1</strong>), subregion <em>sr </em>(from HDST), brain region <em>r </em>(midbrain or temporal cortex), and subject <em>s</em>. <em>S </em>and <em>n </em>will be random terms, whereas <em>sr</em>, <em>r </em>and <em>ct </em>are fixed categorical variables with multiple categories in each. An initial model with a relatively saturated set of relevant predictor terms will be run, including important 2- and 3-way interactions of interest, e.g., <em>gt </em>x <em>sr </em>x <em>d</em>&hellip; Nonsignificant higher order terms will be removed one at a time until a model with significant predictor terms remains. Analyses will be adjusted for known (age, sex, batch, RIN, etc.) and latent covariates<sup>33</sup>. We will use permutation with scrambled labels to identify permutation-based <em>P </em>values allowing for both non-normality of the transcript data and linkage disequilibrium (LD) among the SNPs<sup>34</sup>. We will conservatively limit our analysis to <em>cis</em>-regulatory mechanisms for which our data are most powerful; we will progress to evaluating <em>trans</em>-effects in future goals using large- scale meta-analyses.</p>\n<p><strong>Significance</strong></p>\n<p><strong> </strong><em>P </em>values <em>&pound;</em><em> </em>the Bonferroni-threshold of 3.6 <em>&acute;</em><em> </em>10<sup>-8</sup> will be considered significant (e.g. 0.05 divided by the <em>actual </em>total number of unique 1.37 million SNP-gene pairs tested; e.g. ~15,000 SNP-gene pairs for each of 90 GWAS signals (representing ~34 genes x ~200-450 SNPs per GWAS signal)<sup>34</sup>. This is conservative as the number of independent tests is lower considering LD<sup>34</sup>. Regulatory trait concordance (RTC) analysis will be used to reveal the variant-transcript pair that best explains disease risk when accounting for local LD structure<sup>35</sup>. Power for sn-eQTL analysis is &gt;82.8%<strong> (Table 1) </strong>--- much higher than the 6.5% power afforded by bulk RNAseq of the same samples, because snRNAseq captures <em>thousands of individual cell transcriptomes per sample </em>compared to only one transcriptome per sample for bulk RNAseq. These eQTL data will be implemented in a scalable user-interface (which we term Open Genome Translator) that links GWAS variants to expression in spatially resolved single cells and reveals whether these eQTLs.</p>\n<p>Independent replication through cellular deconvolution of bulk RNAseq data of 964 human control cortices --- all with both RNAseq and genotyping data already available in the Scherzer lab. Cell type-like features (e.g. &ldquo;neuron-like&rdquo;,&rdquo;astrocyte-like&rdquo;, etc.) will be deconvoluted from the bulk RNAseq data and included in the eQTL analysis similar to Refs.<sup>36,37</sup>. <em>P </em>values <em>&pound;</em><em> </em>0.05 will be considered significant for replication. Replication power is &gt;99% for eQTLs for MAFs as low as 2% for one SD change; <em>a</em><em> </em>= 0.05; <em>N </em>= 964<sup>4</sup>.</p>\n<p><strong>Pitfall&nbsp;and solution</strong></p>\n<p><strong> </strong>eQTLs exclusively found in dopamine neurons (DA) cannot be deconvoluted from cortex, only shared eQTLs. However, DA-specific eQTLs will be replicated in already available lcRNAseq<sup>31</sup> data from DA laser-captured from &gt;130 human midbrains (initial batches published in Ref.<sup>31</sup>). Exploratory analyses will search for genetic effects on shifts in the proportions of cell types<sup>22,38</sup>, on cell sub-clusters (e.g. pro- inflammatory astrocytes), their spatial interactions, and their dynamic changes with progression. eGenes and implicated pathways (<strong>Fig. 3</strong>, Refs.<sup>12,14</sup>) that modify <em>a</em>-Syn toxicity in <em>Drosophila </em>(from P4) and hPSCs (from P5 below) will inspire iterative rounds of <em>in situ </em>examination in human brain cells, e.g. with RNA <em>in situ </em>hybridization<sup>22,38</sup>, sn-qPCR, tailored computational and experimental strategies as we reported<sup>12,14</sup>.</p>\n<p><strong>Expected results</strong></p>\n<p>We will discover and replicate novel eGenes through which GWAS loci function in spatially barcoded, single brain cells. Multiple GWAS loci will regulate more than one gene. We anticipate that 300 eGenes will reach genome-wide significance and these will be forwarded for mechanistic analyses</p>\n<h2>2 - Mechanistically testing putative causal GWAS genes in neurons and glia</h2>\n<p>See Fig. 1f-g</p>\n<p><strong>Project 4 (Feany) </strong>and <strong>Project 5 (Zhang) </strong>will exam these eGenes in a new <em>Drosophila </em>model of <em>a</em>-synucleinopathy and human pluripotent stem cells (hPSC). Tests will consider cell type and spatial interactions in both systems and disease progression over time in the fly model. Testing will start with a genetic screen in <em>Drosophila. </em>eGenes that significantly enhance or suppress <em>a</em>-Syn toxicity in <em>Drosophila </em>will be forwarded for detailed mechanistic dissection in both hPSCs and flies. We will begin our mechanistic testing immediately with the 185 current eGenes (<strong>Fig. 2</strong>), starting with two genes in the vesicle membrane/trafficking pathway (<strong>Fig. 3</strong>): <strong><em>BIN3 </em></strong>(top eQTL-<em>P </em>value of 10<sup>-150</sup>), a BAR domain protein<sup>39</sup> implicated in membrane bending, and <strong><em>RIT2</em></strong><em><sup>40</sup> </em>(a small GTPase that we already began to test in <em>Drosophila </em>(<strong>Fig. 3b-d</strong>). We expect that up to 300 eGenes (from Aim 1) meeting genome-wide significance during interim analyses at month 12, 24, 36 will be evaluated in Aim 2.</p>\n<p><strong>Genetic screen in the new <em>Drosophila </em>model of <em>a</em>-synucleinopathy </strong></p>\n<p><strong>(Fig. 1f; Fig. S2; </strong>and <strong>Neuron, 2018<sup>41</sup> --- attached</strong>) recently developed in the Feany lab. eGenes will be screened using locomotion and neurodegeneration assays and neuron- and glia-specific genetic engineering. The model relies on expression of human&nbsp; wild&nbsp; type&nbsp; <em>a</em>-Syn&nbsp; since&nbsp; the&nbsp; wild&nbsp; type&nbsp; protein is deposited in patients with PD and dementia with Lewy bodies, the most common <em>a</em>-synucleinopathies. Importantly, our model recapitulates key features of PD and related disorders, including age-related locomotor dysfunction, degeneration of dopaminergic neurons and robust aggregation of <em>a-</em>Syn (<strong>Fig. S1</strong>, Ref.<sup>41</sup>). In addition, we will utilize a dual bipartite expression system we have recently described to manipulate, independently and at scale, genes in neurons and glia (<strong>Fig. 1f</strong>)<sup>42</sup>. We will manipulate candidate gene expression <strong>in neurons </strong>(using the pan-neuronal <em>nSyb-GAL4 </em>driver) and glia (using the pan-glial <em>repo- GAL4 </em>driver) in flies expressing human <em>a</em>-synuclein in a pan-neuronal pattern (<em>nSyb-QF2 </em>driver). Our general approach will be to use DIOPT<sup>43</sup> to identify fly orthologs of human candidate genes. We have fly orthologs, RNAi lines, and mutants readily available for 86 of the initial eGene candidates. If more than one ortholog is identified, we will assess all strong orthologs. We will identify transgenic RNAi lines and overexpression strains, if available, for each locus. Two RNAi lines per locus will be assessed to ensure maximum coverage and mitigate off target effects. We will screen for modification of <em>a</em>-Syn toxicity using a simple and robust 1. &ldquo;movement exam&rdquo;, the locomotor assay<sup>41</sup> (Fig. S2b) and 2. verify their effect on neurodegeneration with neuron counting (Fig. S2c-e). Candidate genes and pathways passing these two screening tests with statistical significance will undergo a full neuropathology exam including quantification of dopaminergic neurodegeneration and <em>a</em>-synuclein aggregates (Figs. 3d, S2i). Our Preliminary Studies on eGenes <em>Gch1 </em>(Fig. 2b-d) and <em>Rit2 </em>(Fig. 3b-d) provide proof of principle for the proposed studies.</p>\n<h2>3 - Mechanistically dissecting eGenes and their pathways in <em>Drosophila </em>and hPSCs with cell type resolution</h2>\n<p><strong>See Fig. 1g</strong></p>\n<p><strong> </strong>eGenes significantly modifying <em>a</em>-synucleinopathy in the <em>Drosophila </em>model screen will be organized into tightly connected subnetworks (Dong; e.g. Fig. 3a; Ref.<sup>14</sup>), and then six eGenes will be prioritized for mechanistic dissection in hPSCs and flies, and second round-interrogation in human brain cells (see exploratory analyses above) based on five prioritization criteria: 1. Consistency, 2. Novelty, 3. Pathway convergence, 4. Cell type-specificity, and 5. Pathway tractability. 1. We require that the direction of the human eQTL and fly genetics are consistent (e.g. GWAS risk allele is associated with underexpression; KD causes neurodegeneration in the fly model; etc.). 2. We will overlay on these networks information from databases such as OMIM and DisGeneNet to focus on subnetworks that are not already known to be linked to PD. 3. We will identify networks that are regulated by multiple distinct GWAS loci and assess overlap with familial PD genes. For example, our initial data reveal that 17 GWAS peaks regulate 48 eGenes (including the familial gene <em>LRRK2</em>) in one vesicle membrane/trafficking pathway (<strong>Fig. 3</strong>). 4. We will include neuron- specific as well as glial-specific eGenes. 5. The selected candidates/pathways will also be evaluated for mechanistic tractability considering tools, and assays, and lists of drug targets from DGIdb<sup>44</sup>.</p>\n<p>Human pluripotent stem cells (hPSCs) derived midbrain dopamine neurons<sup>45</sup><strong> (Fig. S3), </strong>cortical glutamate neurons<sup>46</sup>, GABA interneurons<sup>47</sup> and region-specific astrocytes<sup>48,49</sup>will be engineered in the Zhang lab. We will use CRISPR-based technologies<sup>50</sup> to knockout (loss-of-function heterozygotes and homozygotes) and overexpress eGenes (e.g. knock-in CAG promoter-driven transgene in the AAVS1 locus) in the iPSC/Genome Editing Core at the Waisman Center established by Zhang. We will use iPSCs from 50- 60 year-olds differentiating the gene-edited and their isogenic iPSCs into the four cell types using our established methods<sup>50-52</sup>.</p>\n<p>In both <em>Drosophila </em>and hPSCs, we will start with standard assessments such as cell death, synapse number and activity, and <em>a</em>-Syn spread and aggregation. The density of synapsin (presynaptic) and PSD95 (post-synaptic) punctae on unit length of neurites, neurite length, as well as synaptic transmission will be measured advanced microscopy and electrophysiology<sup>49</sup>. Effects of glial-specific genetic manipulation on glia and neurons will be examined, particularly evaluating supportive roles for neuron function and neuroprotection (e.g. <strong>Fig. 2b-d</strong>), glial glutamate uptake, and lipid trafficking between glia and neurons<sup>49,53</sup>. We will then proceed to more specialized tests of particular relevance to PD and identified pathways such as vesicle membrane and trafficking, mitochondrial function<sup>14,41</sup>, and cytoskeletal alterations<sup>41</sup> and proceed to assays tailored to the implicated pathway. As a case in point, the Feany lab has recently shown that <em>a</em>-Syn binds to &szlig;-spectrin and thereby alters normal actin cytoskeletal dynamics and mitochondrial bioenergetics in flies<sup>41,54</sup> consistent with human brains transcriptomic data from the Scherzer lab<sup>14</sup>. We will delineate the cellular interactions using cell type-specific expression systems in flies and co-cultures in hPSC models (e.g., midbrain DA neurons + striatal GABA neurons; DA neurons + astrocytes) and neuron- and glia-specific drivers in flies. We will characterize phenotypic changes longitudinally in the fly model and in hPSC models, which will signal the roles of the candidate genes in the initiation and/or progression of the neurodegeneration (stage).</p>\n<p><strong>Statistical analysis</strong></p>\n<p>For behavior experiments at least 60 flies will be tested (6 biological replicates of 10 flies each)<sup>49</sup>. For metabolic, cell biological, and neuropathological analyses at least six fly brains and multiple hPSC lines will be assessed per genotype<sup>41</sup>. <em>P </em>&lt; 0.01 assessed with ANOVA and Tukey&rsquo;s post-hoc test with considered significant.</p>\n<p><strong>Sharing</strong></p>\n<p>All data, tools and protocols generated in this proposal will be rapidly and openly shared.</p>\n<h2>4 - Mechanistically testing putative causal GWAS variants in single brain cells <em>in vivo </em>and <em>in vitro </em></h2>\n<p>See Fig. 1h-i</p>\n<p>The putative causal, gene-regulatory GWAS variants (eSNPs) controlling the expression of the 300 expected eGenes (from Aim 1) will be investigated with three complementary approaches. 1. In cases where multiple eSNPs are implicated in <em>cis</em>-regulating the eGene, cell type-specific epigenetic features from in house (e.g. active enhancers)<sup>12</sup> and external databases (e.g. accessible chromatin from scATACseq<sup>55</sup> and sc-methylomes<sup>56</sup>) will be used to further characterize and rank variants for evaluation. 2. We will verify <em>cis</em>- regulatory effects <em>in vivo </em>in human brain cells with sn-ASE for all expected eGenes (Fig. 1h) in a cell type- specific manner. sn-ASE analysis will build on Levin&rsquo;s expertise in pioneering RNA-Seq protocols<sup>20</sup> such as single cell (Nature Biotechnology, 2020<sup>57</sup> --- attached), targeted, strand-specific, and 5&rsquo; RNAseq protocols<sup>58</sup>. sn-ASE pinpoints the precise effect of each disease-linked vs. reference <em>allele on allele-specific transcripts </em>per cell, while eQTL addresses <em>genetic effects on overall expression of a gene</em>. By evaluating sn- ASE within each cell, power is much higher as technical artifacts are controlled for<sup>59</sup>. Genotypes will be phased using WGS<sup>60</sup>. The same cDNA will be used as for sn-eQTL; R2C2<sup>61</sup> will improve sequencing accuracy. We will perform Nanopore PromethION sequencing and identify ASE as in Ref.<sup>62</sup>. In our pilot, PromethION was superior compared to GridION and Pacific Biosciences sequencers and ASE in a schizophrenia gene was highlighted in GABA interneurons (<strong>Fig. S4</strong>). 3. We will verify <em>cis</em>-regulatory effects <em>in vitro </em>using CRISPR/Cas9 to introduce the eSNPs in the four hPSC-derived brain cell types (Fig. 1i). We will initially evaluate one high-priority neuronal and one glial eSNP (using the same five Prioritization Criteria as in Aim 2) and scale-up during the 2-year extension phase. Expression of the corresponding <em>cis</em>-regulated eGene (using Nanostring and RNAseq) will be altered in eSNP-edited cells compared to those carrying the reference allele and this gene-regulatory mechanism will be most pronounced in the relevant cell type.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/f759cd4a-2d72-453d-b6ca-00c99414e4b7/figure3.jpg\" alt=\"Figure3\" /></p>\n<p><strong>Expected results</strong></p>\n<p><strong> Our collaborative and integrative project will translate the complex human genetics of PD into a dynamic, five-dimensional view of proximal cellular mechanisms.</strong> It will begin to reveal how single nucleotide variation in a person&rsquo;s universal DNA code regulates gene activity (without changing protein sequence) <em>in situ </em>in billions of physiologically specialized neurons and glia cells, and determines, how, when, which, and where brain cells are destined to malfunction. Specifically, our study will discover, replicate, and mechanistically characterize causal GWAS genes and cellular mechanisms in preferentially vulnerable brain cells --- <em>in situ </em>in patients&rsquo; brains, <em>in vivo </em>in <em>Drosophila</em>, and <em>in vitro </em>using hPSC genetics. It will pinpoint causal GWAS variants in the relevant human brain cells with single-nucleus allele-specific expression analysis and variant editing. It will develop new computational methods (5D-eQTL), new experimental methods (sn-ASE), new visualization tools (Open Genome Translator), and new genetic tools (engineered hPSCs and <em>Drosophila </em>lines relevant to common sporadic PD) that together will transform the open science of PD.</p>\n<h1>PROJECT TIMELINE AND MILESTONES</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/09551fa6-c570-4c98-8921-9fa92b69100c/timeline.jpg\" alt=\"Timeline\" /></p>\n<h1>WORKFLOW SCHEMATIC</h1>\n<p>Please see Figure 1</p>\n<h1>ADDITIONAL FIGURE</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/7833bdc7-daf5-4f3f-b8cb-ac943c712d9f/scherzer-additional-figure.png\" alt=\"Scherzer_Additional Figure\" width=\"935\" height=\"1157\" /></p>\n<h1>LITERATURE CITATIONS</h1>\n<ol>\n<li>Nalls M, Blauwendraat C. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <em>Lancet Neurology</em>. 2019; <strong>18</strong>: 1091-102.</li>\n<li>Consortium EP. An integrated encyclopedia of DNA elements in the human genome. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2012; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">489</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 57-74.</span></li>\n<li>Heintzman ND, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2009; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">459</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 108-12.</span></li>\n<li>Cookson W, et al. Mapping complex disease traits with global gene expression. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature reviews Genetics</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2009; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">10</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 184-94.</span></li>\n<li>Soldner F, et al. Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2016; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">533</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 95-9.</span></li>\n<li>Montgomery SB, Dermitzakis ET. From expression QTLs to personalized transcriptomics. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature reviews Genetics</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2011; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">12</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 277-82.</span></li>\n<li>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2017; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">541</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 481-7.</span></li>\n<li>Yun SP, et Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature medicine</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">24</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 931-8.</span></li>\n<li>&nbsp;Zhang W, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">FASEB J</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2005; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">19</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 533-42.</span></li>\n<li>Harms AS, et al. MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">The Journal of neuroscience. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">2013; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">33</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 9592-600.</span></li>\n<li>&nbsp;Savica R, et al. When does Parkinson disease start? <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Arch Neurol</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">67</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 798-801.</span></li>\n<li>Dong X, et al. Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature neuroscience</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">21</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 1482-92.</span></li>\n<li>Mittal S, et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Science</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2017; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">357</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 891-8.</span></li>\n<li>&nbsp; Zheng B, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Sci Transl Med</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2010; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">2</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 52ra73.</span></li>\n<li>Iwaki H, et al. Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Movement disorders. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">2019; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">34</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 1839-50.</span></li>\n<li>Ritz B, et al. alpha-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">PloS one</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2012; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">7</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: e36199.</span></li>\n<li>Habib N, et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature methods</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2017; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">14</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 955-8.</span></li>\n<li>Macosko EZ, et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2015; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">161</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 1202-14.</span></li>\n<li>&nbsp;Satija R, et al. Spatial reconstruction of single-cell gene expression data. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature biotechnology</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2015; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">33</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 495-502.</span></li>\n<li>Ximerakis M, et Single-cell transcriptomic profiling of the aging mouse brain. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature neuroscience</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2019; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">22</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 1696- 708.</span></li>\n<li>Tasic B, et al. Shared and distinct transcriptomic cell types across neocortical areas. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">563</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 72-8.</span></li>\n<li>Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">.</span></li>\n<li>Auluck PK, et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Science</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2002; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">295</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 865-8.</span></li>\n<li>Morales M, Margolis EB. Ventral tegmental area: cellular heterogeneity, connectivity and behaviour. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature reviews Neuroscience</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2017; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">18</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 73-85.</span></li>\n<li>Poplin R, et al. Scaling accurate genetic variant discovery to tens of thousands of samples. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">bioRxiv</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018:</span></li>\n<li>Vickovic S, et al. High-definition spatial transcriptomics for in situ tissue profiling. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature methods</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2019; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">16</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 987-90.</span></li>\n<li>Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiology of aging</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2003; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">24</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 197-211.</span></li>\n<li>Dickson DW, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Acta Neuropathol</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2008; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">115</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 437-44.</span></li>\n<li>DelleDonne A, et al. Incidental Lewy body disease and preclinical Parkinson disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Arch Neurol</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2008; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">65</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 1074- 80.</span></li>\n<li>Jellinger KA. Critical evaluation of the Braak staging scheme for Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Annals of neurology</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">67</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 550.</span></li>\n<li>Dong X, et al. Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature neuroscience</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018: accepted on July 19,</span></li>\n<li>Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neurobiology of aging</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 1997; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">18</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: S1-2.</span></li>\n<li>Parker HS, et Removing batch effects for prediction problems with frozen surrogate variable analysis. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">PeerJ</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2014; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">2</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: e561.</span></li>\n<li>Stranger BE, et al. Genome-wide associations of gene expression variation in humans. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">PLoS genetics</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2005; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">1</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">:</span></li>\n<li>&nbsp;Nica AC, et al. Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">PLoS genetics</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">6</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: e1000895.</span></li>\n<li>Donovan MKR, et al. Cellular deconvolution of GTEx tissues powers discovery of disease and cell-type associated regulatory variants. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature communications</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2020; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">11</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">:</span></li>\n<li>van der Wijst MGP, et al. Single-cell RNA sequencing identifies celltype-specific cis-eQTLs and co-expression QTLs. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature genetics</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">50</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 493-7.</span></li>\n<li>&nbsp; Jakel S, et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2019; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">566</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 543-7.</span></li>\n<li>Simunovic M, et Curving Cells Inside and Out: Roles of BAR Domain Proteins in Membrane Shaping and Its Cellular Implications. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Annu Rev Cell Dev Biol</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2019; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">35</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 111-29.</span></li>\n<li>Fagan RR, et al. Dopamine transporter trafficking and Rit2 GTPase: Mechanism of action and in vivo impact. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">J Biol Chem</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2020; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">295</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 5229-44.</span></li>\n<li>Ordonez DG, et al. alpha-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin<em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Neuron</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">97</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 108-24 e6.</span></li>\n<li>Olsen AL, Feany MB. Glial alpha-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Glia</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2019; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">67</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 1933-57.</span></li>\n<li>Hu Y, et al. An integrative approach to ortholog prediction for disease-focused and other functional studies. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">BMC bioinformatics</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2011; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">12</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">:</span></li>\n<li>Cotto KC, et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nucleic acids research</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">46</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: D1068-D73.</span></li>\n<li>Xi J, et Specification of midbrain dopamine neurons from primate pluripotent stem cells. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Stem cells</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2012; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">30</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 1655- 63.</span></li>\n<li>Li XJ, et al. Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Development</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2009; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">136</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 4055-63.</span></li>\n<li>Liu Y, et al. Medial ganglionic eminence-like cells derived from human embryonic stem cells correct learning and memory deficits. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature biotechnology</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2013; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">31</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 440-7.</span></li>\n<li>&nbsp;Krencik R, et al. Specification of transplantable astroglial subtypes from human pluripotent stem cells. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature biotechnology</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2011; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">29</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 528-34.</span></li>\n<li>Bradley RA, et al. Regionally specified human pluripotent stem cell-derived astrocytes exhibit different molecular signatures and functional properties. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Development</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2019; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">146</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">.</span></li>\n<li>&nbsp;Chen Y, et al. Engineering Human Stem Cell Lines with Inducible Gene Knockout using CRISPR/Cas9. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell stem cell</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2015; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">17</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 233-44.</span></li>\n<li>Wang L, et al. Tissue and cellular rigidity and mechanosensitive signaling activation in Alexander disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature communications</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">9</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">:1899</span></li>\n<li><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Weick JP, et al. Deficits in human trisomy 21 iPSCs and neurons. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Proceedings of the National Academy of Sciences of the United States of America</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2013; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">110</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 9962-7.</span></li>\n<li>Jones JR, et al. Mutations in GFAP Disrupt the Distribution and Function of Organelles in Human Astrocytes. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell reports</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">25</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 947-58 e4.</span></li>\n<li>Scherzer CR, et al. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Human molecular genetics</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2003; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">12</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 2457-66.</span></li>\n<li>Lake BB, et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature biotechnology</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">36</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 70-80.</span></li>\n<li>Luo C, et Single-cell methylomes identify neuronal subtypes and regulatory elements in mammalian cortex.<em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Science</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2017; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">357</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 600-4.</span></li>\n<li>Ding J, et al. Systematic comparison of single-cell and single-nucleus RNA-sequencing methods. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature biotechnology</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2020.</span></li>\n<li>Adiconis X, et al. Comprehensive comparative analysis of 5'-end RNA-sequencing methods. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature methods</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018;</span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">15</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 505-11.</span></li>\n<li>Edsgard D, et al. scphaser: haplotype inference using single-cell RNA-seq data. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Bioinformatics</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2016; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">32</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 3038-40.</span></li>\n<li>&nbsp;Castel SE, et al. Rare variant phasing and haplotypic expression from RNA sequencing with phASER. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature communications</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2016; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">7</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 12817.</span></li>\n<li>Volden R, et al. Improving nanopore read accuracy with the R2C2 method enables the sequencing of highly multiplexed full-length single-cell cDNA. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Proceedings of the National Academy of Sciences of the United States of America</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2018; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">115</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 9726-31.</span></li>\n<li>&nbsp;Mohammadi P, et al. Quantifying the regulatory effect size of cis-acting genetic variation using allelic fold change. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genome Res</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">. 2017; </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">27</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">: 1872-84</span></li>\n</ol>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:15Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": " IMPACT-PD: Implications of PolyAmine and GlucosylCeramide Transport for Parkinsons Disease"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1QJw3Vu1UaAx68oMenfY8U4pYvSHseybB/view?usp=sharing"
    },
    "adminNotes": {
      "iv": "Peter Vangheluwe, Tim Ahfeldt, Veerle Baekelandt, Joseph Lyons, Ellen Sidransky"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:15Z"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "Mapping the PD Brain: Oligomer-driven Functional Genomics"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>Project Summary</h1>\n<p>We aim to provide a comprehensive description of the genetic factors and biological processes that cause Parkinson&rsquo;s disease (PD). Our strategy involves 4 steps: <strong>(1) </strong>We will generate a map of the PD brain at nanoscale resolution using &alpha;-synuclein oligomers as early stage biomarkers; <strong>(2) </strong>By using &alpha;-synuclein oligomers as labels, we will single out affected cells at the earliest stages, and perform single-cell transcriptomics and genomics; <strong>(3) </strong>Using network theory and computational methods we will interrogate these data to reveal the genes and processes responsible for neuronal damage; and <strong>(4) </strong>We will validate the most relevant factors through induced pluripotent stem cell models. This project will create, and make freely available, the first oligomer map of the PD brain and the resulting genes and pathways. This unique resource will enable the community to develop new hypotheses, explore disease mechanisms and identify new therapeutic targets.</p>\n<h1>Rationale and Preliminary Data</h1>\n<p>The emerging genetic landscape of PD reveals that a progressive impairment of protein homeostasis underlies PD<sup>1-3</sup>. Growing evidence, including from our International Parkinson's Disease Genomics Consortium, shows that many of the known Mendelian and sporadic genetic risk factors perturb the complex balance of synthesis, folding, trafficking and clearance of proteins, which normally ensure proteome stability<sup>2,3</sup>. In particular, the aberrant aggregation of &alpha;-synuclein leads to the formation of Lewy bodies, which are mature assemblies that mark the end stage of the disease, whereas small diffusible oligomeric assemblies, known as oligomers, can be observed at the initial stages. These observations underlie our first hypothesis, that <strong>(1) &alpha;-synuclein oligomers are highly accurate biomarkers of early stage PD. </strong>Advances in cutting-edge microscopy methods enabled us to identify single molecules in brain tissue, and we adapted these methods to reveal the positions and form of individual &alpha;-synuclein oligomers in human brain <strong>(Fig. 1).</strong></p>\n<p><strong><img src=\"https://cloud.squidex.io/api/assets/asap-hub/383a8a59-4f0f-4155-868b-bc593214643c/wood-fig-1-wp1-.png\" alt=\"Wood_Fig 1 (WP1)\" width=\"938\" height=\"268\" /></strong></p>\n<p><strong>Figure 1. In WP1 we will use advanced microscopy methods to identify the positions and number of oligomers in different regions of the PD brain.</strong></p>\n<p><strong>&nbsp;</strong></p>\n<p>Describing the density and distribution of oligomers across the brain requires sufficient <strong>sensitivity </strong>to detect oligomers, and sufficient <strong>speed </strong>to cover 8 brain regions. We have selected two microscopy techniques that, in our laboratories, have the proven capability to image oligomers in the human brain,&nbsp;(i) our bespoke <em>single-molecule wide-field microscopy and (ii) the light sheet microscope</em>. The commercial LLS system from 3i uses a special objective pair, which affords the necessary sensitivity. It can be used in two modes: <em>tiling lattice light sheet (tLLS) on tissue blocks</em>, and <em>lattice light sheet (LLSM) on tissue sections</em>. Single molecule microscopy (used in WP2) is a highly sensitive approach but lacks the speed for surveying large amounts of tissue. This leads us to propose 3 microscopy approaches for WP1a.</p>\n<p>Our strategy is to generate the oligomer map in early PD brains, in which we observe a spatio-temporal gradient of brain pathology, and select regions at different stages of disease. This oligomer mapping will reveal the nanoscale staging of PD, leading to our second hypothesis, that <strong>(2) imaging individual oligomers can single out the small fraction of cells where disease processes are taking place. </strong>We will thus crucially increase the signal-to-noise ratio in transcriptomics studies by directing this technique to regions and single cells, affected at the early stages of the disease. Preliminary single-nucleus RNAseq (snRNAseq) data from post-mortem brain samples with synucleinopathies demonstrates: i) the feasibility and potential of this approach to generate &lsquo;omic profiles for all, including rare, cell types, and ii) the utility of combining single-cell and bulk-tissue RNAseq data for assessment of changes in cell type proportions (<strong>Fig. 2</strong>)<sup>4</sup>.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/f03e5f2f-6442-49c2-b0e9-368d81ed6fac/wood-fig-2-wp2-.png\" alt=\"Wood_Fig 2 (WP2)\" width=\"928\" height=\"362\" /></p>\n<p><strong>Figure 2. In WP2 we will perform transcriptomics and genomics on the oligomer-containing cells.</strong></p>\n<p><strong>&nbsp;</strong></p>\n<p>Together, this spatial and molecular map underlies our third hypothesis, that <strong>(3) transcriptomic and genomic analyses of oligomer-containing cells can reveal the genes and pathways responsible for the onset and progression of the disease. </strong>We will use a range of statistical genetic tools to distinguish between the molecular changes driving the pathology and those that are compensatory or responsive.</p>\n<p>&nbsp;</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/278ce143-44c5-4cd3-8a87-8fb28c714ba3/wood-fig-3-wp3-.png\" alt=\"Wood_Fig 3 (WP3)\" width=\"935\" height=\"388\" /></p>\n<p><strong>Figure 3. In WP3 we build a complex network of PD-related genes and processes using the data from WP1 and WP2.</strong></p>\n<p>&nbsp;</p>\n<p>We have successfully used regional gene expression, eQTL and co-expression network analyses (<strong>Fig. 3</strong>) to understand genetic risk data, and we will apply similar approaches in this proposal<sup>5</sup>. To complete our programme, we will validate the causative genes and pathways <em>in vitro </em>using our established human induced pluripotent stem cell synucleinopathy platform, which captures the key genetic factors that disrupt protein homeostasis to cause PD (<strong>Fig. 4</strong>). Interrogation of specific genes from the map in human cells using gene editing, single oligomer imaging, transcriptomics, and functional assays, will confirm their role in the protein homeostasis network. Overall, this interdisciplinary program will uncover the genetic factors and fundamental mechanisms underlying PD.</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/8d3075f9-6014-403a-b191-978d0ddf587f/wood-fig-4-wp4-.png\" alt=\"Wood_Fig 4 (WP4)\" width=\"954\" height=\"304\" /></p>\n<p><strong>Figure 4. In WP4 we will use iPSCs to validate the genes and processed identified in WP3.</strong></p>\n<h1>Research Tools, Models, and Resources</h1>\n<ul>\n<li><strong>Human brain tissue: </strong>The Gandhi lab and the UCL Queen Square Brain Bank have collected human post-mortem brain tissue from 22 control (C) and 22 Braak 3/4 PD individuals (mean disease duration&nbsp;11.75 yrs). Samples are matched for age (mean C:74 yrs, PD:79 yrs), post-mortem delay (mean C: 9.21 hrs; PD: 7.92 hrs) and pH (mean C: 6.30, PD: 6.35). The average RNA integrity number is 5.4. Tissue is microdissected from 8 Braak stage regions<sup>6,7</sup>: substantia nigra, caudate, putamen, cingulate cortex, parahippocampal cortex, temporal cortex, frontal cortex, and parietal cortex for the WP1a oligomer survey. Semi-quantitative immunohistochemistry is used to re-annotate the regions pathologically as &lsquo;severe&rsquo; (substantia nigra), &lsquo;moderate&rsquo; (putamen), &lsquo;mild&rsquo; (anterior cingulate cortex), or &lsquo;unaffected&rsquo; (parietal cortex), defining the 4 regions for WP1b and WP2. Existing label free quantitative mass spectrometry<sup>8</sup> provides unbiased large-scale protein profiling in all 8 brain regions, confirming a spatial biochemical gradient of &alpha;-synuclein pathology within each brain, enhancing the value of this well characterised sample set. 20 additional matched Braak stage 3/4 brains and controls have been resourced from UK brain banks.</li>\n<li><strong> </strong><strong>Microscopy: </strong>The Lee lab has a track record of developing new forms of single-molecule and super- resolution (SR) imaging, to probe protein oligomerization <sup>9,10</sup>, as well as building large-scale SR pipelines in brain<sup>11</sup>. 6 flexible and adaptable SR rigs, are capable of the analyses described in WP1, including spectral multiplexing, hydrophobicity (sPAINT)<sup>12</sup>, extended depth of field measurement (DH-PSF)<sup>13</sup> <em>b</em>- sheet content and structural order of oligomers<sup>14</sup> optical trapping and laser microdissection. The Lee lab has experience in custom analysis and quantification, critical to establishing class averages in large data sets. Open source analysis will be made publicly available via our online repositories (https://github.com/TheLeeLab)</li>\n<li><strong> </strong><strong>Genomics &amp; Transcriptomics: </strong>The Gandhi, Wood and Ryten labs utilise the Crick advanced sequencing facility and 10x platform for single cell RNAseq, single cell ATACseq and the 10x Visium spatial analyses (WP2). Bulk tissue RNAseq is performed at the UCL Genomics facility with access to an Illumina NovaSeq (WP2). Our collaborator network includes Dr. Rusty Nicovich (Allen Brain Atlas) to aid seqFISH, and Dr Ben Taylor (AstraZeneca) for expertise in MERFISH (WP4)</li>\n<li><strong> </strong><strong>Transcriptomics data processing pipelines: </strong>The RytenLab GitHub has made publicly available pipelines for quality control, covariate correction, splicing, annotation-independent quantification and cell type deconvolution methods (<u>https://github.com/SoniaRuiz/RytenLab_MVC</u>). snRNASeq data pipelines jointly developed between the Crick Bioinformatics &amp; Ryten Lab, include the generation of gene expression counts per cell, removal of doublets, imputation of missing values and unsupervised clustering for cellular subtype identification.<strong> </strong></li>\n<li><strong>Data integration pipelines: </strong>Integration of spatial information on oligomer location with transcriptomic data and finally genomic data on PD risk will be led by the Vendruscolo and Wood labs. With the growth in brain-relevant transcriptomic data and well-powered GWAS for neurological phenotypes<sup>2,3,15</sup>, we have driven the generation of multiple integration methods, and implemented pipelines for TWAS, MR-based methods, LDscore, SumHer, MAGMA and Coloc<sup>2,5,16</sup>.</li>\n<li><strong> </strong><strong>Induced pluripotent stem cells: </strong>9 iPSC lines from patients with SNCA mutations (A53T, A53E, G51D, SNCAx3, SNCA x2/x2), and isogenic controls (A53T, SNCAx3, G51D (in progress)) have been generated internally, or acquired, and validated for pluripotency, differentiation potential, and Directed differentiation into highly enriched cultures of cortical<sup>17</sup>, midbrain neurons<sup>18,19</sup>, astrocytes<sup>20</sup>, microglia<sup>21</sup>, and oligodendrocytes<sup>22</sup> is performed using internally adapted and validated protocols. Validation of differentiation is performed using RNAseq (for single cell &amp; bulk analyses, separately funded), and functional imaging and electrophysiology for cell maturity. RNAseq datasets on these SNCA lines will be made publicly available. iPSCs will be used for cross-validation.<strong> </strong></li>\n<li><strong>Designed antibody platform: </strong>We will use a recently developed antibody discovery method (Vendruscolo lab) based on rational <em>in silico </em>design<sup>23-26</sup>. This approach enables us to target specific regions of a given protein (i.e. the epitopes), by the fragment-based design of a peptide complementary to the target epitope, and its subsequence grafting on a complementarity-determining region (CDR) of a scaffold These designed antibodies (DesAbs) are already available for &alpha;-synuclein and amyloid<em>b</em><em> </em>oligomers<sup>26</sup>.</li>\n</ul>\n<h1>Study Plan</h1>\n<h2>WP1. An oligomer map of the PD brain.</h2>\n<p><strong>The aims are: (a) to define the regions and cells containing&nbsp;&alpha;-synuclein oligomers, and (b) to determine how they differ in health and disease.</strong></p>\n<p><strong>WP1a: First oligomer survey of the PD brain (~250 nm resolution): </strong>With high speed, single-oligomer sensitivity and diffraction-limited spatial resolution, we will generate an oligomer survey of the PD brain. We will characterise oligomer numbers and cellular location across 8 Braak stage regions from 20 PD and 20 age-matched control brains. In the last decade, light sheet microscopy has emerged as a powerful and versatile imaging tool<sup>27,28</sup> that can image samples ranging in size from single cells<sup>29</sup> to whole sections of cleared brain<sup>30</sup>. A recent further development, tilling Lattice light sheet (tLLS) uses both an optical lattice for increased resolution<sup>31</sup> and moves the sheet by focusing through the sample. tLLS is able to survey larger tissue samples and we have already demonstrated its use for single-oligomer resolution in human brain sections<sup>32</sup> (<strong>Fig. 1</strong>). We will initially use tLLS microscopy to rapidly generate a fast periodic diffraction-limited oligomer survey of tissue (<strong>Fig. 1</strong>), that can identify oligomers in individual cell types using cell markers: neurons (neurofilament, <em>b</em>-tubulin), astrocytes (GFAP, GLAST), microglia (Iba1, LN3) and oligodendrocytes (Olig2, NogoA, MOG).</p>\n<p><strong>WP1b: Oligomer fingerprinting with super-resolution imaging (~20 nm resolution): </strong>Using a range of multi-dimensional SR (md-SR) methods, we will determine oligomer sizes and morphologies, &beta;-sheet content, hydrophobicity and heterogeneity. We will thus define an oligomer fingerprint in 4 regions representing 4 disease stages of 20 early PD brains (severe: SN; moderate: putamen; mild: ant cingulate cortex; unaffected: parietal cortex), and 20 controls. The methodological toolkit of md-SR includes: <strong>i) md-SR: Spectral. </strong>We recently introduced sPAINT, a new spectrally-resolved SR fluorescence microscopy method<sup>12</sup>, with a spatial resolution of ~20 nm. We have already successfully applied sPAINT in recombinant &alpha;-synuclein aggregates and directly quantified 2 discrete hydrophobic states between oligomeric and fibrillar proteins<sup>27</sup>. <strong>ii) md-SR: Structural. </strong>We developed an all-optical fluorescence microscopy method to characterise the structure of individual protein-aggregates based on fluorescence anisotropy by a rotating linear-polariser mounted between the dichroic and the tube lens of the microscope<sup>31</sup> <strong>iii) md-SR: 3D intracellular locations. </strong>We developed a 3D SR microscope gaining axial information using the double-helix point spread function<sup>13,33</sup> and demonstrated the first example of its use in eukaryotic cell imaging of up to 20 &micro;m thick samples and tissue achieving 10-20 nm precision.</p>\n<h2>WP2: Single-cell functional genomics of the PD brain.</h2>\n<p><strong>The aim is to generate a functional genomics map using sequential tissue sections from the same samples in WP1. This map will enable oligomer features generated by WP1 to be associated with transcriptomic features within specific cell types to create a rich dataset for integrative analyses.</strong></p>\n<p>We will generate comprehensive &lsquo;omics data on 4 Braak stage regions sampled from 20 early PD (Braak stage 3/4) brains and 20 aged-matched normal brains (total samples = 160, as used in WP1a). These samples will be analysed using: i) spatial transcriptomics through the 10x Visium platform and higher resolution methods (MERFISH) ii) snRNAseq and snATACseq (10x Genomics platform), iii) bulk tissue RNAseq for splicing analyses, and iv) long-read RNAseq of <em>SNCA </em>transcripts using the PacBio platform. Using the 10x Visium platform, we will generate genome-wide, spatial transcriptomics data on tissue sections. For some genes or transcripts of interest, additional higher resolution spatial transcriptomics data will be generated using MERFISH, a fluorescence-based imaging method capable of simultaneously measuring the copy number and spatial distribution of multiple RNA species in single cells<sup>34</sup>. Sequential tissue sections will be used for snRNAseq, snATACseq, and paired bulk-tissue RNAseq data generation. The paired nature of the data will enable high quality deconvolution by cell type and so splicing analyses which account for disease-related changes in cell type proportions<sup>4</sup>. The remaining tissue sections will be used to analyse <em>SNCA </em>transcript usage through targeted long read RNAseq with the aim of identifying novel <em>SNCA </em>transcripts, and building on our recent analyses, which suggest the existence of an unannotated <em>SNCA </em>exon<sup>35</sup>.</p>\n<p><strong>Data-driven approach to guide the sampling for the oligomer map</strong></p>\n<p>Given the constraints on sample volume, imaging time and feasible coverage imposed by the technologies for oligomer mapping described above we have developed a data-driven approach to direct the sampling towards the most relevant regions for the onset and progression of PD from the outset of the project. To achieve this goal, we will build on existing public data, and our own data, to direct these analyses.</p>\n<ul>\n<li><strong><em> </em></strong><strong><em>Generation of additional snRNAseq datasets and analyses. </em></strong>As part of a pilot project, we have generated snRNAseq data using human post-mortem anterior cingulate cortex samples from non- neurological control individuals and those with Lewy body diseases. These data captured a range of cell clusters, including excitatory neurons (shown in coral), as well as inhibitory neurons (shown in green). We found that within this region of the brain there is significant heterogeneity in <em>SNCA </em>expression, such that excitatory neurons have high levels of <em>SNCA </em>expression, whilst inhibitory neurons have lower <em>SNCA </em> Importantly, our preliminary data also suggests that the cell types with the highest <em>SNCA </em>expression are likely to be the cell types predominantly lost in advanced PD (with dementia). Together these data suggest that the <em>SNCA </em>expression in certain cell types underlies the vulnerability of that cell type to disease.</li>\n</ul>\n<p>These approaches will enable us to: (i) select the brain region of greatest relevance, (ii) label the proposed cell type with the most specific markers, and (iii) define the oligomer burden, and the type of oligomers within the cell type of interest, and (iv) correlate that information with the paired transcriptomic data.</p>\n<p>&nbsp;</p>\n<h2>WP3: An integrated map of the PD brain.</h2>\n<p><strong>The aims are: a) to generate MapPD, a unique resource integrating the regional oligomer location and its cellular and transcriptomic context, and b) to prioritise the outputs of MapPD to identify molecular targets.</strong></p>\n<p><strong>WP3a: Generation of mapPD. </strong>We will: i) Extract the key features differentiating between oligomer quantity, nature and cellular/subcellular location in PD and control tissues from WP1; ii) Extract the key features differentiating between the transcriptomic architectures of PD and control tissues in specific cell types from WP2; iii) Integrate these higher level data features within a single descriptive map covering all brain regions analysed and accounting for cellular location; and iv) Use these higher level data features to generate a model defining the genomic response to oligomer load. The resulting gene expression signatures of oligomer load will be analysed to explore how they relate to known PD-specific, molecular and biological processes, i.e. what modulates <em>a</em>-syn oligomersiation and the corresponding cellular responses.</p>\n<p><strong>WP3b: Prioritisation of the outputs from MapPD to determine causality</strong>. We will leverage our current understanding of the genetics of PD to differentiate between cell type-specific transcriptome signatures, which drive pathogenesis versus those representing a response to the disease process. This set of analyses will be based on the assumption that pathways driving disease will be enriched for genes,&nbsp;which are associated either through common or rare genetic variation, with PD causation. Given that the PD GWAS has largely identified loci within non-coding genomic regions, this analysis will require a variety of bioinformatics and analytical tools to dissect and prioritize the genomic signals underlying the peaks identified in our large scale GWAS data (IPDGC and ASAP GP2) studies, and integrating these data with other functional data, such as GTEx, Braineac, eQTL, and mQTL. We will combine these analyses with approaches such as Coloc<sup>5</sup>, Mendelian randomization<sup>37</sup> and SMR<sup>2,38</sup> The output of WP3 will be a set of transcripts, genes and pathways of interest, which are both associated with high risk oligomers in specific cell types and for which there is a genetic basis for prioritisation.</p>\n<h2>WP4: Validation of cell-specific PD processes.</h2>\n<p><strong>The aims are: (a) to detect and validate key genes identified in WP3 in human cell models, and (b) to determine their causal mechanism.</strong></p>\n<p><strong>WP4a: Detection of key genes: </strong>We will generate the relevant cell types from the SNCA iPSC lines (<strong>Fig. 5</strong>) and deploy spatial approaches, such as MERFISH (<strong>Fig. 3</strong>), as well as interrogate existing single-cell and bulk RNAseq data sets of our SNCA lines, to confirm transcripts of interest. Detection of key proteins, including oligomeric proteins, will be performed with conformation specific DesAbs<sup>26</sup> (Vendroscolo lab), and commercially available antibodies. Using DesAbs with Exchange-PAINT<sup>38</sup>, multiple targets (eg cell type, oligomer type, and new targets) can be visualized simultaneously in cells. <strong>WP4b: Functional validation by gene editing: </strong>To achieve rapid, multiplexable and inducible genome editing in hPSCs, we will generate one control and one SNCA hPSC line with robust, doxycycline- inducible expression of Cas9 in the safe locus AAVS1 (iCas9-FL-BCP-hPSC). By transfecting iCas9 hPSCs with gRNAs targeting different genes, we will generate knockout hPSC lines for target genes with high efficiency. This platform may also be used for double- and triple-gene knockout hPSC lines in a single step. <strong>Downstream phenotypes. </strong>(a) <u>Cellular physiology: </u>The Gandhi lab has defined several mechanisms of oligomer-induced toxicity<sup>39</sup> in iPSC systems, including inflammation<sup>40</sup>, lipid metabolism<sup>41</sup>, mitochondrial function<sup>42</sup>, oxidative stress<sup>43</sup>, and impaired calcium signalling<sup>44</sup>. We will use single-cell fluorescence imaging techniques to study a range of cellular processes in gene-edited cell models, to understand the role of the WP3 target genes and their proteins in PD pathways. (b) <u>Protein</u> <u>aggregation: </u>We have developed a suite of single molecule and super resolution tools to quantify and characterise the structure of intracellular and extracellular protein aggregates, including the use of antibody DNA-PAINT<sup>42</sup>, aptamer-based PAINT<sup>45</sup> (<strong>Fig. 5</strong>), smFRET of labelled &alpha;-synuclein<sup>46</sup> in iPSC derived neurons. These tools will be applied to gene-edited cells to determine whether target genes affect the accumulation of oligomers in cells. (c) <u>Cell-cell interactions: </u>Once cell-specific subtypes that are crucial to disease are identified, we will establish relevant co-culture systems (neuron-astrocyte and neuron-microglia) <em>in vitro </em>and perform cross sectional, and longitudinal imaging<sup>20</sup> and transcriptional analyses (<strong>Fig. 5</strong>) under different co-culture conditions to define both cell autonomous and non-cell autonomous mechanisms of disease.</p>\n<p><strong>Risks and alternative strategies</strong>. <strong>WP1a. </strong>We have rapidly surveyed 3 tissue sections (146&times;106&times;28 &micro;m) in ~5 seconds (<strong>Fig. 1</strong>) using tLLS, (~61% sensitivity compared to single-molecule imaging). If necessary, we will reduce the size of the regions to be imaged, and augment these data with the md-SR data from WP1b. <strong>WP1b</strong>. We have mitigated risks of performing md-SR imaging in human brain, by proof-of- principle (<strong>Fig. 1</strong>) and published work<sup>9,10,11</sup>. An alternative strategy to SR <em>in situ </em>involves isolating oligomers from soaked brains prior to imaging.<sup>47</sup> <strong>WP2. </strong>The risk of access to post-mortem human brain tissue of sufficient quality to generate transcriptomic data is significantly reduced by our experience with: i) bulk tissue RNAseq data generation<sup>48,49</sup> ii) snRNAseq data generation on post-mortem brains<sup>4</sup> (<strong> 3</strong>), and iii) working with UK and international PD brain banks (with a further 26 Braak 3/4 PD brains identified). If tissue quality remains a concern, we will optimise sequencing protocols to improve data quality. <strong>WP3. </strong>If the tools based on gene co-expression network analysis prove insufficient to define the topology and individual components of the network, we will use more sophisticated methods, including network de-noising and enrichment, network motif identification, and pathway deregulation analysis<sup>50</sup>. <strong>WP4. </strong>Alternative genome-engineering approaches include working with (i) a dox-inducible NGN2 iPSC line with stable integration of dCas9-BFP-KRAB in CLYBL safe harbour locus<sup>51</sup> (collaboration with UCL DRI) (ii) OPTiKD (Crick gene editing platform) providing dose-responsive, and reversible gene knockdown by single-step genetic engineering&nbsp; of the AAVS1&nbsp; genomic safe harbor with an &nbsp;optimized tetracycline-responsive cassette driving one or more inducible short hairpin RNAs (shRNAs). Generation of OPTiKD hPSCs in commonly used culture conditions is simple (plasmid), rapid (2 weeks), and highly efficient (&gt;95%).</p>\n<h1>Power Calculations and Statistical Analyses Plan</h1>\n<p><strong>Oligomer sampling</strong>: Using SR microscopy in end stage PD frontal cortex, we measured 0.03 (<em>&plusmn; </em>0.01) oligomers/&micro;m<sup>3</sup>,&nbsp; &nbsp;therefore&nbsp; &nbsp;the&nbsp; &nbsp;total&nbsp; &nbsp;number&nbsp; &nbsp;of&nbsp; &nbsp;oligomers&nbsp; &nbsp;captured&nbsp; &nbsp;in&nbsp; &nbsp;the&nbsp; &nbsp;program&nbsp; &nbsp;will&nbsp; &nbsp;be&nbsp;~1*10<sup>12</sup>. Assuming a conservative 20% dynamic range in oligomer number across samples based on Lewy body pathology in PD <em>vs. </em>controls<sup>52</sup>, we determined a strong effect using Cohen&rsquo;s D=1.06, Glass&rsquo;&nbsp;=1.315, and Hedges g=9.8. Furthermore, these tests confirm that our sample effect and cohort size have sufficient power to detect statistically significant values for changes in oligomer density between PD and controls as low as 4%.</p>\n<p><strong>Cell-specific transcriptomics</strong>: For bulk RNAseq, assuming 20 samples/group, we will have 80% power to detect a 2-fold change in expression between groups at FDR 5% (assuming a minimum read count over prognostic genes of 10, a maximum dispersion of 0.2, the total number of genes tested is 15,000 and the top 300 genes are prognostic). For snRNAseq analysis, assuming 20 samples/group, and 5K nuclei/sample, we will have &gt;80% power to detect a subset consisting of 3% of nuclei sampled at FDR 5% (assuming mapping of &gt;90% of reads and classification of &gt;95% of nuclei to a major cell type).</p>\n<h1>Project Timeline and Milestones</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/8702eb3c-13b3-41ac-b41f-138ba5f4de50/wood-timeline-milestones.png\" alt=\"Wood_Timeline &amp; Milestones\" width=\"834\" height=\"331\" /></p>\n<h1>Workflow Schematic</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/17d76103-8f3b-43dc-b104-3c1ad00451f0/wood-workflow-schematic.png\" alt=\"Wood_Workflow Schematic\" width=\"782\" height=\"1051\" /></p>\n<h1>Literature Citations</h1>\n<ol>\n<li>Knowles TP, Vendruscolo M and Dobson CM. The amyloid state and its association with protein misfolding diseases. <em> Rev. Mol. Cell Biol. </em>15:384-396 (2014).</li>\n<li>Nalls MA <em>et al. </em>Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <em>Lancet Neurol</em>. 18:1091-1102 (2019).</li>\n<li>Nalls MA <em>et al. </em>Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&rsquo;s disease <em> Genet. </em>46, 989-993 (2014).</li>\n<li>Reynolds RH, Feleke R, Smith A, Tilley B, Hardy J, Matthews P, Gentleman S, Owen D, Johnson M, Srivastava P, Ryten Dysregulation of splicing in human brain from individuals with Lewy body disease informs disease mechanisms. ESHG 2020. Abstract</li>\n<li>Kia DA <em>et al. </em>Integration of eQTL and Parkinson&rsquo;s disease GWAS data implicates 11 disease genes. <em>BioRxiv </em>2019 doi: https://doi.org/10.1101/627216</li>\n<li>Braak, H. &amp; Del Tredici, K. Neuropathological staging of brain pathology in sporadic Parkinson&rsquo;s disease: separating the wheat from the chaff. <em>Journal of Parkinson's disease </em>7, S71-S85 (2017).</li>\n<li>Jellinger, A. A critical reappraisal of current staging of Lewy-related pathology in human brain. <em>Acta Neuropathol. </em>116, 1 (2008).</li>\n<li>Murray CE, Gami-Patel P, Gkanatsiou E, Brinkmalm G, Portelius E, Wirths O, et The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. Acta Neuropathol Commun.;6(1):62. (2018)</li>\n<li>Horrocks, M.H., Lee, S.F., Gandhi, S., Magdalinou, N.K., Chen, S.W., Devine, M.J., Tosatto, L., Kjaergaard, M., Beckwith, J.S., Zetterberg, H., Iljina, M., Cremades, N., Dobson, C.M., Wood, N.W., Klenerman, D. Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids. <em>ACS Chemical Neuroscience</em>, 7 (3), 399-406. (2016)</li>\n<li>Lee, J.-E., Sang, J.C., Rodrigues, M., Carr, A.R., Horrocks, M.H., De, S., Bongiovanni, M.N., Flagmeier, P., Dobson, C.M., Wales, D.J., Lee, S.F., Klenerman, Mapping Surface Hydrophobicity of &alpha;-Synuclein Oligomers at the Nanoscale. <em>Nano Letters</em>, 18 (12), pp. 7494-7501. (2018)</li>\n<li>Broadhead, M.J., Horrocks, M.H., Zhu, F., Muresan, , Benavides-Piccione, R., DeFelipe, J., Fricker, D., Kopanitsa, M.V., Duncan, R.R., Klenerman, D., Komiyama, N.H., Lee, S.F., Grant, S.G.N. PSD95 nanoclusters are postsynaptic building blocks in hippocampus circuits. <em>Scientific Reports</em>, 6, art. no. 24626, (2016)</li>\n<li>Bongiovanni, M.N., Godet, J., Horrocks, M.H., Tosatto, L., Carr, A.R., Wirthensohn, D.C., Ranasinghe, R.T., Lee, J.-E., Ponjavic, A., Fritz, J.V., Dobson, C.M., Klenerman, D., Lee, S.F. Multi-dimensional super-resolution imaging enables surface hydrophobicity mapping. <em>Nature Communications</em>, 7, art. no. 13544. (2016)</li>\n<li>Carr, A.R., Ponjavic, A., Basu, S., McColl, J., Santos, A.M., Davis, S., Laue, E.D., Klenerman, D., Lee, S.F. Three-Dimensional Super-Resolution in Eukaryotic Cells Using the Double-Helix Point Spread Function <em>Biophysical Journal</em>, 112 (7), pp. 1444-1454. (2017)</li>\n<li>Varela, J.A., Rodrigues, M., De, S., Flagmeier, P., Gandhi, S., Dobson, C.M., Klenerman, D., Lee, S.F. Optical Structural Analysis of Individual &alpha;-Synuclein Oligomers <em>Angewandte Chemie - International Edition</em>, 57 (18), pp. 4886-4890. (2018)</li>\n<li>Reynolds RH <em>et al. </em>Informing disease modelling with brain-relevant functional genomic annotations. <em>Brain </em>142:3694-3712 (2019).</li>\n<li>Reynolds RH, Bot&iacute;a J, Nalls MA, et al. Moving beyond neurons: the role of cell type- specific gene regulation in Parkinson's disease heritability. <em>NPJ Parkinsons Dis</em>. 2019;5:6. (2019)</li>\n<li>Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nature protocols.;7(10):1836-46. (2012).</li>\n<li>Little, D. <em>et al. </em>A single cell high content assay detects mitochondrial dysfunction in iPSC- derived neurons with mutations in SNCA. <em> Rep. </em>8, 9033 (2018).</li>\n<li>Kriks, S. <em>et al. </em>Dopamine neurons derived from human ES cells efficiently engraft animal models of Parkinson&rsquo;s disease. <em>Nature </em>480, 547&ndash;551 (2011).</li>\n<li>Hall, C. E. <em>et al. </em>Progressive motor neuron pathology and the role of astrocytes in a human stem cell model of VCP-related ALS. <em>Cell Rep. </em>19, 1739-1749 (2017).</li>\n<li>Garcia-Reitboeck P, Phillips A, Piers TM, Villegas-Llerena C, Butler M, Mallach A, et Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis. Cell Rep.;24(9):2300-11. (2018)</li>\n<li>Magnani D, Chandran S, Wyllie DJA, Livesey MR. In Vitro Generation and Electrophysiological Characterization of OPCs and Oligodendrocytes from Human Pluripotent Stem Cells. Methods Mol Biol. 2019;1936:65-77</li>\n<li>Sormanni P, Aprile FA and Vendruscolo Third generation antibody discovery methods: In silico rational design. <em>Chem. Soc. Rev. </em>47:9137-9157 (2018).</li>\n<li>Sormanni P, Aprile FA and Vendruscolo Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins. <em>Proc. Natl. Acad. Sci. USA </em>112:9902-9907 (2015).</li>\n<li>Aprile FA <em>et al. </em>Selective targeting of primary and secondary nucleation pathways in A<em>b</em>42 aggregation using a rational antibody scanning method. <em>Sci. Adv. </em>3:e1700488 (2017).</li>\n<li>Aprile FA <em>et al. </em>Rational design of a conformation-specific antibody for the quantification of A<em>b </em>oligomers. <em>Proc. Natl. Acad. Sci. USA</em>, in press.</li>\n<li>Huisken, J., Swoger, J., Del Bene, F., Wittbrodt, J. &amp; Stelzer, E. Optical sectioning deep inside live embryos by selective plane illumination microscopy. <em>Science </em>305, 1007-1009 (2004).</li>\n<li>Theer, P., Dragneva, &amp; Knop, M. &pi;SPIM: high NA high resolution isotropic light-sheet imaging in cell culture dishes. <em>Sci. Rep. </em>6, 32880 (2016).</li>\n<li>Kumar, A. <em>et al. </em>Using stage-and slit-scanning to improve contrast and optical sectioning in dual-view inverted light sheet microscopy (diSPIM). <em> Bull. </em>231, 26-39 (2016).</li>\n<li>Stefaniuk, M. <em>et al. </em>Light-sheet microscopy imaging of a whole cleared rat brain with Thy1-GFP transgene. <em> Rep. </em>6, srep28209 (2016).</li>\n<li>Chen, B.-C. <em>et al. </em>Lattice light-sheet microscopy: imaging molecules to embryos at high spatiotemporal resolution. <em>Science </em>346, 1257998 (2014).</li>\n<li>Fu, Q., Martin, B. L., Matus, Q. &amp; Gao, L. Imaging multicellular specimens with real- time optimized tiling light-sheet selective plane illumination microscopy. <em>Nat. Comm. </em><strong>7</strong>, 11088 (2016).</li>\n<li>Lew, M.D., Lee, S.F., Ptacin, J.L., Lee, M.K., Twieg, R.J., Shapiro, L., Moerner, W.E. Three-dimensional superresolution colocalization of intracellular protein superstructures and the cell surface in live Caulobacter crescentus <em>Proceedings of the National Academy of Sciences </em>(USA), 108 (46), pp. E1102-E1110. (2011)</li>\n<li>Chen, K.H., Boettiger, A.N., Moffitt, J.R., Wang, S., Zhuang, Spatially resolved, highly multiplexed RNA profiling in single cells Science, 348 (6233) (2015)</li>\n<li>Zhang D, et al. Incomplete annotation of OMIM genes is likely to be limiting the diagnostic yield of genetic testing, particularly for neurogenetic disorders. Science Advances, in press.</li>\n<li>Noyce AJ <em>et al. </em>Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. <em>PLoS Med. </em>14:e1002314 (2017).</li>\n<li>Noyce, S Bandres-Ciga, J Kim, Karl Heilbron, D Kia, G Hemani, A Xue, DA. Lawlor, G Davey Smith, R Duran, Z Gan-Or, C Blauwendraat, J. R Gibbs, 23andMe Research Team<sup>5</sup>, International Parkinson's Disease Genomics Consortium (IPDGC), DA. Hinds, J Yang, P Visscher, J Cuzick, H Morris, J Hardy, NW. Wood, MA. Nalls, AB. Singleton. The Parkinson's Disease Mendelian Randomization Research Portal. Mov Disord. Dec; 34(12): 1864&ndash;1872. (2019)</li>\n<li>Wang Y, Woehrstein JB, Donoghue N, Dai M, Avendano MS, Schackmann RCJ, et al. Rapid Sequential in Situ Multiplexing with DNA Exchange Imaging in Neuronal Cells and Tissues. <em>Nano Lett</em>.;17(10):6131-9. (2017)</li>\n<li>Choi ML, Gandhi S. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases. <em>The FEBS journal</em>.;285(19):3631-44. (2018)</li>\n<li>Hughes, C. D. <em>et al. </em>Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson&rsquo;s disease pathogenesis. <em>Acta Neuropathol.</em>, Jul;136(1):19-40(2018)</li>\n<li><em> </em>Angelova P, Choi ML et al. Alpha synuclein aggregation induces ferroptosis: an interplay of calcium, iron and lipid peroxidation. Cell Death and Differentiation (2020), <em>in press.</em></li>\n<li>Ludtmann, H. <em>et al. </em>&alpha;-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson&rsquo;s disease. <em>Nat. Comm. </em><strong>9</strong>, 2293 (2018).</li>\n<li>Deas, E. <em>et al. </em>Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease. <em> Redox Signaling </em><strong>24</strong>, 376-391 (2016).</li>\n<li>Angelova, P. R. <em>et al. </em>Calcium is a key factor in &alpha;-synuclein induced neurotoxicity. <em> Cell Sci.</em>, jcs. 180737 (2016).</li>\n<li>Whiten, R. <em>et al. </em>Nanoscopic characterization of individual endogenous protein aggregates in human neuronal cells. <em>ChemBioChem </em>(2018).</li>\n<li>Iljina M, Garcia GA, Horrocks MH, Tosatto L, Choi ML, Ganzinger KA, et Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. <em>Proc Natl Acad Sci </em>U S A. ;113(9):E1206-15. (2016)</li>\n<li>Hong, W., Wang, Z., Liu, W., O&rsquo;Malley, T.T., Jin, M., Willem, M., Haass, C., Frosch, M.P., Walsh, D.M. Diffusible, highly bioactive oligomers represent a critical minority of soluble A&beta; in Alzheimer&rsquo;s disease brain Acta Neuropathologica, 136 (1), pp. 19-40. (2018)</li>\n<li>Sibley CR, Emmett W, Blazquez L, et Recursive splicing in long vertebrate genes. <em>Nature</em>.;521(7552):371-375. doi:10.1038/nature14466 (2015)</li>\n<li>Guelfi S, D'Sa K, Bot&iacute;a JA, et Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information. <em>Nat Commun</em>. 2020;11(1):1041. Published 2020 Feb 25. doi:10.1038/s41467-020-14483-x (2020).</li>\n<li>Fu H, &hellip;, Vendruscolo M, Duff A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. <em>Nat Neurosci. </em>2019 Jan;22(1):47-56. doi: 10.1038/s41593-018-0298-7. Epub 2018 Dec 17.</li>\n<li>Tian R, Gachechiladze MA, Ludwig CH, Laurie MT, Hong JY, Nathaniel D, et al. CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons. <em>Neuron</em>. 2019;104(2):239-55 e12 (2019)</li>\n<li>Iacono, D., Geraci-Erck, M., Rabin, M.L., Adler, C.H., Serrano, G., Beach, T.G., Kurlan, R. Parkinson disease and incidental Lewy body disease: Just a question of time? <em>Neurology</em>, 85 (19)pp. 1670-1679. (2015)</li>\n</ol>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:14Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "The Genome-Microbiome Axis in the Cause of Parkinson disease: Mechanistic Insights and Therapeutic Implications from Experimental Models and a Genetically Stratified Patient Population"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>PROJECT SUMMARY</h1>\n<p>Glucocerebrosidase gene (GBA) mutations are found in 5-15% of Parkinson disease (PD) patients. Approximately 30% of those with GBA mutations develop PD. At present it is not known what other genetic or environmental factors may influence penetrance of GBA mutations to produce PD.</p>\n<p>The gut microbiome has been implicated in the generation and spread of alpha-synuclein (A-SYN) pathology and PD pathogenesis. The microbiome is an important source of inflammatory signals. Specialised enteroendocrine cells in the gut wall have a monosynaptic connection via the vagus nerve to the dorsal medulla. Injection of A-SYN fibrils into the gut wall results in ascent of A-SYN pathology to the brain, and overexpression of A-SYN in the midbrain causes long-distance protein transfer to the gut (1,2).</p>\n<p>We will use our cohort of GBA mutation positive and negative PD patients and carrier subjects as well as specific mouse and cell models, to investigate the role of the microbiome in PD risk/development, and the conversion of GBA mutation carriers to PD. We postulate that glucocerebrosidase and the microbiome could be targeted therapeutically to reduce this risk. This is an innovative integrated research program designed to provide insights into the interaction of genetic predisposition, the microbiome and immunological effects determining conversion to PD pathology. Our group comprises experts in PD pathogenesis, two new investigators Drs. Deleidi and Macnaughtan, the latter without previous experience of PD research, and a prominent group from France with expertise in the microbiome, specifically to bring novel scientific rigor to the study of the relationship of this component to PD pathology.</p>\n<h1>RATIONALE AND PRELIMINARY DATA</h1>\n<h2>Central question</h2>\n<p>How does genetic predisposition interact together with the microbiome and inflammatory signals to promote aggregation and spreading of A-SYN and hence induce PD pathology?</p>\n<p><strong>We propose the novel mechanism whereby the biochemical effects of GBA mutations interact with a specific microbiome signature to enhance the accumulation, aggregation and spread of A-SYN to precipitate PD pathology in a proportion of GBA carriers.</strong></p>\n<h2>Hypotheses</h2>\n<ol>\n<li><strong> </strong><strong>Clinical<em>, </em>biochemical, inflammatory and microbiome profiles </strong>identify those glucocerebrosidase mutation carriers who will most likely convert to</li>\n<li><strong> </strong><strong>Amyloid-forming proteins generated by the gut microbiome </strong>promote the aggregation and spread of A-SYN and inflammatory reactions and this effect is magnified by PD genetic risk factors such as glucocerebrosidase</li>\n<li><strong> </strong><strong>Modification of the microbiome and of GBA activity separately and together </strong>will influence PD risk in our genetically stratified population of GBA mutation</li>\n</ol>\n<p>A critical gap in our knowledge is why only some and not all GBA mutation carriers convert to PD, what determines that conversion, and whether factors modulating the effects of GBA mutations are also relevant to PD in general. In this application, we propose a novel and perhaps unconventional hypothesis that the gut microbiome plays an important role in this conversion from GBA carrier to PD patient. This idea is based on evidence linking GBA enzyme (GCase) activity to A-SYN pathology and the emerging data suggesting that A-SYN accumulation begins in the gut and spreads via the vagus nerve to the brain to cause PD.</p>\n<h2>The gut-brain axis is important in the pathogenesis of PD</h2>\n<p>Recent epidemiological and experimental studies strongly support the importance of the gut in PD pathogenesis. Data from experimental work include:</p>\n<ol>\n<li>Toxin-induced A-SYN changes, AAV-induced overexpression of A-SYN in the vagal system or injection of A-SYN pre-formed fibrils into the duodenum and pyloric muscle layer result in the spreading of aggregate A-SYN pathology following an ascending pattern; gut-to-brain transfer of this pathology can be prevented by transection of the vagus nerve (1, 3-6).</li>\n<li>Significant differences in A-SYN brain deposition and microgliosis have been reported in rats with different microbiota. In particular, increased brain A-SYN aggregation and neuroinflammation were observed in animals exposed to wild-type <em> Coli </em>as compared to animals exposed to <em>E. Coli </em>lacking csgBA and csgDEFG operons and therefore unable to produce the extracellular bacterial amyloid protein <strong>curli </strong>(7).</li>\n<li>In A-SYN overexpressing mice, gut microbiota affected motor deficits, microglial activation and A-SYN pathology (8). The parkinsonian effects of the microbiota in these mice were primarily due to curli-producing <em> Coli </em>and to the amyloidogenic properties of the CsgA protein (9). CsgA fibrils are the major component of extracellular curli fibrils.</li>\n<li>Multiple lines of evidence implicate the toll-like receptor (TLR) endotoxin-sensing pathways in PD pathogenesis (10-13).</li>\n</ol>\n<p>We will focus on specific mechanisms linking the microbiome to A-SYN pathology (e.g., discrete inflammatory pathways and A-SYN-curli interactions). <strong>We will investigate the possibility that GBA mutations and changes in the microbiome may not only work as independent risk factors but could act additively or synergistically on the development of PD pathology.</strong></p>\n<p>Microbiome studies in PD have been limited by small numbers, heterogeneity and no data on csgA- and curli-encoding bacterial genes. Importantly, all studies to date have been conducted in idiopathic PD without any genetic stratification. <strong>This project seeks to evaluate a well- defined cohort of patients carrying GBA mutations to determine the role of the microbiome in conversion of mutation carriers to PD. </strong>Microbiome genome-wide association studies will be performed and correlated with clinical and metabolomic end-points. The results of these studies will:</p>\n<ol>\n<li>&nbsp; &nbsp; Provide evidence for a unique interaction between genetic predisposition and the nature of an individual&rsquo;s gut microbiome to precipitate disease.</li>\n<li>Enable manipulation of the microbiome to reduce the risk and potentially prevent PD onset or progression, providing personalised medicine for this genetically stratified</li>\n</ol>\n<h2>Preliminary Data &ndash; Clinical cohort and bio-samples</h2>\n<p>We are in our 3<sup>rd</sup> year of recruitment of our GBA RAPSODI cohort, now with &gt;850 participants. We have comprehensive clinical data on motor function, olfaction and cognition and questionnaire data on sleep and autonomic function, together with DNA and urine specimens. Information and samples will be shared with the other ASAP participants for genome-microbiome interactions and additional analyses. For preliminary data from animal models and in vitro studies, please refer to supporting data.</p>\n<h1>RESEARCH TOOLS, MODELS AND RESOURCES</h1>\n<p>We already have the following resources:</p>\n<ol>\n<li><strong>Human subjects, </strong>clinically and biochemically phenotyped and genotyped for the collection of additional samples for microbiome analyses (see RAPSODI study above).</li>\n<li><strong>Mice </strong>with the <strong>L444P </strong><em>Gba1 </em>mutation, used in a previous UCL-DZNE collaboration (14), will receive a human A-SYN-AAV injection into the vagus nerve; using this unique paradigm, we will induce A-SYN overexpression within gut vagal terminals (see supporting data) (2). Mice will then receive pyloric/duodenal injections of CsgA CsgA fibrils with the same structure as native curli will be generated from monomeric CsgA (15,16).</li>\n<li><strong>iPSCs </strong>are available from GBA L444P, N370S, E326K mutation/variant carriers with and without PD, and will be used for the generation of 3D mid-brain DA neurons, myeloid cells (macrophages and microglia) as well as mid-brain and intestinal organoids (17- 20). Primary macrophages (21) will be used for the cytokine/chemokine gene expression and secrotome profile, lysosomal and mitochondrial function and A-SYN</li>\n<li><strong>Human HuTu-80 and murine STC-1 enteroendocrine cells </strong>are available - these cells increase A-SYN levels in response to TLR 2 and 4 activation (see supporting data).</li>\n<li><strong>Integrated and ISO9001-certified standard pipeline for stool and saliva shotgun microbiome analysis</strong>, extending from sample collection, storage and processing, through highly automated DNA sequencing and primary sequence analysis, to the cutting-edge bioinformatics and biostatistical analysis, including machine learning and artificial intelligence approaches is available at INRAE Metagenopolis\n<ol>\n<li>The applicants have published widely both together and separately on the techniques required for the analyses described here and below.</li>\n</ol>\n</li>\n</ol>\n<h1>STUDY PLAN</h1>\n<h2>GBA Cohort Human Microbiome Analysis</h2>\n<p>This comprises UK and Italian integrated patient cohorts of GBA mutation carriers with and without PD and PD patients without GBA mutations as well as matched controls (https://www.rapsodistudy.com). The UK and Italian cohort microbial signatures, using identical sampling and storage, will be analyzed separately and compared for their risk for GBA-PD penetrance; this will control for dietary effects on the microbiome. We have completely sequenced the GBA gene using Nanopore MinION (22). From the UK cohort we will select: 1. GBA -, PD - (controls); 2. GBA -, PD + (idiopathic PD); 3. GBA + PD - (GBA carriers); 4. GBA + PD + (GBA-PD). Each group will comprise 60 individuals matched for age (mean &gt;65 years). The Italian cohort will comprise GBA-PD and idiopathic PD (n=60/group). All subjects will provide data on the microbial signature of the saliva, intestine (stool) and urine and will represent the largest microbiome analysis in PD performed to date (23). Data will be analyzed at INRAE and correlated with data on clinical (motor, olfaction-UPSIT, cognitive, sleep and autonomic function) and biochemical parameters (plasma A-SYN levels, GBA activity, sphingolipids, exosome-associated A-SYN, peripheral inflammatory profile and PBMC studies, gut hormone profiling) and assayed together. Microbiome samples will be used for metagenomic, proteomic and metabolomic high throughput analyses. Samples will be collected and processed in accordance with the International Human Microbiome Standards standard operating procedures (24). Shotgun metagenomic analysis of bacterial DNA will be conducted together with metabolomic analysis using 1NMR spectroscopy, Gas Chromatography Mass Spectrometry and Electrospray Quadrupole-Time of Flight Mass Spectrometry (ESI-QTOF) coupled to a Nano UPLC. Comparison of the results between subject groups will identify a composite risk for PD in this genetically stratified group comprising clinical, biochemical, inflammatory and microbiome profiles.</p>\n<h2>Animal Models</h2>\n<p>We will carry out comparative studies in 15- to 18-week L444P mice and wild-type littermate controls in parallel at the UCL and DZNE-Bonn sites. Twenty wild-type mice (10 mice will be used for histopathological analyses after tissue fixation and the other 10 for biochemical analyses on fresh unfixed tissue) and 20 L444P mice will receive: <strong>(i) </strong>an intravagal injection of human A-SYN-AAVs (25) plus (4 weeks later) 4 injections of CsgA fibrils, 2 in the pylorus and 2 in the duodenum (1), or <strong>(ii) </strong>an intravagal injection of either empty vectors or green fluorescent protein-AAVs instead of A-SYN-AAVs plus injections of CsgA fibrils (as above), or <strong>(iii) </strong>a vagal injection of A-SYN-AAVs plus gut injections of vehicle instead of CsgA fibrils. To further characterize A-SYN-CsgA interactions, separate groups of wild-type (n=20/group) and L444P mice (n=20/group) will receive: <strong>(iv) </strong>a vagal injection of A-SYN-AAVs plus 4 gut injections of monomeric CsgA, or <strong>(v) </strong>a vagal injection of A-SYN-AAVs plus 4 gut injections of a peptide spanning an amyloidogenic CsgA domain (9,16), or <strong>(vi) </strong>a vagal injection of A-SYN-AAVs plus 4 gut injections of a peptide spanning a non-amyloidogenic CsgA domain (9,16).</p>\n<p>Animals will be sacrificed at 1, 3 and 6 months after the gut injections. Samples will be collected and measurements performed at baseline, during the course of the experiments and at the time of animal sacrifice to assess motor behavior, inflammatory markers in the blood, gut motility and gut microbiome and metabolome (in collaboration with INRAE). Additional histological and biochemical assays will be carried out in post-mortem samples from the gut, vagus nerve and brain to evaluate: (i) development and spreading of A-SYN pathology (e.g., analysis of aggregate pathology containing phoso A-SYN; measurements of aggregated and post- translationally modified A-SYN using PLA), (ii) neurodegenerative changes (e.g., neuronal counts in the nucleus of the vagus nerve and the SNpc), and (iii) neuroinflammation (e.g., morphological and quantitative evaluation of microglia and astrocytes; measurements of cytokines and TLR receptors). The effects of GBA mutations and amyloidogenic bacterial proteins on <em>in vivo </em>A-SYN pathology and neuroinflammation will be compared to data obtained from parallel <em>in vitro </em>experiments and from analyses of human specimens.</p>\n<h2>Cell Medels and 3D Organoids</h2>\n<p><strong>HuTu-80 (human) and STC-1 (murine) enteroendocrine cell lines express A-SYN </strong>(see pilot data and 26). We will use these cells to determine the expression of A-SYN upon exposure to specific microbial factors (LPS, short chain fatty acids: butyrate, propionate, acetate, iso- butyrate, isovalerate and valerate), CsgA monomers and curli fibrils and the effect of TLR2 and 4 inhibitors (Anti-mouse/human TLR2 mAb, clone T2.5 (InvivoGen), TAK-242). We will knock-in the L444P and N370S GBA mutations to study the effect of these factors on GBA mutant STC-1 cells. We hypothesize that GCase activity will be reduced and A-SYN expression increased compared to wild-type (WT) cells, similar to the effect of conduritol b-epoxide (see pilot data). Human iPSC dopaminergic (DA) neurons and microglia from GBA-PD patients (L444P, N370S, and E326K) and isogenic controls (n=3 each), will be exposed to the microbial factors, CsgA monomer or fibrils as above, and A-SYN expression, cell viability, and GCase activity assayed. Microglial phagocytosis and cytokines/chemokines will be quantified using Latex beads and Luminex assays, respectively. The cells will also be exposed to the microbial ligands with or without A-SYN preformed fibrils (PFF) and A-SYN expression and inter-neuronal spread compared to WT cells. We hypothesize that A-SYN expression and spread will be increased in the mutant lines. To dissect the role of neuro-immune interactions in A-SYN spreading, cocultures of iPSC-derived DA neurons with microglia or astrocytes will be employed. We will develop 3D midbrain organoids (see pilot data) from GBA-PD patients and controls. To determine the interaction between a prior immune challenge and GBA-related genetic vulnerability, control and GBA-PD microglia-containing midbrain organoids at day in vitro 90 will be first exposed to CsgA monomer/fibrils alone or in combination with A-SYN PFFs/vehicle control. Organoids from patients and controls will be fixed at 1,3,6, and 12 months, cryosectioned and immunostained. Neural progenitors, DA neurons, and glia will be quantified with stereological analyses. Neurotoxicity will be assessed by stereological quantification of TH and NeuN positive cell bodies. Axonal pathology will be examined by Tau immunolabeling. To monitor A-SYN inclusions and the quantity and size of the aggregates, we will use Thioflavin T in combination with immunohistochemical staining for pSer129 A-SYN. To examine the different species of A-SYN monomers and oligomers, we will perform sequential protein extraction and separate soluble and insoluble fractions, followed by western blot analysis. Microglia morphology, proliferation, migration, and synaptic phagocytosis will be assessed using multiple human microglial markers. Cytokine/chemokine production will be assessed using Luminex technology. To evaluate whether and how GBA modulates neuro-immune interactions in the intestine, we will employ human intestinal organoids (HIOs). HIOs will be co-cultured with human iPSC-derived macrophages (M&Phi;s) from the same donor and we will also attempt to establish HIOs containing M&Phi;s and enteric neurons. HIOs will be exposed to CsgA monomers or fibrils. One week after injection, HIOs will be exposed to A-SYN PFFs, A-SYN monomers, or a vehicle control. HIOs will be fixed and immunostained at 2, 4, and 6 weeks after injection to identify posterior hindgut, epithelial cell, goblet cell, enteroendocrine cell, M&Phi;, and enteric neuron markers. We will track cell-specific transcriptional changes during the process of inclusion formation and cell death and A-SYN pathology as described above. To dissect neuro- immune interactions at single-cell resolution, 10x Genomics scRNA-seq will be performed in both midbrain organoid and HIO models.</p>\n<h1>POWER CALCULATIONS AND STATISTICAL ANALYSES PLAN</h1>\n<p>We have already confirmed that the human subject cohort size (n=60/group) is sufficient to provide statistical power (&lt;0.05) using the parameters under investigation for clinical and biochemical phenotyping (27,28). A 77.6% decrease in the composition of bacterial families (specifically Prevotellaceae) is reported in PD patients compared to control subjects (29). Considering an effect size d=0.77, standard deviation of each group of 1.01, significance level 0.05, power 0.8 and Bonferroni correction for multiple comparison, the sample size needed to detect a significantly difference between the four groups is estimated to be N=54 subjects per group. Microbiome analyses will have a similar power for determination of an over-arching descriptor of the microbiome &ndash; its richness, which was observed to decline in PD relative to control groups (30).To determine the minimum number of animals/group required for the <em>in vivo </em>experiments, a power analysis was carried out using G-Power software and the following assumptions: (i) effect sizes (0.8) calculated from earlier experiments (25), (ii) &alpha; error probability 0.005 and Power 0.95, and (iii) 20% failure of surgical procedures.</p>\n<h1>PROJECT TIMELINE AND MILESTONES</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/ab69fc5b-8e80-4ec4-a6eb-c668f922b121/schapira-timeline.jpg\" alt=\"Schapira timeline\" /></p>\n<h1>WORKFLOW SCHEMATIC</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/f2b68901-2077-4b4b-b552-a4deb46bb647/schapira-workflow.jpg\" alt=\"Schapira workflow\" /></p>\n<p>The consortium builds on existing funded collaborations between UCL, DZNE and Pavia, and introduces the INRAE for microbiome analysis.</p>\n<ol>\n<li><strong> </strong>The clinical samples obtained from the UCL and Mondino-Pavia sites will be analyzed at INRAE and the microbiome data integrated with <strong>2. </strong>the combined clinical and biochemical data generated at the two clinical sites to identify the clinical substrate and risk profile of genotype- microbiome interactions in determining PD penetrance. <strong>3. </strong>The information on the PD-GBA microbiome signatures will be shared with DZNE-Tubingen to inform which bacterial ligands to use in assessing A-SYN expression, inflammatory response and related pathology in iPSC and 3-D organoid work. <strong>4. </strong>The iPSCs held by UCL will be shared with DZNE-Tubingen to ensure sufficient lines are available for study. <strong>5. </strong>The PD-GBA microbiome data will also be used by the UCL and INRAE groups to inform the ligand exposures for the STC-1 and HuTu-80 lines assessing A-SYN levels and TLR mediated responses. <strong>6. </strong>The GBA mice held by UCL will be used in collaboration with DZNE-Bonn for the ASYN in vivo studies. This will involve transfer of personnel and samples to complete as previously (14). <strong>7. </strong>The microbiome samples from the GBA mice and the A-SYN in vivo studies will be analyzed at INRAE to determine the background microbiome signatures and any baseline genotype-microbiome interaction. Results of experiments with curli fibrils will be correlated to data on curli-encoding genes in humans. <strong>8. </strong>Data and reagents will be shared between the DZNE sites at Bonn and Tubingen to perform parallel experiments in vivo and in vitro.</li>\n</ol>\n<h1>LITERATURE CITATIONS</h1>\n<ol>\n<li>Kim S et al. Neuron. 2019;103:627-641</li>\n<li>Ulusoy A et al. Acta Neuropathol. 2017;133:381-393.</li>\n<li>Pan-Montojo F et al. Sci Rep. 2012;2:898.</li>\n<li>Ulusoy A et al. EMBO Mol Med. 2013 ;5:1119-27.&nbsp;</li>\n<li>Liu B et al. Neurology 2017;88:1996-2002</li>\n<li>Fitzgerald E et al Front Neurosci. 2019;13:369-382&nbsp; &nbsp; &nbsp;</li>\n<li>Chen SG, et al. Sci Rep. 2016;6:34477.</li>\n<li>Sampson TR, et al. Cell. 2016;167:1469-80.</li>\n<li>Sampson TR, et al. Elife. 2020;9:e53111.</li>\n<li>Kim C et al. Sci Rep. 2016;6:30891.</li>\n<li>Shao QH et al. Acta Pharmacol. Sin. 2019;40: 1503-1512 12</li>\n<li>Perez-Pardo P et al. Gut. 2019;68:829-843.</li>\n<li>Sun MF et al. Brain Behav Immun. 2018; 70: 48-60.</li>\n<li>Migdalska-Richards A Brain. 2017;140:2706-2721.</li>\n<li>Horvath I, et al. J Am Chem Soc. 2012;134:3439-44.</li>\n<li>Perov S, et al. PLoS Pathog. 2019;15:e1007978</li>\n<li>Sch&ouml;ndorf DC, et al. Nat Comm. 2014; 5:4028.</li>\n<li>Sch&ouml;ndorf DC, et al. Cell Reports. 2018; 23:2976-2988.</li>\n<li>De Cicco S, et al. BioRxiv. 2020; org/10.1101/2020.01.30.925222</li>\n<li>Ivanyuk, Perez et al. BioRxiv. 2019; org/10.1101/2020.01.27.919522.</li>\n<li>Welsh N et al Haematologica. 2019 Sep 26. pii: 2019.224717.</li>\n<li>Leija-Salazar M et al. Mol Genet Genomic Med. 2019 7:e564</li>\n<li>Shen, L. Microb Cell Fact. 2020;19:50.</li>\n<li>Costea, P. et al. Nat Biotechnol. 2017; 35:1069&ndash;1076. 25</li>\n<li>Helwig M et al. Brain. 2016;139:856-70.</li>\n<li>Chandra R et al JCI Insight. 2017 Jun 15;2(12). pii:</li>\n<li>Avenali M et al. J Neurol Neurosurg Psychiatry. 2019;90:1091-1097.</li>\n<li>Mullin S et al. Mov Disord. 2019;34:1365-1373.</li>\n<li>Scheperjans F et al. Mov Disord. 2015;30:350-8.</li>\n<li>Li C et al. Front Mol Neurosci. 2019;12:171.&nbsp;</li>\n</ol>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:14Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "Defining the Cellular and Molecular Determinants of Variable Genetic Penetrance in Parkinsons disease"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": "<h1>PROJECT SUMMARY</h1>\n<p>Single gene variants are poor predictors of phenotypic conversion to clinical PD (&ldquo;incomplete penetrance&rdquo;). Here, we utilize cutting-edge stem-cell tools to study three complementary classes of &ldquo;second hit&rdquo; factors that convert genetic vulnerability into PD: i) <strong>gene-gene interactions</strong>; ii) <strong>glial-neuronal interactions</strong>; iii) <strong>age-related factors</strong>. We leverage exciting preliminary data, versatile stem cell technologies, isogenic iPSC lines for <em>SNCA</em>(&alpha;S)/<em>LRRK2</em>/<em>GBA </em>(GCase) and computational methods to integrate experimental datasets into coherent networks. Our molecular networks will aid in interpreting large-scale genetic data in the field, facilitate patient stratification and may yield novel approaches for early diagnosis and precision treatment.</p>\n<h1>RATIONALE AND PRELIMINARY DATA</h1>\n<p>Strong PD risk mutations in <em>GBA </em>and <em>LRRK2 </em>confer incomplete penetrance (20-50%<sup>1,2</sup>). <strong>We hypothesize that single genetic vulnerabilities are insufficient to cause PD, and that the interplay of genetic risk variants, distinct CNS cell types, and age-related factors leads to PD pathogenesis. </strong>Here, we will delineate molecular networks that drive i) cell-autonomous, intracellular toxicity; ii) non-cell autonomous glial-neuronal toxicity; iii) age-related vulnerabilities. Given prior difficulties in translating insights from rodent models, we focus on pluripotent (PSC) approaches to define networks in a <em>human </em>biological context. <strong>Khurana </strong>and <strong>Peng </strong>(with late Susan Lindquist) established proof-of-concept that computational tools (TransposeNet and ResponseNet) can integrate high-throughput screening data into biologically meaningful networks and testable hypotheses<sup>3</sup>. Networks established from genetic/physical &alpha;S-interaction screens in yeast and primary neurons tied protein trafficking, mRNA metabolism and calcium homeostasis to &alpha;S toxicity (<strong>Fig. 1A</strong>). They linked disparate genetic risk factors, identified novel pathologies in PD brain and iPSC neurons<sup>4-8</sup> and helped advance novel druggable targets to clinical trials<sup>9,10</sup>.</p>\n<p>Using insights from such networks, <strong>Khurana </strong>identified direct interactions between &alpha;S and trafficking proteins<sup>11</sup>, and now with specific RNA-granule proteins, leading to defective mRNA stability/translation (<strong>Fig. 1A)</strong>. <strong>Peng </strong>applied networks to stratify PD patients in the PPMI cohort (<strong>Fig. 1Aii)</strong>. Targeted exome sequencing of network genes in ~500 patients then uncovered rare variants (<strong>Fig. 1Ai</strong>) in regulators of actin polymerization (<strong>Fig. 1B)</strong>, enriched in <em>GBA</em>(N370S) and <em>LRRK2 </em>(G2019S) patients (<strong>Fig. 1C</strong>). The high expression of several hits in glial cells implicates them in PD penetrance. Genome-wide CRISPR screens in a transgenic human &alpha;S model confirmed the link of cytoskeletal defects to protein trafficking (<strong>Fig. 1C</strong>). Here, we will use advanced stem cell tools to pursue mechanistic studies and build disease-related biological networks. Tools developed in the <strong>Studer </strong>lab include scalable human PSC dopamine (DA) neurons enriched for the A9 subtype and a unique triculture system to study glial-neuronal interactions<sup>12</sup>. This tripartite culture (pure neurons, astrocytes and microglia), mixed at ratios that mimic <em>in&nbsp; vivo </em>conditions, enables mechanistic studies of neuroinflammatory crosstalk<sup>10</sup>. <strong>Croft </strong>and colleagues have shown that <em>PARKIN </em>and <em>LRRK2 </em>mutant astrocytes are toxic to DA neurons via &alpha;S accumulation and inflammation<sup>13</sup> and that control astrocytes can partially rescue disease phenotypes in <em>LRRK2</em>-DA neurons.</p>\n<p>In <strong>Aim 1A </strong>and <strong>2A, </strong>cytoskeletal hits from the human exome screen will be examined in hPSC-DA neurons and in glial-neuronal cultures. In <strong>Aim 3A</strong>, the <strong>Studer </strong>lab will study age-related hits. Intriguingly, one hit, <em>NEDD8, </em>regulates cytoskeletal dynamics. <strong>Aims 1B, 2B </strong>and <strong>3B </strong>will use our technical resources to generate unique transcriptional, cell-type specific and age-related datasets for mediators of PD phenotypic penetrance, using CROP-seq, scRNA-seq, and CRISPR-Cas9 screens in multiplexed cultures. Equally critical are analytical pipelines (<strong>Powell</strong>) and data synthesis including AI approaches (<strong>Peng</strong>) to yield biologically tractable networks. <strong>Aims 1C, 2C </strong>and <strong>3C </strong>use these networks to interrogate rapidly growing whole-genome PD datasets, to place common/rare variants in context of distinct biological networks and druggable targets, and to inform mechanistic exploration using the hPSC models and assays we developed.</p>\n<h1>RESEARCH TOOLS, MODELS AND RESOURCES</h1>\n<p><strong><em>hPSC differentiation</em></strong><em>: </em>A9 enriched DA neurons; defined triculture; sorting strategies for DA neurons, astrocytes, microglia; rapid glial induction and neuronal maturation, access to CNS, PNS, ENS neurons. <strong><em>Knock-in reporters</em></strong><em>: </em>Knock-in TH-TdTomato, NURR1, NURR1/SOX6 (A9 selective), hESC trafficking/organelle lines, multi-color reporters in GPI locus (resistant to silencing).</p>\n<p><strong><em>Transgenic Piggybac synucleinopathy models</em></strong>: All-in-one Piggybac tools for rapid &alpha;S expression + Ngn2- iN differentiation. &alpha;S-E3xK model<sup>14</sup> exhibits inclusions (pale/Lewy bodies; <strong>Fig. 1D, </strong>upper<strong>; 1E</strong>) toxic to neurons (<strong>Fig. 1I</strong>). &alpha;S amyloid-rich fibrillar models by pre-formed fibrils (PFFs; <strong>Fig. 1D</strong>, lower).</p>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/ce64a53c-e88f-47db-b71a-d4c8bbeeac13/table1.jpg\" alt=\"Table1\" /><strong><em>Single-cell computational genomics</em>: scPred</strong>,<sup>15</sup> machine learning cell classification. <strong>scSplit<sup>16</sup></strong>, demultiplexing for single-cell genotyped or non-genotyped data. <strong>ASCEND<sup>17</sup></strong>, workflow for QC, visualization, statistical testing in scRNA-seq data. <strong>CROP-seq</strong><sup>18</sup> workflow to identify perturbed gene networks. Dana Pe&rsquo;er (MSKCC) consults for scRNA-seq work.</p>\n<p><strong><em>Network analysis and modeling</em>: ResponseNet</strong>, constructing cascades of multi-level influence networks from genetic perturbations and transcriptomic data<sup>12</sup> <strong>TransposeNet</strong>, building modular networks from genetic screens and transcriptomics<sup>4</sup>. <strong>Mashup</strong>, integrative analysis of multiple networks<sup>13</sup>.</p>\n<p><strong><em>Machine learning for imaging analysis</em></strong>: Deep convolutional neural networks, learning hierarchical features to predict PD phenotype labels and endophenotypes from raw image data. Multitask deep learning, incorporating high-level features such as individual morphometry.</p>\n<h1>STUDY PLAN</h1>\n<h2>Aim 1. Gene-gene (cell-autonomous) interactions</h2>\n<p>Rare variants in regulators of actin polymerization were found in patients with pathogenic <em>LRRK2 </em>(G2019S) and <em>GBA</em>/GCase (N370S) mutations (<strong>Figs. 1B,C</strong>). Here, <strong>we hypothesize that compromised actin polymerization contributes to phenotypic penetrance in part via perturbed trafficking of lysosomal hydrolases (Fig. 1C, right). </strong>Actin polymerization is critical for vesicle trafficking<sup>19</sup>, and &alpha;S and LRRK2 directly impact trafficking and activity of lysosomal hydrolases<sup>5,8,20-22</sup>. This involves retromer-mediated M6PR and LIMP2 shuttling to Golgi and endolysosomal trafficking of the receptor-bound hydrolases<sup>23</sup>. LRRK2 impacts this process via hydrolase deactivation<sup>23</sup>. In our tg-&alpha;S model (<strong>Figs. 1F-1I</strong>), neurotoxicity is linked to dysregulation of actin polymerization (<strong>Fig. 1F</strong>) and mislocalization of M6PR (<strong>Fig. 1G</strong>) and Rab, substrates of LRRK2 kinase (<strong>Fig. 1H</strong>). A genome-wide CRISPR/Cas9 screen in this model revealed cytoskeleton factors as a top determinant of vulnerability, supporting our hypothesis (<strong>Fig. 1B, left</strong>).</p>\n<p><span style=\"text-decoration: underline;\"><strong>Determine the role of cytoskeletal hits in PD iPSC models</strong></span></p>\n<p>In two pairs of &alpha;S hPSC discovery lines (transgenic (tg)-&alpha;S and &alpha;S-triplication; <strong>Table 1</strong>), we will target the top cytoskeleton/trafficking hits and the top mRNA metabolism hit (11 genes in total; <strong> 1B</strong>). For tg-&alpha;S lines, we will initially use Ngn2-induced cortical neurons while for &alpha;S-triplication pair (4-copy/2-copy), we will implement optimized hPSC DA neuron protocols (Studer lab) enriched for A9 (LMO3, GIRK2, ALDH1A1; <strong>Fig. 3A</strong>). Differentiated neurons (day 21 (iN); day 60 (DA neurons) will be transduced with all-in-one lentiviral Cas9/gRNA constructs for candidate hits or treated with pharmacologic modulators of actin stabilization (cytochalasin, latrunculin). As in <strong>Table 2</strong>, we will: i) track longitudinal measures of viability (<strong>Fig. 1I</strong>); ii) biochemical and image-based measures of actin stabilization and cofilin rod formation; iii) GBA trafficking<sup>5,8</sup>, activity and lysosomal flux<sup>24</sup>. These sentinel assays will be repeated in discovery iPSC lines (<strong>Table 1</strong>). Additional assays (<strong>Table 2</strong>) will test whether LIMP-2, M6PR (tagged constructs) and stabilized actin are mislocalized with respect to late endosome (Rab7), retromer (Vps35) and lysosomal (LAMP1) markers. Dynamic colocalization (+/- &alpha;S) will be assessed using inducible tagged &alpha;S PiggyBac constructs. Finally, FLIM- based assays will probe LIMP-2 and M6PR association in GCase trafficking<sup>23</sup>. Similar to our prior clinical candidates<sup>9,10</sup> (lipid/trafficking modulators), we will test druggability of these phenotypes.</p>\n<p><span style=\"text-decoration: underline;\"><strong>CROP-seq in human DA neurons to classify transcriptional responses of hit genes</strong></span></p>\n<p>CROP-seq is a powerful tool to analyze scRNA-seq changes upon knockout of many specific genes in parallel in a defined genetic background (such as a PD driver mutation). Here, we will assess 50 genes, including cytoskeletal hits (Aim 1A), and additional hits in Ca<sup>2+</sup>-homeostasis and mRNA metabolism. 10 isogenic iPSC pairs (tg- &alpha;S, SNCA, LRRK2, GBA + isogenic controls; <strong>Table 1</strong>) are differentiated at scale to DA neurons, followed by extensive QC and cryopreservation (day 25). If required (&lt; 75% DA neurons) CD49e-/CXCR4+ MACS will be used to further purify<sup>25</sup>. DA neurons are thawed into pooled cultures (related Studer method in press<sup>26</sup>) to reduce variability and cost, and checked for equal genotype representation (Powell). gRNAs are delivered at day 50 (pool of 2 gRNA each, 50 target, 10 control genes). At 48h, DNA and RNA is sequenced to identify the locations of gRNA insertions, and cells are harvested for scRNA-seq using the 3&rsquo; mRNA assay (10X Genomics). We aim to sequence 240,000 multiplexed cells (assuming 50% gRNA detection/insertion rate and 50 cells/gRNA/line). Cells are demultiplexed using scSplit (Powell), and data is processed to cluster transcriptional responses to perturbed genes. In parallel, multiplexed DA neurons are sorted for low/medium/high GBA activity (<strong>Table 2</strong>) to determine which of the 50 perturbations modulates GBA activity and to link transcriptional changes in scRNA-seq with GCase-related biochemical changes.</p>\n<p><span style=\"text-decoration: underline;\"><strong>Generation of regulatory networks for mechanistic analysis and patient clustering</strong></span></p>\n<p>The scRNA-seq data in 1B will be used to build gene-specific regulatory networks via ResponseNet to link genotype to expression<sup>3</sup>. We will build a global network that captures shared common regulatory mechanisms and perform differential analysis to construct gene-specific networks, using Peng lab algorithms. This will generate a prioritized list of candidate regulators driving actin polymerization, mRNA metabolism and protein, and we will assess their inter-relationship to the GBA, LRRK2 and &alpha;S risk A subset of candidates will be nominated for mechanistic follow-up studies using the sentinel and secondary assays (<strong>Table 2</strong>). Next, we will apply clustering algorithms (e.g., hierarchical clustering and Gaussian mixture models) to integrate PD patient transcriptomic data from PPMI/ROSMAP/AMP-PD cohorts. We will determine how our experimental networks stratify patients based on genotype, UPDRS scores in PPMI and on PD-related endophenotypes (e.g. the Lewy body pathological score) in ROSMAP.</p>\n<p><span style=\"text-decoration: underline;\"><strong>Pitfalls and Alternative Strategies</strong></span></p>\n<p>Disease variants may not be effectively modeled by knockouts. The Khurana/Studer labs routinely use CRISPRi/a approaches in hPSC neurons to tune expression changes to +/- 40-60% control. Perturbations of the actin cytoskeleton can induce many effects beyond hydrolase trafficking. Our sentinel assays will give us an early indication how many of the hits may have broader effects. Some of our assays may not be dynamic enough to reliably identify alterations in protein trafficking. We thus enlisted Tom Kirchhausen (Harvard), a renowned expert in visualizing endocytic trafficking with lattice sheet microscopy and other methods, as an unpaid collaborator. Our discovery models do not develop fibrillar &alpha;S aggregates. However, these models, if needed, are readily available in the Khurana lab (via exogenous synthetic or brain-derived pre-formed &alpha;S fibril exposure; <strong>Fig 1D, </strong>lower).</p>\n<h2>Aim 2. Glial-neuronal interactions</h2>\n<p>We will: <strong>A</strong>) test the hypothesis that trafficking dysfunction induces &alpha;S transfer-mediated neurotoxicity in the LRRK2 astrocyte:DA neuron co-cultures. However, LRRK2 astrocytes also show inflammatory phenotypes. Furthermore, LRRK2 is highly expressed in microglia, and microglia potentiate astrocyte inflammatory cues. Thus, we will also address whether inflammatory crosstalk between DA neurons, astrocytes, and microglia contributes to LRRK2-mediated neurotoxicity. <strong>B</strong>) address whether similar &alpha;S- transfer and neuroinflammatory interactions occur in GBA and &alpha;S mutant cells: using isogenic lines across all three risk genes, we will systematically test the effect of each gene across each cell type in triculture via multiplexed single-cell phenotypic and scRNA-seq readouts. <strong>C</strong>) integrate (<strong>A</strong>,<strong>B</strong>) data to establish cell type- specific networks and generate novel, testable hypotheses of glial-neuronal interaction.</p>\n<p><span style=\"text-decoration: underline;\"><strong>Define mechanisms of glial neurotoxicity in LRRK2 PD</strong></span></p>\n<p>&nbsp;Neuron viability, &alpha;S handling, and astrocyte activation will be quantified for each cell type in LRRK2 astrocyte:isogenic control DA neuron co-cultures (<strong>Table 2</strong>) by high resolution 3D high-content imaging (Phenix) and unbiased image analysis (Harmony, Imaris, Metamorph) supplemented by CNN machine learning (Peng lab). In parallel we will profile inflammatory cytokines (Luminex cytokine array<sup>27</sup>, C3/IL-6 ELISA) and cell-type specific transcriptional signatures (scRNA-seq).</p>\n<p><strong>To determine the mechanism of &alpha;S transfer between astrocytes and neurons </strong>we will <strong>1</strong>) test candidate mechanisms by lentiviral CRISPR knockdown (<strong> 1C </strong>astrocyte hits, FREM2, ARGHEF1, SREBF1, USP53; and LRRK2, &alpha;S, GBA; Rab8, clathrin); <strong>2</strong>) use live and fixed super- resolution imaging (iSIM, STED) to register &alpha;S with candidate organelles and adapter proteins; <strong>3</strong>) biochemically characterize &alpha;S-independent toxic activity in astrocyte conditioned medium<em>. </em></p>\n<p><strong>T</strong><strong>o dissect neuroinflammatory crosstalk between neurons, astrocytes and microglia, </strong>we will <strong>4) </strong>define LRRK2 microglia-intrinsic phenotypes using cytokine, phagocytosis, and motility assays (Table 2<sup>27</sup>) and test candidate genes (<strong>Fig. 1C </strong>microglia hits PRKCD, USP53, PKN2; NFKB, LRRK2, &alpha;S, GBA) as in 2a1; <strong>5, </strong>dissect intercellular crosstalk by mix and match of LRRK2 vs. isogenic control astrocytes, microglia and neurons in triculture system with full imaging, cytokine (Table 2) and scRNA-seq readouts<em>; </em>and <strong>6, </strong>test cell- type specific roles in disease phenotypes by long-term live imaging (Table 2) of dilute LRRK2 cells (3- color GPI-labeled astrocytes, neurons, microglia). This aim will define cellular mechanisms of LRRK2 astrocyte neurotoxicity, reveal microglia-intrinsic PD phenotypes, dissect microglia-astrocyte-neuron inflammatory crosstalk, and define a substantially richer, fully human cell model of PD pathology.</p>\n<p><span style=\"text-decoration: underline;\"><strong>Determine combinatorial cell-type and genotype-specific interactions in defined triculture</strong></span></p>\n<p><strong>1</strong>, Determine optimal time point to assess neurotoxicity for each risk gene ( LRRK2, &alpha;S,GBA) in triculture with all cell types mutant assessing cell viability (TH:TdT), interactions and inflammation over time (<strong>Table 2). 2</strong>, Combinatorial matrix of risk gene and cell type at optimized time points, 3 isogenic pairs, 3 cell types, (8 combinations/risk gene and 6 single cell-types) x 3 replicates= 378 with fully integrated readouts (<strong>Table 2</strong>) and scRNA-seq as in 2A5. <strong>3, </strong>studies of spreading and progression as in 2A6 for relevant combinations. This aim addresses evidence of glial neurotoxicity and rescue for 2 additional major PD risk factors, measures &alpha;S trafficking within and between cells and monitors neuroinflammation in parallel. For scRNA- seq analysis, cells will be classified via scPred<sup>15</sup> (Powell), and changes in transcript abundances between cell-types, and conditions identified using log-likelihood ratio tests. We will assess the relationship between scRNA-seq profiles, imaging, and inflammatory readouts.</p>\n<p><span style=\"text-decoration: underline;\"><strong>Data integration, network creation and hypothesis generation</strong></span></p>\n<p>The algorithms in 1C will be used to integrate differentially expressed scRNA-seq hits into genome-wide convergent networks shared across genotypes and cell types, as well as establish genotype/cell-type-specific networks. Selected candidate regulators of cell-type specific responses will be tested for a mechanistic role in LRRK2/GBA/&alpha;S glial neurotoxicity in 2A and validated in independent As in 1C, we will use genotype and cell-type specific transcriptional profiles for patient stratification (PPMI and other cohorts).</p>\n<p><span style=\"text-decoration: underline;\"><strong>Pitfalls and Alternative Strategies</strong></span></p>\n<p>hPSC-derived astrocytes<sup>28</sup> should be highly enriched across hPSC lines, but if needed can be sorted for a novel surface marker identified at NYSCF<sup>27</sup>. If candidate genes do not affect &alpha;S trafficking or toxicity, we will test top LRRK2 vs. control astrocytes, genes, e.g. ECM which may also relate to trafficking<sup>13</sup>. If GBA and SNCA phenotypes are subtle or delayed compared to LRRK2, we will test disease-relevant stressors: &alpha;S fibrils, toxicants, or age-related drivers (Aim 3). Collaborator Beth Stevens (Harvard) will aid interpretation and <em>in vivo </em>correlation of microglia data. Oligodendrocytes increasingly appear crucial in PD<sup>29</sup>, and we may leverage expertise of NYSCF colleague Valentina Fossati. Gene ontology can be used to prioritize candidates if networks are overfitted.</p>\n<h2>Aim 3. Age-related modifiers</h2>\n<p>Age is the greatest risk factor for phenotypic penetrance in PD patients<sup>30</sup>. Age is poorly captured in iPSCs given an epigenetic reset of age-related factors during reprogramming<sup>31</sup>. Direct conversion of fibroblasts to neurons was proposed as an alternative<sup>32</sup>, but it suffers from lack of scalability, and the age-related signatures may reflect fibroblast rather than neuronal aging. To identify age-related factors contributing to PD pathogenic penetrance, we take advantage of two exciting findings (Studer lab): i) results of a genome- wide CRISPR-screen in hPSC neurons with NEDD8 as a hit linked to cytoskeletal dynamics; ii) work on SATB1-mediated DA neuronal senscence<sup>25</sup>. We propose mechanistic studies to investigate (<strong>A</strong>) whether <em>NEDD8 </em>modulates cytoskeletal dynamics and &alpha;S trafficking, and whether SATB1-senescence triggers phenotypes in PD-DA neurons via autonomous or non-autonomous mechanisms. In (<strong>B</strong>) we extend our genome-wide screening platform to &alpha;S, LRRK2 and GBA-DA neurons and in (<strong>C</strong>) test whether age-related networks are shared across genotypes and linked to networks identified in Aims 1&amp;2.</p>\n<p><span style=\"text-decoration: underline;\"><strong>Mechanism of NEDD8 and SATB1-mediated disease features in human dopamine</strong></span></p>\n<p><strong><em>NEDD8 </em></strong>was identified in a screen of hPSC-derived APP<em><sup>Swe</sup> </em>vs isogenic cortical neurons for gene perturbations that trigger selective degeneration in disease but not control neurons, and induce cellular hallmarks of age (<strong>Table 2</strong>). <em>NEDD8 </em>is of particular interest given its known role in regulating cofilin<sup>33</sup>, a regulator of actin dynamics and cofilin rods. We will use inducible KO of <em>NEDD8 </em>via CRISPRi technology<sup>34</sup> and pharmacological inhibition of neddylation in isogenic pairs of GBA, &alpha;S and LRRK2 DA neurons (discovery lines; <strong>Table 1</strong>). Target specificity is confirmed by NEDD8 western blot. DA neurons are assessed for viability, &alpha;S trafficking, GBA activity and markers of cellular age (<strong>Table 2</strong>). Mechanistically, we will test whether activation levels of cofilin are critical for both cytoskeletal and age- related phenotypes. ii) <strong><em>SATB1 </em></strong>is a master transcription factor in DA neurons that prevents p21-dependent senescence<sup>25</sup>. Here, we will assess whether SATB1-mediated DA neuron senescence (<strong> 3B</strong>) triggers age- and disease-related phenotypes (viability, trafficking, degeneration; <strong>Table2</strong>) in LRRK2, GBA, SCNA DA neurons (discovery lines). Mechanistically, we will perform dilution studies, inducing senescence in a defined proportions of DA neurons to assess cell autonomous vs non-autonomous effects of SATB1-mutant cells. Conditioned media and transwell assays will determine effects dependent on secreted (SASP) factors and rescue studies include exposure to senolytics (e.g. fisetin) acting via p21 modulation<sup>25</sup>.</p>\n<p><span style=\"text-decoration: underline;\"><strong>Genome-wide screen for age-related modifiers in PD-iPSC derived DA neurons</strong></span></p>\n<p>Using the scalable DA neuron platform (suitable for manufacturing up to 10<sup>10</sup> neurons), the genome-wide CRISPR screen for age-related factors is translated to LRRK2, GBA and &alpha;S discovery lines. The Brunello library<sup>35</sup> of gRNAs is stably introduced (0.3 MOI) at 1000x library representation. Knockout of library is triggered conditionally after DA neuron induction via iCRISPR<sup>34</sup> technology, and DA neurons are isolated at day 60 (isogenic pair, +/- transient dox; <strong>Fig. 3C</strong>). At day 60, PD phenotypes (e.g. &alpha;S accumulation) under basal conditions are detected w./o. obvious loss of DA neuron numbers<sup>36,37</sup>. Hits are identified using the MAGeCK pipeline<sup>30</sup> modified for postmitotic cells and for triplicate run of screen. Validated hits are subjected to two secondary screens: i) flow-based assay for age-related markers (<strong>Fig. 3C</strong>) and ii) for sentinel (trafficking, GCase) and secondary assays (<strong>Table 2</strong>) in collaboration with the Khurana lab (as in Aim 1).</p>\n<p><strong><span style=\"text-decoration: underline;\">Network algorithms to define age-related networks</span></strong></p>\n<p>The results from LRRK2, GBA, &alpha;S screen are integrated to determine shared and distinct age-related modifiers. Validated hits are used to build modular networks (Peng lab) following network interference methods, including the prize-collecting Steiner forest algorithm implemented by TransposeNet<sup>5</sup>. We hypothesize that age-related modifier data result in networks partly distinct from the genetic interaction network (independent risk). To validate and refine age-related networks, we will integrate RNA-seq data (recently generated in Studer lab) from aged vs. young human substantia nigra (n=20). To probe experimental validity, we will perform perturbation experiments of hub genes to assess age-related and PD- related phenotypes (<strong>Table 2</strong>). For patient stratification, we will perform random-walk smoothing of patients&rsquo; mutational profile on the networks and develop a genetics-based patient stratification<sup>38</sup>. Such stratification will include large-scale PD genetic datasets, such as PPMI/AMP-PD and forthcoming ASAP cohorts. Genetic interaction networks developed from the genome-wide screens will nominate additional candidate genetic loci of variable penetrance to increase robustness and saturation level of our initial approach (<strong>Fig. 1A</strong>) using richer cell/genotype/age-related networks from human neurons.</p>\n<p><strong><span style=\"text-decoration: underline;\">Pitfalls and alternative strategies</span></strong></p>\n<p><strong><em> </em></strong>While the scope of Aim 3 is ambitious, we routinely run the proposed screening platform in the lab and are aware of all major technical challenges (cell purity and identity, neuronal silencing of Cas9 or batch-batch variability). Cell line QC is critical for success (SOP for genomic, transcriptional and lineage QC (with NYSCF)). Conceptually, cellular aging is poorly understood, and age- related markers do not capture all aspects of neuronal aging. Furthermore, many aspects of neuronal aging involve non-cell autonomous (glial-neuronal, vascular, endocrine) factors not modeled here. Therefore, our aim is focused on defining age-related markers that trigger phenotypic penetrance in our hPSC models and will not pursue broader questions related to neuronal aging in the current proposal.</p>\n<h1>POWER CALCULATIONS AND STATISTICAL ANALYSES PLAN</h1>\n<p><span style=\"text-decoration: underline;\"><strong>Mechanistic Studies</strong></span></p>\n<p>Experimental design is guided by our extensive iPSC experience (earliest patient iPSCs<sup>39</sup> and disease phenotypes<sup>40</sup> systematic evaluation of clonal vs donor variability<sup>41</sup>, first corrected PD lines<sup>42</sup>, scalable iPSC reprogramming, differentiation, and QC<sup>43</sup>). For discovery, we will use highly- validated, isogenic disease/corrected pairs (per genotype), followed by validation in n&ge;2 pairs from independent donors/genotype (<strong>Table 1</strong>). Assays are performed as biological triplicates. Appropriate assumptions guide selection of parametric/nonparametric comparison for a multiple testing significance threshold of <em>p</em>&lt;0.05. For cell tracking Cox proportional hazard analysis is used with logrank test: &ge;200 cells.</p>\n<p><span style=\"text-decoration: underline;\"><strong>Computational Genomics</strong></span></p>\n<p>CROP-seq: scRNA-seq data from &gt;10 cells per gRNA each will be taken for further analysis. Differences in the expression of each gene will be tested with a log-likelihood ratio (LR) test, which is robust to class imbalance. To overcome multiple testing thresholds (across genes), we will calculate an empirical distribution of the LR test statistic using permutations, to evaluate the rank position of each gene&rsquo;s test statistic in the permuted data.</p>\n<p><span style=\"text-decoration: underline;\"><strong>Network Biology</strong></span></p>\n<p>Statistical robustness of networks will be established by injecting noise to edge weights in the reference interactome, applying random permutations and shuffling of reference network connectivity to obtain background distribution for assigning empirical p-values.</p>\n<h1>PROJECT TIMELINE AND MILESTONES</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/fc48f666-afbf-438d-85df-5d3673505b32/timeline.jpg\" alt=\"timeline\" /></p>\n<h1>WORKFLOW SCHEMATIC</h1>\n<p><img src=\"https://cloud.squidex.io/api/assets/asap-hub/ba6d84c6-f59c-48fe-9850-84fceeb44cc5/workflow.jpg\" alt=\"Workflow\" width=\"649\" height=\"839\" /></p>\n<h1>LITERATURE CITATIONS</h1>\n<ol>\n<li>Rana, H. Q., Balwani, M., Bier, L. &amp; Alcalay, R. N. Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling. <em>Genet Med </em><strong>15</strong>, 146-149, doi:10.1038/gim.2012.107 (2013).</li>\n<li>Lee, A. J. <em>et al. </em>Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. <em>Mov Disord </em><strong>32</strong>, 1432-1438, doi:10.1002/mds.27059 (2017).</li>\n<li>Yeger-Lotem, E. <em>et al. </em>Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. <em>Nat Genet </em><strong>41</strong>, 316-323, doi:10.1038/ng.337 (2009).</li>\n<li>Lam, I., Hallacli, E. &amp; Khurana, V. Proteome-Scale Mapping of Perturbed Proteostasis in Living Cells. <em>Cold Spring Harb Perspect Biol </em><strong>12</strong>, doi:10.1101/cshperspect.a034124 (2020).</li>\n<li>Khurana, V. <em>et al. </em>Genome-Scale Networks Link Neurodegenerative Disease Genes to alpha- Synuclein through Specific Molecular Pathways. <em>Cell Syst </em><strong>4</strong>, 157-170 e114, doi:10.1016/j.cels.2016.12.011 (2017).</li>\n<li>Jarosz, F. &amp; Khurana, V. Specification of Physiologic and Disease States by Distinct Proteins and Protein Conformations. <em>Cell </em><strong>171</strong>, 1001-1014, doi:10.1016/j.cell.2017.10.047 (2017).</li>\n<li>Chung, C. Y. <em>et al. </em>In Situ Peroxidase Labeling and Mass-Spectrometry Connects Alpha-Synuclein Directly to Endocytic Trafficking and mRNA Metabolism in Neurons. <em>Cell Syst </em><strong>4</strong>, 242-250 e244, doi:10.1016/j.cels.2017.01.002 (2017).</li>\n<li>Chung, C. Y. <em>et al. </em>Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. <em>Science </em><strong>342</strong>, 983-987, doi:10.1126/science.1245296 (2013).</li>\n<li>Tardiff, D. F. <em>et al. </em>Yeast reveal a \"druggable\" Rsp5/Nedd4 network that ameliorates alpha-synuclein toxicity in neurons. <em>Science </em><strong>342</strong>, 979-983, doi:10.1126/science.1245321 (2013).</li>\n<li>Vincent, B. M. <em>et al. </em>Inhibiting Stearoyl-CoA Desaturase Ameliorates alpha-Synuclein <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell reports </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">25</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 2742-2754 e2731, doi:10.1016/j.celrep.2018.11.028 (2018).</span></li>\n<li>Sanz, R. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">In Situ Peroxidase Labeling and Mass Spectrometry of Alpha-Synuclein in Rat Cortical </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Methods Mol Biol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">1948</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 235-246, doi:10.1007/978-1-4939-9124-2_18 (2019).</span></li>\n<li>Guttikonda, S. R. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Fully defined human PSC-derived microglia and tri-culture system reveals cell type specific potentiation of complement C3 production in a model of Alzheimer&rsquo;s disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Neurosci </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(in revision) </strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2020).</span></li>\n<li>di Domenico, A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell- Autonomous Neurodegeneration in Parkinson's Disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Stem Cell Reports </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">12</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 213-229, doi:10.1016/j.stemcr.2018.12.011 (2019).</span></li>\n<li>Dettmer, U., Newman, A. J., von Saucken, V. E., Bartels, T. &amp; Selkoe, D. KTKEGV repeat motifs are key mediators of normal alpha-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Proceedings of the National Academy of Sciences of the United States of America </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">112</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 9596-9601, doi:10.1073/pnas.1505953112 (2015).</span></li>\n<li>Alquicira-Hernandez, J., Sathe, A., Ji, H. P., Nguyen, Q. &amp; Powell, J. E. scPred: accurate supervised method for cell-type classification from single-cell RNA-seq data. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genome Biol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">20</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 264, doi:10.1186/s13059-019-1862-5 (2019).</span></li>\n<li>Xu, J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genotype-free demultiplexing of pooled single-cell RNA-seq. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genome Biol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">20</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 290, doi:10.1186/s13059-019-1852-7 (2019).</span></li>\n<li>Senabouth, A. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">ascend: R package for analysis of single-cell RNA-seq data. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Gigascience </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">8</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, doi:10.1093/gigascience/giz087 (2019).</span></li>\n<li>Datlinger, P. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Pooled CRISPR screening with single-cell transcriptome readout. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Methods </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">14</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 297-301, doi:10.1038/nmeth.4177 (2017).</span></li>\n<li>Kjos, I., Vestre, K., Guadagno, N. A., Borg Distefano, M. &amp; Progida, C. Rab and Arf proteins at the crossroad between membrane transport and cytoskeleton dynamics. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Biochim Biophys Acta Mol Cell Res </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">1865</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1397-1409, doi:10.1016/j.bbamcr.2018.07.009 (2018).</span></li>\n<li>Mazzulli, R., Zunke, F., Isacson, O., Studer, L. &amp; Krainc, D. alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America 113, 1931-1936, doi:10.1073/pnas.1520335113 (2016).</li>\n<li>Zhao, Y. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Brain </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">141</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 486-495, doi:10.1093/brain/awx344 (2018).</span></li>\n<li>Burbulla, F. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Sci Transl Med </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">11</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, doi:10.1126/scitranslmed.aau6870 (2019).</span></li>\n<li>Zhao, Y., Ren, J., Padilla-Parra, S., Fry, E. E. &amp; Stuart, D. I. Lysosome sorting of beta- glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature communications </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">5</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 4321, doi:10.1038/ncomms5321 (2014).</span></li>\n<li>Atashrazm, F. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Sci Rep </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">8</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 15446, doi:10.1038/s41598-018-33921-x (2018).</span></li>\n<li>Riessland, M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Stem Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">25</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 514-530 e518, doi:10.1016/j.stem.2019.08.013 (2019).</span></li>\n<li>Cederquist, G. Y. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A multiplex human pluirpotent stem cell platform defines molecular and functional subtypes of autism. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Stem Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(in press) </strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(2020).</span></li>\n<li>Barbar, L. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">(Neuron (in press), 2020).</span></li>\n<li>Tchieu, <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">NFIA is a gliogenic switch enabling rapid derivation of functional human astrocytes from pluripotent stem cells. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Biotechnol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">37</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 267-275, doi:10.1038/s41587-019-0035-0 (2019).</span></li>\n<li>Bryois, J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Genet</em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, doi:10.1038/s41588-020-0610-9 (2020).</span></li>\n<li>Trinh, J., Guella, I. &amp; Farrer, M. J. Disease penetrance of late-onset parkinsonism: a meta-analysis. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">JAMA neurology </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">71</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1535-1539, doi:10.1001/jamaneurol.2014.1909 (2014).</span></li>\n<li>Studer, L., Vera, E. &amp; Cornacchia, D. Programming and Reprogramming Cellular Age in the Era of Induced Pluripotency. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Stem Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">16</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 591-600, doi:10.1016/j.stem.2015.05.004 (2015).</span></li>\n<li>Mertens, J. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Directly Reprogrammed Human Neurons Retain Aging-Associated Transcriptomic Signatures and Reveal Age-Related Nucleocytoplasmic Defects. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Stem Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">17</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 705-718, doi:10.1016/j.stem.2015.09.001 (2015).</span></li>\n<li>Vogl, A. M. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Struct Mol Biol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">27</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 210-220, doi:10.1038/s41594-019-0370-3 (2020).</span></li>\n<li>Gonzalez, F. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Stem Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">15</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 215-226, doi:10.1016/j.stem.2014.05.018 (2014).</span></li>\n<li>Doench, J. G. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Biotechnol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">34</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 184-191, doi:10.1038/nbt.3437 (2016).</span></li>\n<li>Chung, S. Y. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and alpha-Synuclein Accumulation. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Stem Cell Reports </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">7</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 664-677, doi:10.1016/j.stemcr.2016.08.012 (2016).</span></li>\n<li>Miller, J. D. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Human iPSC-based modeling of late-onset disease via progerin-induced aging. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell Stem Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">13</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 691-705, doi:10.1016/j.stem.2013.11.006 (2013).</span></li>\n<li>Wang, S. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Typing tumors using pathways selected by somatic evolution. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature communications </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">9</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 4159, doi:10.1038/s41467-018-06464-y (2018).</span></li>\n<li>Dimos, J. T. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Science </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">321</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 1218-1221, doi:10.1126/science.1158799 (2008).</span></li>\n<li>Lee, G. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nature </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">461</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 402-406, doi:10.1038/nature08320 (2009).</span></li>\n<li>Boulting, G. L. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">A functionally characterized test set of human induced pluripotent stem </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Biotechnol </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">29</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 279-286, doi:10.1038/nbt.1783 (2011).</span></li>\n<li>Soldner, F. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Cell </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">146</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 318-331, doi:10.1016/j.cell.2011.06.019 (2011).</span></li>\n<li>Paull, D. <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">et al. </em><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. </span><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">Nat Methods </em><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">12</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">, 885-892, doi:10.1038/nmeth.3507 (2015).</span></li>\n</ol>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-22T14:42:13Z"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-15T07:05:12Z"
    }
  },
  {
    "title": {
      "iv": "Testing Authors (updated)"
    },
    "type": {
      "iv": "Presentation"
    },
    "subtype": {
      "iv": "ASAP subgroup meeting"
    },
    "addedDate": {
      "iv": "2021-04-02T00:00:00Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-06T15:40:55Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "<p><strong>World Bank</strong>&nbsp;president&nbsp;<strong>David Malpass</strong>&nbsp;has said the institution does not support waiving intellectual property rights for Covid-19 vaccines at the World Trade Organization out of concern that it would hamper innovation in the pharmaceuticals sector.</p>\n<p>As WTO negotiations over the proposed waiver resumed in Geneva, Malpass was asked whether he supports a potential vaccine IP waiver, which&nbsp;<strong>India</strong>,&nbsp;<strong>South Africa</strong>&nbsp;and other emerging market countries argue is needed to expand vaccine access</p>\n<p>He said: &ldquo;We don&rsquo;t support that, for the reason that it would run the risk of reducing the innovation and the R&amp;D in that sector.&rdquo;</p>\n<p>The comment puts Malpass, a Trump administration nominee, at odds with the Biden administration, which is supporting text-based WTO negotiations for vaccine intellectual property rights, led by&nbsp;<strong>US</strong>&nbsp;trade representative Katherine Tai.</p>\n<p>Major vaccine makers and the pharmaceutical industries have opposed the waiver.<br />However, Malpass reiterated his calls for wealthy countries to quickly donate their excess vaccine doses to the developing world as quickly as possible.</p>\n<p>Three of the leading Covid vaccine manufacturers have paid out $26bn in dividends and stock buyouts to shareholders in the last year &ndash; enough to cover the cost of vaccinating the population of Africa, say campaigners.</p>"
    },
    "tags": {
      "iv": [
        "test",
        "Covid",
        "Trump",
        "David Malpass"
      ]
    },
    "accessInstructions": {
      "iv": "<p>The comment puts Malpass, a Trump administration nominee, at odds with the Biden administration, which is supporting text-based WTO negotiations for vaccine intellectual property rights, led by&nbsp;<strong>US</strong>&nbsp;trade representative Katherine Tai.</p>"
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": [
        "b8f0d946-bfef-4673-b1f6-be2e9a97b1b2",
        "c5937d7b-5e51-4118-ad56-ff6af0c66d66",
        "dcb76a67-be47-4821-805f-f262965240cc",
        "d13bef92-9f61-499f-8238-abc55b0e496b",
        "83c2befb-2c78-4994-aa4d-70fad211d7e7"
      ]
    },
    "asapFunded": {
      "iv": "Yes"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Yes"
    },
    "publishDate": {
      "iv": "2021-04-02T00:00:00Z"
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "LRRK2RCKW single molecule kinesin motility assays"
    },
    "type": {
      "iv": "Protocol"
    },
    "subtype": {
      "iv": "Cell Culture & Differentiation"
    },
    "addedDate": {
      "iv": "2020-11-28T15:39:00Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-06T15:39:42Z"
    },
    "link": {
      "iv": "https://www.protocols.io/view/lrrk2rckw-single-molecule-kinesin-motility-assays-bp6hmrb6"
    },
    "description": {
      "iv": "<h1 class=\"nova-e-text nova-e-text--size-m nova-e-text--family-sans-serif nova-e-text--spacing-none nova-e-text--color-inherit\">Comparison between LRRK2RCKW and integrative models built into cryo-ET maps of LRRK2 filaments in cells and docking of LRRK2RCKW into those maps a, Root-mean-square deviation (r.m.s.d.) between the atomic model of LRRK2RCKW and each of the 1,167 integrative models previously generated. r.m.s.d. values were calculated in Chimera&sup2; using 100% residue similarity and with pruning iterations turned off. r.m.s.d. values are grouped into 53 clusters of related models (see ref.  for details), with the mean and standard deviation shown whenever the cluster contains two or more models. Integrative models that gave the lowest, median and highest r.m.s.d. values are shown. The models are coloured according to the per-residue r.m.s.d. with the atomic model of LRRK2RCKW. b, The WD40s in the crystal structure of a dimer of the LRRK2 WD40 (PDB code: 6DLP) were replaced with the WD40s from our cryo-EM structure of LRRK2RCKW. c, The resulting dimer was fitted into the 14&nbsp;&Aring; cryo-ET map of cellular microtubule-associated LRRK2 filaments. d, Two views of the same fitting shown in c, displayed with a higher threshold for the map to highlight the fitting of the WD40 &beta;-propellers into the density. The white arrows point towards the holes at the centre of the &beta;-propellers densities. e, Four copies of LRRK2RCKW were docked into the cryo-ET map by aligning their WD40 domains to the docked WD40 dimer. f, Model containing the four aligned LRRK2RCKW. g&ndash;j, Modelling of the kinase-closed form of LRRK2RCKW. g,&nbsp;h, The structure of ITK bound to an inhibitor (PDB code 3QGY)&sup3;, which is in a closed conformation, was aligned to LRRK2RCKW using only the C-lobes of the two kinases. i, The N-terminal portion of LRRK2RCKW, comprising ROC, COR-A, COR-B and the N-lobe of the kinase, was aligned to ITK using only the N-lobes of the kinases. ROC,</h1>"
    },
    "tags": {
      "iv": [
        "LRRK2",
        "motility assay",
        "kinesin",
        "imaging",
        "single-molecule"
      ]
    },
    "accessInstructions": {
      "iv": "<p>Test instructions for this document. If you want to access this you can <a title=\"contact Beatriz\" href=\"mailto:beatriz@yld.io\" target=\"_blank\" rel=\"noopener\">contact Beatriz </a>or you can go to <a href=\"http://www.parkinsonsroadmap.com\">www.parkinsonsroadmap.com</a>&nbsp;</p>"
    },
    "labs": {
      "iv": [
        "cd7be402-84d7-4d21-a360-82e2695f2dd9"
      ]
    },
    "authors": {
      "iv": [
        "c853f2fa-21bf-4bab-bfd3-0421102ed546",
        "0f3f3478-9af0-497f-a6e7-896bc801ff7b",
        "9273b747-cb9d-4d06-a20d-732260d5858a",
        "58d375d7-df18-4083-a421-3d1f9c55a537"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "Test Proposal"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-09-29T20:37:07Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-06T10:01:32Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": ""
    },
    "tags": {
      "iv": [
        "Human"
      ]
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": [
        "83c2befb-2c78-4994-aa4d-70fad211d7e7"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "Test Proposal 1234"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-05-21T13:18:31Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-06T10:00:30Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": null
    },
    "tags": {
      "iv": null
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": [
        "9273b747-cb9d-4d06-a20d-732260d5858a",
        "c5937d7b-5e51-4118-ad56-ff6af0c66d66",
        "fe122335-bd30-44c7-b46e-76a6081bae40",
        "c853f2fa-21bf-4bab-bfd3-0421102ed546",
        "63c411b2-f7b2-4369-a5a5-a9d79ac0c4e6",
        "73f5606b-dbac-48aa-98fa-a76ae4018fc9",
        "065b7ecf-4cc0-4863-bad5-84bc0dee7724",
        "d13bef92-9f61-499f-8238-abc55b0e496b",
        "c15ec5dc-b906-4fb5-a293-39f552bb99f5",
        "1cd802c3-4aba-431d-8d62-1e4cada19003"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": "2021-05-21T13:18:31Z"
    },
    "adminNotes": {
      "iv": "sdfsdfsdfsd assssssss"
    }
  },
  {
    "title": {
      "iv": "Testing dates - Proposal - added date: 1 April | published date: 2 April | created date: 30 of April"
    },
    "type": {
      "iv": "Grant Document"
    },
    "subtype": {
      "iv": "Proposal"
    },
    "addedDate": {
      "iv": "2021-04-02T00:00:00Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-06T10:00:29Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": null
    },
    "tags": {
      "iv": null
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": [
        "50a605e0-1305-4258-a9f9-fc895e09ebf2",
        "26d05399-8352-497a-a2f1-2d3ef50f121e",
        "edce70d2-95da-4514-968b-b2abfcc9857c",
        "be3ecff3-afd6-4259-9872-d008adb92782",
        "e32b78bd-5dd1-4f6c-9279-35ab581e9c5a",
        "da7638a9-6cfb-460f-b931-2569a8947f68"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": "2021-04-02T00:00:00Z"
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "Testing dates - Proposal - added date: 1 April | published date: NONE | created date: 30 of April"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": null
    },
    "link": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-04-01T00:00:00Z"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-06T10:00:28Z"
    },
    "subtype": {
      "iv": "Proposal"
    }
  },
  {
    "title": {
      "iv": "Testing dates - Proposal - added date: NONE | published date: 2 April | created date: 30 of April"
    },
    "type": {
      "iv": "Grant Document"
    },
    "description": {
      "iv": null
    },
    "link": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-04-02T00:00:00Z"
    },
    "publishDate": {
      "iv": "2021-04-02T00:00:00Z"
    },
    "tags": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-12-06T10:00:28Z"
    },
    "subtype": {
      "iv": "Proposal"
    }
  },
  {
    "title": {
      "iv": "Test Bioinformatics"
    },
    "type": {
      "iv": "Bioinformatics"
    },
    "subtype": {
      "iv": "Genetic Data - DNA"
    },
    "addedDate": {
      "iv": "2021-09-29T20:42:06Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-09-29T20:41:48Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": ""
    },
    "tags": {
      "iv": [
        "Human"
      ]
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": [
        "83c2befb-2c78-4994-aa4d-70fad211d7e7"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "Test Dataset"
    },
    "type": {
      "iv": "Dataset"
    },
    "subtype": {
      "iv": "Genetic Data - DNA"
    },
    "addedDate": {
      "iv": "2021-09-29T20:40:37Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-09-29T20:40:21Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": ""
    },
    "tags": {
      "iv": [
        "Humans"
      ]
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": []
    },
    "authors": {
      "iv": [
        "83c2befb-2c78-4994-aa4d-70fad211d7e7"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "Testing authors and dates - Presentation - added date: 1 April | published date: 2 April"
    },
    "type": {
      "iv": "Presentation"
    },
    "subtype": {
      "iv": "Genetic Data - DNA"
    },
    "addedDate": {
      "iv": "2021-04-02T00:00:00Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-09-24T11:48:50Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": null
    },
    "tags": {
      "iv": null
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": [
        "63c411b2-f7b2-4369-a5a5-a9d79ac0c4e6",
        "dcb76a67-be47-4821-805f-f262965240cc",
        "d13bef92-9f61-499f-8238-abc55b0e496b",
        "21a434d0-8441-4bbb-b70f-41326eb9ecbc",
        "48660c96-8b18-44f8-a168-e6c93a19dca5",
        "4b77945f-77a4-4ecd-9fc5-dd8941a9f9d7"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": "2021-04-02T00:00:00Z"
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "Testing multiple teamss"
    },
    "type": {
      "iv": "Presentation"
    },
    "subtype": {
      "iv": "Microscopy"
    },
    "addedDate": {
      "iv": "2021-04-02T00:00:00Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-09-24T11:21:47Z"
    },
    "link": {
      "iv": null
    },
    "description": {
      "iv": "<p><a href=\"http://localhost:3000/shared-research/94518d88-9925-4164-a178-9476f2cee427\">http://localhost:3000/shared-research/94518d88-9925-4164-a178-9476f2cee427</a></p>\n<p><a href=\"https://dev.hub.asap.science/shared-research/94518d88-9925-4164-a178-9476f2cee427\">https://dev.hub.asap.science/shared-research/94518d88-9925-4164-a178-9476f2cee427</a></p>\n<p>&nbsp;</p>\n<p><a href=\"http://localhost:3000/shared-research/94518d88-9925-4164-a178-9476f2cee427?test=123\">http://localhost:3000/shared-research/94518d88-9925-4164-a178-9476f2cee427?test=123</a></p>\n<p>&nbsp;</p>\n<p><a href=\"http://localhost:3000/shared-research/94518d88-9925-4164-a178-9476f2cee427?test=123#123\">http://localhost:3000/shared-research/94518d88-9925-4164-a178-9476f2cee427?test=123#123</a></p>\n<p><a href=\"http://localhost:3000/shared-research/94518d88-9925-4164-a178-9476f2cee427#123\">http://localhost:3000/shared-research/94518d88-9925-4164-a178-9476f2cee427#123</a></p>"
    },
    "tags": {
      "iv": null
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": [
        "dcb76a67-be47-4821-805f-f262965240cc",
        "c5937d7b-5e51-4118-ad56-ff6af0c66d66"
      ]
    },
    "asapFunded": {
      "iv": "Yes"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Yes"
    },
    "publishDate": {
      "iv": "2021-04-02T00:00:00Z"
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    }
  },
  {
    "title": {
      "iv": "2021-02-05 Quarterly Update from UK based ASAP PIs - 4 teams"
    },
    "type": {
      "iv": "Presentation"
    },
    "subtype": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-02-01T00:00:00Z"
    },
    "lastUpdatedPartial": {
      "iv": "2021-09-10T11:36:11Z"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1KYXhfiyza5RWUQRLJ3CgHoVolLbomXnP/view?usp=sharing"
    },
    "description": {
      "iv": null
    },
    "tags": {
      "iv": [
        "LRRK2",
        "GBA",
        "PINK1/Parkin",
        "Transcriptomics",
        "Super-resolution imaging",
        "Nanopore sequencing",
        "mitochondria"
      ]
    },
    "accessInstructions": {
      "iv": null
    },
    "labs": {
      "iv": [
        "f2235d49-af87-4834-8f0f-57cc1a4354a9",
        "a61a6e09-29f3-46f4-99db-b03e50dce6b3"
      ]
    },
    "authors": {
      "iv": [
        "83c2befb-2c78-4994-aa4d-70fad211d7e7",
        "c5937d7b-5e51-4118-ad56-ff6af0c66d66"
      ]
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "publishDate": {
      "iv": null
    },
    "rrid": {
      "iv": null
    },
    "accession": {
      "iv": null
    },
    "labCatalogNumber": {
      "iv": null
    },
    "doi": {
      "iv": null
    },
    "adminNotes": {
      "iv": "Teams: Alessi, Hardy, Wood, Schapira - Quarterly Update from UK based ASAP PIs"
    }
  },
  {
    "type": {
      "iv": "Protocol"
    },
    "title": {
      "iv": "Rab29 fast exchange mutants: characterization of a challenging Rab GTPase"
    },
    "link": {
      "iv": "https://www.protocols.io/view/rab29-fast-exchange-mutants-characterization-of-a-bp5kmq4w"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "Nucleotide binding",
        "Rab GTPase",
        "fast exchange mutant",
        "Rab29"
      ]
    },
    "description": {
      "iv": "From Team Alessi || Authors: Rachel C. Gomez, Edmundo G. Vides, Suzanne Pfeffer."
    },
    "addedDate": {
      "iv": "2020-11-27T10:26:00Z"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:28Z"
    }
  },
  {
    "type": {
      "iv": "Protocol"
    },
    "title": {
      "iv": "Analysis of Primary Cilia in Rodent Brain By Immunofluorescence Microscopy"
    },
    "link": {
      "iv": "https://www.protocols.io/view/analysis-of-primary-cilia-in-rodent-brain-by-immun-bnwimfce"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "primary cilia",
        "measuring",
        "immunofluorescence",
        "IF",
        "microscopy",
        "brain",
        "sectioning",
        "OCT",
        "LRRK2"
      ]
    },
    "description": {
      "iv": "We describe here our method for immunostaining of primary cilia in brain sections from wild type and LRRK2 or other mutant mice. Included are procedures for perfusion, tissue harvesting, sectioning and staining, image acquisition and analysis. \n || From Team Alessi || Authors: Shahzad S. Khan, Herschel S. Dhekne, Francesca Tonelli, Suzanne R. Pfeffer."
    },
    "addedDate": {
      "iv": "2020-10-23T20:47:00Z"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:30Z"
    }
  },
  {
    "type": {
      "iv": "Protocol"
    },
    "title": {
      "iv": "Introducing GolgiTag to Cells and Immunoprecipitation of Golgi"
    },
    "link": {
      "iv": "https://www.protocols.io/view/introducing-golgitag-to-cells-and-immunoprecipitat-bp87mrzn"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "golgi",
        "golgi apparatus",
        "anti-HA magnetic beads",
        "immunoprecipitation",
        "IP",
        "TMEM115"
      ]
    },
    "description": {
      "iv": "From Team Alessi || Authors: Rotimi Y. Fasimoye, Dario R. Alessi."
    },
    "addedDate": {
      "iv": "2020-11-30T21:22:00Z"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:30Z"
    }
  },
  {
    "type": {
      "iv": "Protocol"
    },
    "title": {
      "iv": "Quantitative Immunoblotting Analysis of LRRK2 Signalling Pathway"
    },
    "link": {
      "iv": "https://www.protocols.io/view/quantitative-immunoblotting-analysis-of-lrrk2-sign-bsgrnbv6"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "LRRK2",
        "Rab GTPases",
        "quantitative immunoblotting",
        "lysate preparation",
        "cells and tissues"
      ]
    },
    "description": {
      "iv": "Accurate, quantitative analysis of protein expression and modifications (such as phosphorylation) is critical when studying cell signalling. Here we describe our method for efficient immunoblotting analysis of the LRRK2 signalling pathway components in cell and mouse tissue extracts. Specifically, we immunoblot using rigorously validated and characterized antibodies for LRRK2-total and LRRK2-pSer935 (multiplexed), Rab10-total and Rab10-pThr73 (multiplexed), Rab12-total and Rab12-pSer105 (multiplexed) and GAPDH or tubulin (loading control), although the protocol described here can also be applied to different cell components. Included are procedures for sample preparation from cultured cells and mouse tissue, gel electrophoresis, protein transfer, and antibody incubation. \n\nNote: If analysing cells isolated from human blood (neutrophils, monocytes or PBMCs), please refer to the specific protocols deposited in Protocols.io on how to isolate these cells. These lysates can then be analysed by immunoblotting as described here ( See Section \"Preparation of samples for immunoblot analysis\" to Section \"Image acquisition and Analysis\").\n || From Team Alessi || Authors: Francesca Tonelli, Dario Alessi."
    },
    "addedDate": {
      "iv": "2021-02-16T22:53:00Z"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:30Z"
    }
  },
  {
    "type": {
      "iv": "Protocol"
    },
    "title": {
      "iv": "Sample preparation protocol for metabolomics harvesting using lysosome immunoprecipitation (Metabolomics LysoIP, updated 02/09/21)"
    },
    "link": {
      "iv": "https://www.protocols.io/view/sample-preparation-protocol-for-metabolomics-harve-br9zm976"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": []
    },
    "description": {
      "iv": "From Team Alessi || Authors: Wentao Dong, Nouf Laqtom, Monther Abu-Remaileh."
    },
    "addedDate": {
      "iv": "2021-02-09T22:39:00Z"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:32Z"
    }
  },
  {
    "type": {
      "iv": "Protocol"
    },
    "title": {
      "iv": "Dundee Monocyte Isolation protocol (from whole blood)"
    },
    "link": {
      "iv": "https://www.protocols.io/view/dundee-monocyte-isolation-protocol-from-whole-bloo-bnhumb6w"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "monocyte",
        "monocyte isolation",
        "whole blood"
      ]
    },
    "description": {
      "iv": "From Team Alessi || Authors: Francesca Tonelli, Andrew J.M. Howden, Dario R. Alessi, Esther M. Sammler."
    },
    "addedDate": {
      "iv": "2020-10-16T01:11:00Z"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:32Z"
    }
  },
  {
    "type": {
      "iv": "Protocol"
    },
    "title": {
      "iv": "Sample preparation protocol for total proteomic analysis of mouse tissues including brain"
    },
    "link": {
      "iv": "https://www.protocols.io/view/sample-preparation-protocol-for-total-proteomic-an-bs3tngnn"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "proteomic analysis",
        "mouse",
        "brain",
        "tissue",
        "sample praparation",
        "total proteomic analysis",
        "proteomic"
      ]
    },
    "description": {
      "iv": "From Team Alessi || Authors: Raja S. Nirujogi, Houjiang Zhou, Dario R Alessi."
    },
    "addedDate": {
      "iv": "2021-03-07T18:45:00Z"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:32Z"
    }
  },
  {
    "title": {
      "iv": "Dundee neutrophil isolation protocol (from whole blood)"
    },
    "type": {
      "iv": "Protocol"
    },
    "link": {
      "iv": "https://www.protocols.io/view/dundee-neutrophil-isolation-protocol-from-whole-bl-bnhtmb6n"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "neutrophil",
        "isolation",
        "neutrophil isolation",
        "whole blood"
      ]
    },
    "description": {
      "iv": "We describe a fast and efficient immunomagnetic negative isolation method to purify peripheral blood neutrophils for LRRK2 kinase pathway analysis in humans\nGain of kinase function mutations in the Leucine rich repeat kinase 2 (LRRK2) are associated with causing Parkinsons disease. LRRK2 phosphorylates a subgroup of Rab GTPases and their phosphorylation levels mirror LRRK2 kinase activation status. Here, we describe a facile and robust method for isolating peripheral blood neutrophils by immunomagnetic negative selection, subsequent treatment with and without the specific LRRK2 kinase inhibitor MLi-2 to ensure that any effect seen is LRRK2 kinase dependent and cell lysis. Neutrophil lysates can then be used to quantify LRRK2 kinase pathway activity by measuring LRRK2-mediated phosphorylation of its endogenous Rab GTPase substrates either by quantitative immunoblotting or targeted mass-spectrometry. The benefit of using peripheral blood neutrophils is that they are an abundant and homogenous white blood cell population that express relatively high levels of LRRK2, Rab10 and other Rab GTPases. The downside is their high intrinsic elastase serine protease activity that necessitates using the neurotoxic, but efficient serine protease inhibitor Diisopropyl fluorophosphate (DIFP) when lysing the cells. Using this assay, we have demonstrated significantly elevated LRRK2 kinase pathway activity in human peripheral blood neutrophils of patients carrying specific mutations such as LRRK2 R1441G (doi:https://doi.org/10.1101/2021.01.28.21249614) and VPS35 D620N (PMID:29743203). This assay can also be used for pharmacodynamic and target engagement studies of small molecule LRRK2 kinase inhibitors. \n || From Team Alessi || Authors: Ying Fan, Andrew J.M. Howden, Dario R. Alessi, Esther M. Sammler."
    },
    "addedDate": {
      "iv": "2020-10-16T00:23:00Z"
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:34Z"
    }
  },
  {
    "type": {
      "iv": "Protocol"
    },
    "title": {
      "iv": "Sample preparation protocol for total proteomic analysis of mouse tissues including brain"
    },
    "link": {
      "iv": "https://www.protocols.io/view/sample-preparation-protocol-for-total-proteomic-an-bpcsmiwe"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "proteomic analysis",
        "mouse",
        "brain",
        "tissue",
        "sample praparation",
        "total proteomic analysis",
        "proteomic"
      ]
    },
    "description": {
      "iv": "From Team Alessi || Authors: Raja S. Nirujogi, Houjiang Zhou, Dario R Alessi."
    },
    "addedDate": {
      "iv": "2020-11-03T04:32:00Z"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:37Z"
    }
  },
  {
    "title": {
      "iv": "Sample preparation protocol for lipidomics harvesting using lysosome immunoprecipitation (Lipidomics LysoIP, updated 02/09/21)"
    },
    "type": {
      "iv": "Protocol"
    },
    "description": {
      "iv": "From Team Alessi || Authors: Wentao Dong, Nouf Laqtom, Monther Abu-Remaileh."
    },
    "link": {
      "iv": "https://www.protocols.io/view/sample-preparation-protocol-for-lipidomics-harvest-br9ym97w"
    },
    "addedDate": {
      "iv": "2021-02-09T22:35:00Z"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": []
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": null
    },
    "adminNotes": {
      "iv": "MISSING AUTHORS: <non-Hub author 1>, <non-Hub author 2>,"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:38Z"
    }
  },
  {
    "type": {
      "iv": "Protocol"
    },
    "title": {
      "iv": "Dundee peripheral blood mononuclear cell (PBMC) isolation protocol (from whole blood)"
    },
    "link": {
      "iv": "https://www.protocols.io/view/dundee-peripheral-blood-mononuclear-cell-pbmc-isol-bnhxmb7n"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "peripheral blood mononuclear cell",
        "PBMC",
        "PBMC isolation",
        "whole blood"
      ]
    },
    "description": {
      "iv": "We describe a fast and efficient peripheral blood mononuclear cell (PBMC) isolation for LRRK2 kinase pathway analysis \nGain of kinase function mutations in the Leucine rich repeat kinase 2 (LRRK2) are associated with causing Parkinsons disease. LRRK2 phosphorylates a subgroup of Rab GTPases and their phosphorylation levels mirror LRRK2 kinase activation status. Here, we describe a facile and robust method for isolating PBMCs by facilitated density gradient centrifugation, subsequent treatment with and without the specific LRRK2 kinase inhibitor MLi-2 to ensure that any effect seen is LRRK2 kinase dependent and cell lysis. PBMC lysates can then be used to quantify LRRK2 kinase pathway activity by measuring LRRK2-mediated phosphorylation of its endogenous RabGTPase substrates in human peripheral blood neutrophils either by quantitative immunoblotting or targeted mass-spectrometry. The benefits of using PBMCs are that they are routinely used as a biomatrix for Parkinsons research and their isolation procedure is significantly faster and easier than that for example of neutrophils or monocytes from peripheral blood. However, their heterogeneity in terms of cellular composition and highly variable expression levels of LRRK2 and its substrates including Rab10 make PBMC a suboptimal biomatrix for reliably measuring LRRK2 kinase pathway activity. A potential use could be target engagement studies in clinical trials targeting LRRK2. \n || From Team Alessi || Authors: Adil R. Sarhan, Andrew J.M. Howden, Dario R. Alessi, Esther M. Sammler."
    },
    "addedDate": {
      "iv": "2020-10-16T01:47:00Z"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:43Z"
    }
  },
  {
    "title": {
      "iv": "Testing dates - Presentation - added date: 1 April | published date: NONE | created date: 30 of April"
    },
    "type": {
      "iv": "Presentation"
    },
    "description": {
      "iv": "<p>I've just added description to test last updated date</p>"
    },
    "link": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-05-05T00:00:00Z"
    },
    "publishDate": {
      "iv": "2021-05-05T00:00:00Z"
    },
    "tags": {
      "iv": null
    },
    "labs": {
      "iv": null
    },
    "authors": {
      "iv": null
    },
    "adminNotes": {
      "iv": "ddddd"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-28T13:02:56Z"
    },
    "subtype": {
      "iv": "Electrophysiology"
    },
    "accessInstructions": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Yes"
    },
    "usedInAPublication": {
      "iv": "No"
    }
  },
  {
    "title": {
      "iv": "How to Prepare Pipets Used to Triturate the Cells (test)"
    },
    "type": {
      "iv": "Protocol"
    },
    "description": {
      "iv": "<p><span class=\"highwire-citation-author first hw-author-orcid-logo-wrapper has-tooltip hasTooltip author-popup-hover\" data-delta=\"0\" data-hasqtip=\"5\" aria-describedby=\"qtip-5\"><strong><span class=\"nlm-given-names\">Olivia</span></strong>&nbsp;<em><span class=\"nlm-surname\">Harding</span></em></span>, <span class=\"highwire-citation-author hw-author-orcid-logo-wrapper has-tooltip hasTooltip\" data-delta=\"1\" data-hasqtip=\"4\" aria-describedby=\"qtip-4\"><span class=\"nlm-given-names\">Chantell S.</span>&nbsp;<span class=\"nlm-surname\">Evans</span></span>, J<span class=\"highwire-citation-author hw-author-orcid-logo-wrapper has-tooltip hasTooltip\" data-delta=\"2\" data-hasqtip=\"3\"><span class=\"nlm-given-names\">unqiang</span>&nbsp;<span class=\"nlm-surname\">Ye</span></span>, J<span class=\"highwire-citation-author hw-author-orcid-logo-wrapper has-tooltip hasTooltip\" data-delta=\"3\" data-hasqtip=\"0\"><span class=\"nlm-given-names\">onah</span>&nbsp;<span class=\"nlm-surname\">Cheung</span></span>, T<span class=\"highwire-citation-author hw-author-orcid-logo-wrapper has-tooltip hasTooltip\" data-delta=\"4\" data-hasqtip=\"2\"><span class=\"nlm-given-names\">om</span>&nbsp;<span class=\"nlm-surname\">Maniatis</span></span>,&nbsp;<span class=\"highwire-citation-author hw-author-orcid-logo-wrapper has-tooltip hasTooltip\" data-delta=\"5\" data-hasqtip=\"1\" aria-describedby=\"qtip-1\"><span class=\"nlm-given-names\">Erika L.F.</span>&nbsp;<span class=\"nlm-surname\">Holzbaur</span></span></p>\n<p><span class=\"highwire-citation-author hw-author-orcid-logo-wrapper has-tooltip hasTooltip\" data-delta=\"5\" data-hasqtip=\"1\" aria-describedby=\"qtip-1\"><span class=\"nlm-surname\">TANK-binding kinase 1 (TBK1) is a multi-functional kinase with an essential role in mitophagy, the selective clearance of damaged mitochondria. More than 90 distinct mutations in TBK1 are linked to amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD), including missense mutations that disrupt the ability of TBK1 to dimerize, associate with the mitophagy receptor optineurin (OPTN), auto-activate, or catalyze phosphorylation. We investigated how ALS-associated mutations in TBK1 affect Parkin-dependent mitophagy using imaging to dissect the molecular mechanisms involved in clearing damaged mitochondria. Some mutations cause severe dysregulation of the pathway, while others induce limited disruption. Mutations that abolish either TBK1 dimerization or kinase activity were insufficient to fully inhibit mitophagy, while mutations that reduced both dimerization and kinase activity were more disruptive. Ultimately, both TBK1 recruitment and OPTN phosphorylation at S177 are necessary for engulfment of damaged mitochondra by autophagosomal membranes. Surprisingly, we find that ULK1 activity contributes to the phosphorylation of OPTN in the presense of either WT- or kinase inactive TBK1. In primary neurons, TBK1 mutants induce mitochondrial stress under basal conditions; network stress is exacerbated with further mitochondrial insult. Our study further refines the model for TBK1 function in mitophagy, demonstrating that some ALS-linked mutations likely contribute to disease pathogenesis by inducing mitochondrial stress or inhibiting mitophagic flux. Other TBK1 mutations exhibited much less impact on mitophagy in our assays, suggesting that cell-type specific effects, cumulative damage, or alternative TBK1-dependent pathways such as innate immunity and inflammation also factor into the development of ALS in affected individuals.</span></span></p>"
    },
    "link": {
      "iv": "https://www.protocols.io/view/how-to-prepare-pipets-used-to-triturate-the-cells-bqpjmvkn"
    },
    "addedDate": {
      "iv": "2020-12-13T23:41:00Z"
    },
    "publishDate": {
      "iv": null
    },
    "tags": {
      "iv": [
        "pipetting",
        "trituration",
        "mechanical dissociation",
        "tissue"
      ]
    },
    "labs": {
      "iv": null
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:39Z"
    }
  },
  {
    "title": {
      "iv": "Team-Alessi_ASAP-Update-Meeting_December2020_Hub"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/15Hv4gEfBdS-3l_ZBHN9gIB-X6-Iylzsw/view?usp=sharing"
    },
    "tags": {
      "iv": [
        "LRRK2",
        "PINK1/Parkin",
        "lysosomes",
        "mitochondria",
        "ciliogenesis"
      ]
    },
    "description": {
      "iv": null
    },
    "addedDate": {
      "iv": "2020-12-01T00:00:00Z"
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:08Z"
    }
  },
  {
    "title": {
      "iv": "Mapping the LRRK2 signaling pathway and its interplay with other Parkinsons disease components "
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1bX46Tr27d4wmSvsDDkTTdFJgXZWNEpx2/view?usp=sharing"
    },
    "addedDate": {
      "iv": "2020-11-30T00:00:00Z"
    },
    "adminNotes": {
      "iv": "Dario Alessi (Kinases) Suzanne Pfeffer (Rab GTPases) Monther Abu Remaileh (Lysosomes) Miratul Muqit (Mitochondria)"
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:08Z"
    }
  },
  {
    "title": {
      "iv": "Team-Alessi_ASAP-Update-Meeting_October2020_Hub"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1nX6bmx7srJPCUsl-iLVT00LzdKN0SQhK/view?usp=sharing"
    },
    "tags": {
      "iv": [
        "LRRK2",
        "PINK1/Parkin",
        "lysosomes",
        "mitochondria",
        "ciliogenesis"
      ]
    },
    "description": {
      "iv": null
    },
    "addedDate": {
      "iv": "2020-10-01T00:00:00Z"
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:06Z"
    }
  },
  {
    "title": {
      "iv": "Team-Alessi_ASAP-Update-Meeting_January2021_Hub"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1_b0GCVj4aqixcGM_XXE2v70l9-kvp-C9/view?usp=sharing"
    },
    "tags": {
      "iv": [
        "LRRK2",
        "PINK1/Parkin",
        "lysosomes",
        "mitochondria",
        "ciliogenesis"
      ]
    },
    "description": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-01-01T00:00:00Z"
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:02Z"
    }
  },
  {
    "title": {
      "iv": "Team-Alessi_ASAP-Update-Meeting_February2021_Hub"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1zP52shD-seBws16tG186N4hBonErYuSH/view?usp=sharing"
    },
    "tags": {
      "iv": [
        "LRRK2",
        "PINK1/Parkin",
        "lysosomes",
        "mitochondria",
        "ciliogenesis"
      ]
    },
    "description": {
      "iv": null
    },
    "addedDate": {
      "iv": "2021-02-01T00:00:00Z"
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:01Z"
    }
  },
  {
    "title": {
      "iv": "Team-Alessi_ASAP-Update-Meeting_November2020_Hub"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1wiNjoF4hXMfIe20h8Ff9o4oJqQwI7Wft/view?usp=sharing"
    },
    "tags": {
      "iv": [
        "LRRK2",
        "PINK1/Parkin",
        "lysosomes",
        "mitochondria",
        "ciliogenesis"
      ]
    },
    "description": {
      "iv": null
    },
    "addedDate": {
      "iv": "2020-11-01T00:00:00Z"
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:00Z"
    }
  },
  {
    "title": {
      "iv": "Team-Alessi_ASAP-Update-Meeting_September2020_Hub"
    },
    "type": {
      "iv": "Presentation"
    },
    "link": {
      "iv": "https://drive.google.com/file/d/1697O-OTX9GDNnkXoy093JRXfufmCXWa8/view?usp=sharing"
    },
    "tags": {
      "iv": [
        "LRRK2",
        "PINK1/Parkin",
        "lysosomes",
        "mitochondria",
        "ciliogenesis"
      ]
    },
    "description": {
      "iv": null
    },
    "addedDate": {
      "iv": "2020-09-01T00:00:00Z"
    },
    "adminNotes": {
      "iv": null
    },
    "sharingStatus": {
      "iv": "Network Only"
    },
    "asapFunded": {
      "iv": "Not Sure"
    },
    "usedInAPublication": {
      "iv": "Not Sure"
    },
    "lastUpdatedPartial": {
      "iv": "2021-05-14T14:48:00Z"
    }
  }
]